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Preface 
This thesis addresses the genetic and dietary influences of serum urate levels and gout risk. 
In New Zealand gout is an extremely prevalent disease, affecting 3.7% of the adult 
population (Winnard et al., 2012). This prevalence varies significantly between ethnic 
groups in New Zealand and current evidence indicates differing genetic backgrounds 
contribute, at least partially, to this difference (Merriman, 2011). Gout risk is determined 
through exposure to a number of genetic and environmental elements, which further modify 
risk through a series of complicated interactions (Merriman, 2015). Whilst much is known 
about gout epidemiology and work investigating the aetiology of gout has identified many 
important factors involved in disease onset and progression, there is still more to be 
understood about this complex disease. When studying a complex disease, cross-
disciplinary research allows a greater consideration of the many elements that influence 
disease risk. Therefore, this thesis is a cross-disciplinary piece of work, incorporating 
methodologies from the fields of genetics, nutritional epidemiology, and anthropology.  
 
Chapter 1 is made up of three sections that provide the broad context for this research. The 
first section (Section 1.1) introduces the field of complex disease research, the aetiology, 
epidemiology, and prevalence of gout, and the importance of conducting this work within 
New Zealand populations. Section 1.2 details the specific purpose for the research, and the 
personal context within which it was conducted. Chapter 2 to Chapter 4 contain the major 
research findings of this thesis. The focus of Chapter 2 is on the genetic influences of gout, 
first providing an introduction to the presently known or hypothesised genetic contributors 
to gout and serum urate levels (Section 2.1). This chapter then focuses on the specific 
contributions of two uric acid transporter genes in gout risk, discussing an association 
analysis of common variants spanning the gene region (Section 2.2). It then characterises 
rare coding sequence variants found within these two genes (Section 2.3). Chapter 3 takes 
the focus of this thesis away from the biological “behind-the-scenes” causes of gout and 
brings it into the aspects of gout that patients experience in everyday life. This chapter 
begins with an anthropological analysis concerned with identifying the causes of gout that 
gout patients consider of greatest importance to their lives (Section 3.1). It then details the 
frequency and variety of foods identified as acute gout attack triggers by patients (Section 
3.2); one of the most important causes of gout identified in the previous section. Chapter 4 
takes the focus of this thesis back into the biological “behind-the-scenes” causes of gout 
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and serum urate levels. It uses the findings of the previous section to inform the analysis 
direction, focusing on the dietary contributors. This chapter begins by introducing the 
currently understood contributions of diet to serum urate levels and gout (Section 4.1) 
before adding to this pool of knowledge through several nutritional epidemiology analyses. 
In Section 4.2 and Section 4.3, two complementary analyses focused on tomatoes are 
undertaken, as tomatoes are identified by gout patients as important in their disease 
presentation in Section 3.2, but they have not been previously investigated for an 
involvement in either gout or serum urate levels. This chapter concludes with a 
“hypothesis-free”, diet-wide association study aimed at further identifying novel dietary 
influences of gout risk (Section 4.4). Chapter 5 aims to tie the previous chapters together 
and complete this thesis. It discusses the relationships between each of the previous 
chapters and sections, providing an overall conclusion to this work and placing it within 
the field of gout research as a whole. The limitations of this work and suggestions for future 
research are also made within Chapter 5. A pictorial representation of how the three major 
research sections of this thesis link together with brief summaries of the conclusions that 
can be drawn from each section is presented in Figure 1 as a pictorial abstract. 
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Figure 1: Pictorial overview of the discrete sections of research within this thesis. 
 
  
CHAPTER 2: GENETIC ASSOCIATIONS
There are variants in our uric acid 
transporter genes that people without gout 
are less likely to have, these variants make 




CHAPTER 4: DIETARY INFLUENCES
Diet changes our urate. Gout trigger foods 
raise our urate. An overall healthier diet 
lowers our urate, but it effects our urate 
much less than our genes do.
GENERAL POPULATION
BIOLOGICAL CAUSES
CHAPTER 3: EXPERIENCES OF GOUT
We understand gout in the context of pain, 
overall health, treatment, food triggers, and 
building knowledge to prevent attacks in 
ourselves and our family members.
Lots of different foods trigger our gout. 
Seafood, alcohol, red meat, and tomatoes are 
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Abstract 
Gout is a complex human disease characterised by attacks of extreme, debilitating pain 
followed by asymptomatic periods of indeterminate length. Within New Zealand gout is a 
serious health issue. Approximately 7% of New Zealand Māori and Pacific Island people 
are affected by gout, whilst 3% of New Zealand Europeans are affected. It has become so 
prevalent in this country that South Auckland has been labelled the “gout capital of the 
world.” This thesis aims to find reasons for this high disease prevalence by searching for 
genetic and dietary influences of serum urate levels and gout risk in quantitative studies, 
whilst also including a qualitative study of the understandings of disease held by New 
Zealand gout patients. 
 
Gout develops as an inflammatory response to monosodium urate crystals within the joints. 
These crystals are able to form when an individual’s serum urate (the anionic form of uric 
acid) reaches an unusually high level within the blood (hyperuricaemia). Crystals begin to 
build-up within the joints (most often the big toe) and can result in a gout attack. Urate 
levels are maintained through a delicate balance between hepatic production and 
(primarily) renal excretion. Multiple proteins are involved in maintaining this balance. 
Genetic variants in the genes encoding these proteins can disrupt this balance, resulting in 
a greater genetic predisposition to developing gout. Polynesian and European ancestry-
specific genetic effects were identified for common variants within or near two uric acid 
transporter genes (SLC22A11 (OAT4) and SLC22A12 (URAT1)). Rare variants within 
these same two genes were also identified and a greater prevalence of non-synonymous 
mutations that result in protection from hyperuricaemia was found in European individuals 
compared to Polynesian. These results indicate SLC22A11 (OAT4) and SLC22A12 
(URAT1) may significantly contribute to the large difference in gout prevalence between 
Māori and Pacific Island men compared to New Zealand European men. 
 
A genetic predisposition is not the only possible cause of gout. Certain foods, drinks, and 
activities (called triggers) can influence serum urate levels and/or initiate gout attacks. 
These triggers are not strictly considered to be causes of gout, but rather influence when a 
person who is already predisposed to gout develops the disease. However, ethnographic 
interviews with gout sufferers revealed that this distinction is not often emphasised and 
patients had a greater focus on the dietary and lifestyle factors involved in gout risk over 
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the genetic or biochemical aspects. In response to this observation a series of analyses were 
conducted to assess the contributions individual food items have in the risk of gout, acute 
gout attack onset, and serum urate levels. Almost two hundred different food items were 
listed as gout trigger foods by New Zealand gout patients, with over 70% of gout patients 
naming at least one personal trigger food. New Zealand Māori and Pacific Island 
individuals were twice as likely to list any trigger food than New Zealand European 
individuals. Of all the food items listed as triggers, those that were most commonly 
mentioned (seafood, alcohol, and tomatoes) were also significantly associated with raised 
serum urate levels, and tomatoes (a novel urate-influencing food) interacted with the uric 
acid transporter gene SLC22A12 (URAT1) to further influence serum urate. Other foods 
that were rarely mentioned as gout triggers (brown bread, peanuts, margarine, and eggs) 
had novel associations with lowered serum urate levels. Dietary factors explained 3.1% of 
variation in urate levels, but an estimate of each individual’s overall dietary habits only 
explained 0.1% of the variation in serum urate levels. Both measures explained less 
variation in serum urate than genetic factors (5% to 7%). 
 
The results within this thesis show that both genes and diet significantly contribute toward 
the determination of an individual’s serum urate levels and risk of gout. This work 
highlights the importance of integrating patient and researcher understandings of disease 
to open up new or unthought-of avenues of investigation, focus research aims, and provide 
support for previously disregarded patient claims. It is a step towards an improved 
understanding of the experience of gout in New Zealand and the genetic and dietary 
influences of this complex disease. 
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Section 1.1. Gout in New Zealand: An Introduction 
1.1.1. Complex Disease 
Complex diseases are conditions that are influenced by multiple genetic, environmental, 
and interacting factors (Craig, 2008; Donaldson et al., 2016; Lobo, 2008). Most common 
human diseases (such as mental conditions, allergies or intolerances, and metabolic 
disorders) are complex in nature (Mitchell, 2012; Sham and Cherny, 2011). Complex 
diseases are often characterised by an unpredictable (non-Mendelian) inheritance pattern, 
with many affected children having unaffected parents, and a low disease concordance in 
twin sets (6 to 60% pairwise concordance in monozygotic twins; Table 1.1) (Craig, 2008; 
Donaldson et al., 2016). In addition, the prevalence of a complex disease is often higher in 
specific ethnic and gender groups (Lobo, 2008). These common disease features are due to 
the multitude of factors which contribute to complex disease risk. A single genetic variant 
may contribute a minimal amount toward the overall risk of disease development, whilst 
together these variants may explain a much larger portion of disease risk (Wray et al., 
2007). The specific contribution of each genetic variant is also modified by the presence or 
absence of other genetic variants and environmental exposures. Variants are able to interact 
with each other in a non-additive fashion, creating a lower (or higher) level of disease risk 
than a genetic model that only includes additive genetic effects would predict (Zuk et al., 
2012). The complexities of genetic contributions to disease make determining overall 
disease risk difficult, and this is further compounded by the role of environment in complex 
disease. 
 
Twin studies investigating the heritability of complex diseases have documented varied 
contributions of genetic and environmental factors (both shared and non-shared; Table 1.1). 
These studies use several assumptions about the similarities and differences of twin pairs 
to infer the differing contributions of genes and environments to a particular disease 
(Jensen, 1967). Monozygotic twins share ~100% of their genetic variation, whilst dizygotic 
twins only share ~50%. But dizygotic twins share a more similar environment than siblings 
of different ages, as do monozygotic twins, allowing researchers to assume that any 
difference in disease concordance in monozygotic twins is due to non-shared 
environmental factors, whilst in dizygotic twins it could be due to non-shared genetic or 
environmental factors (Duffy et al., 1990; Jensen, 1967; Krishnan et al., 2012). A selection 
of twin studies of complex diseases is presented in Table 1.1 demonstrating the range of 
Chapter 1 | Introduction 
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variation in genetic heritability that can be attributed to these diseases and the relative 
contributions of shared and non-shared environmental factors. 
 
All but one of the twin studies presented in Table 1.1 demonstrated a significant 
contribution of genetic variants to the complex disease/phenotype studied (indicated by an 
h2 > 0) (Jensen, 1967; Sham and Cherny, 2011; Zuk et al., 2012). Most also show a 
significant contribution of non-shared environmental factors (e2 > 0) and to a lesser extent 
shared environmental factors (E2 > 0) (Jensen, 1967). Interestingly, the genetic heritability 
of these diseases ranges from ~0% (in gout) to ~100% (in Crohn’s disease) (Kuo et al., 
2012; Tysk et al., 1988), with an average of 57%. Of note, although the twin study 
conducted by Krishnan et al. (2012) found no evidence for a role of genetics in gout onset 
a broader population-based study of gout heritability amongst Taiwanese families 
determined the genetic heritability of gout was 35.1% in men and 17.0% in women (Kuo 
et al., 2012). In addition, the estimate of genetic heritability of gout produced by Krishnan 
et al. (2012) was less than zero (h2 = -0.12), an impossible value, indicating the common 
assumptions of twin studies did not hold in this analysis (Jensen, 1967). No other twin 
studies have investigated the heritability of gout; however, both hyperuricaemia and 
fractional excretion of uric acid (FEUA) have been studied, and both are part of the 
underlying mechanism of gout (explained in detail below). The genetic heritability scores 
for these two phenotypes were greater than zero (h2 = 0.38 and 0.58, respectively), 
indicating genetic variants contribute to two complex phenotypes that significantly 
contribute to an individual’s gout risk (Emmerson et al., 1992; Krishnan et al., 2012). 
Heritability estimates are specific to the study population they were calculated in and can 
vary substantially between population groups, reflective of the common complex disease 
features mentioned earlier (Jensen, 1967; Lobo, 2008). This makes the generalisability of 
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Twin studies are also limited by the inherent assumptions they make, which disregard the 
possibility of gene-gene or gene-environment interactions and assume dizygotic twins 
always share 50% of their genetic code (identity-by-descent estimates in over 4,000 full 
sibling pairs indicate genetic similarity of full siblings ranges from 37% to 62% (Visscher 
et al., 2006)). These assumptions encourage overestimation of genetic heritability scores 
and may play a role in the variability of results between study populations (Manolio et al., 
2009; Zuk et al., 2012). Twin studies are however, beneficial as they allow the estimation 
of overall genetic heritability of a disease without any knowledge of the disease causing 
genetic variants. 
 
In contrast, other research approaches (such as association and linkage studies) are able to 
give an indication of the specific single nucleotide polymorphisms (SNPs), genes, and gene 
pathways involved in disease aetiology (Sham and Cherny, 2011). Association studies are 
also able to identify important environmental influences of disease. The inclusion of gene-
gene or gene-environment interaction terms in these association analyses can give an 
indication of the non-additive effects at play in disease aetiology. Many other research 
methodologies are also of use in the study of complex disease, encouraging cross-
disciplinary collaborations to further the understandings of disease causes. Complex 
disease research requires a diverse array of research methods to encourage discoveries that 
will ultimately lessen the impact of these diseases on individuals and societies. 
 
1.1.2. Gout 
1.1.2.1. Pathophysiology of Gout 
Gout is a complex disease. It is an extremely painful and debilitating form of arthritis 
characterised by intermittent attacks of extreme pain. Gout attacks are the consequence of 
an innate immune reaction to monosodium urate crystals (explained in more detail below) 
within the joints. In 50% of cases gout presents within the metatarsal phalangeal (big toe), 
but it can also occur within the wrists, hands, ankles, elbows, and knees (Underwood, 
2006). Attacks are so painful that sufferers are unable to withstand the touch of a single bed 
sheet on the affected joint, and these attacks can last for several weeks without the use of 
anti-inflammatory drugs (Lindsay et al., 2011; Snaith, 2003). 
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The patient … is awakened by a pain which usually seizes the great toe, but sometimes 
the heel … or the ankle. The pain resembles that of a dislocated bone ... and … grows 
gradually more violent every hour ... the parts affected … become so exquisitely 
painful as not to endure the weight of the clothes nor the shaking of the room from a 
person walking briskly therein. [Thomas Sydenham, 1683]. 
 
If left untreated acute gout can progress to a chronic phase. Chronic gout, or advanced gout, 
is characterised by a low level of constant pain (which may increase in severity over time) 
and frequent intermittent flares of severe pain (Choi et al., 2005b; Lindsay et al., 2011). 
Untreated gout can also lead to severe disability. Large insoluble deposits of monosodium 
urate crystals, called tophi, may form in the joints and cartilage if preventative measures 
are not taken. These tophi restrict movements and can cause irreparable joint damage along 
with being visually distressing (Choi et al., 2005b).  
 
1.1.2.2. Gout in History 
Gout is an ancient disease, with archaeological evidence suggesting it has been around for 
thousands of years. A mummified Egyptian individual from approximately 2000 BC 
showed evidence of gouty lesions within its joints (from crystal deposits), whilst seven of 
20 individuals from a 3,000 year old grave site in Vanuatu had similarly affected joints 
(Bhattacharjee, 2009; Buckley, 2011). The first known record of gout pathophysiology is 
attributed to the medical notes of Hippocrates in 400 BC, who described gout as a severely 
painful disease. He attributed it to an abnormal accumulation of one of the four humours 
(medical professionals of the time believed all illnesses could be attributed to an imbalance 
between the four humours; black bile, yellow bile, blood and phlegm (Subbarayappa, 
2001)), which medicine had no hope of curing (Bhattacharjee, 2009). It was also noted in 
this and other historical medical texts that gout attacks predominantly affected wealthy men 
who had access to large amounts of rich food or alcohol and commonly struck after a period 
of overindulgence (Nuki and Simkin, 2006; Porter and Rousseau, 1998). Gout became 
known as “morbus dominorum et dominus morborum,”1 an affliction of the wealthy 
(Scholtens, 2008). Many of the kings of France and England had this condition and 
members of their court and extended nobility were similarly afflicted. The familial 
                                                
1 Translation from Latin: “disease of lords and lord of diseases.” 
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inheritance of this disease only served to solidify the belief that gout was a disease of 
nobility (Bhattacharjee, 2009; Scholtens, 2008). 
 
By the 16th century gout had become firmly associated with the “high living” of the 
privileged few and became a marker of social status and wealth. It was seen as a cure for 
or prevention of all other diseases (as all diseases were believed to be mutually exclusive) 
and became a desirable condition despite the pain (Scholtens, 2008). But toward the end of 
the 18th century this favourable view began to diminish and satirical artworks (like that 
shown in Figure 1.1) became popular. These often depicted a gouty individual proudly 
displaying their foot upon a footstool whilst they ate and drank the foods that apparently 
caused their gouty attacks (Gow et al., 2011; Porter and Rousseau, 1998). 
 
Figure 1.1: Nineteenth century satirical artwork depicting a wealthy man suffering 
from gout as a consequence of excess. 
 
“An Exquisite Taste, with an Enlarged Understanding” (1827) Drawn by E. Esq; engraved by G. Hunt; 
published by T. McLean. 
 
Over time this unfavourable view of gout has become more prominent and this has 
coincided with a lowering of the gout prevalence amongst the “upper classes” and an 
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increase in prevalence in the “lower classes” (Gow et al., 2011; Snaith, 2003). The present 
day notion of gout commonly reflects the idea that gout is a shameful, and self-inflicted 
disease, brought on by an unhealthy lifestyle and drinking to excess (Lindsay et al., 2011). 
With the increase in biochemical knowledge of gout it has been recognised by some that 
many non-modifiable factors (such as genetics, gender, and ethnicity) make up a significant 
portion of gout risk (Gow et al., 2011; MacFarlane and Kim, 2014). The observation that 
certain food items increase an individuals risk of gout attacks has now been confirmed 
through case-crossover trials (Neogi et al., 2014; Zhang et al., 2012) and association studies 
have shown certain foods are able to modify serum urate levels and gout (detailed in Section 
4.1) (Kuo et al., 2015; Roddy and Choi, 2014; Towiwat and Li, 2015). However, whilst 
consumption of certain foods exacerbates an individual’s risk of gout attacks this food 
consumption is not the primary cause of gout onset. 
 
1.1.2.3. Hyperuricaemia 
The primary risk factor for gout is an increased level of urate within the blood 
(hyperuricaemia). When serum urate levels are above approximately 420 µmolL-1, 
monosodium urate crystals are able to form and deposit within the joints. In some people 
an auto-inflammatory response is initiated by the presence of these crystals, making the 
area inflamed and extremely painful – an acute gout attack (Choi et al., 2005b). The normal 
concentration range of serum urate for women is generally lower than that in men, most 
likely due to different hormonal environments (Snaith, 2003). In childhood serum urate 
levels in boys and girls are equivalent (~200 µmolL-1), but during puberty urate levels in 
men rise to ~350 µmolL-1 (world-wide average), whilst in women they remain constant. 
When women go through menopause their serum urate levels rise to a concentration 
comparative to that in men (Franco et al., 2006; Gosling et al., 2014; Harkness and Nicol, 
1969; Snaith, 2003). This natural difference in serum urate levels results in a greater risk 
of gout in men than women until older age. 
 
1.1.2.3.1. Uric Acid Production 
Uric acid (the acid form of urate) is a by-product of the purine metabolism pathway. Purine 
metabolism occurs mainly in the liver. Proteins and nucleotides are broken down into 
hypoxanthine and xanthine through a series of enzymatic steps (Figure 1.2). Xanthine is 
then converted to uric acid via the enzyme xanthine oxidase (Bobulescu and Moe, 2012; 
Johnson et al., 2009). In most fish, amphibians, and non-primate mammals, uric acid is 
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further broken down into allantoin or other more soluble and easily excreted metabolites, 
like urea (Choi et al., 2005b; Johnson et al., 2009). However, humans and other great apes 
(orangutan, gorilla, and chimpanzee) are unable to break-down uric acid due to ancient 
mutations that make the enzyme responsible for this activity (uricase) non-functional (Oda 
et al., 2002; Wu et al., 1992). Two non-synonymous variants resulting in premature stop 
codons were introduced to the uricase gene at different evolutionary time points. The first, 
before the evolutionary split between humans/chimpanzees and gorillas/orang-utans 15 
million to 20 million years ago, and the second, six to eight million years ago after this split 
but before the split between humans and chimpanzees (Choi et al., 2005b; Johnson et al., 
2009; Kratzer et al., 2014). Before these non-synonymous mutations were introduced to 
the uricase gene, a series of promoter mutations also occurred, slowly reducing the 
expression of uricase before the protein became non-functional (Kratzer et al., 2014; Oda 
et al., 2002). This lack of uricase significantly changes the processing of uric acid within 
humans (and great apes) compared to other animals. 
 
Figure 1.2: Simplified schematic of purine metabolism within the human liver. 
 
The red cross indicates the metabolic step which no longer occurs in humans and other great apes. Adapted 
from (Choi et al., 2005b) and (Johnson et al., 2009). XO – xanthine oxidase. XDH – xanthine dehydrogenase. 
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1.1.2.3.2. Uric Acid Excretion 
Uric acid is excreted from the human body through two mechanisms. One quarter to one 
third of uric acid is secreted into the intestines where it is broken down by the gut micro 
flora via a process called intestinal uricolysis (Buzard et al., 1955; Sorensen, 1965). The 
by-products of this process are then excreted in the faeces. The remaining uric acid is 
absorbed into the blood stream (serum urate) before being processed in the kidneys. Uric 
acid processing within the kidneys involves both the secretion and absorption of uric acid 
by transport molecules lining the basolateral and apical membranes of the proximal tubule 
(Mandal and Mount, 2015; Merriman and Flynn, 2013). Based on experiments performed 
in the 1970’s this excretory system is commonly described as a four-step process involving 
glomerular filtration (step 1), near complete absorption (step 2), secretion (step 3), and post-
secretory reabsorption (step 4) (Bobulescu and Moe, 2012; Enomoto and Endou, 2005; Sica 
and Schoolwerth, 2002). However, new evidence along with reinterpretations of the 1970’s 
experiments have lead to the rejection of this four-step system and replacement with a 
revised model (Figure 1.3) (Bobulescu and Moe, 2012; Mount, 2005). This model begins 
with the complete glomerular filtration of uric acid, but does not progress to discrete 
absorption and secretion steps. Instead it has been suggested that absorption and secretion 
occur concurrently throughout the proximal tubule, perhaps mediated by co-transport of 
other anions also present in the tubule (Bobulescu and Moe, 2012; Mount, 2005). 
 
In either model only a small portion of the total uric acid that is filtered through the kidneys 
is excreted (7% to 12%), whilst the remainder is reabsorbed into the blood stream (Enomoto 
and Endou, 2005; Sica and Schoolwerth, 2002). An individual’s serum urate levels are 
determined through an intricate balance between the amount of uric acid produced in the 
liver and the amount excreted through both the intestinal and renal pathways (Johnson et 
al., 2005). Within this balance, renal excretion of uric acid is the major mechanism 
determining an individual’s overall urate levels, and impaired renal excretion of uric acid 
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Figure 1.3: The traditional four-step model (A) and the revised model (B) of uric acid 
transport within the kidney proximal tubule.  
 
Model A is adapted from Figure 2 published in (Enomoto and Endou, 2005). Model B is derived from the 
information in (Bobulescu and Moe, 2012) and (Mount, 2005). Arrow size is suggestive of the percentage of 
uric acid involved through the different processes. 
 
1.1.2.4. Prevalence 
Hyperuricaemia is commonly defined as serum urate levels ≥ 416 µmolL-1 in men and ≥ 
357 µmolL-1 in women (Gosling et al., 2014; Snaith, 2003). These cut-off values mean men 
with hyperuricaemia have serum urate levels within the physiological range for 
monosodium urate crystal formation (≥ 420 µmolL-1), whilst women classified with 
hyperuricaemia may not have serum urate levels high enough for crystal formation (≥ 357 
µmolL-1; ≤ 416 µmolL-1) (Perez-Ruiz and Lioté, 2007; Snaith, 2003). The average recorded 
serum urate levels within a population range from 243.9 µmolL-1 in Brazilian men, to 469.9 
µmolL-1 in Taiwanese Aborigine men and from 221.6 µmolL-1 in Brazilian women, to 368.8 
µmolL-1 in Tibetan women (Acheson and Florey, 1969; Chen et al., 2010; Chou and Lai, 
1998; Gimeno et al., 2009; Gosling et al., 2014). Therefore, some populations (such as 
Taiwanese Aborigines, Tibetans, Cook Island Māori, and New Zealand Māori) have an 
average serum urate level in the hyperuricaemic range (Brauer and Prior, 1978; Chou and 
Lai, 1998; Evans et al., 1968). This high average serum urate level results in a higher 
prevalence of hyperuricaemia in these populations. For instance, between 1993 and 1996 it 
was estimated that 72.6% of Taiwanese Aborigines had urate levels that fit within the 
A B 
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definition of hyperuricaemia, whilst in 1966 it was estimated that 43.8% of Cook Island 
Māori individuals had hyperuricaemia (Chang et al., 2001; Prior et al., 1966).  
 
Not all individuals with hyperuricaemia go on to develop gout. Whilst Taiwanese 
Aborigines have the highest recorded rates of hyperuricaemia, it is Australasia that has the 
highest rates of gout. A recent world-wide survey conducted by the World Health 
Organisation estimated that approximately 0.13% of men and 0.03% of women across the 
world suffer from gout, with a combined prevalence of 0.08% (equivalent to approximately 
5,500,000 gout sufferers world-wide) (Smith et al., 2014). The prevalence rates per region 
ranged from 0.02% of people in South Asia (Afghanistan, Bangladesh, Bhutan, India, 
Nepal, and Pakistan) to 0.39% of people in Australasia (Australia and New Zealand). Of 
note, in this assessment of gout prevalence, the study authors did not distinguish between 
the Australian and New Zealand contributions to this high prevalence of gout in 
Australasia; however, estimates of gout prevalence based on national health data have been 
published for both these countries. In Australia the prevalence of gout has been estimated 
at 1.5% in adults ≥ 20 years old, whilst in an equivalent study based in New Zealand the 
gout prevalence was estimated at 3.8%, over two times higher than that seen in Australia 
(Robinson et al., 2015; Winnard et al., 2012). 
 
Interestingly, within the New Zealand gout prevalence study, it was the differing 
contributions of each ethnicity that was most striking. New Zealand European individuals 
had a prevalence of 3.2%, whilst New Zealand Pacific Island individuals had the highest 
gout prevalence at 7.6% (Winnard et al., 2012). New Zealand Māori individuals also had a 
high prevalence of gout (6.2%), almost double that of New Zealand European individuals 
(Winnard et al., 2012). The prevalence of gout in New Zealand Māori individuals has been 
estimated several times (Figure 1.4), with reported rates getting progressively higher over 
time (from 4.9% in 1962/63 to 10.4% in 2012) and this same trend has been noted in many 
other countries and ethnicities around the world (Kuo et al., 2015; Robinson et al., 2012; 
Roddy et al., 2007; Zhu et al., 2011). In contrast, the rate of hyperuricaemia in New Zealand 
Māori has steadily decreased (from 45.5% in 1962/63 to 17.1% in 2012), a trend that has 
not been noted in other populations and that is inconsistent with the rising gout prevalence 
observed (Brauer and Prior, 1978; Klemp et al., 1997; Prior et al., 1966; Stamp et al., 2013). 
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Figure 1.4: Estimated prevalence of hyperuricaemia and gout in New Zealand Māori 
over time. 
 
1962/63 prevalence estimated from 366 men and 381 women (Brauer and Prior, 1978); 1966 prevalence 
estimated from 388 men and 378 women (Prior et al., 1966); 1992 prevalence estimated from 130 men and 
212 women (Klemp et al., 1997); 2009 prevalence (gout only) estimated from nation wide data (176,946 men 
and 197,585 women) (Winnard et al., 2012); 2012 prevalence estimated from 215 men and 280 women 
(Stamp et al., 2013). 
 
1.1.2.5. Risk of Comorbid Diseases 
As the world-wide prevalence of gout and hyperuricaemia has increased so has the 
knowledge of the far reaching health consequences of high serum urate levels and gout. In 
addition to raising the risk of developing gout, hyperuricaemia has also been associated 
with an increased risk of chronic kidney disease, type 2 diabetes, cardiovascular disease, 
and obesity (Choi and Ford, 2007; Niskanen et al., 2004; Zhu et al., 2012). As serum urate 
levels increase, an individual’s risk of developing type 2 diabetes increases (RR = 1.003 
[1.001 to 1.004] per 1 µmolL-1 increase in serum urate levels) and their serum lipid profile 
begins to reflect a cardiovascular risk profile (increased low-density lipoprotein and 
triglycerides, decreased high-density lipoprotein) (Kodama et al., 2009; Moriarity et al., 
2000). Raised serum creatinine levels, indicative of reduced kidney function, also associate 
with increased serum urate levels. However, a recent genetic analysis (Mendelian 
randomisation) intended to tease out the causal element of this association has suggested 
that a genetically higher serum urate level (as opposed to higher serum urate levels due to 
environmental factors) decreases serum creatinine levels – a contradictory finding to 
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current understandings (Bellomo et al., 2010; Hughes et al., 2014). Similarly, Mendelian 
randomisation analysis of serum urate levels and type 2 diabetes has shown genetically 
higher serum urate does not associate with type 2 diabetes, despite measured serum urate 
levels strongly associating with an increased risk of type 2 diabetes (Sluijs et al., 2015).  
Irrespective of the true causal relationships between hyperuricaemia and metabolic 
conditions, hyperuricaemia could be considered an early warning sign, indicating lifestyle 
changes that reduce serum urate levels should be encouraged to reduce risk of disease onset.  
 
The components of the metabolic syndrome (cardiovascular disease, type 2 diabetes, 
kidney disease, obesity, hypertension, and hyperlipidaemia) are also common 
comorbidities of gout. A study by Kuo et al. (2014) which assessed the prevalence of all 
comorbidities and gout in a large sample of the general population of the United Kingdom 
found that individuals with gout are more likely to have at least one component of the 
metabolic syndrome at diagnosis than individuals without gout. They are also more likely 
to develop further comorbidities (of any kind) within a shorter time frame (average time to 
comorbidity diagnosis 43 months for individuals with gout compared to 111 months for 
matched controls without gout) (Kuo et al., 2014). Additionally, gout is associated with 
greater all-cause mortality, primarily due to death from cardiovascular or kidney disease 
(Choi and Curhan, 2007b; Stamp and Chapman, 2013; Teng et al., 2012). This substantial 
increase in health complications in individuals with gout results in lower health-related 
quality of life, and an increased demand on healthcare resources (Dalbeth et al., 2011; Lee 
et al., 2009b). 
 
1.1.2.6. Treatment 
To lessen the impact of gout on both patients and the community adequate management of 
this disease must be employed. Multiple studies have shown that gout is poorly diagnosed 
and managed. Up to 50% of doctors do not treat gout according to the current best practice 
recommendations, which is made worse by the frequent non-adherence to long-term 
treatment plans by gout patients (De Vera et al., 2014; Harrold et al., 2013; Nasser-Ghodsi 
and Harrold, 2015). To sufficiently treat gout there are two aspects of the disease which 
must be addressed. Firstly, an anti-inflammatory medication must be taken during acute 
attacks to alleviate pain and break the inflammatory cycle (Khanna et al., 2012a). The 
second aim of gout treatment is to lower serum urate levels to a concentration low enough 
(< 360 µmolL-1) to prevent the formation of monosodium urate crystals, recurrent gout 
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attacks, and to allow dissolution of any crystals deposited within the joints as tophi (Khanna 
et al., 2012b; Perez-Ruiz and Lioté, 2007). 
 
1.1.2.6.1. Anti-Inflammatory Medications 
Colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids effectively 
interrupt the cycle of inflammation initiated during an acute gout attack through various 
mechanisms (Crittenden and Pillinger, 2013; Dubchak and Falasca, 2010). Daily use of 
these drugs is required during an attack to manage pain and inflammation, and once the 
attack is resolved, they are no longer necessary (Dalbeth and Gow, 2007; Khanna et al., 
2012b). Long-term dependency on some of these anti-inflammatories can have severe side-
effects and they are unable to prevent the progression from acute to chronic gout and 
subsequent joint damage (Crittenden and Pillinger, 2013; Dubchak and Falasca, 2010). To 
achieve these goals, urate-lowering drugs must be regularly taken at a sufficient dose for 
the rest of the patients life (Dalbeth and Gow, 2007; Khanna et al., 2012a). 
 
1.1.2.6.2. Urate-Lowering Medications 
1.1.2.6.2.1. Uricosuric Drugs 
There are three forms of urate-lowering drugs; uricosuric agents, xanthine oxidase 
inhibitors, and recombinant uricase (Crittenden and Pillinger, 2013; Dubchak and Falasca, 
2010). Uricosuric agents encourage the secretion of uric acid within the kidneys. The most 
effective uricosuric currently produced, Benzbromarone, is able to lower serum urate levels 
to < 300 µmolL-1 in 92% of patients using the “standard dose” (100 mg/day), which makes 
it more effective than other common urate-lowering drugs (Probenecid and Allopurinol) 
(Reinders et al., 2009b). However, in 2003 the United States Food and Drug Administration 
(FDA) approval of Benzbromarone was withdrawn due to reports of severe hepatotoxic 
responses (Lee et al., 2008b). Despite these reports such severe side-effects are rare 
(approximately one in 17,000 patients) and prior evidence suggested Benzbromarone is 
safe for general use (Masbernard and Giudicelli, 1981). This drug is on the list of 
PHARMAC (Pharmaceutical Management Agency) subsidised medications within New 
Zealand (under certain conditions), but it remains unavailable in many other countries. In 
contrast, Probenecid is a uricosuric agent that is readily available, but < 5% of gout patients 
are prescribed it. This is likely because it has a lower efficacy than Benzbromarone, has a 
greater degree of drug-drug interactions, requires more frequent dosing, and loses efficacy 
in people with renal disease (Dubchak and Falasca, 2010). 
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1.1.2.6.2.2. Xanthine Oxidase Inhibitors 
The most commonly prescribed urate-lowering therapy is Allopurinol, a xanthine oxidase 
inhibitor. Xanthine oxidase inhibitors influence xanthine oxidase activity through 
competitive binding with uric acid at xanthine oxidase, xanthine dehydrogenase, or both. 
This inhibits the break-down of xanthine to uric acid within the liver (Figure 1.2) – reducing 
serum urate levels through reduced production (Crittenden and Pillinger, 2013; Hu and 
Tomlinson, 2008). Allopurinol is often prescribed at a “standard dose” of 300 mg/day, but 
this prescription is frequently inadequate with only 30% to 50% of individuals in clinical 
trials achieving a serum urate below the recommended target concentration of 360 µmolL-
1 (Dalbeth et al., 2006; Hatoum et al., 2014; Perez-Ruiz and Lioté, 2007; Singh et al., 2015). 
In contrast, the “standard dose” of Febuxostat (another xanthine oxidase inhibitor) is able 
to achieve target serum urate levels in 50% to 60% of gout patients – a statistically 
significant increase in effect (Hatoum et al., 2014; Singh et al., 2015). Best practice 
recommendations require the use of regular serum urate measurements to titrate the 
Allopurinol dosage required to hit the target serum urate level. Allopurinol doses as high 
as 1,200 mg/day are considered safe (Day et al., 1988), and as such increasing Allopurinol 
dose above the “standard dose” with the use of titrating urate measurements results in the 
sufficient lowering of serum urate levels in 80% to 90% of people (Reinders et al., 2009a; 
Stamp et al., 2011). 
 
1.1.2.6.2.3. Recombinant Uricase 
The most effective urate-lowering drug is Pegloticase, a pegylated form of the uricase 
enzyme (Crittenden and Pillinger, 2013; Sundy et al., 2008). This drug artificially restores 
the function of uricase, allowing the break-down of uric acid to allantoin (Figure 1.2) and 
other more soluble products (Sundy et al., 2008). Pegloticase is able to reduce an 
individual’s serum urate concentration to almost undetectable levels, and in 40% of people 
with tophaceous gout, the large monosodium urate deposits in their joints can be completely 
eradicated within six months (Dubchak and Falasca, 2010). However, sustained use of 
Pegloticase (and other uricase based therapies) can lead to the development of immune 
resistance or an anaphylactic response resulting in a loss of efficacy of this drug over time 
(Crittenden and Pillinger, 2013; Dubchak and Falasca, 2010). Pegloticase is also 
logistically difficult to administer, as it has the best effects when 8 mg is taken 
intravenously every two weeks (Sundy et al., 2008). At present Pegloticase has only been 
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FDA approved for use in individuals that are resistant to other gout treatments, and is not 
commonly prescribed to gout patients (Crittenden and Pillinger, 2013). 
 
1.1.2.6.3. Medication Side-Effects 
Each urate-lowering therapy is associated with several positive and negative attributes 
which must be considered by healthcare professionals during prescription. Cost, 
availability, drug-drug interactions, potential side-effects, and other practical concerns 
inform the decisions made in clinical practice (Khanna et al., 2012a). However, for all 
urate-lowering therapies there is a major negative attribute that cannot be avoided. Rapid 
decreasing of serum urate levels is the most efficient gout attack trigger known, as the 
lowered ambient serum urate level encourages monosodium urate crystal shedding within 
the joints (Doherty, 2009; Rees et al., 2014). Crystal shedding then initiates the 
inflammatory response of an acute gout attack. As a result, many gout sufferers experience 
an increase in gout flares immediately after initiation of urate-lowering therapy. With 
appropriate prophylaxis these flares can be prevented or reduced, but not all doctors 
prescribe these medications concomitantly at urate-lowering therapy initiation (Perez-Ruiz, 
2009; Rees et al., 2014). This adverse response to urate-lowering therapies can lead to some 
individuals ceasing to take their drugs (not on doctor’s advice). 
 
1.1.2.6.4. Adherence Barriers 
The increase in gout flares at medication initiation is not the only barrier to treatment 
adherence in gout. A significant body of work has investigated the real world situations 
that make individuals more or less likely to adhere to medications. Studies have 
consistently found age to be a key influence, with individuals who are older being more 
likely to adhere to medication recommendations than younger individuals (Harrold et al., 
2009; Riedel et al., 2004; Solomon et al., 2008; Zandman-Goddard et al., 2013). Use of 
other chronic medications is also often identified as a factor which encourages adherence 
(Riedel et al., 2004; Sarawate et al., 2006; Zandman-Goddard et al., 2013). However, 
qualitative research has also found that the need for concomitant medications can be a 
barrier to medication adherence if appropriate organisational methods are not in place 
(Singh, 2014b). Qualitative studies have also indicated the sporadic nature of gout attacks 
encourages non-adherence due to a perception of wellness (Singh, 2014b). Confusion over 
appropriate treatment regimes also plays a role in non-adherence.  A survey focused on 
New Zealand gout patients’ knowledge of their condition and its treatment found 48% of 
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people did not know urate-lowering therapies must be taken every day (Martini et al., 
2012). Qualitative studies in New Zealand have also identified a significant number of 
people who had never heard about urate-lowering therapies until the interviewer questioned 
them, in one particular case this lack of knowledge had lead to severe symptoms of chronic 
gout, requiring surgery to prevent further disability and complications (Te Karu et al., 
2013). Surveys of gout patients in the United States and United Kingdom have identified 
similar trends (Singh, 2014b; Spencer et al., 2012). 
 
1.1.2.6.5. Adherence Rates 
Treatment with urate-lowering medications is a life-long therapy regime. Evidence from 
the World Health Organisation suggests only ~50% of adults with a chronic disease 
requiring life-long medication adhere to the treatment (World Health Organization, 2003). 
Studies suggest this adherence rate is much lower in gout patients. Research focused on 
medication adherence in American gout patients has determined that 9.7% of the people 
studied discontinued their medication within two years of their first prescription of 
Allopurinol (Riedel et al., 2004). Studies following gout patients for four years after initial 
Allopurinol prescription documented as many as 33.7% of patients discontinuing their 
medication (Harrold et al., 2010a; Singh et al., 2009). Of those individuals who continue 
to take their urate-lowering medication, the number of people that take them precisely as 
prescribed is also low (17% to 44%) (De Vera et al., 2014). Studies have further shown 
this non-adherence to treatments has a significant impact on the likelihood that patients will 
reach the target serum urate concentration of < 360 µmolL-1. Of 433 people who had 
recently begun taking urate-lowering drugs, 167 (38.6%) achieved a serum uric acid < 360 
µmolL-1 within 90 days. 64% of these people were adherent with their drug regime 
(Halpern et al., 2009). Several New Zealand based studies have identified similar non-
adherence trends, with an estimated 29% to 60% of gout patients not completely following 
their doctor’s advice when taking urate-lowering therapies, this fact along with the high 
prevalence of gout in New Zealand results in a high impact of this disease on the New 
Zealand healthcare system (Dalbeth et al., 2012; Dalbeth et al., 2011; Martini et al., 2012). 
 
1.1.3. New Zealand 
New Zealand (otherwise known as Aotearoa) is an island nation within the Pacific Ocean. 
Two islands (the North Island and the South Island) make up the majority of New Zealand’s 
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land mass (Figure 1.5), whilst many offshore islands are also part of New Zealand’s official 
territory (Walrond, 2015b). 
 
1.1.3.1. New Zealand Settlement 
New Zealand was first populated by migrants from Polynesia. These migrants became 
known as Māori, the indigenous people of New Zealand (Mein Smith, 2011). Radiocarbon 
dating of archaeological sites from the earliest known Māori settlements estimate that these 
migratory voyages began ~700 years ago (1280 AD to 1300 AD), and Māori oral histories 
indicate they continued for some time (Higham et al., 1999; Wilmshurst et al., 2011). Based 
on the material culture and layout of these early archaeological sites, it is commonly 
thought that the migrant waka (canoes) originated from central eastern Polynesia (the Cook 
Islands or nearby) and linguistic and mitochondrial DNA analyses have corroborated this 
hypothesis (Buckley et al., 2009; Knapp et al., 2012). The settlement of New Zealand has 
been classified into three archaeological periods, the “Māori” period (1250 AD to 1792 
AD), the “Pākehā” period (1792 AD to 1860 AD), and the “Kiwi” period (1860 AD to 
present) (Smith, 2008). The “Māori” period of New Zealand settlement is initially 
characterised by small coastal villages, evidence of big game hunting (moa and seals), and 
limited agricultural success due to incompatible crops and growing techniques for the New 
Zealand climate (Furey, 2006; Smith, 2008). Over time agricultural advances led to a 
greater need for crop storage and it has been suggested this could have played a role in the 
development of hill forts (Pā), built in strategic areas across each rohe (territory) from the 
16th century onwards (Furey, 2006; Schmidt, 1996). These Pā were commonly built on 
defendable hills, had ample storage for crops, and contained several living spaces. They 
were built to defend crops and land from other iwi (tribes) and many Pā were spread 
throughout a rohe, maintained by the hapū (clans) within the immediate area (Smith, 2008). 
By the time European explorers discovered New Zealand at least 40 major iwi were living 
throughout New Zealand, with an established but varied Māori culture and identity, which 
included a warrior class (Ballara, 1998; Smith, 2008). 
 
The Dutch explorer Abel Tasman became the first European to discover New Zealand in 
1642, naming the country Nieuwe Zeeland. Tasman and his crew encountered “hostile” 
Māori tribesmen resulting in several small skirmishes and the death of a number of 
Tasman’s crew, discouraging them from staying in New Zealand. Tasman’s encounters 
also discouraged further exploration of New Zealand by others and it was not until much 
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later that European explorers became interested in New Zealand again and the “Pākehā” 
period (1792 AD to 1860 AD) of New Zealand archaeological history began (Mein Smith, 
2011; Smith, 2008). In 1769 Captain James Cook began a series of voyages around the 
entire coastline of New Zealand, producing an extremely detailed map of the land. Captain 
Cook also endeavoured to establish friendly relations with the indigenous Māori people 
(King, 2003; Mein Smith, 2011). Captain Cook’s maps and reports of an abundant land 
encouraged more European voyagers to make the journey to New Zealand, although 
initially this was only as small groups of missionaries, sealers, and adventurers (King, 
2003). Māori individuals also began to make journeys to the cities of nearby Australia as 
negotiators, entrepreneurs, and tourists, and to seek out trade items from European visitors 
for the advantages they afforded iwi in day to day living (King, 2003; Mein Smith, 2011). 
In the late 1830’s concentrated colonisation of New Zealand by European settlers began, 
with the formation of the New Zealand Company (formerly Association) and the 
progressive colonisation of port towns with the vision of transforming these areas into 
thriving cities (King, 2003; Mein Smith, 2011). 
 
Figure 1.5: Map of New Zealand. 
 
Major islands and New Zealand Gout Case-Control Cohort collection cities (detailed in Appendix A.1; page 
255) are labelled. Map obtained from www8.garmin.com. 
 
Chapter 1 | Introduction 
Page | 22 
This influx of new migrants to New Zealand is classified as the beginnings of the “Kiwi” 
period (1860 AD to present) of New Zealand settlement.  This archaeological period is 
defined as the point in time when European immigrants out-numbered the Māori 
population, just after formal British colonial governance began with the signing of the 
Treaty of Waitangi in 1840 (Smith, 2008). Colonisation of New Zealand was further 
encouraged when gold was discovered in rivers in both the North and South Islands of New 
Zealand. Three major gold rushes during the 1860’s led to an influx of Australian and 
British miners colonising Otago, the West Coast, and the Coromandel in the early 1860’s. 
In 1866 miners from Guangdong Province in Southern China were also encouraged to move 
to New Zealand to work in the Otago gold fields after the European miners moved to the 
gold mines of the West Coast (Walrond, 2015a). These historical encounters, voyages, and 
colonisation efforts have shaped the population of New Zealand today. 
 
1.1.3.2. Modern New Zealand 
Present day New Zealand is home to over four million people, who identify with many 
different ethnic groups. The majority of the population are of European descent (74.0%), 
whilst the next most prominent ethnicities are the indigenous Māori population (14.9%), 
individuals of Asian descent (11.1%), and a large population of individuals of Pacific Island 
heritage (total: 7.4% – Samoan: 3.6%; Cook Island Māori: 1.5%; Tongan: 1.5%; Other 
Pacific Island: < 1.0%) (Statistics New Zealand, 2013). In 2013 76% of the population of 
New Zealand lived in the North Island, with over 30% of the population living in a single 
city – Auckland. In addition, almost a quarter (23.9%) of New Zealand’s Māori individuals 
and two thirds of New Zealand’s Pacific Island individuals (total: 65.9%; Samoan: 66.5%; 
Cook Island Māori: 59.8%; Tongan: 82.8%) live within the Auckland region (Statistics 
New Zealand, 2013). There are certain discrepancies in the ethnic distribution within socio-
economic indicators. Māori and Pacific individuals are less likely to have any level of 
qualification and are more likely to earn an hourly wage within the lower income brackets 
(Statistics New Zealand, 2013). Research has found evidence that gout is more prevalent 
within individuals of a lower socio-economic status (Hayward et al., 2013; Winnard et al., 
2012), and this along with the greater prevalence of gout within Māori and Pacific Island 
individuals (due to naturally higher serum urate levels) is likely to be a contributing factor 
to the extremely high prevalence of gout within New Zealand. South Auckland has been 
labelled the “gout capital of the world” to reflect the large concentration of gout sufferers 
in this region (Lindsay, 2007). 
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1.1.3.3. Gout in New Zealand 
1.1.3.3.1. Awareness Campaigns 
A collection of New Zealand rheumatologists, nurses, scientists, health educators, and 
others have recognised the substantial burden of gout in New Zealand and have been 
working toward improving the treatment of gout within the primary healthcare setting. 
These individuals are supported by Arthritis New Zealand (www.arthritis.org.nz), a charity 
organisation formed in 1966 with the goal of providing information and support to people 
with any of 140 different kinds of arthritis, including gout. In 2008, an organisation called 
the Māori Gout Action Group (http://maaorigoutactiongroup.co.nz), based in South 
Auckland (Counties Manukau District Health Board), was also formed to specifically target 
resources toward the largest population of New Zealanders at risk of gout – working age 
Māori and Pacific Island men (Winnard et al., 2008). The efforts of both these groups have 
encouraged a greater awareness of gout (specifically it’s treatments) in New Zealand’s 
general population, although there are still many issues that need to be addressed. As part 
of these efforts a public health advertisement campaign “Don’t be trapped by gout” 
(http://goutnz.org.nz) was released earlier this year (March, 2015), featuring a New 
Zealand rugby union player (Neemia Tialata), and focusing on the simple message “if you 
think you have gout, go and see your GP” (general practitioner). Arthritis New Zealand 
have also created a volunteer “Gout Champions Programme” where people with gout, or 
whose whānau/family members have gout, are trained to educate others in their community 
about this condition. They are taught ways to counteract the common negative stereotypes 
of gout and to spread the message that gout is a treatable disease. Additionally, an “Outing 
Gout” hui (meeting) is held at a marae (meeting ground) each year. These hui are run by 
the Māori Gout Action Group and aim to educate community members and healthcare 
providers about gout, encouraging awareness of gout within the New Zealand community, 
particularly the Māori community. 
 
1.1.3.3.2. Research Groups 
Within New Zealand there is a large network of research groups working on different 
aspects of gout. These groups are spread throughout the country’s major centres, with the 
majority of researchers based in Auckland (Dalbeth Group, Peter Gow, Karen Lindsay, 
Susan Reid, and Doone Winnard), several groups in Dunedin (Bahn Laboratory, Merriman 
Laboratory, Te Morenga Laboratory), and some researchers in Wellington (Harrison Group 
and William Taylor) and Christchurch (Stamp Group). Research topics within these groups 
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focus on a wide variety of contributors to gout, such as the clinical presentation, healthcare 
outcomes, medication side-effects, mechanistic pathways, medication efficacy, genetic 
influences, dietary/nutritional influences, comorbid diseases, inflammatory onset, and 
social perceptions of disease. Many of these research groups collaborate together on 
projects, and also have collaborators from all over the world, particularly Australia, the 
United States of America, Europe, and the United Kingdom. New Zealand gout researchers 
are considered world-wide experts in the field (Nicola Dalbeth: #1, Lisa Stamp #11, Tony 
Merriman #23, William Taylor #25, and Peter Gow #60) and the Universities of Otago and 
Auckland are two of the top three world-leading institutes in gout research 
(www.expertscape.com/leaders/gout). The results of these groups’ research have helped 
inform the awareness campaigns that have been instigated in New Zealand, and each group 
is continuing to work within their area of interest to improve the understandings of gout 
and lessen the impact of this disease on individual New Zealanders and their communities. 
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Section 1.2. Research Context 
1.2.1. Personal Synopsis 
Individuals conduct research. Whilst these individuals cannot change the statistical or 
factual results of research, their personal interests and goals inform the way they interpret 
these results. These personal interests can create unintentional researcher biases. This effect 
is considered a particular problem in qualitative research, as the researcher has an intimate 
level of involvement in the data collection process, but quantitative studies are not exempt 
from researcher bias (Burke, 1997). Therefore, it is pertinent to begin any research thesis, 
be it qualitative or quantitative, with a short synopsis that informs the reader of the personal 
context within which the research was conducted. 
 
I have lived in New Zealand my entire life. My mother’s family have been in New Zealand 
for generations, primarily living within the Taranaki region of the North Island. My father 
was born in Northern Ireland and grew up in England, before meeting my mother and 
moving to New Zealand. He suffers from gout, but rarely has attacks and controls his serum 
urate with Allopurinol. I grew up in a small town called Waitara within the northern 
Taranaki region. The town’s population is approximately 6,500 people, with 73.5% of 
people of European descent, 39.9% of Māori descent, and 2.2% of Pacific Island descent 
(Statistics New Zealand, 2013). I was educated at three local schools (Tikorangi Primary 
School, Manukorihi Intermediate, and Waitara High School), each with a small school roll 
and an ethnic diversity that reflects that of the town. These schools all incorporated Māori 
culture into everyday school life, through a focus on learning about Māori language, songs, 
and traditions. I have spent time on several different marae for various reasons throughout 
my life, but I only know about Māori culture from an outsider’s perspective, being of 
European descent.  
 
In 2007 I moved to Dunedin, a city in the Otago region of the South Island, to study genetics 
at the University of Otago. Dunedin city has a population of approximately 120,000 people, 
with 21,000 of these people being University students. A much lower percentage of people 
in Dunedin are of Māori descent than in my home town (7.7%) whilst a greater proportion 
are of European and Pacific Island descent (88.3% and 2.5%, respectively) (Statistics New 
Zealand, 2013; University of Otago, 2015). Initially I enrolled in a single undergraduate 
degree, a Bachelor of Science with Honours in genetics, but by late 2007 I had enrolled in 
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an additional undergraduate degree, a Bachelor of Arts in anthropology. From 2007 to 2011 
I spent my time working toward obtaining both these degrees. In 2010 I spent time in the 
Gemmell Laboratory (Department of Anatomy) completing my genetics honours research 
project. My research during this year aimed to create androgenetic zebrafish clones to 
enable research of the physiological effects of mitochondrial DNA mutations in a constant 
nuclear DNA background. Whilst I enjoyed this research year I struggled to see the direct 
benefits of the research topic, and felt it was not where my true interests lay. In the summer 
of 2009/10 I had spent my time working within the Merriman Laboratory (Department of 
Biochemistry), researching the involvement of genetics in gout risk. I felt this work was 
more in-line with the style of research I wanted to continue with, returning for a second 
summer research project after the completion of my honours dissertation. In 2011 I 
completed my anthropology degree, with a major focus on the social aspect of 
anthropology, learning about the diverse, confusing, and fascinating ways in which people 
understand the world.  
 
In January of 2012 I began research for my PhD thesis, working within the Merriman 
Laboratory, initially continuing the research I had conducted during my summer projects. 
I was also keen to include a social anthropology section within my research, to tie together 
the two halves of my undergraduate education and create a cross-disciplinary piece of work. 
Throughout this work I have taken advantage of the many resources at my disposal and the 
advice I have been offered, and attempted to minimise my personal biases although my 
background education and experiences have inevitably informed and directed my research 
decisions. 
 
1.2.2. Research Purpose and Aims 
The purpose of this thesis was to develop a greater understanding of the genetic and dietary 
contributors to gout risk in New Zealand. The specific aims of this thesis began with two 
initial aims; to assess the genetic influences of gout risk in New Zealand, and to gain an 
understanding of the different ways people with gout think about and live with their 
condition. Further aims for this project were developed in response to the knowledge gained 
through assessing gout patients’ lived experiences of disease. This knowledge was used to 
inform the direction of further biomedical research in this thesis. 
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This thesis consists of three research sections, each with their own sub-section aims; 
1. Genetic associations (quantitative research): 
a. To test the hypothesis that common, haplotype defining, variants within two 
uric acid transporter genes (SLC22A11 (OAT4) and SLC22A12 (URAT1)) 
are independently involved in gout risk in Polynesian (Māori and Pacific 
Island) and European New Zealanders. 
b. To identify and characterise rare variants within the genetic sequences of 
SLC22A11 (OAT4) and SLC22A12 (URAT1) and test the hypothesis that 
these rare variants collectively have an influence on hyperuricaemia in New 
Zealand European and Polynesian individuals. 
2. Experiences of gout (qualitative research): 
a. To discover what understandings some people with gout have surrounding 
their disease and test the hypothesis that these people’s understandings of 
gout will focus on the visible, environmental aspects of gout aetiology. 
b. To test the hypothesis that a wide variety of foods are identified as acute 
gout attack triggers at a high frequency, by New Zealand gout patients. 
3. Dietary influences (quantitative research): 
a. To test the hypothesis that the novel foods identified as common acute gout 
attack triggers increase serum urate levels to a similar degree to the known, 
accepted, gout attack trigger foods. 
b. To perform a “hypothesis-free” diet-wide association study to identify 
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Section 2.1. The Genetics of Serum Urate and Gout: A 
Brief Overview 
Table 2.1 to Table 2.5 and Figure 2.2 are updated versions of those published in a review 
article in eLS: Genetics and Disease, 2013: 
Merriman TR and Flynn TJ (2013) Molecular Genetics of Hyperuricaemia and Gout. in eLS: Genetics and Disease. 
Chichester: John Wiley & Sons, Ltd. 
 
2.1.1. Genome-Wide Association Studies of Serum Urate 
Hyperuricaemia is the primary risk factor for gout, therefore understanding the genetic 
influences of serum urate levels is an important step in understanding the genetics of gout. 
The development of genome-wide genotyping technologies, detailed human variant 
reference panels, and the collection of large population-based cohorts has helped progress 
the genetic understandings of many complex diseases/phenotypes, such as serum urate 
levels and gout (Mitchell, 2012; Sham and Cherny, 2011). The key analysis methodology 
that has been made possible by these new technologies is that of genome-wide association 
studies (GWAS). These are “hypothesis-free” association analyses that scan the whole-
genome for loci where single nucleotide polymorphisms (SNPs) show a difference in allele 
frequency between individuals with or without the disease of interest, or have a linear 
relationship with a measured phenotype (Sham and Cherny, 2011). The identification of 
common SNPs (minor allele frequency > 5%) in areas of the genome containing genes or 
other genetic elements that influence the disease/phenotype of interest has been facilitated 
by these studies. These genomic regions could be previously known areas of interest found 
through familial genetic studies, functional analyses, or other hypothesis-driven research; 
or they could be novel regions that the current knowledge of disease aetiologies would be 
unlikely to identify as causal (Sham and Cherny, 2011). In 2007 the first genome-wide 
association study of serum urate levels was conducted. 4,305 individuals from Sardinia, 
Italy were genotyped for ~350,000 SNPs spread across the entire genome and their serum 
urate levels were associated with each of these SNPs in a series of independent linear 
regression analyses (Li et al., 2007). After correction for multiple-testing a small sub-set 
of 38 SNPs within a single region containing the SLC2A9 (GLUT9) gene were identified 
as significantly associated with serum urate levels (“top-hit”: rs6855911; β = -14.04 
µmolL-1, Pβ = 2.0×10-16) (Li et al., 2007). This was a novel and unexpected association at 
the time. Subsequent analyses (both genome-wide association studies and targeted 
analyses) have confirmed this significant association, identifying SLC2A9 as the strongest 
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genetic influence of serum urate levels (detailed further below) (Kottgen et al., 2013). A 
number of genome-wide association studies of serum urate levels have been performed 
since the publication of this first study, with progressively larger cohorts being used and a 
greater range of ethnic groups being analysed. These studies have not only consistently 
found a strong association between variants within the SLC2A9 region, but have also 
progressively added to the list of gene regions involved in the regulation of serum urate 
levels (Figure 2.1). 
 
2.1.2. Genetics of Uric Acid Transporters 
The loci identified in genome-wide studies have been dominated by those areas of the 
genome that contain uric acid transporter genes. As impaired renal excretion of serum urate 
is the cause of hyperuricaemia in up to 90% of people this trend is unsurprising (Becker et 
al., 2014; Riches et al., 2009). The current model of uric acid transport within the kidney 
proximal tubule includes eleven proteins that are involved in the direct secretion (ABCG2, 
MRP4, NPT1, NPT4, OAT1, OAT2, and OAT3) and absorption (GLUT9, OAT4, OAT10, 
UAT, and URAT1) of uric acid within the kidneys, whilst four other proteins are thought 
to be indirectly involved in transport (PDZK1, SDCT2, SMCT1, and SMCT2; Figure 2.2) 
(Anzai and Endou, 2011; Mandal and Mount, 2015). Variants within or near approximately 
half the genes that encode these uric acid transporter proteins have shown significant 
associations with serum urate levels in genome-wide association studies (ABCG2 
(ABCG2), PDZK1 (PDZK1), SLC2A9 (GLUT9), SLC17A1 (NPT1), SLC17A3 (NPT4), 
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Figure 2.2:	Current knowledge of uric acid transporters within the kidney proximal 
tubule. 
 
Transporters are labelled using their protein names. Gene names are ABCC4 (MRP4), ABCG2 (ABCG2), 
LGALS9 (UAT), PDZK1 (PDZK1), SLC2A9 (GLUT9) [two isoforms SLC2A9a (GLUT9L), SLC2A9b 
(GLUT9S)], SLC5A8 (SMCT1), SLC5A12 (SMCT2), SLC13A3 (SDCT2), SLC17A1 (NPT1), SLC17A3 
(NPT4), SLC22A6 (OAT1), SLC22A7 (OAT2), SLC22A8 (OAT3), SLC22A11 (OAT4), SLC22A12 
(URAT1), and SLC22A13 (OAT10). The specific order of protein expression within the kidney proximal 
tubule is currently unknown. The apical membrane is on the lumen side of the cell and the basolateral 
membrane is on the blood side of the cell. Proteins shown in blue are involved in absorption, those shown in 
green are involved in secretion, and those in red/orange are thought to be indirectly involved. UA – uric acid. 
OAs – organic anions. MCs – monocarboxylates. DCs – dicarboxylates. Cr – creatinine. ATP – adenosine 
triphosphate. ADP – adenosine diphosphate. 
 
2.1.2.1. Uric Acid Absorption 
The absorption of uric acid back into the blood stream appears to be a major influence on 
overall serum urate levels. Functional evidence suggests five proteins are involved in the 
absorption of uric acid (SLC2A9 (GLUT9), SLC22A11 (OAT4), SLC22A13 (OAT10), 
LGALS9 (UAT), and SLC22A12 (URAT1); Figure 2.2) (Anzai and Endou, 2011; Mandal 
and Mount, 2015). Three of these proteins have a greater level of support for this function 
than the other two, with genetic associations with serum urate being found in the SLC2A9, 
SLC22A12, and SLC22A11 genes, but not in SLC22A13 and LGALS9 (Tin et al., 2011; 
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Yang et al., 2014). In addition SLC2A9 and SLC22A12 are two of the three most often and 
most strongly associated uric acid transporter genes in genome-wide studies (Figure 2.1) 
and non-synonymous variants that result in the loss of protein function have been identified 
in both genes as the cause of severe hypouricaemia (low serum urate) in a number of people 
(serum urate from 0.6 µmolL-1 to 47.6 µmolL-1; fractional excretion of uric acid (FEUA) 
from 35% to > 500%) (Dinour et al., 2011; Dinour et al., 2010; Dinour et al., 2012; Ichida 
et al., 2004; Iwai et al., 2004; Kawamura et al., 2011; Komoda et al., 2004; Stiburkova et 
al., 2011). 
 
2.1.2.1.1. SLC2A9a (GLUT9L) and SLC2A9b (GLUT9S) 
The SLC2A9 gene encodes GLUT9, a glucose transporter expressed in the liver, kidneys, 
and placenta (Vitart et al., 2008). In 2007, when SLC2A9 was first associated with serum 
urate levels, it was proposed that this association was likely due to an indirect effect on 
urate transport through changes in glucose levels in the liver and kidneys and the 
consequent downstream effects (Li et al., 2007). There was no evidence at this time to 
suggest GLUT9 could transport uric acid, but subsequent functional analyses of the GLUT9 
protein have found that it is a low affinity, high capacity uric acid transporter, which 
exchanges uric acid for glucose (Figure 2.2) (Caulfield et al., 2008; Vitart et al., 2008). 
Two isoforms of GLUT9 exist, a long form (GLUT9L, SLC2A9a) and a short form 
(GLUT9S, SLC2A9b), which differ at their N terminus by 28 amino acids (GLUT9L: 540 
amino acids; GLUT9S: 512 amino acids) (Kimura et al., 2014). These two isoforms are 
differentially expressed, with mRNA for SLC2A9a being found in the liver, kidney, 
placenta, lung, leukocytes, and brain, whilst SLC2A9b is expressed less widely, with 
mRNA being found only in kidney and placenta tissues (Augustin et al., 2004). The two 
forms are also located within different areas of the kidney proximal tubule, with GLUT9L 
present on the basolateral membrane, whilst GLUT9S is primarily found on the apical 
membrane, although expression analyses suggest it may also be present on the basolateral 
membrane (Bobulescu and Moe, 2012; Kimura et al., 2014). Both these isoforms are 
involved in the absorption of uric acid into the blood stream, and it has been suggested 
GLUT9 is the only (or most important) basolateral absorption protein involved in 
maintaining serum urate levels (Bobulescu and Moe, 2012; Mandal and Mount, 2015). 
 
In support of this claim, variants within SLC2A9 have consistently produced the strongest 
signal (Pβ = 3.0×10-8 to < 1.0×10-700) in genome-wide association studies of serum urate 
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levels in African American, Chinese, Croatian, European, and American Indian populations 
(Figure 2.1) (Kottgen et al., 2013; Tin et al., 2011; Voruganti et al., 2013; Yang et al., 
2014; Zemunik et al., 2009). Estimates from these and other studies have suggested 
SLC2A9 explains from 3% to 5% of the variation in serum urate levels, with a larger effect 
in women than men (Bobulescu and Moe, 2012; Dehghan et al., 2008; Kolz et al., 2009; 
Kottgen et al., 2013). A complicated array of independent association signals have been 
found across the SLC2A9 gene region (750 kb downstream to 200 kb upstream) which no 
one variant is able to explain (Wei et al., 2014). Several non-synonymous variants have 
shown evidence of a serum urate-influencing effect in individuals with normal serum urate 
levels (rs16890979 (V235I): β = -28.29 µmolL-1, Pβ = 2×10-17; rs2280205 (P321L): β = -
7.14 µmolL-1, Pβ = 0.01; rs3733591 (R265H): β = 21.42 µmolL-1, Pβ = 0.01; Table 2.1), 
however none have such a strong influence as the main genome-wide association variants 
(Kottgen et al., 2013; Tin et al., 2011; Voruganti et al., 2013; Yang et al., 2014; Zemunik 
et al., 2009).  
 
Along with being within a large complex association region, SLC2A9 has shown evidence 
for interactions with many environmental factors, such as sugar-sweetened drinks, diuretic 
use, and alcohol; and with other phenotypes like sex, menopausal status, and age (Batt et 
al., 2013; McAdams-DeMarco et al., 2013; Topless et al., 2015; Voruganti et al., 2014). 
SNPs across this gene have also been associated with variability in serum urate levels (as 
opposed to mean serum urate levels), with several independent association signals across 
the gene region as observed in traditional genome-wide studies (Topless et al., 2015). It 
has been suggested that the variants driving the SLC2A9 associations may be influencing 
protein function through expression levels (as opposed to the direct modification of protein 
function) due to the lack of an obvious causal variant, complicated association pattern, and 
multitude of interacting factors (Bobulescu and Moe, 2012). No matter how these variants 
are influencing SLC2A9 function, current evidence indicates this gene has a key role in 
determining serum urate levels, and is likely to work with SLC22A12 (URAT1) to transport 
the majority of serum urate that is absorbed into the blood stream during renal filtration 
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2.1.2.1.2. SLC22A12 (URAT1) 
SLC22A12 encodes a high affinity uric acid transporter that was first characterised in 2002. 
It was thought to be the main protein involved in uric acid absorption at this time. The 
SLC22A12 protein was given a name to reflect this belief “urate transporter 1” (URAT1) 
(Enomoto et al., 2002). With the discovery of GLUT9’s ability to transport uric acid and 
the greater percentage of serum urate levels explained by SLC2A9 variants this is a less 
accepted belief; however, URAT1 does play a significant role in uric acid transport 
(Mandal and Mount, 2015). URAT1 is expressed on the apical membrane of the proximal 
tubule and is responsible for the uptake of uric acid from the lumen in exchange for 
monocarboxylates (such as lactate and nicotinate) (Anzai et al., 2007; Enomoto et al., 
2002). Expression of the SLC22A12 gene has also been detected in the brain, liver, 
pancreas, prostate, heart, and many other tissues, but expression is at a much higher level 
in the kidneys (Bleasby et al., 2006).  
 
The first genetic analysis of SLC22A12 was conducted in 2004 in a targeted assessment of 
the SLC22A12 gene sequence in 32 Japanese individuals with idiopathic renal 
hypouricaemia (serum urate < 119 µmolL-1, increased risk of exercise induced kidney 
failure, and increased development of kidney stones (Ichida et al., 2004; Komoda et al., 
2004)). All but two of these people had a non-synonymous mutation within the SLC22A12 
gene, with all but one of these people having the specific nonsense variant W258X 
(rs121907892), which results in a truncated protein and loss of URAT1 function (Ichida et 
al., 2004). Interestingly, this variant has an allele frequency of 2.4% in the Japanese 
population, where hypouricaemia has a population prevalence of 0.15% to 0.23% (Tasic et 
al., 2011). In Korea, where hypouricaemia has a prevalence of 3.3%, the allele frequency 
of the W258X variant is 11.7% (Lee et al., 2008a). This variant has not been found in other 
populations to date (1000 Genomes Phase III). In addition, whilst in most populations 
SLC2A9 has the strongest effect on serum urate levels, in the Japanese population 
SLC22A12 has consistently shown a stronger effect. A genome-wide study of 8,868 
Japanese individuals published in 2010 identified four genome-wide significant 
associations (SLC22A12, SLC2A9, ABCG2, and LRP2 (chromosome 2)) with SLC22A12 
showing the strongest effect (rs506338: β = 13.62 µmolL-1, Pβ = 2.3×10-31) and explaining 
1.5% of the variation in serum urate levels (Kamatani et al., 2010). In this study SLC2A9 
explained a lesser amount of variation in serum urate levels (1.3%) and was not as 
prominent as in European studies (rs11722228: β = 9.76 µmolL-1, Pβ = 7.1×10-24) 
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(Kamatani et al., 2010). A second larger GWAS of 33,074 East Asian individuals 
(Japanese: 85.3%; Korean: 8.7%; Chinese: 5.9%) reported a similar situation with four 
significantly associated loci (SLC22A12, SLC2A9, ABCG2, and MAF (chromosome 16)) 
and the most associated variant within SLC22A12 showing a stronger effect on serum urate 
levels than the other three associations (rs504915: β = 13.39 µmolL-1, Pβ = 3.3×10-63; β ≤ 
10.62 µmolL-1, Pβ ≤ 1.6×10-65; for SLC22A12 and other loci, respectively) (Okada et al., 
2012). Follow-up of both these studies has also reported a stronger effect for SLC22A12 in 
Japanese individuals than any other genetic loci involved in serum urate (rs505802: β = 
14.63 µmolL-1, Pβ = 2.4×10-50; β ≤ 10.71 µmolL-1, Pβ ≤ 2.0×10-44; for SLC22A12 and other 
loci, respectively) (Takeuchi et al., 2013). These associations have all been with common 
SNPs in low linkage disequilibrium with the W258X non-synonymous variant (r2 ≤ 0.11; 
Table 2.2). 
 
Interestingly, in a genome-wide study of 3,451 Chinese individuals, SLC22A12 showed no 
significant association with serum urate levels, although targeted analyses of this loci have 
found some evidence for associations (Table 2.2) (Yang et al., 2014). Genome-wide studies 
of European and African American individuals have significantly associated serum urate 
with SLC22A12 (URAT1) although it does not have the strongest effect on serum urate 
levels in these populations (Kolz et al., 2009; Kottgen et al., 2013; Tin et al., 2011). Of 
note, within the genome-wide studies identifying a significant association with SLC22A12, 
the region of association also includes variants within another uric acid transporter, 
SLC22A11 (OAT4). In several studies this association is reported separately to that of 
SLC22A12, whilst in others only one of these two genes is listed (Kamatani et al., 2010; 
Kolz et al., 2009; Kottgen et al., 2013; Okada et al., 2012; Tin et al., 2011; Yang et al., 
2010). 
 
2.1.2.1.3. SLC22A11 (OAT4) 
SLC22A11 (OAT4) is located just upstream of SLC22A12 (URAT1) on chromosome 11 
(11q13.1) and is the other half of this organic anion transporter pair (Eraly et al., 2003). 
SLC22A11 has a more restricted expression pattern than SLC22A12, only producing mRNA 
within kidney, placenta, and adrenal gland tissues; but the expressed protein has a much 
wider range of transport substrates (Bleasby et al., 2006; Hagos et al., 2007). OAT4 is able 
to transport multiple organic anions and is involved in the low affinity absorption of uric 
acid across the apical membrane of the kidney proximal tubule “driven by an outwardly 
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directed dicarboxylate gradient,” or pH gradient (Ekaratanawong et al., 2004). OAT4 
transports other organic anions with a much higher affinity, including oestrone sulphate (a 
precursor to oestrogen and oestradiol) and other circulating hormones; and is able to 
transport several drug compounds, such as Methotrexate, Cimetidine, and Zidovidine (Cha 
et al., 2000; Lee and Kim, 2004). Transport activity of this protein is also inhibited by 
various medications, including Probenecid and nonsteroidal anti-inflammatory drugs, both 
used in the treatment of gout (Section 1.1.2.6) (Lee and Kim, 2004). 
 
Genetic studies of serum urate levels and SLC22A11 (OAT4) have identified two variants 
in high linkage disequilibrium (r2 = 0.98) that significantly associate with serum urate in 
European individuals (rs17300741: β = 3.69 µmolL-1, Pβ = 6.7×10-14; rs2078267: β = 4.34 
µmolL-1, Pβ = 9.4×10-38; Table 2.2) (Kolz et al., 2009; Kottgen et al., 2013). An association 
between this gene and serum urate levels in a non-European population has only been tested 
for once, with no significant findings (β = -2.99 µmolL-1, Pβ = 0.49; Table 2.2) (Sun et al., 
2014). Interestingly, whilst simple genetic association models have not indicated a large 
influence for OAT4 on serum urate levels, a more complicated methodology called 
Mendelian randomisation (mentioned briefly in Section 1.1.2.5) has indicated OAT4 
transport activity is extremely important in the regulation of normal kidney function, which 
in turn modifies uric acid excretion (Hughes et al., 2014). This analysis predicted serum 
urate levels based on genetic risk, and associated these predicted values with serum 
creatinine (SCr) – as a marker of kidney function. As genetically determined serum urate 
levels rose, serum creatinine levels dropped (β = -19.23 µmolL-1 SCr, Pβ = 0.07, PDH < 
1.0×10-4), indicating improved kidney function. This effect contradicted the simple 
association of serum creatinine with measured serum urate (β = 38.32 µmolL-1 SCr, Pβ = 
7.3×10-35) which was consistent with other epidemiological studies of serum urate and 
kidney function (Bellomo et al., 2010; Hughes et al., 2014; Weiner et al., 2008). Whilst 
this is an important finding in its own right, the additional evidence that this genetic effect 
is driven by the activity of SLC22A11 (OAT4) (β = -296.40 µmolL-1 SCr, Pβ = 0.08, PDH < 
1.0×10-4), as opposed to other uric acid transporters (β ≥ -85.23 µmolL-1 SCr, Pβ ≥ 0.29, 
PDH ≥ 0.01) that have a greater influence on serum urate levels, suggests that OAT4 
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2.1.2.2. Uric Acid Secretion 
Another important process in the determination of serum urate levels is uric acid secretion. 
Seven proteins are thought to be part of this process within the kidney proximal tubule 
(Figure 2.2) (Anzai and Endou, 2011; Mandal and Mount, 2015). Genome-wide studies 
have found evidence for association between three of these genes and serum urate levels 
(ABCG2 (ABCG2), SLC17A1 (NPT1), and SLC17A3 (NPT4); Figure 2.1), and another of 
these proteins (SLC22A7 (OAT2)) had an unreplicated weak association in the most recent 
large European genome-wide study (Kottgen et al., 2013). However, the current evidence 
suggests renal absorption and extra-renal secretion (mediated by ABCG2) may be the two 
more influential mechanisms in determining overall serum urate levels, as opposed to renal 
secretion. 
 
2.1.2.2.1. ABCG2 (ABCG2) 
ABCG2, encodes an ATP-dependent uric acid transporter (ABCG2, synonym BCRP) 
responsible for uric acid secretion in the kidneys, liver, and intestines (Nakayama et al., 
2011). A non-synonymous variant (rs2231142) in exon five of this gene is responsible for 
the replacement of glutamine (Q) at amino acid residue 141 with lysine (K) reducing 
ABCG2 protein activity to half that of the wild-type protein (Matsuo et al., 2009; 
Nakayama et al., 2011). The lysine encoding T allele of rs2231142 is found in 12% of 
people (1% in African populations to 29% in East Asian populations – 1000 Genomes 
Phase III) and has been consistently associated with increased serum urate levels in 
European, Japanese, Chinese, African American, Native American, and Mexican cohorts 
(Table 2.3) (Kottgen et al., 2013; Takeuchi et al., 2013; Yang et al., 2014; Zhang et al., 
2013). Further analysis of this variant has lead to the recent conclusion that ABCG2 has a 
greater influence on serum urate levels through transport activity in the intestines (extra-
renal uric acid excretion) than renal transport activity (Ichida et al., 2012). Studies of rat 
Abcg2 have shown excretion within the intestines directly correlates with Abcg2 expression 
levels, with the highest expression and excretion occuring within the ileum (Hosomi et al., 
2012). Additionally, Abcg2 knock-out mice display decreased extra-renal excretion, 
increased fractional excretion of uric acid, and overall increased serum urate levels (Ichida 
et al., 2012). When ABCG2 is not functioning at full capacity, less uric acid is secreted in 
the intestines creating a higher level of circulating serum urate and a consequent increase 
in renal uric acid excretion (Figure 2.3). This increased urinary uric acid excretion in 
response to ABCG2 dysfunction has been observed in Japanese individuals (Pβ = 3.6×10-
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10), as has increased fractional excretion of uric acid (FEUA) in European individuals (µ141K 
= 8.7%, µ141Q = 5.9%, Pdifference < 0.01) (Dalbeth et al., 2014; Ichida et al., 2012). This 
situation has been termed renal overload hyperuricaemia – a condition which has an intitial 
presentation similar to that of over production hyperuricaemia (Ichida et al., 2012; Matsuo 
et al., 2014). 
 
Figure 2.3: Changes in renal and extra-renal excretion rates according to ABCG2 
(rs2231142) genotype. 
 
When ABCG2 is functioning normally ~30% of the total uric acid produced is excreted in the intestines 
(extra-renal excretion) (Buzard et al., 1955; Sorensen, 1965). This leaves ~70% of the uric acid to be 
processed in the kidneys, where ~90% of this remaining uric acid is absorbed and ~10% is excreted in urine 
(renal excretion) (Enomoto and Endou, 2005; Sica and Schoolwerth, 2002). When the rs2231142 141K allele 
is present ABCG2s secretory ability is reduced to half the normal rate (Matsuo et al., 2009; Nakayama et al., 
2011). This results in less extra-renal excretion and a greater proportion of uric acid being processed in the 
kidneys. Assuming the renal processing of uric acid is unchanged (still absorbing ~90% of the uric acid being 
processed, although the observed increase in fractional excretion of uric acid indicates this assumption may 
be flawed) the percentage of overall uric acid being renally excreted increases from ~7% to ~9%, observed 
as an increase in both urinary uric acid excretion and overall serum urate levels in these individuals (Ichida 
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Several variants within ABCG2 besides rs2231142 (Q141K) have also been associated with 
serum urate levels (Table 2.3). The East Asian genome-wide association study by Okada 
et al. (2012) identified a downstream variant (rs2725220) in moderate linkage 
disequilibrium (r2 = 0.50) with rs2231142 as the most strongly associated SNP within the 
ABCG2 region (β = 8.03 µmolL-1, Pβ = 4.2×10-30), whilst other non-synonymous variants 
within ABCG2 have also been analysed in Japanese individuals (rs72552713: Q126X, 
rs2231137: V50M) (Matsuo et al., 2009; Okada et al., 2012). 
 
2.1.2.2.2. SLC17A1 (NPT1) and SLC17A3 (NPT4) 
As ABCG2 appears to have a greater involvement in extra-renal excretion than renal 
excretion, other proteins involved in the secretion of uric acid within the proximal tubule 
may have a greater influence on the rate of renal uric acid secretion. SLC17A1 (NPT1) and 
SLC17A3 (NPT4) are located together on chromosome 6 (6p21.3 to 6p22.2) as part of the 
SLC17A gene family cluster (SLC17A1, SLC17A2 (NPT3), SLC17A3, and SLC17A4 
(NPT5)). These two genes encode sodium-dependent phosphate transporter proteins that 
are able to transport organic anions, including uric acid, across the apical membrane of the 
proximal tubule (Figure 2.2) (Iharada et al., 2010; Jutabha et al., 2010; Uchino et al., 2000). 
The SLC17A gene family was first associated with serum urate levels in a genome-wide 
study of 11,847 European individuals, with the “top-hit” in the region falling within 
SLC17A3 (rs1165205: βstandardised = -0.09, Pβ = 1.9×10-9) (Dehghan et al., 2008). Within this 
publication, the association was replicated in a second European cohort of 11,024 
individuals (βstandardised = -0.09, Pβ = 8.4×10-11), but did not replicate in an African American 
cohort (n = 3,843, βstandardised = -0.03, Pβ = 0.33; Table 2.4) (Dehghan et al., 2008). Since 
this time, significant associations have been limited to European individuals, with genome-
wide studies of other populations showing no evidence for an association between variants 
in this gene family region and serum urate (Figure 2.1) (Kamatani et al., 2010; Kottgen et 
al., 2013; Okada et al., 2012; Tin et al., 2011; Yang et al., 2014). A single association 
between this gene region and serum urate has been identified in a non-European population 
(Japanese) in a study attempting to replicate the associations found in European genome-
wide studies (Table 2.4). A strong association with a consistent direction and effect size 
was identified (rs1165196: β = -8.09 µmolL-1, Pβ = 7.1×10-16), but the lack of replication 
in both the Japanese and East Asian (mostly Japanese) genome-wide studies calls into 
question the validity of this association (Kamatani et al., 2010; Okada et al., 2012; 
Takeuchi et al., 2013). 
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An interesting aspect of the SLC17A1 and SLC17A3 genes is their close proximity to each 
other. The location of the “top-hit” within European genome-wide studies has varied 
substantially, with intronic variants in both SLC17A1 (rs1183201, rs1165151) and 
SLC17A3 (rs1165205) being reported, along with non-synonymous variants in SLC17A1 
(rs1165196: T269I) and SLC17A4 (rs11754288: A142T; Table 2.4) (Dehghan et al., 2008; 
Kolz et al., 2009; Kottgen et al., 2013; Middelberg et al., 2011; Yang et al., 2014). This 
has led to difficulties in determining whether associations seen within this area are 
attributable to one gene, both SLC17A1 and SLC17A3, or the entire SLC17A gene cluster 
(Dehghan et al., 2008; Kolz et al., 2009; Kottgen et al., 2013; Middelberg et al., 2011; 
Yang et al., 2014). In addition to this, SLC17A2 (NPT2) and SLC17A4 (NPT5), the other 
two genes in this gene cluster, have not had the proteins they encode functionally 
characterised to determine what substrates they are able to transport (Reimer, 2013). There 
is potential for these two proteins to transport uric acid (particularly NPT5 due to the urate-
modifying non-synonymous variant identified within the SLC17A4 gene), and the genetic 
associations seen across this region to be relevant to these genes also. 
 
2.1.2.2.3. SLC22A7 (OAT2); SLC22A6 (OAT1) and SLC22A8 (OAT3) 
At present several proteins are thought to be involved in the basolateral secretion of uric 
acid, but genetic studies have not been able to identify a significant role for these 
transporters in determining serum urate levels. SLC22A6 (OAT1) and SLC22A8 (OAT3) 
are located together on chromosome 11 (11q12.3), upstream of SLC22A11 (OAT4) and 
SLC22A12 (URAT1) (Eraly et al., 2003). These two genes encode a pair of very similar 
organic anion transporters from the SLC22A family (Eraly et al., 2003). Both are expressed 
in the kidney proximal tubule and functional analysis indicates that they are capable of 
transporting a large range of substrates (including uric acid) across the basolateral 
membrane in exchange for dicarboxylates (Bakhiya et al., 2003; Sekine et al., 1997). 
Evidence from in vitro studies indicates that these proteins have the ability to transport uric 
acid in both directions across the basolateral membrane, although it is thought the in vivo 
dicarboxylate gradient within kidney proximal tubule cells forces these proteins to 
primarily secrete uric acid (Bahn et al., 2002; Bakhiya et al., 2003; Sekine et al., 1997; 
Zhang et al., 2004). To date, these two genes have not shown a genetic association with 
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SLC22A7 (OAT2), another member of the SLC22A family, is located on chromosome 6 
(6p21.1) and is the only member of this family that is not part of a transporter pair or cluster 
(Eraly et al., 2003). OAT2 is expressed on the basolateral membrane of the kidney proximal 
tubule, and as with OAT1 and OAT3, functional assays indicate OAT2 is able to transport 
uric acid (Sato et al., 2010). There is nominal evidence for a genetic association between 
this gene and serum urate levels from the largest European genome-wide association study 
(β = -2.02, Pβ = 1.2×10-6); however, the effect size is small and no replication of this 
association has been reported to date (Kottgen et al., 2013). 
 
2.1.2.3. Indirect Involvement in Uric Acid Transport 
2.1.2.3.1. PDZK1 (PDZK1) 
When the first model of renal uric acid transport was proposed, proteins other than uric 
acid transporters were included in the system. Specifically, co-operation between the 
primary uric acid/anion exchanger and a sodium anion co-transporter was included in the 
model, as the creation of substrate gradients improves uric acid transport efficiency (Roch-
Ramel and Guisan, 1999). Several proteins that may fill the role of this sodium anion co-
transporter have been suggested, with some evidence for the sodium monocarboxylate 
transporters SLC5A8 (SMCT1) and SLC5A12 (SMCT2), and the sodium dicarboxylate 
transporter SLC13A3 (SDCT2) being involved in uric acid transport as these gradient 
creators (Gopal et al., 2004; Gopal et al., 2007). The major evidence for this involvement 
comes from the interaction between PDZK1 and these proteins. 
 
PDZK1 encodes a multivalent PDZ domain binding protein (PDZK1) and has been 
identified in European genome-wide studies as an important determinant of serum urate 
levels (rs1471633: β = 3.51 µmolL-1, Pβ = 1.2×10-29; Figure 2.1) (Kolz et al., 2009; Kottgen 
et al., 2013; Sulem et al., 2011; Yang et al., 2010). Yeast two-hybrid assays have 
determined that PDZK1 is able to bind with many of the uric acid transporter proteins 
(ABCG2, URAT1, OAT4, NPT1, and NPT4), along with the sodium monocarboxylate 
transporters SMCT1 and SMCT2 (Anzai et al., 2004; Fukutomi, 2011; Jutabha et al., 2010; 
Miyazaki et al., 2005; Shimizu et al., 2011; Srivastava, 2009). It has been suggested that 
PDZK1 influences serum urate levels by directing the co-localisation of proteins within the 
kidney proximal tubule, putting those that transport the same substrates or co-substrates 
together for efficient transport activity (Anzai and Endou, 2011). Dysfunction of this 
protein could therefore result in abnormal localisation of proteins in relation to each other 
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and a lower efficiency of transport. This situation has been observed in the development of 
a number of human diseases, whereby the disruption of the interaction between PDZ 
proteins and the proteins they bind causes abnormal protein function and disease risk 
(Shimizu et al., 2011; Yeruva et al., 2015). 
 
2.1.2.3.2. SLC16A9 (MCT9) 
The only monocarboxylate transporter gene that has shown a significant association with 
serum urate levels is SLC16A9 (MCT9). This gene associated with serum urate levels in 
European individuals (rs12356193: β = 4.76 µmolL-1, Pβ = 1.7×10-8); however, this 
association has not been reliably replicated in targeted analyses (β = 2.78 µmolL-1, Pβ = 
0.05) (Kolz et al., 2009; Kottgen et al., 2013). The exact mechanism by which MCT9 
influences serum urate is currently unknown. The substrates that it transports are also 
unknown, although association analysis evidence suggests the MCT9 protein may transport 
carnitine-related compounds (Kolz et al., 2009). This gene is expressed in both the kidneys 
and intestines, meaning it could be involved in either renal uric acid excretion or extra-
renal uric acid excretion (Nakayama et al., 2013). A Japanese study found a significant 
association between SLC16A9 and renal overload related gout (defined as 
hyperuricaemia/gout in the presence of high urinary uric acid excretion: UUE > 25 
mg/h/1.73 m2), but no evidence for an association with non-renal overload gout (UUE ≤ 25 
mg/h/1.73 m2) (Nakayama et al., 2013). The authors of this work suggested this difference 
in effect indicates SLC16A9 (MCT9) may be influencing serum urate through the extra-
renal excretion pathway; however, the evidence for this is currently tenuous. 
 
2.1.2.4. Non-Transporter Associations 
2.1.2.4.1. GCKR (GKRP) 
Whilst uric acid transporter proteins and their co-transporters make up the majority of 
serum urate associations and explain the highest percentage of serum urate variance (4.8%), 
they are not the only genes and pathways that have been associated with serum urate levels 
in both genome-wide and targeted analyses (Kamatani et al., 2010; Kolz et al., 2009; 
Kottgen et al., 2013; Okada et al., 2012; Sulem et al., 2011; Tin et al., 2011; Yang et al., 
2010). In the largest genome-wide study to date (110,347 European individuals) thirty 
association peaks were observed, with 24 of these peaks from areas of the genome that do 
not contain known uric acid transporter genes (Kottgen et al., 2013). It was proposed within 
this paper that these newly associated genes may influence serum urate levels through 
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several pathways – an inhibin-activin pathway, a growth factor network, and a glucose 
regulation pathway (Kottgen et al., 2013). Of these associated non-transporter genes, 
GCKR (GKRP) has the most support for a role in determining serum urate levels. This gene 
has been associated with serum urate levels in European, Chinese, Japanese, and East Asian 
populations with an effect size similar to that of the SLC17A gene cluster, SLC22A11 
(OAT4), and PDZK1 (β = 2.7 µmolL-1 to 9.2 µmolL-1) (Kottgen et al., 2013; Okada et al., 
2012; Sun et al., 2014; Takeuchi et al., 2013). 
 
GCKR encodes the glucokinase (hexokinase 4) regulatory protein (GKRP), which has a 
central role in glucose homeostasis. This protein regulates glucokinase (GCK (GK)) 
activity, determining the rate of glucose phosphorylation and insulin secretion (Kolz et al., 
2009; van der Harst et al., 2009). Over expression of Gckr in mice and rats has been shown 
to improve glycaemic control and insulin sensitivity, whilst Gckr knock-out mice show the 
opposite effect along with reduced glucokinase production (Farrelly et al., 1999; Grimsby 
et al., 2000). The T allele of a non-synonymous variant rs1260326 (P466L) within this gene 
has been associated with not only increased serum urate levels, but also decreased glucose 
levels, decreased insulin resistance, lower risk of type 2 diabetes, and increased triglyceride 
levels (Sparso et al., 2008; Vaxillaire et al., 2008). Functional characterisation of the GKPR 
466L protein has identified a reduction in gene expression, aberrant protein localisation, 
reduced interaction with fructose-6-phosphate or fructose-1-phosphate, and no difference 
in response between a high and a low glucose environment (Beer et al., 2009; Rees et al., 
2012). This lowered GKRP activity allows an increase in glucokinase activity, encouraging 
faster conversion of glucose to glucose-6-phosphate and a subsequent increase in AMP and 
ribose-5-phosphate levels – both precursors to uric acid (Choi et al., 2005b; Johnson et al., 
2009). This increased glucokinase activity also leads to an increase in glyceraldehyde-3-
phosphate, which is part of the triglyceride synthesis pathway (van der Harst et al., 2009; 
Yang Chou and Mansfield, 1999). Therefore, reduced GKRP activity results in decreased 
glucose levels, increased triglyceride levels, and increased serum urate levels, consistent 
with the associations observed in various human studies (Janecke et al., 2001; Sparso et 
al., 2008; van der Harst et al., 2009; Vaxillaire et al., 2008). Changes in glucose 
homeostasis may also influence GLUT9 (SLC2A9) uric acid transport activity, as this 
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2.1.3. Genetics of Gout 
2.1.3.1. Serum Urate Related Genes 
As with serum urate, the genetics of gout has been dominated by uric acid transporter genes, 
along with other serum urate associated genes. However, recent work by members of the 
Merriman Laboratory, which analysed 28 loci that have associated with serum urate in 
relation to gout in New Zealand European and Polynesian individuals, showed a lack of 
correlation between the effect sizes in serum urate and gout (Phipps-Green et al., 2016). In 
both the New Zealand European and Polynesian cohorts ABCG2 had the strongest effect 
on gout risk (rs2231142: OR = 2.01, POR = 1.7×10-14; OR = 2.45, POR = 1.9×10-19; 
respectively), despite SLC2A9 (GLUT9) having the strongest effect on serum urate levels 
(Phipps-Green et al., 2016). This strong association between ABCG2 and gout has also 
been seen in Japanese, Chinese, Mexican American, and other European populations (Table 
2.3), with evidence for a younger age of gout onset associated with this variant in a Japanese 
cohort (Kottgen et al., 2013; Matsuo et al., 2013; Matsuo et al., 2015; Zhang et al., 2013; 
Zhou et al., 2014). 
 
Associations between gout and SLC2A9 (GLUT9) and SLC22A12 (URAT1) were also 
observed in both the New Zealand European and Polynesian groups in the study by Phipps-
Green et al. (2014), whilst the SLC17A gene cluster was only associated in the New Zealand 
European cohort, consistent with serum urate association results (Phipps-Green et al., 
2016). These three genes have all associated with gout in Japanese cohorts (Table 2.1, Table 
2.2, and Table 2.4), whilst SLC2A9 and SLC22A12 have also associated with gout in 
Chinese cohorts, and SLC2A9 and the SLC17A gene cluster have associated with gout in 
other European cohorts (Dehghan et al., 2008; Kottgen et al., 2013; Li et al., 2014; Matsuo 
et al., 2015; Tu et al., 2010b; You et al., 2013). SLC22A12 has shown an inconsistent 
association with gout in European cohorts, with a study of Spanish individuals identifying 
a similar effect to that seen in the New Zealand European cohort (rs11231825: OR = 1.63, 
POR = 0.03; rs3825018: OR = 1.24, POR = 0.01; respectively, r2 = 1.00), whilst other studies 
of European individuals have not shown significant effects (rs505802: OR = 0.99, POR = 
0.78, r2 = 1.00) (Phipps-Green et al., 2016; Stark et al., 2009; Torres et al., 2012). 
SLC22A11 (OAT4) has shown a similar mixture of results in European studies, with the 
analysis by Phipps-Green et al. (2014) not reporting an association with gout, but the 
Spanish study by Torres et al. (2012) detecting a weak effect (OR = 1.85, POR = 0.02) 
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(Torres et al., 2012). A genome-wide association analysis of gout conducted alongside the 
Kottgen et al. (2013) serum urate genome-wide study also identified a nominally 
significant association between SLC22A11 and gout, but only in prevalent cases (OR = 
1.16, POR = 4.4×10-6) (Kottgen et al., 2013). PDZK1 has never shown a significant 
association with gout. 
 
Interestingly, in the analysis by Phipps-Green et al. (2014), GCKR (GKRP) had the third 
and fourth strongest association in Polynesian and New Zealand European individuals with 
gout, respectively (OR = 1.38, POR = 6.6×10-5; OR = 1.31, POR = 1.1×10-4). This same 
strong association has also been observed in Chinese and Japanese cohorts (Table 2.5) 
(Matsuo et al., 2015; Wang et al., 2012; Zhou et al., 2015). In addition, in the New Zealand 
European cohort PRKAG2 and PKLR, two genes encoding proteins involved in the glucose 
regulation pathway, are also strongly associated with gout (Phipps-Green et al., 2016). 
These results suggest this non-transporter pathway plays an important role in gout 
development. 
 
2.1.3.2. Gout Specific Associations 
With only an estimated 18% of people with hyperuricaemia developing gout (range 0% to 
71.7% (Gosling et al., 2014)), and video evidence showing differing responses to 
monosodium urate crystals by different people’s immune cells (Johnson, 2012a), it is 
evident that other elements than those that lead to raised serum urate levels are necessary 
for the development of gout. This aspect of gout genetics is not well understood. Recently 
several genome-wide association studies of gout have been performed in an attempt to find 
some of these other elements (Kottgen et al., 2013; Li et al., 2015; Matsuo et al., 2015; 
Sulem et al., 2011; Yang et al., 2010). Three of these genome-wide studies have been 
conducted in European individuals with self-reported or physician diagnosed gout 
alongside serum urate genome-wide studies. All three did not manage to find gout 
associations that were not also found in their serum urate analysis (Kottgen et al., 2013; 
Sulem et al., 2011; Yang et al., 2010). In contrast, two other studies have focused solely 
on performing a genome-wide analysis of clinically ascertained gout patients (Li et al., 
2015; Matsuo et al., 2015). Matsuo et al. (2015) compared the allele frequencies of 570,442 
SNPs in 1,993 Japanese gout cases (as ascertained by American College of Rheumatology 
criteria (Wallace et al., 1977)) to 2,547 normouricaemic Japanese controls, and identified 
six loci significantly associated with gout (Matsuo et al., 2015). Three of these associations 
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were in regions that are associated with serum urate levels (ABCG2, SLC2A9, and GCKR), 
whilst the other three were in novel locations. The study attributed these associations to the 
MYL2 and CUX2, CNIH-2, and MAP3K11 genes; however, these findings require further 
replication and functional analyses to confirm which genes within the associated regions 
are responsible for the detected effect and that these associations are independent of serum 
urate levels (Matsuo et al., 2015). This study also classified the individuals with gout into 
those who have renal under excretion type gout (n = 509) and those who have renal 
overload gout (n = 375) and compared the associations in these sub-groupings. 
Unsurprisingly, this analysis only found significant differences in association with SNPs 
involved in determining serum urate levels (SLC2A9: rs3775948, and ABCG2: 
rs2231142), as individuals are classified into these gout sub-types based on how they 
process uric acid (Ichida et al., 2012; Matsuo et al., 2015). The other genome-wide study 
of clinically ascertained gout cases was performed in Chinese individuals. This study 
initially performed a genome-wide analysis using a small cohort of 1,255 gout cases 
(ascertained using American College of Rheumatology criteria) and 1,848 healthy controls 
before attempting to replicate any nominal association (POR ≤ 5×10-5) that fell outside of a 
known serum urate-influencing locus in a larger cohort of 3,020 gout cases and 4,424 
healthy controls (Li et al., 2015). In addition, this study recruited a cohort of Chinese 
individuals who had serum urate levels in the hyperuricaemic range, had never taken urate-
lowering medications, had been hyperuricaemic for at least ten years, and had never 
developed gout. These controls were used to confirm that the associations found within this 
study were relevant to gout risk and not to serum urate levels (Li et al., 2015). Three novel 
loci were identified, one on chromosome 9 (9p24.2), one on chromosome 11 (11p15.5), 
and one on chromosome 17 (17q23.2). The authors of this study did not attempt to assign 
these results to the effect of a particular gene, preferring to discuss the potential candidate 
inflammatory genes within each region (Li et al., 2015). 
 
2.1.3.3. Inflammasome Genes 
Targeted analyses of genes in the inflammasome have also been conducted to assess the 
contribution of these genes to acute gout attack onset (Chen et al., 2015; McKinney et al., 
2015; Qing et al., 2013). A multitude of proteins are involved in innate immunity and 
several of these have shown some evidence of association with gout. Functional analyses 
indicate the TLR4 (toll-like receptor 4) protein is involved in inflammation in response to 
monosodium urate crystals and the rs2149356 variant within the TLR4 gene has been 
Gout in New Zealand 
Page | 53 
associated with gout in the presence of hyperuricaemia (Liu-Bryan et al., 2005; Qing et al., 
2013; Rasheed et al., 2014b). Additionally, this variant has been associated with serum IL-
1β levels (a pro inflammatory cytokine) in Chinese individuals, and the IL1B gene which 
encodes (IL)-1β, the precursor form of IL-1β, has also been weakly associated with gout in 
Polynesian individuals (McKinney et al., 2015; Qing et al., 2013). A third gene, CARD8, 
which encodes a protein that is involved in the regulation of the conversion of (IL)-1β to 
active IL-1β and the subsequent secretion of this molecule has also been associated with 
gout in Chinese and Polynesian individuals (Chen et al., 2015; McKinney et al., 2015). 
Collectively this supports the experimental evidence that the release of active IL-1β in 
response to TLR mediated activation of an inflammatory cascade is central to gout 
development; however, this aspect of gout genetics is not as well understood as the serum 
urate-influencing genes and pathways. 
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Section 2.2. Association Analysis of the SLC22A11 
(OAT4) and SLC22A12 (URAT1) Uric Acid Transporter 
Locus in a New Zealand Gout Case-Control Cohort. 
A reduced version of the analyses in this section was published in Arthritis Research & 
Therapy in 2013: 
Flynn TJ, Phipps-Green A, Hollis-Moffatt JE et al. (2013) Association analysis of the SLC22A11 (organic anion 
transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control 
sample sets reveals multiple ancestral-specific effects. Arthritis Research & Therapy, 15(6): R220. 
 
2.2.1. Background 
In January 2012, multiple SNPs across chromosome 11 had been significantly associated 
with serum urate in genome-wide association studies of African American, European, and 
Japanese individuals. (Kamatani et al., 2010; Kolz et al., 2009; Kottgen et al., 2013; Tin et 
al., 2011; Yang et al., 2010)1. These SNPs fell within a 1.7 Mb region of chromosome 11 
containing the uric acid transporter gene pair – SLC22A11 (OAT4) and SLC22A12 
(URAT1). The SNP with the strongest association in these studies varied, with the African 
American study identifying a missense variant within SLC22A12 as the “top-hit” 
(rs12800450: G65W), whilst the Japanese study identified a SNP downstream of 
SLC22A12 (rs506338: 71 kb downstream, within NRXN2 (Neurexin 2)) (Kamatani et al., 
2010; Tin et al., 2011). The three European studies all identified an intronic variant within 
SLC22A11 as the most associated SNP (rs17300741 or rs2078267, r2 = 0.96), whilst two 
of these studies also listed SNPs near SLC22A12 as having a strong effect independent of 
that seen at SLC22A11 (rs505802: 12.7 kb upstream of SLC22A12, and rs478607: 108.2 kb 
downstream in NRXN2) (Kolz et al., 2009; Kottgen et al., 2013; Yang et al., 2010). 
Targeted association studies had also identified significant associations between SLC22A12 
gene variants and serum urate in Chinese and Korean sample sets, whilst no non-European 
study had reported an association in SLC22A11 (Jang et al., 2011; Jang et al., 2008; Li et 
al., 2010). These studies, along with the low linkage disequilibrium (average r2 = 0.05) 
between the SLC22A11 and SLC22A12 genes, suggested a complex ancestry-specific 
pattern of association between this gene region and serum urate. 
                                                
1 Analyses were expanded to include the results of Kottgen et al. (2013) after the online publication was 
released in December 2012. 
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Several studies had also tested SLC22A11 and SLC22A12 SNPs for a role in gout risk. In 
European individuals no association of the SLC22A12 serum urate associated variants 
rs505802 (POR = 0.78) or rs478607 (POR = 0.41) had been identified (Kottgen et al., 2013; 
Stark et al., 2009). In Chinese sample sets a similar lack of association had been reported 
(rs893006: POR = 0.35, in complete linkage disequilibrium with rs505802) (Guan et al., 
2009). However, another common SLC22A12 variant in low linkage disequilibrium (r2 = 
0.33) with these SNPs had shown a significant protective effect in a different Chinese 
sample set (rs475688: OR = 0.51, POR = 0.01) (Tu et al., 2010a). Rare non-synonymous 
variants in SLC22A12 had also been tested for association with gout in African American 
and Japanese individuals. The missense mutation (rs12800450: G69W) identified in the 
genome-wide association analysis of African American individuals conveyed no protection 
against gout (POR = 0.20) despite its significant serum urate-lowering effect, whilst a 
nonsense mutation (rs121907892: W258X) in 2% of Japanese individuals associated with 
a significant reduction in risk of prevalent gout (OR = 0.00, POR = 2.0×10-3) (Taniguchi et 
al., 2005; Tin et al., 2011). 
 
The two intronic SNPs within SLC22A11 identified through genome-wide association 
studies had also been tested for association with gout, with rs2078267 associating with 
prevalent gout (OR = 1.16, POR = 4.4×10-6) in European individuals, but rs17300741 
showed no evidence for association with gout in another European cohort (OR = 1.02, POR 
= 0.80), despite the strong linkage disequilibrium between these two variants (Kottgen et 
al., 2013; Stark et al., 2009). As with serum urate, no studies had assessed the association 
of SLC22A11 variants with gout in non-European populations at this time. Ambiguity 
surrounding the associations of SLC22A11 and SLC22A12 with gout was evident within 
the research available in January 2012. Reports had studied different population groups, of 
vastly different sizes, and with both candidate SNP and genome-wide approaches. But one 
major difference between these studies was the methods used to determine gout status. 
 
The “gold standard” for gout diagnosis is the detection of monosodium urate crystals 
within the synovial fluid of joints during an acute gout attack (sensitivity 95.3%, specificity 
97.2%) (Dalbeth et al., 2013a; Lumbreras et al., 2005; Wijnands et al., 2011). However, 
there are many barriers within the clinical setting that prevent this test from being 
conducted (eg. lack of expertise, lack of time, lack of necessary equipment) (Wijnands et 
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al., 2011). These barriers are further compounded during the collection of large cohorts for 
epidemiological studies, the recognition of which has lead to the creation of several gout 
classification criteria (Dalbeth et al., 2013a; Wijnands et al., 2011). A range of these criteria 
had been variably applied in the published genetic studies of gout available in January 
2012; with self-report or use of gout medications (Kottgen et al., 2013; Tin et al., 2011; 
Yang et al., 2010); a combination of self-report, general practitioner diagnosis, and 
examination of medical records (Stark et al., 2009); or the clinical ascertainment of gout 
using the 1977 American College of Rheumatology (ACR; previously known as American 
Rheumatism Association) criteria being used across the various studies (Guan et al., 2009; 
Taniguchi et al., 2005; Tu et al., 2010a). 
 
Table 2.6: Gout classification criteria sensitivity and specificity. 
Study Classification Size Sensitivity Specificity PPV 
Fraction 
Correct 




















































Each classification criteria is compared to gout diagnosis through the identification of monosodium urate 
crystals with joint synovial fluid during an acute attack. In (Lumbreras et al., 2005) identification of 
monosodium urate crystals by recently trained clinicians was compared to classification by an experienced 
rheumatologist. Sensitivity – percentage of true positives identified. Specificity – percentage of true negatives 
identified. PPV – positive predictive value, the percentage of true positives within all positive test results. 
Fraction correct – percentage agreement between the classification criteria and the “gold standard”. GP – 
general practitioner/family physician. ACR – American College of Rheumatology. MSU – monosodium 
urate. 
 
Assessments of these different classification criteria have shown moderate sensitivity (> 
60%) and specificity (> 60% for self-report and American College of Rheumatology 
criteria, 28% for general practitioner diagnosis) when compared to the “gold standard” of 
crystal identification (Table 2.6) (Janssens et al., 2010a; Janssens et al., 2010b; Malik et 
al., 2009; Richette et al., 2015). Arguably the most important characteristic of a disease 
classification criterion for use in genetic studies is the reduction in the classification of both 
Gout in New Zealand 
Page | 57 
false negatives and false positives (as reflected by a high “fraction correct”), as the power 
to detect a real association is reduced by the incorrect classification of both cases and 
controls (Brenner and Savitz, 1990; Mote and Anderson, 1965). Both self-report of gout 
status and the application of the American College of Rheumatology classification criteria 
appear to be reliable in this respect (Table 2.6), whilst the lower “fraction correct” (66.9%) 
and extremely low specificity (27.9%) of general practitioner diagnosis make this the least 
favourable classification for use (Janssens et al., 2010a). Reliability of self-reported gout 
status does; however, seem to be dependent on disease progression or duration, with the 
gout patients who were receiving treatment from a trained rheumatologist (studied by 
Richette et al. (2015)) reporting their gout status with a much higher sensitivity (90.2% vs. 
61.2%) and specificity (81.7% vs. 69.7%) than those treated only by their family physician 
(studied by Janssens et al. (2010)). Interestingly, the positive predictive value reported in 
these two studies was equivalent (Table 2.6).  
 
In response to the evident ambiguity of gout associations at variants within both SLC22A11 
(OAT4) and SLC22A12 (URAT1), the lack of association tests in non-European individuals 
at SLC22A11, and the variety of different sub-optimal gout classification criteria used in 
many of the studies available in January 2012, this work aimed to clarify the association 
between gout (according to the American College of Rheumatology classification criteria) 
and variants from the 1.7 Mb region of chromosome 11 containing SLC22A11 and 
SLC22A12. Specifically, it aimed to test the hypothesis that common, haplotype defining 
variants within the SLC22A11 and SLC22A12 locus independently influence gout risk in 
multiple ancestral groups drawn from the New Zealand population, including Māori and 
Pacific Island individuals. 
 
2.2.2. Patients and Methods 
2.2.2.1. Study Participants 
Individuals from the New Zealand Gout Case-Control Cohort (detailed further in Appendix 
A.1; page 255) were included in this analysis. In January 2012 the New Zealand Gout Case-
Control Cohort consisted of 1,003 gout cases and 1,156 controls. All gout cases fulfilled 
the American College of Rheumatology classification criteria. Individuals who partially 
fulfilled the classification criteria or who reported having diuretic induced gout were 
excluded from analyses. The controls consisted of 452 individuals who self-reported no 
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history of gouty arthritis during their recruitment into the New Zealand Gout Case-Control 
Cohort and 704 additional controls. The additional controls were individuals recruited as 
part of another study focused on the genetic risk factors for rheumatoid arthritis (Hollis-
Moffatt et al., 2009a). 505 European people, 75 Māori people, and 38 Pacific Island people 
were recruited as controls for this study and self-reported no history of arthritis, whilst 69 
Māori and 17 Pacific Island people had a confirmed diagnosis of rheumatoid arthritis by a 
rheumatologist and were diagnosed according to the 1987 American College of 
Rheumatology criteria for rheumatoid arthritis (Arnett et al., 1988). As there is a widely 
accepted lack of co-existence between gout and rheumatoid arthritis (only 15 concurrent 
cases of gout and rheumatoid arthritis were reported between 1964 and 1996; Zonana-
Nacach et al., 1996) these patients were able to serve as a valid control group for this gout 
genetic association study. Recruitment of rheumatoid arthritis patients was approved by the 
NZ Multi-Region Ethics Committee (OTA/99/02/007) and recruitment of the additional 
controls was approved by the Lower South Ethics Committee (OTA/99/11/098). A brief 
demographic summary of the cohort is presented in Table 2.7. 
 
Participants were divided into four sample sets according to their self-reported 
grandparental ancestry: New Zealand European individuals – Pākehā, British/Irish, Dutch, 
German, Australian (420 cases, 638 controls); Eastern Polynesian – New Zealand Māori, 
Cook Island Māori, and Tahitian (315 cases, 349 controls); Western Polynesian – Tongan, 
Samoan, Tokelauan, and Niuean (249 cases, 144 controls); and a small mixed Eastern and 
Western Polynesian ancestry group (19 cases, 25 controls). These groupings were based on 
previous evidence for genetic heterogeneity between individuals from Eastern and Western 
Polynesia found in both genome-wide analyses of population structure in the Pacific 
(Friedlaender et al., 2008; Kayser et al., 2006; Wollstein et al., 2010), and more specifically 
in prior work published by the Merriman Laboratory (Phipps-Green et al., 2010). Groups 
were defined using a hierarchy system, with individuals of any Polynesian ancestry being 
included in their respective group first before those individuals with any other ancestry 
(such as, Indian, Chinese, or Fijian) were excluded. The individuals included in the New 
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Table 2.7: Demographic details of the New Zealand Gout Case-Control Cohort (2012). 
 
 Polynesian  European 
 Gout (583) Non-Gout (518)  Gout (420) Non-Gout (638) 
Baseline Information 
Sex (% Female)  87 (14.92%) 301 (58.11%)  69 (16.43%) 364 (57.05%) 
Age (Years)  51 ± 13 41 ± 14  61 ± 13 45 ± 17 
BMI (kg/m2)  36.13 ± 8.18 33.06 ± 7.36  30.33 ± 5.18 27.70 ± 5.68 
Serum Urate (µmolL-1)  420.67 ± 114.79 353.93 ± 84.75  369.97 ± 106.83 288.97 ± 76.80 
Relative with Gout  346 (59.35%) 132 (25.48%)  201 (47.86%) 23 (3.61%) 
Ancestry 
East Polynesian  315 (54.03%) 349 (67.37%)  - - 
West Polynesian  249 (42.71%) 144 (27.80%)  - - 
Grandparental Ancestry (%)  86.17 ± 22.09 69.57 ± 30.17  96.95 ± 12.26 98.40 ± 8.89 
Self-Reported Co-morbidities 
Diabetes  113 (19.39%) 40 (7.72%)  62 (14.76%) 22 (3.45%) 
High Blood Pressure  271 (46.48%) 68 (13.13%)  199 (47.38%) 92 (14.42%) 
High Cholesterol  264 (45.28%) 49 (9.46%)  197 (46.90%) 81 (12.70%) 
Heart Problems  153 (26.24%) 23 (4.44%)  140 (33.33%) 41 (6.43%) 
Kidney Problems  112 (19.21%) 3 (0.58%)  81 (19.29%) 3 (0.47%) 
Gout Severity 
Age at Onset  37 ± 14 -  47 ± 16 - 
Years since Diagnosis  13.40 ± 10.76 -  14.84 ± 12.10 - 
Urate at Diagnosis (µmolL-1)  545.60 ± 119.59 -  480.07 ± 122.65 - 
On Urate-Lowering 
Medication 
 419 (71.87%) -  308 (73.33%) - 
Number of Attacks  11.39 ± 30.03 -  6.49 ± 20.96 - 
Tophi Present  238 (40.82%) -  154 (36.67%) - 
Total number of participants is shown in brackets. Data are shown as the mean ± standard deviation, or as 
number of participants (percentage). 
 
The Eastern Polynesian sample set (85.1% New Zealand Māori) was further split into two 
groups to compensate for the distinctly different number of self-reported Polynesian 
grandparents in the case and control samples (average = 3.2 Eastern Polynesian 
grandparents in cases and 2.5 Eastern Polynesian grandparents in controls, t = 7.6, Pt = 
1.6×10-13). As the prevalence of gout in New Zealand Māori individuals is much higher 
than in New Zealand European individuals and the New Zealand Māori population is highly 
admixed, incorporating a significant level of European genetic variability into the 
population (genome-wide microsatellite data for 30 New Zealand Māori individuals 
estimated ~15% of markers were derived from European lineages with the remaining ~85% 
being derived from Polynesian lineages (Friedlaender et al., 2008)) it is unsurprising that 
individuals with a higher percentage of European ancestry are somewhat protected from 
developing gout. Without compensation for this known difference between cases and 
controls, any genetic analysis in this dataset would be significantly confounded, therefore 
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the Eastern Polynesian sample set was split into two groups with similar levels of Eastern 
Polynesian ancestry levels (a high ancestry and low ancestry group). 
 
To determine which individuals should be included in the two groups, genotypes for 67 bi-
allelic ancestry-informative markers were obtained (through TaqMan® or MassArray 
Sequenom genotyping; Appendix Table B.1; page 263) and estimates of individual Eastern 
Polynesian ancestry proportion were calculated in STRUCTURE 2.0 (Pritchard et al., 
2000). STRUCTURE ancestry estimates were calculated assuming a maximum of two 
populations (European and Polynesian); a burn in period of 30,000; 1,000,000 Markov 
chain Monte Carlo iterations; and the controls from the New Zealand European sample set 
as an ancestral reference population to aid population clustering (an Eastern Polynesian 
ancestral reference population could not be added in this analysis). 
 
Table 2.8: Reported and estimated fraction of Polynesian and European ancestry. 
Sample Set Affection 
Polynesian  European  Other 
Reported Estimated  Reported Estimated  Reported 
East Polynesian 
Case 0.79 ± 0.26 0.82 ± 0.21  0.18 ± 0.25 0.18 ± 0.22  0.03 ± 0.11 
Control 0.61 ± 0.30 0.67 ± 0.27  0.35 ± 0.31 0.33 ± 0.27  0.04 ± 0.12 
East Polynesian (High) 
Case 0.87 ± 0.18 0.91 ± 0.09  0.09 ± 0.16 0.09 ± 0.09  0.03 ± 0.12 
Control 0.80 ± 0.23 0.89 ± 0.09  0.16 ± 0.22 0.11 ± 0.09  0.04 ± 0.11 
East Polynesian (Low) 
Case 0.45 ± 0.25 0.43 ± 0.17  0.53 ± 0.25 0.57 ± 0.17  0.02 ± 0.08 
Control 0.39 ± 0.21 0.42 ± 0.17  0.58 ± 0.24 0.58 ± 0.17  0.04 ± 0.12 
West Polynesian 
Case 0.93 ± 0.15 -  0.03 ± 0.10 -  0.04 ± 0.11 
Control 0.88 ± 0.21 -  0.06 ± 0.15 -  0.06 ± 0.14 
East/West Polynesian 
Case 0.89 ± 0.18 -  0.10 ± 0.18 -  0.01 ± 0.03 
Control 0.72 ± 0.27 -  0.22 ± 0.24 -  0.06 ± 0.12 
New Zealand European 
Case 0.00 ± 0.00 -  0.97 ± 0.12 -  0.03 ± 0.12 
Control 0.00 ± 0.00 0.01 ± 0.02  0.99 ± 0.06 0.99 ± 0.02  0.01 ± 0.06 
Data are presented as mean ± standard deviation. Reported – number of grandparents listed divided by four. 
Estimated – based on the STRUCTURE ancestry estimates. East Polynesian (High) – Eastern Polynesian 
individuals with a high estimated level of Polynesian ancestry (≥ 0.67). East Polynesian (Low) – Eastern 
Polynesian individuals with a low estimated level of Polynesian ancestry (< 0.67). 
 
Estimated and reported Polynesian ancestry levels had a correlation of 73.1% (t = 25.4, Pt 
= 3.3×10-95), and the significant difference in ancestry levels between Eastern Polynesian 
cases and controls was maintained in the ancestry estimates (average = 0.82 in cases and 
0.67 in controls, t = 7.8, Pt = 1.8×10-14; Table 2.8). Individuals with an estimated ancestry 
≥ 0.67 (the geometric mean of the cases and controls together) formed the Eastern 
Polynesian high ancestry sub-set (256 cases, 187 controls) and those with an estimated 
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ancestry < 0.67 formed the Eastern Polynesian low ancestry sub-set (59 cases, 162 
controls). 
 
2.2.2.2. Variant Selection 
Haplotype blocks based on the linkage disequilibrium for all SNPs previously associated 
with serum urate in genome-wide association studies within the 1.7 Mb region of 
chromosome 11 were defined using the 1000 Genomes phase II data 
(www.1000genomes.org) for European (“CEU”: Utah residents with Northern and 
Western European ancestry) and Chinese samples (“CHB”: Han Chinese in Beijing, 
China); as the most closely related and available population to the New Zealand Māori and 
Pacific Island populations (Figure 2.2). Four distinct haplotype blocks were identified 
(Block 1: ~26 kb upstream, Block 2: SLC22A11, Block 3: SLC22A12 and downstream 
genes, and Block 4: ~840 kb downstream) and this information was then used to select 
variants representing each haplotype block. 
 
For block 1 and block 4 both the variant most associated with serum urate (rs17299124: Pβ 
= 8.6×10-16 and rs642803: Pβ = 4.5×10-14, respectively) and the most associated “tag-SNP” 
– in high linkage disequilibrium with all other associated SNPs (rs475414: Pβ = 3.1×10-12 
and rs12289836: Pβ = 6.6×10-14, respectively) were chosen (Kolz et al., 2009; Kottgen et 
al., 2013; Tin et al., 2011; Yang et al., 2010). For block 2 (SLC22A11) one “tag-SNP” 
common to the 1000 Genomes European and Chinese samples was identified (rs693591) 
and combined with the previously studied variants rs17300741 and rs2078267 (Kottgen et 
al., 2013; Yang et al., 2010). One “tag-SNP” for block 3 (SLC22A12) was selected 
(rs476037) and included with the previously studied SNPs rs3825018 (in complete linkage 
disequilibrium with rs505802), rs475688, and rs7932775 (Kottgen et al., 2013; Yang et al., 
2010). A fifth variant (rs478607: Pβ = 4.4×10-11) from block 3 was also added to represent 
the second independent (of SLC22A11), but weaker effect reported by Kottgen et al. (2013) 
(Kottgen et al. 2013). 
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Figure 2.4: Inter-marker linkage disequilibrium in European (A) and Chinese (B) 
samples for all chromosome 11 variants previously associated with serum urate. 
 
 
Figures generated using Haploview 4.2. European data is from the 1000 Genomes “CEU” population (Utah 
residents with Northern and Western European ancestry) and Chinese data is from the 1000 Genomes “CHB” 
population (Han Chinese in Beijing, China). Approximate gene positions are marked (SLC22A11: left, 
SLC22A12: right) along with defined linkage disequilibrium blocks in red (Block 1: left, 49.5 kb; Block 2: 















Block 1 (Upstream) Block 2 (SLC22A11) Block 3 (SLC22A12) Block 4 (Downstream)
A 
B 
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Table 2.9: Haplotype block summary and representative variants. 
Haplotype Start End Genes SNP Position Reason 
Block 1 64223527 64273034 - 
rs475414 64241844 “tag-SNP” 
rs17299124 64256859 most assoc 
Block 2 64299330 64334114 SLC22A11 
rs693591 64325069 “tag-SNP” 
rs17300741 64331462 previous assoc 
rs2078267 64334114 previous assoc 
Block 3 64351721 64581658 
SLC22A12, NRXN2, 
RASGRP2, PYGM, SF1, 
MAP4K2, MEN1 
rs3825018 64358809 previous assoc 
rs475688 64364291 previous assoc 
rs7932775 64367862 previous assoc 
rs476037 64369540 “tag-SNP” 
rs478607 64478063 most assoc 
Block 4 65419364 65566719 
RELA, KAT5, PP1030, 
RNASEH2C, OVOL1 
rs12289836 65436888 “tag-SNP” 
rs642803 65560620 most assoc 
Haplotype block start and end positions are based on the most upstream and most downstream SNPs included 
in the block. Base position is according to Genome Reference Consortium human genome build 37 
(GRCh37). Genes within the block region according to Ensembl and HapMap data are included. “tag-SNP” 
– in high linkage disequilibrium with all other associated variants. 
 
None of the chosen variants were in high linkage disequilibrium with each other in the 
European (1000 Genomes and New Zealand), Chinese (1000 Genomes), and Polynesian 
(New Zealand) data (Figure 2.5). Three of the chosen variants have a known or predicted 
biological function according to the National Institutes of Health (NIH) web look up tool 
FuncPred (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm); rs3825018 is situated in a 
potential transcription factor binding site and may enhance or silence splicing, rs7932775 
may also enhance or silence splicing, and rs476037 is situated at a potential micro RNA 
binding site. In addition rs17299124 is located within a DNase hypersensitivity region 
identified in renal tissues (Section 2.3). 
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Figure 2.5: Inter-marker linkage disequilibrium between the 12 genotyped variants 
in the 1000 Genomes (European (A) and Chinese (B)) and New Zealand (European 
(C) and Polynesian (D)) genotype data. 
   
   
Figures generated using Haploview 4.2. European data is from the 1000 Genomes “CEU” population (Utah 
residents with Northern and Western European ancestry) and the New Zealand Gout Case-Control Cohort 
(2012). Chinese data is from the 1000 Genomes “CHB” population (Han Chinese in Beijing, China). 
Polynesian data is from the New Zealand Gout Case-Control Cohort (2012). Linkage disequilibrium blocks 
are shown in red. 
 
2.2.2.3. Genotyping 
The chosen variants were genotyped using either TaqMan® assays (ThermoFisher 
Scientific, Waltham) in a Lightcycler® 480 Real-Time PCR System (Roche, Indianapolis) 
(rs17300741: assay ID C_3234214_10; rs3825018: C_27162391_10; rs475688: 
C_925797_10; rs476037: C_3108662_20; rs693591: C_925815_10; rs7932775: 
C_3108664_10), or the MassArray system (Sequenom iPLEXassay, San Diego): 
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2.2.2.4. Single Variant Association Analysis 
Allelic odds ratios (OR) for each SNP were obtained for each sample set using sex-adjusted 
logistic regressions in PLINK 1.07 (Purcell et al., 2007b). These were relevant to the allele 
in-phase with the rs3825018 G allele, where possible, as determined using the European 
1000 Genomes linkage disequilibrium data. Individuals with missing or partial data were 
excluded. 
 
Inverse-variance weighted fixed-effect meta-analysis to combine the independent sample 
sets was performed in STATA 8.0 (http://www.stata.com/). A Q-statistic was calculated to 
determine the heterogeneity between combined sample sets. For those SNPs with 
significant evidence for heterogeneity (PQ < 0.05), the fixed-effect model was replaced with 
a random-effect model. 
 
2.2.2.5. Simple Haplotype Association Analysis 
All SNPs from within a linkage disequilibrium block were included in the calculation of 
“most likely haplotype calls” for each individual using the default settings of the haplotype 
imputation by expectation maximisation function (--hap-impute) in PLINK. The 
imputation was performed on each sample set separately and haplotypes with a frequency 
< 0.01 were excluded. A new map and pedigree file set was created during haplotype 
imputation. These contained two columns for each possible haplotype and individuals were 
given a code indicating the presence or absence of the specified haplotype as shown in 
Equation 2.1. 
 
Equation 2.1: Example of haplotype imputation coding within the PLINK pedigree 
file for the T|A haplotype at linkage disequilibrium block 1. 
column one = 1	have T|A													2	have C|C or T|C 
column two = 1	have T|A													2	have C|C or T|C 
These two columns combine to create an equivalent genotype 
genotype =
  homozygous for 1
heterozygous      
  homozygous for 2
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Imputed haplotypes were then treated as bi-allelic markers and sex-adjusted logistic 
regressions were performed in PLINK to obtain the odds ratio for the effect of each 
haplotype within a linkage disequilibrium block compared to all other haplotypes within 
the block. Inverse-variance weighted fixed-effect meta-analysis was performed in STATA 
to combine the independent datasets as described for the single variant allelic association 
analysis (above). Individuals with no genotype call for any of the SNPs in the haplotype 
being imputed, were excluded from analyses. 
 
2.2.2.6. Conditional Haplotype-Based Analysis 
To test for independent effects between each haplotype block, conditional haplotype-based 
sex-adjusted association tests (--chap) were performed specifying the independent effect 
parameter (--independent-effect) in PLINK (Purcell et al., 2007a). These functions 
compared each haplotype block with each other haplotype block, creating new haplotypes 
from all the SNPs within the two blocks being compared and comparing the effect of these 
new haplotypes (alternate hypothesis: dependent effects) to those within a single block (null 
hypothesis: independent effect). This comparison calculated p-values for each possible 
haplotype within each block (Psub). An overall p-value (Pall) based on a likelihood ratio test 
was also calculated to reflect the level of independence between the two blocks being 
compared.  
 
2.2.2.7. Statistical Significance and Study Power 
A p-value of (POR < 0.05) was considered nominally significant in all analyses. The 
experiment-wide significance threshold was defined by applying a Bonferroni correction 
to the single variant and simple haplotype association analyses. For the single variant 
analysis, a correction factor of 60 was applied based on the testing of 12 SNPs across five 
sample sets (POR < 8.3×10-4). In the simple haplotype analysis, a correction factor of 15 
was applied reflecting three haplotype blocks tested in five sample sets (POR < 3.0×10-3). 
In all regression analyses, individuals with missing or partial data were disregarded. 
 
Study power was calculated for a nominal p-value of POR = 0.05 (Johnson et al., 2001). All 
sample sets were adequately powered (> 80%) to detect moderate effects (OR = 1.5) at a 
minor allele frequency > 0.1 (Figure 2.6). 
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Figure 2.6: Detection power in New Zealand European (A) and Polynesian (B) sample 
sets across a range of minor allele frequencies and odds ratio effect sizes. 
   
Power calculations were based on 420 cases and 638 controls in New Zealand European and 583 cases and 
518 controls in Polynesian. 
 
2.2.3. Results  
2.2.3.1. Single Variant Allelic Associations 
The New Zealand European sample set revealed nominally significant (POR < 0.05) 
associations with gout at two linkage disequilibrium block 3 variants (SLC22A12): 
rs475688 (OR = 1.26, POR = 0.04) and rs7932775 (OR = 1.32, POR = 0.03; Table 2.10). The 
Eastern Polynesian high ancestry sample set revealed four nominally significant 
associations within linkage disequilibrium block 1 (upstream) (rs17299124: OR = 2.77, 
POR = 0.02); linkage disequilibrium block 2 (SLC22A11) (rs693591: OR = 1.41, POR = 
0.03); and two linkage disequilibrium block 3 variants, (rs3825018: OR = 1.46, POR = 0.03; 
and rs476037: OR = 1.56, POR = 0.02); whereas the Eastern Polynesian low ancestry sample 
set showed no significant associations. The Western Polynesian sample set revealed a 
similar association to the Eastern Polynesian high ancestry group at the linkage 
disequilibrium block 1 SNP rs17299124 (OR = 5.65, POR = 0.01) and the New Zealand 
European group at the linkage disequilibrium block 3 SNP rs7932775 (OR = 1.49, POR = 
0.02). The mixed Eastern and Western Polynesian sample set revealed a single, strong 
susceptibility effect at rs693591 (OR = 4.55, POR = 0.03; Table 2.10). None of these 
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Polynesian (High)  Polynesian  All Ancestries 
OR 
[95% CI] POR PQ  
OR 
[95% CI] POR PQ  
OR 
[95% CI] POR PQ 
Block 1 (Upstream) 
rs475414 T/C 1.15 
[0.92; 1.43] 
0.23 0.73  1.12 
[0.92; 1.34] 






-04 0.67  
1.95 
[1.21; 3.15] 0.01 0.15  
1.71 
[0.89; 3.28] 0.11 0.01 
Block 2 (SLC22A11) 
rs693591 C/G 1.25 
[1.00; 1.57] 
0.05 0.05  1.23 
[1.00; 1.51] 





[0.78; 1.38] 0.79 0.17  
1.10 
[0.86; 1.40] 0.47 0.25  
1.07 




0.01 0.80  
1.51 
[1.06; 2.14] 








0.02 0.57  
1.34 
[1.08; 1.66] 







0.68 0.22  
1.03 
[0.84; 1.27] 







0.10 0.26  
1.23 
[1.00; 1.51] 







0.48 0.01  
1.19 
[0.75; 1.89] 




rs478607 G/A 1.04 
[0.79; 1.36] 
0.79 0.15  1.13 
[0.88; 1.44] 
0.34 0.11  1.19 
[1.00; 1.43] 
0.06 0.17 
Block 4 (Downstream) 
rs12289836 A/G 0.89 
[0.70; 1.13] 
0.33 0.72  0.91 
[0.73; 1.14] 
0.42 0.79  0.88 
[0.76; 1.02] 
0.09 0.86 
rs642803 T/C 0.95 
[0.76; 1.19] 
0.66 0.86  1.00 
[0.81; 1.23] 
0.98 0.73  0.96 
[0.84; 1.11] 
0.59 0.82 
Linkage disequilibrium blocks are defined as shown in Figure 2.4 and Table 2.9. Polynesian (High) – includes 
the Eastern Polynesian high ancestry, Western Polynesian, and mixed Eastern and Eastern Polynesian 
samples sets. Polynesian – also includes the Eastern Polynesian low ancestry sample set. All odds ratios are 
calculated relevant to the effect allele defined as the allele in-phase with rs3825018 G allele according to 
1000 Genomes linkage disequilibrium data. OR – inverse-variance weighted meta-analysis odds ratio 
(adjusted for sex). 95% CI – 95% confidence intervals. POR – meta-analysis p-value. PQ – Q-statistic p-value, 
the fixed-effect model was replaced with a random-effect model if PQ < 0.05. 
 
Inverse-variance weighted meta-analysis combining all four Polynesian sample sets 
produced nominally significant associations at variants within linkage disequilibrium 
blocks 1, 2, and 3 (rs17299124: OR = 1.95, POR = 0.01; rs2078267: OR = 1.51, POR = 0.02; 
and rs3825108: OR = 1.34, POR = 0.01). By combining only the high ancestry Polynesian 
sample sets (Eastern Polynesian high ancestry, Western Polynesian, and mixed Eastern and 
Western Polynesian), the association at linkage disequilibrium block 1 was strengthened 
(rs17299124: OR = 3.38; POR = 6.1×10-4), producing an experiment-wide significant 
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association. The effect seen with this variant appeared to be Polynesian specific (New 
Zealand European: OR = 0.91, POR = 0.40) with the heterogeneity p-value (PQ) for 
rs17299124 in the meta-analysis combining all five sample sets indicating a significant 
difference between sample sets (PQ = 0.01). Similarly, the effect seen between the block 2 
(SLC22A11) SNP rs2078267 and gout was only present in the Polynesian sample sets and 
the association was slightly strengthened when the Eastern Polynesian low ancestry 
individuals were not included in the combined analysis, although this strengthening was 
mild compared to that seen at rs17299124 (rs2078267: OR = 1.84, POR = 0.01). 
Susceptibility effects approaching experiment-wide significance were seen in the block 3 
variants rs3825018 and rs7932775 when all five sample sets were combined (OR = 1.27, 
POR = 1.6×10-3; OR = 1.26, POR = 4.1×10-3, respectively; Table 2.11). 
 
2.2.3.2. Simple Haplotype Association Analysis 
Haplotype analysis revealed several nominally significant associations within the 
individual sample sets (Table 2.12). Within block 1 both the Eastern Polynesian high 
ancestry and Western Polynesian sample sets showed evidence for an association with a 
rare protective haplotype in linkage disequilibrium block 1 (rs475414 | rs17299124 – T|A: 
OR = 0.35, POR = 0.02; and OR = 0.12, POR = 0.01; respectively). The effect direction of 
the Eastern Polynesian low ancestry and mixed Eastern and Western Polynesian sample 
sets for this haplotype were equivalent although non-significant (OR = 0.81, POR = 0.53; 
and OR = 0.33, POR = 0.46; respectively). No haplotype within block 1 in the New Zealand 
European sample set showed any sign of association (OR ≈ 1.00) and the T|A haplotype 
was observed at a much higher frequency than in the high ancestry Polynesian sample sets 
(haplotype frequency = 0.25 and 0.03, respectively).  
 
At linkage disequilibrium block 2 (SLC22A11), a single nominally significant association 
was seen in the Western Polynesian sample set for the rs693591 | rs17300741 | rs2078267 
– G|G|C haplotype (OR = 1.72, POR = 0.03) which was not seen in any of the other 
Polynesian sample sets (OR ≈ 1.00). The New Zealand European sample set had a 
haplotype frequency below the imputation cut-off threshold (frequency < 0.01) for this 
particular combination of alleles (Table 2.12). Linkage disequilibrium block 3 had evidence 
for a single haplotype association in the separate sample sets, with the rs3825018 | rs475688 
| rs7932775 | rs476037 | rs478607 – G|T|C|G|G haplotype producing a nominally significant 
susceptibility effect in the New Zealand European and low ancestry Eastern Polynesian 
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sample sets (OR = 1.33, POR = 0.04; and OR = 2.03, POR = 0.04; respectively). The three 
high ancestry Polynesian sample sets all showed a consistent protective direction of effect 
at this haplotype (OR = 0.31 to 0.64), although these were non-significant (Table 2.12). 
 
By combining the haplotype association results of all four Polynesian sample sets, 
nominally significant associations were seen within all three linkage disequilibrium blocks 
(Table 2.13). At block 1, both a risk (rs475414 | rs17299124 – T|C: OR = 1.29, POR = 0.02) 
and a protective haplotype (T|A: OR = 0.50, POR = 0.01) were identified, following the 
effect direction of rs17299124. When only the high ancestry Polynesian sample sets were 
combined, the T|A haplotype showed a much stronger association (OR = 0.28, POR = 
6.0×10-4), reaching experiment-wide significance. The T|C association remained 
approximately the same (OR = 1.30, POR = 0.02). Neither haplotype showed a significant 
association when the New Zealand European sample set was added, and the T|A haplotype 
had a significant heterogeneity p-value (PQ = 0.01) indicating distinct ancestry-specific 
effects (Table 2.13). 
 
Two protective haplotypes in linkage disequilibrium block 2 were found when the high 
ancestry Polynesian sample sets were combined (Table 2.13). The rs693591 | rs17300741 
| rs2078267 – G|A|C haplotype showed only a weak protective effect in the high ancestry 
Polynesian group (OR = 0.78, POR = 0.04), and this nominally significant effect became 
non-significant when the low ancestry Eastern Polynesian sample set was added to the 
combined Polynesian group (OR = 0.83, POR = 0.08). The G|G|T haplotype was nominally 
significant in both the high ancestry Polynesian and full Polynesian combined sample sets 
(OR = 0.57, POR = 0.02; OR = 0.69, POR = 0.04; respectively). Neither haplotype was 
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Table 2.13: Simple haplotype meta-analysis of linkage disequilibrium blocks 1 to 3. 
Haplotype 
Polynesian (High)  Polynesian  All Ancestries 
OR 
[95% CI] 
POR PQ  
OR 
[95% CI] 




Block 1 (rs475414 | rs17299124) 
C|C 0.89 
[0.71; 1.11] 
0.31 0.88  0.91 
[0.74; 1.11] 





6.01×10-04 0.51  0.50 
[0.31; 0.82] 





[1.04; 1.63] 0.02 0.91  
1.29 
[1.04; 1.56] 0.02 0.97  
1.14 
[0.98; 1.33] 0.09 0.57 
Block 2 (rs693591 | rs17300741 | rs2078267) 
C|A|C 
1.24 
[0.98; 1.56] 0.07 0.13  
1.20 
[0.98; 1.49] 0.08 0.22  
1.10 




0.04 0.45  
0.83 
[0.67; 1.03] 







0.09 0.37  
1.31 
[0.94; 1.83] 




0.02 0.80  
0.69 
[0.49; 0.99] 








0.04 0.27  
0.77 
[0.62; 0.97] 







0.11 0.97  
1.23 
[0.91; 1.67] 






0.12 0.70  1.29 
[0.91; 1.81] 
0.15 0.75  - - - 
G|T|C|G|A 0.93 
[0.63; 1.39] 
0.73 0.91  - - -  - - - 
G|T|C|G|G 
0.63 
[0.41; 0.95] 0.03 0.82  
0.86 
[0.41; 1.80] 0.69 0.03  
1.01 




0.57 0.03  
1.07 
[0.84; 1.36] 




Linkage disequilibrium blocks are defined as shown in Figure 2.4 and Table 2.9. Polynesian (High) – includes 
the Eastern Polynesian high ancestry, Western Polynesian, and mixed Eastern and Western Polynesian sample 
sets. Polynesian – also includes the Eastern Polynesian low ancestry sample set. Mixed Eastern and Western 
Polynesian individuals were excluded from the meta-analysis of G|C|C|G|A due to co-linearity issues in the 
prior odds ratio calculation for this haplotype (Table 2.12). Haplotypes are listed in alphabetical order within 
each block. All odds ratios are calculated relevant to the haplotype listed compared to all other possible 
haplotypes found within the linkage disequilibrium block. OR – inverse-variance weighted meta-analysis 
odds ratio (adjusted for sex). 95% CI – 95% confidence intervals. POR – meta-analysis p-value. PQ – Q-
statistic p-value, the fixed-effect model was replaced with a random-effect model if PQ < 0.05. 
 
Linkage disequilibrium block three revealed a protective haplotype that had a consistent 
effect across all five sample sets. rs3825018 | rs475688 | rs7932775 | rs476037 | rs478607 
– A|C|G|T|A was not significant in any single sample set (Table 2.12), but after inverse-
variance weighted fixed-effect meta-analysis of all five sample sets, the consistent 
protective effect seen across groups was approaching experiment-wide significance (OR = 
0.80, POR = 3.6×10-3; Table 2.13). A second, Polynesian specific protective haplotype was 
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also seen in linkage disequilibrium block 3, with the G|T|C|G|G haplotype producing a 
nominally significant association in the combined high ancestry Polynesian sample sets 
(OR = 0.63, POR = 0.03) and significant heterogeneity p-values when the low ancestry 
Eastern Polynesian sample set and the New Zealand European ancestry sample set were 
added to the meta-analysis (PQ = 0.03, and PQ = 0.01, respectively). 
 
2.2.3.3. Conditional Haplotype-Based Analysis 
A non-significant p-value for a haplotype that showed a significant (or nominally 
significant) association in the simple haplotype analysis was interpreted as an independent 
effect in the conditional haplotype-based analysis (Purcell et al., 2007a). This interpretation 
was based on the specific null (independent effect) and alternate (dependent effect) 
hypotheses defined by the --chap analysis. Independent effects could be inferred between 
all three linkage disequilibrium blocks, with the conditional p-value (Psub) of each 
haplotype that showed a nominally significant effect in the simple haplotype association 
analysis (Table 2.12) being non-significant (Table 2.14). In general, the overall p-value for 
each block, conditioned on each other block, was also non-significant (Block 1: Pall = 0.75 
to 0.02; Block 2: Pall = 0.97 to 0.08; Block 3: Pall = 0.92 to 0.01) – indicating independent 
effects between all three blocks. In the Western Polynesian sample set, the analysis of block 
3 conditioned on block 1 and block 3 conditioned on block 2, produced significant overall 
p-values (Pall = 0.02, and Pall = 0.01, respectively) indicating potential dependent effects. 
However, the significant effects were driven by haplotypes that showed no significant 
effect in the simple haplotype analysis (A|C|G|T|A: Psub = 3.0×10-3; G|C|C|G|A: Psub = 0.01) 
and the reverse analyses of block 1 and 2 conditioned on block 3 produced non-significant 
overall p-values (Pall = 0.40, Pall = 0.12, respectively). A similar situation was seen when 
block 1 was conditioned on block 2 in the mixed Eastern and Western Polynesian sample 
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2.2.4. Discussion 
This work demonstrates evidence for independent associations between gout and 
variants/haplotypes in the 1.7 Mb region of chromosome 11 that has previously been 
associated with serum urate in European individuals and contains the uric acid transporter 
gene pair SLC22A11 (OAT4) and SLC22A12 (URAT1). A complex pattern of ancestry-
dependent associations was revealed, with a higher frequency of protective haplotypes in 
European individuals than in people of Polynesian ancestry. This higher frequency of 
protective haplotypes in European individuals could partially explain their lower 
prevalence of hyperuricaemia and gout, whilst common variation in this locus may be part 
of the explanation for the higher average serum urate levels and prevalence of gout in 
Polynesian people (Hollis-Moffatt et al., 2012; Winnard et al., 2012). However, the effect 
sizes seen here are modest, particularly when compared with that of other uric acid 
transporters that have been analysed in New Zealand sample sets, such as SLC2A9 
(GLUT9) and ABCG2 (OR ≈ 2.0), or the SLC17A gene cluster (NPT1 to NPT4) (OR ≈ 1.5) 
(Hollis-Moffatt et al., 2012; Hollis-Moffatt et al., 2009b; Phipps-Green et al., 2010). 
 
The linkage disequilibrium block 1 region ~26 kb upstream of SLC22A11 has not 
previously been studied for association with gout. The single variant association data of 
rs17299124 (C allele) showed the strongest effect in the high ancestry Polynesian sample 
sets (OR = 3.38), with non-significant effects (OR ≈ 1.00) in the European and low ancestry 
Eastern Polynesian (~56.5% European ancestry) sample sets. This variant is therefore a 
novel candidate to test for association with gout in other Polynesian or ancestrally related 
(Asian, Melanesian, and Micronesian) populations. Haplotype analysis indicated that the 
effect seen in high ancestry Polynesian individuals was driven by a haplotype that protects 
from gout and is more common in New Zealand European (who had no effect at this locus) 
than Polynesian people. The lack of any known gene within this upstream region (Ensembl 
release 70 (Flicek et al., 2013)) suggests that the effect seen could be due to modification 
of the expression of a nearby gene, perhaps SLC22A11 or SLC22A12. Korbel et al. (2007) 
characterised structural variations within the human genome, and identified two inversions 
and a deletion spanning this region, which may be able to cause a difference in the 
regulation of gene expression (Korbel et al., 2007). In addition, this SNP maps to a renal 
tissue specific DNase hypersensitivity peak (peak: 11:64256398 - 64258122, mean fold 
change of 11.8; rs17299124: 11:64256859) found in 15 out of 19 renal cell samples 
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(Appendix Table B.2; page 264) supporting the hypothesis that this variant is modifying 
the regulation of gout risk genes (more details in Section 2.3). Of note, this upstream region 
only shows an association in the Polynesian cohorts, similar to variants in SLC22A11, and 
as such a relationship to SLC22A11 expression/activity is more strongly supported than to 
SLC22A12.  
 
In the Polynesian analysis of SLC22A11, there was nominal evidence for association 
between gout and rs2078267 (C allele), a variant that has previously been associated with 
gout in European individuals (OR = 1.14, POR = 2.3×10-5) (Kottgen et al., 2013). The risk 
effect seen in the Polynesian sample set (OR = 1.51, POR = 0.02) was consistent with the 
urate-increasing effect of this allele in European individuals (Kottgen et al., 2013). 
However, this association was not significant when corrected for multiple-testing due to 
the low minor allele frequency of this variant (< 0.1 in the high ancestry Polynesian sample 
sets), reducing the detection power to < 50% for a moderate effect size (OR = 1.5) at the 
experiment-wide significance level (POR < 8.3×10-4). A larger sample size is required for 
more robust conclusions about the possible role of SLC22A11 in gout in Polynesian people.  
 
In the New Zealand European sample set, no evidence for association at either rs2078267 
or rs17300741 (r2 = 0.97) was seen (OR = 0.98, POR = 0.82; and OR = 1.05, POR = 0.61; 
respectively), despite the prior association of these variants with gout in European 
individuals (Kottgen et al., 2013). This difference in association could reflect the 
differences in gout classification criteria used between studies. The association seen in 
Kottgen et al. (2013) was restricted to their prevalent gout case-control cohort (ngout = 
2,115, OR = 0.86, POR = 4.4×10-6), with their incident gout cohort showing no significant 
effect (ngout = 1,372, OR = 0.96, POR = 0.55). Gout ascertainment of the prevalent gout 
cases was primarily based on self-reported gout status or medical records indicating the use 
of “gout medications” (urate-lowering medications and Colchicine), whereas the incident 
gout cases were from the Nurse’s Health Study and the Health Professionals Follow-Up 
Study (detailed in Appendix A.2.5 and Appendix A.2.7; page 260), which used a similar 
gout ascertainment method to the New Zealand Gout Case-Control Cohort – through the 
use of a self-administered American College of Rheumatology classification criteria 
questionnaire (Choi et al., 2004b). As use of the American College of Rheumatology 
classification criteria for gout is considered a superior ascertainment method, with a higher 
specificity, sensitivity, and “fraction correct” than other methods (Table 2.6), it is strange 
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that the association of SLC22A11 is restricted to gout cases ascertained by less stringent 
criteria. In addition, a cohort of gout cases classified using the American College of 
Rheumatology criteria should all have definite hyperuricaemia, whilst self-reported gout or 
gout classification based on medications may include people in the gout cases who are 
normouricaemic. As SLC22A11 has been reliably associated with serum urate levels, it is 
surprising that the associations found at this locus are weaker in the well ascertained gout 
cohorts that should reflect a hyperuricaemia versus normouricaemia analysis. 
Understanding this paradox may reveal new information on the role of SLC22A11 (OAT4) 
in the control of serum urate and risk of gout. 
 
The study by Choi et al. (2004) was focused on incident gout cases, excluding individuals 
who had gout at the baseline recruitment examination from analyses (Choi et al., 2004b). 
It is possible this study is biased against finding strong genetic influences of gout as 
presumably the effects would be most evident in people with early onset gout. By studying 
prevalent gout cases in this section, any individuals with early onset gout are included in 
the analysis (101 Polynesian and 38 European individuals reported experiencing a gout 
attack by the age of 25). In addition, as SLC22A11 encodes a low affinity uric acid 
transporter (OAT4) with the ability to transport multiple other organic anions, there is 
potential for competitive transport to modify the effect of variants within this gene on gout. 
Perhaps the inconsistencies in association are created by a differing prevalence of 
comorbidities between studies which are (either directly or through prescribed medications) 
involved in this competitive transport. Physiological studies indicate that OAT4 is able to 
mediate hydrochlorothiazide induced hyperuricaemia and there is also evidence for an 
interaction between rs2078267 and diuretic use in determining the risk of gout, although 
this has not been replicated (Bao et al., 2015; Hagos et al., 2007; McAdams-DeMarco et 
al., 2013). It is possible that non-additive interaction with diuretics could be a factor in the 
inconsistencies seen between this and other studies.  
 
Unlike SLC22A11, associations at SLC22A12 were found in both the New Zealand 
European and Polynesian sample sets with the clearest evidence of association coming from 
the haplotype analysis. The identification of a gout protective haplotype (rs3825018 | 
rs475688 | rs7932775 | rs476037 | rs478607 – A|C|T|G|A) with a consistent direction of 
effect in Polynesian and European individuals, and a haplotype (G|T|C|G|G) with opposing 
effects in the Polynesian and European sample-sets, suggests that multiple common 
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variants within SLC22A12 (and downstream genes) contribute to the risk of gout in a 
population-dependent manner. This is further supported by the single variant associations 
found in this and other work. Multiple studies have searched for an association between 
gout and a group of SNPs in complete linkage disequilibrium (r2 = 1.0) that span the 
promoter region and transcription start site of SLC22A12 (6,500 bp upstream to within 
intron 2) (Guan et al., 2009; Stark et al., 2009; Tin et al., 2011; Tu et al., 2010a; Yakut et 
al., 2012). These have been conducted in European (rs505802: OR = 0.99, POR = 0.78), 
Chinese (rs893006: OR = 0.83, POR = 0.35), and Solomon Island (rs3825106: non-
significant, specific results not presented) ethnic groups with no success, whilst the 
Polynesian sample set analysed here showed a clear nominally significant association with 
rs3825018 (OR = 1.34, POR = 0.01), despite being ancestrally related to both the Chinese 
and Solomon Island populations (Friedlaender et al., 2008; Kayser et al., 2008; Wollstein 
et al., 2010). The lack of association between rs3825018 and gout in the New Zealand 
European group is consistent with prior studies of this region. 
 
The nominally significant associations seen at rs475688 and rs7932775 (in low linkage 
disequilibrium with the promoter SNPs, r2 < 0.35) in the New Zealand European sample 
set are the first report of an association between SLC22A12 (URAT1) and gout in European 
individuals. Interestingly, the risk effect attributable to the rs475688 T allele (OR = 1.26, 
POR = 0.04), is consistent with reports that this allele increases serum urate levels in 
European individuals (β = 3.28 µmolL-1, Pβ = 1.3×10-17) (Kottgen et al., 2013). However, 
in Han Chinese and Solomon Island (Melanesian) sample sets the T allele of rs475688 has 
been associated with a gout protective effect (OR = 0.54, POR = 1.0×10-4) and decreased 
serum urate levels (β = -11.90 µmolL-1, Pβ = 0.02) (Tu et al., 2010a). These opposing 
effects between European individuals and two populations that have a close ancestral link 
with Polynesian populations are consistent with the opposing direction of association seen 
between the high ancestry Polynesian and New Zealand European sample sets with the 
linkage disequilibrium block 3 haplotype G|T|C|G|G (rs475688 is the second marker). The 
differing haplotype effects between European and Polynesian individuals may reflect 
ancestry-specific recombination events. This could be used to fine map the region in the 
search for causal variants. Further testing of this haplotype for association with serum urate 
and gout in other Asian and Pacific populations is required to replicate the findings here 
and help clarify the causal element within this association. 
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2.2.4.1. Study Strengths and Limitations 
The relatively low number of individuals within each separate Polynesian sample set limits 
this study through lack of association detection power. The power to detect a moderate 
effect (OR = 1.5) at minor allele frequencies ranging from 0.01 to 0.5 was 7.1% to 84.4% 
in the high ancestry Eastern Polynesian sample set; 3.5% to 47.1% in the low ancestry 
Eastern Polynesian group; 6.6% to 78.0% in the Western Polynesian sample set; and 2.5% 
to 15.7% in the mixed Eastern and Western Polynesian group. This limitation is, however, 
counteracted by combining the Polynesian sample sets through inverse-variance weighted 
meta-analysis. This methodology allows for variation between the sample sets to be 
visualised (through odds ratio direction and the Q-statistic) whilst still increasing the power 
(power in the combined Polynesian cohort was increased to 13.5% to 99.7% for a moderate 
effect (OR = 1.5) and allele frequency range between 0.01 and 0.5).  
 
This study is also limited by the inclusion of the 86 Maori/Pacific Island people with 
rheumatoid arthritis in the control group. Whilst cases of concurrent gout and rheumatoid 
arthritis are rare, it is possible a gouty individual may have been in this group (Zonana-
Nacach et al., 1996). This is also a possibility for the 618 control individuals who were 
originally collected for the study focused on the genetic risk factors of rheumatoid arthritis. 
These individuals were asked about their history arthritis, in general, and not specifically 
their history of gout. With this being a self-reported medical history, and the possible lack 
of recognition that gout is a form of arthritis by the general public (Gow et al., 2011), it is 
potentially more likely that some of these controls have gout as opposed to the controls 
with rheumatoid arthritis. Despite this possibility the use of these controls was necessary 
to create cohorts large enough to have an adequate detection power (> 80%) for SNPs with 
an allele frequency greater than 0.1 and a moderate effect (OR = 1.5). This was particularly 
true for the European cohort, which had only 133 controls collected specifically as part of 
the New Zealand Gout Case-Control Cohort at this time. 
 
The use of American College of Rheumatology gout classification criteria to ascertain gout 
status is a benefit of this study as it lowers the possibility of non-gouty individuals being 
included in the case set (as can happen when gout is ascertained using less strict criteria, 
such as self-report of gout, use of “gout medications”, or use of medical records and 
physician diagnosis (Kottgen et al., 2013; Stark et al., 2009; Tin et al., 2011; Yang et al., 
2010)). In addition, by ensuring individuals with gout secondary to other causes (such as 
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diuretic use) have been removed from the case groupings, the potential for confounding 
caused by non-additive interaction effects with hypertensive medications is reduced. 
 
Furthermore, the creation of a split Eastern Polynesian cohort based on estimated 
Polynesian ancestry levels reduced the possibility of confounding caused by admixture. As 
the Western Polynesian and mixed Eastern and Western Polynesian groups had more 
similar average levels of European ancestry between cases and controls (0.93 ± 0.15 and 
0.88 ± 0.21 (Pt = 0.01) in Western Polynesian cases and controls, respectively; and 0.89 ± 
0.18 and 0.72 ± 0.27 (Pt = 0.01) in mixed Eastern and Western Polynesian cases and 
controls, respectively), this same cohort splitting was not required. The evident differences 
in association seen between the two Eastern Polynesian sub-sets further justified this 
methodology, although it does represent a post hoc analysis and replication of the results 
shown here using other methods that account for admixture should be conducted. 
 
2.2.4.2. SLC22A11 (OAT4) and SLC22A12 (URAT1) Since Publication 
Since the publication of this work a number of articles have reported on SLC22A11 (OAT4) 
and SLC22A12 (URAT1) and their role in serum urate levels or gout (Table 2.2). These 
studies have varied in focus from the assessment of single variants (similar to this study), 
analyses of these genes involvement in other phenotypes related to gout or serum urate, and 
genome-wide association studies in non-European populations and gout (Bao et al., 2015; 
Hughes et al., 2014; Li et al., 2014; Okada et al., 2012; Phipps-Green et al., 2016; 
Sakiyama et al., 2013; Sun et al., 2014; Takeuchi et al., 2013; Urano et al., 2013; Wan et 
al., 2014). The first of these studies was released in August 2012, after the major analysis 
for this section was completed, but before publication. This study carried out a genome-
wide association analysis of serum urate levels in a group of 33,074 East Asian individuals 
(Japanese: 85.3%; Chinese: 5.9%; Korean: 8.7%). Genome-wide significant associations 
were identified in four genes (Figure 2.1), with the “top-hit” at SLC22A12 showing the 
strongest effect on serum urate levels in the entire analysis (rs504915: β = 13.39, Pβ = 
3.3×10-63) (Okada et al., 2012). In addition to this strong effect at SLC22A12, a much larger 
region of chromosome 11 (2.7 Mb) was associated with serum urate in the East Asian 
genome-wide study, covering eight linkage disequilibrium blocks (Okada et al., 2012). 
 
Several studies of gout in Chinese individuals have also been published since this section’s 
analysis was first conducted. A genome-wide study of gout in 1,255 Chinese individuals, 
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showed no evidence for an association at the SLC22A11 and SLC22A12 locus in the overall 
analysis, but assessment of the specific contribution of previously associated variants in 
this region revealed a nominally significant association between rs505802 and gout in this 
cohort (OR = 0.77, POR = 0.03) (Li et al., 2015). Another study also identified a significant 
association between a SLC22A12 variant in high linkage disequilibrium with rs505802 and 
gout in a Chinese cohort (rs559946: OR = 0.70, POR = 4.0×10-3) (Li et al., 2014). And a 
third study identified a significant effect for rs505802 in gout risk in Chinese individuals, 
but not for rs17300741 (OR = 0.75, POR = 9.9×10-4; OR = 1.27, POR = 0.13; respectively) 
(Zhou et al., 2015). Interestingly, a genome-wide association study of serum urate levels 
in 3,451 Chinese individuals was unable to identify a significant effect at the SLC22A11 
and SLC22A12 locus, and specific analysis of previously associated variants from these 
two genes did not produce any suggestion of an effect (Pβ > 0.09) (Yang et al., 2014).  
 
Of most relevance to this work is the recently published research by other members of the 
Merriman Laboratory (mentioned in Section 2.1.3) assessing the association between the 
SLC22A11 variant rs2078267 and the SLC22A12 variant rs3825018 and gout risk in a larger 
cohort of New Zealand European and Polynesian individuals (Phipps-Green et al., 2016). 
This work was performed on many of the same individuals as used in the analysis presented 
in this section, but an additional 1,140 New Zealand European individuals and 882 
Polynesian individuals were included. The majority of these individuals (468 European, 
882 Polynesian) were collected for the New Zealand Gout Case-Control Cohort (after 
January 2012). The remaining 672 New Zealand European individuals were collected as 
part of a different New Zealand study (the Abdominal Aortic Aneurysm cohort (Jones et 
al., 2013; Roberts et al., 2011)). In this larger dataset, the effect of rs3825018 in Polynesian 
individuals was maintained (OR = 1.21, POR = 0.03) and the European cohort also showed 
a significant association with an effect size equivalent to that reported here (OR = 1.24, 
POR = 0.01). However, the association seen between rs2078267 and gout in Polynesian 
individuals did not replicate in this larger cohort, although without the full haplotype 
analysis being performed, it can not be said for certain that SLC22A11 is not involved in 
gout in Polynesian individuals. The influence of the upstream SNP, rs17299124, was not 
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2.2.4.3. Conclusion 
In conclusion, the first association between gout and SLC22A11 (OAT4) in a non-European 
population is presented in this section, although later work by Merriman Laboratory 
members did not substantiate this finding. The first association between gout and 
SLC22A12 (URAT1) in a European population is also presented here and has been 
replicated in a larger New Zealand European cohort. A novel region involved in the control 
of serum urate levels ~26 kb upstream of SLC22A11 was identified. This region contained 
no known genes, evidence for potential regulatory elements, and was also associated with 
gout in Polynesian individuals. The research presented here provides evidence for multiple 
SNPs of importance in this region, and several ancestry-dependent effects. Further work to 
confirm these findings and identify the causal variants within this region is required to 
further understand the role of SLC22A11 (OAT4) and SLC22A12 (URAT1) in gout risk. 
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Section 2.3. Exon Sequencing of the SLC22A11 (OAT4) 
and SLC22A12 (URAT1) Region: Searching for Causal 
Variant Candidates. 
2.3.1. Background 
Whilst many associations within the SLC22A11 (OAT4) and SLC22A12 (URAT1) loci 
have been found between SNPs and serum urate levels or gout (Section 2.1, Table 2.2; and 
Section 2.2), very few of these have been with obviously functional variants (missense or 
nonsense mutations). Often in genome-wide association studies, intronic or intergenic 
variants produce the strongest association with a given phenotype, whilst the more 
obviously functional variants do not have evident effects (Hindorff et al., 2009; Stranger et 
al., 2011). Most genome-wide studies of serum urate or gout have followed this association 
pattern for the SLC22A11 and SLC22A12 locus, with only a single genome-wide study of 
serum urate levels in 5,280 African American individuals identifying a non-synonymous 
SNP in the “top-hits” (rs12800450: G65W in SLC22A12; mentioned in Section 2.2) (Tin 
et al., 2011). 
 
In contrast, several studies have sequenced SLC22A12 to search for non-synonymous 
variants that influence disease. The focus of these sequencing studies has varied from 
assessments of hypouricaemic individuals, the role of non-synonymous variants on 
fractional excretion of uric acid, or their influence on hyperuricaemia and gout risk (Cho et 
al., 2015; Dinour et al., 2011; Graessler et al., 2006; Ichida et al., 2004; Iwai et al., 2004; 
Komoda et al., 2004; Li et al., 2010; Li et al., 2013; Mancikova et al., 2015; Stiburkova et 
al., 2011; Torres et al., 2012; Vazquez-Mellado et al., 2007a; Vazquez-Mellado et al., 
2007b). Familial studies of renal hypouricaemia have been conducted in people from Japan, 
Iraq (Iraqi Jews), China, and the Czech Republic; all identifying rare, population-specific, 
non-synonymous variants within SLC22A12, which functionally reduce the ability of 
URAT1 to absorb uric acid (Dinour et al., 2011; Komoda et al., 2004; Li et al., 2013; 
Mancikova et al., 2015; Stiburkova et al., 2011). In contrast, studies sequencing SLC22A12 
in hyperuricaemic individuals from China, Japan, and Korea have been unable to identify 
non-synonymous variants in these people (Cho et al., 2015; Iwai et al., 2004; Li et al., 
2010). Another study that analysed variants within the coding region of SLC22A12 in 
relation to fractional excretion of uric acid was able to identify a rare non-synonymous 
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variant (rs144328876: R92C) within three (1 homozygote, 2 heterozygote) of the 652 
German individuals sequenced. No further analysis assessing the potential influence of this 
non-synonymous change was conducted because this variant was so rare within their cohort 
(0.6%). However, a study of familial hypouricaemia identified a single 54 year old woman 
from the Czech Republic who had a serum urate level of 57.0 µmolL-1, a fractional 
excretion of uric acid of 40.4% (normal range is 5.5% to 11.1% (Sakiyama et al., 2013)), 
and was heterozygous for the R92C mutation (Mancikova et al., 2015). Functional analysis 
revealed the inclusion of a cystine at the 92nd amino acid residue of URAT1 results in a 
70% reduction in urate uptake as compared to the wild-type protein in vitro (Mancikova et 
al., 2015). 
 
Each of these studies shows an effect consistent with non-synonymous variants in 
SLC22A12 leading to reduced protein function, and therefore lower serum urate levels due 
to a reduction in renal absorption of uric acid causing an increase in fractional excretion of 
uric acid. The lack of identification of non-synonymous variants in individuals with 
hyperuricaemia also supports this hypothesis. In possible opposition to this are the results 
reported by Vazquez-Mellado et al. (2007). Sixty-nine Mexican gout patients had their 
SLC22A12 exons sequenced, as did 29 of these people’s first degree relatives, and 120 
unrelated healthy controls (Vazquez-Mellado et al., 2007b). Six non-synonymous variants 
were identified (R284G, I305S, Q297E, A680Tfs., G290C, and rs121907894: E298D), 
only within the gout patients (or their relatives) with none of the healthy controls having 
any non-synonymous mutations (Vazquez-Mellado et al., 2007b). Of note, 11 of the gouty 
individuals were heterozygous for the R284G variant (allele frequency = 0.08) and these 
individuals had a significantly lower serum urate level than the remaining 58 gout patients 
(377.1 ± 117.2 µmolL-1 compared to 464.0 ± 124.3 µmolL-1; Pdif = 0.04), perhaps indicating 
this variant is reducing URAT1 protein function similar to those found in hypouricaemic 
individuals, but not to an extent that is able to compensate for other genetic risk factors at 
other loci (for example, ABCG2 and SLC2A9) (Vazquez-Mellado et al., 2007b). 
 
Both the SLC22A11 and SLC22A12 gene sequences have been assessed for general 
population variation and selective pressures without any reference to disease (Xu et al., 
2005). Xu et al. (2005) assessed the coding sequences of these two genes in a sample set 
of 192 ethnically diverse individuals from 11 ancestral groups, including Pacific Islanders. 
No non-synonymous variants were found within the SLC22A12 sequence in any 
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population, whilst nine non-synonymous mutations were identified in SLC22A11 (Xu et 
al., 2005). One of these variants, rs748391722: A244V, was present in one of the Pacific 
Island individuals (out of seven) and not in any individuals from the other populations (Xu 
et al., 2005). One nonsense variant in SLC22A11 was also identified in a European 
individual (rs35008345: R48X). Other rare variants were seen in Chinese (rs147522958: 
E278K; 1), Indo-Pakistani (rs200043601: T62R; 1), Sub-Saharan African (rs75976740: 
V13M; 1, and rs756045635: T392I; 1), and North-Saharan African (rs147522958: E278K; 
2) individuals (Xu et al., 2005). Only the E278K variant was found in more than one 
population. 
 
In addition, a single study has conducted a sequence analysis of SLC22A11 (OAT4) in 
relation to disease. This study aimed to assess whether non-synonymous variants in 
SLC22A11 modify the risk of developing osteoporosis through modified transport of 
oestrone sulphate (reduced bone mass, which can lead to osteoporosis, is associated with 
reduced oestrogen levels) (Lee et al., 2008c). Fifty Korean women with osteoporosis and 
another fifty without osteoporosis, had their SLC22A11 exons sequenced and a single non-
synonymous variant (rs147522958: E278K) was identified in the osteoporosis patients. 
Functional characterisation of the resultant protein revealed reduced oestrone sulphate 
transport to approximately 20% capacity (Vmax = 1.8 pmol/oocyte/hour and 0.47 
pmol/oocyte/hour for the E278 and 278K proteins, respectively) (Lee et al., 2008c). Other 
studies assessing the functional impact of SLC22A11 non-synonymous variants have 
identified several protein changes which result in reduced uptake of oestrone sulphate and 
uric acid (Shima et al., 2010; Zhou et al., 2010). No analysis of non-synonymous variants 
in this gene and their relationship with overall serum urate levels or gout risk has been 
published to date. 
 
Intronic variants of both SLC22A11 (OAT4) and SLC22A12 (URAT1) have shown 
associations with serum urate levels or gout risk in Polynesian and European individuals. 
To date no single functional variant responsible for these associations has been identified. 
This study aimed to characterise the exonic sequences of both SLC22A11 and SLC22A12 
in New Zealand European and Polynesian individuals and test the hypothesis that rare 
variants collectively contribute to hyperuricaemia risk and, by proxy, gout.  
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2.3.2. Methods 
2.3.2.1. Study Participants 
A sub-set of the New Zealand Gout Case-Control Cohort (522 individuals) and participants 
of two other cohort studies, the Health Professionals Follow-Up Study (HPFS; 169 
individuals) and the Nurses’ Health Study (NHS; 125 individuals) were selected for 
sequencing.1 Briefly, this cohort consisted of 422 hyperuricaemic cases and 386 
normouricaemic controls. Cases were hyperuricaemic (serum urate levels ≥ 410 µmolL-1, 
average = 528.7 µmolL-1) irrespective of gout status and urate-lowering therapies, whilst 
controls had the lowest serum urate levels within their respective original cohorts (serum 
urate levels ≤ 370 µmolL-1; average = 269.2 µmolL-1) and self-reported no history of gout. 
Individuals from the rheumatoid arthritis study mentioned in Section 2.2 were not 
considered for sequencing. Four control individuals were mildly hypouricaemic (serum 
urate levels ≤ 119 µmolL-1; average = 105.6 µmolL-1). 
 
Table 2.15: Demographic details of the ReSequencing Cohort. 
 











Sex (% Female)  37 (16.16%) 122 (57.01%)  33 (16.67%) 105 (58.99%) 
Age (Years)  45 ± 14 45 ± 14  60 ± 15 - 
BMI (kg/m2)  36.97 ± 7.80 31.56 ± 6.69  30.16 ± 3.83 - 
Serum Urate (µmolL-1)  533.49 ± 64.48 303.04 ± 40.29  523.63 ± 55.83 228.11 ± 33.60 
Relative with Gout  105 (45.85%) 54 (25.23%)  30 (36.59%) - 
Self-Reported Comorbidities 
Diabetes  33 (14.41%) 42 (19.63%)  42 (51.22%) - 
Gout   170 (74.24%) 0 (0.00%)  76 (92.68%) - 
High Blood Pressure  83 (36.24%) 39 (18.22%)  44 (53.66%) - 
High Cholesterol  75 (32.75%) 26 (12.15%)  31 (37.80%) - 
Heart Problems  20 (8.73%) 18 (8.41%)  19 (23.17%) - 
Kidney Problems  22 (9.61%) 5 (2.34%)  13 (15.85%) - 
Gout Severity 
Age at Onset  34 ± 12 -  47 ± 18 - 
Years since Diagnosis  12.31 ± 12.13 -  13.43 ± 11.96 - 
Urate at Diagnosis (µmolL-1)  537.20 ± 92.58 -  527.50 ± 100.51 - 
On Urate-Lowering Medication  120 (52.40%) -  38 (46.34%) - 
Number of Attacks  11.56 ± 37.05 -  4.33 ± 7.56 - 
Tophi Present  57 (24.89%) -  20 (24.39%) - 
Total number of participants is shown in brackets. Data are shown as the mean ± standard deviation, or as 
number of participants (percentage). ^ – phenotype data for the European cohort is based only on the New 
Zealand samples except for sex, and serum urate levels (82 hyperuricaemic, 0 normouricaemic). 
                                                
1 Samples from the Health Professionals Follow-Up Study and Nurses’ Health Study were kindly provided 
by Dr. Hyon Choi (Boston University, Boston, Massachusetts). 
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The cohort was split into two sub-sets based on self-reported ancestry (Polynesian, n = 440; 
and European, n = 368). The Polynesian sub-set was not further split into Eastern and 
Western Polynesian ancestry groups based on the similar associations between these two 
groups identified at the SLC22A11 and SLC22A12 loci (Section 2.2) and the consequent 
reduction of analysis power this split would produce. A summary of the demographic 
details for this cohort is shown in Table 2.15. 
 
2.3.2.2. Sequenced Regions1 
The ReSequencing project was designed to facilitate fine-mapping analyses of genetic loci 
that have previously been associated with hyperuricaemia and/or gout. Genome regions 
with prior evidence for a role in determining serum urate levels or gout risk were selected 
for sequencing based on several criteria. These criteria were: 
1. Genes/gene regions identified in the largest European serum urate genome-wide 
association study, conducted by Kottgen et al. (2013). 
2. Polynesian ancestry-informative markers as described by Hollis-Moffatt et al. 
(2012; Appendix Table B.1; page 263). 
3. Genes/gene regions coding for proteins involved in Allopurinol metabolism. 
4. Genes/gene regions involved in determining body mass index, weight, or renal 
function. 
5. Known uric acid transporters that have not previously shown genetic associations 
with serum urate levels or gout. 
6. Genes/gene regions that have some indication of a role in gout risk via 
inflammation, lipid control, or other unknown mechanisms. 
7. And finally, DNase hypersensitivity regions from 19 renal cell samples available 
on the Gene Expression Omnibus website (www.ncbi.nlm.nih.gov/geo; Appendix 
Table B.2; page 264) were identified and those regions that fell within or near one 
of the other chosen genes/gene regions were also selected for sequencing. 
 
After applying these criteria, a list of 790 distinct genes/loci was developed. This list 
included 182 gene loci from the Kottgen et al. (2013) genome-wide study results, 69 
                                                
1 Regions for sequencing were chosen by Professor Tony Merriman (Supervisor) in collaboration with 
Assistant Professor Eli Stahl (Icahn School of Medicine, Mount Sinai, New York) and Professor Hyon Choi 
(Massachusetts General Hospital, Boston). The specific genome positions to be sequenced were identified by 
Murray Cadzow (Assistant Research Fellow) and Ruth Topless (Assistant Research Fellow).  
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ancestry-informative SNPs (Appendix Table B.1; page 263), 45 genes/proteins involved in 
Allopurinol metabolism, 14 body mass index or renal function influencing gene loci, six 
uric acid transporters genes, 12 regions with some indication of an influence on gout risk, 
and 865 DNase hypersensitivity peaks. For each gene included on this list the exons ± 10 
bp, the 3' and 5' untranslated regions, and 800 bp upstream of the transcription start site(s) 
were sequenced. Ancestry-informative markers were sequenced ± 50 bp either side. DNase 
hypersensitivity regions were sequenced across the entire peak. Overlapping or extremely 
close regions were combined to reduce sequencing primer design, this resulted in the 
sequencing of approximately 2.6 Mb of the genome. 
 
2.3.2.3. Library Preparation and Sequencing1 
For each participant included in the ReSequencing Cohort 250 ng of genomic DNA was 
shipped to the McDonnell Genome Institute (Washington University, St Louis) where 
library preparation and sequencing took place. Illumina indexed libraries were constructed 
using the Nextera DNA Sample Prep kit (Illumina Inc., San Diego) and a modified version 
of the manufacturer’s protocol. In short, DNA was fragmented to range from 100 to 400 bp 
in size using a Covaris E220 DNA Sonicator (Covaris Inc., Woburn) and sequence adapters 
added to the fragment ends. Next, adapter-ligated library fragments were amplified for 
eight cycles to add sequencing primers and indices. Finally, Solid Phase Reversible 
Immobilisation (SPRI) bead clean up (AMPure XP beads) was used for library purification 
and size selection, targeting 300 to 500 bp fragments. After library preparation, fragment 
hybridisation and amplification were performed using a custom Roche NimbleGen SeqCap 
kit (Roche NimbleGen Inc., Madison) following the manufacturers protocol. Sequencing 
was carried out on an Illumina HiSeq 2000 (Illumina, San Diego). Ninety dual-indexed 
samples were combined and captured as a pool and run within a single sequencing lane. On 
average samples produced sequence with 51.2x coverage across the 2.6 Mb of targeted 
sequence. 
  
                                                
1 Sample shipping was handled by Amanda Phipps-Green (Assistant Research Fellow).  
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2.3.2.4. Variant Calling1 
Raw sequence data was aligned and variant called within the Merriman Laboratory using 
the Genome Analysis Tool Kit (GATK) best practice recommendations (van der Auwera 
et al., 2013). FASTQ files were extracted from the raw sequence data files using SAMtools 
1.1.2, then aligned to the human reference genome (build GRCh37) using the MEM 
command of the Burrows-Wheeler Aligner (BWA 0.7.12) (Li and Durbin, 2009; Li et al., 
2009). Resultant binary alignment/map (BAM) files were processed using Picard 1.114 
(www.github.com/broadinstitute/picard) to mark reads that originated from PCR 
duplication. This was followed by indel realignment and base recalibration using GATK 
3.3.0 (McKenna et al., 2010). GNU Parallel and the GATK HaplotypeCaller were used to 
generate genomic variant call format (gVCF) files (DePristo et al., 2011; Tange, 2011). 
GATK was further used to merge the gVCF files in batches of 100 before variant calling 
was performed. The SNPs in the resulting variant call format (VCF) file were processed 
using the GATKs variant quality score recalibration utility taking quality by depth, Fisher 
score, mapping quality rank sum, and read position rank sum into account. This 
recalibration was applied to the VCF file and SNPs with a truth sensitivity of less than 
99.00 were removed. The remaining variants were annotated using GEMINI 0.17.0 
(www.gemini.readthedocs.org) and the Ensembl variant effect predictor (Ve!P: 
http://grch37.ensembl.org/Tools/VEP). These annotations included the gene/transcript 
most likely to be affected by each variant, the variant type (intergenic, intronic, or exonic), 
and reference SNP cluster ID numbers (rs#). 
 
2.3.2.5. Single Variant Association Analysis 
This study focused only on those variants that passed the quality control criteria and fell 
within the SLC22A11 (11:64323098 to 11:64340347) and SLC22A12 (11:64358282 to 
11:64369820) transcribed gene regions (ENST00000301891 and ENST00000377574 co-
ordinates). An allelic odds ratio for each variant was calculated in the European and 
Polynesian sample sets separately. These odds ratios were adjusted for sex. The European 
sample set was additionally adjusted for collection study. All allelic odds ratios were 
calculated relevant to the minor allele within the full ReSequencing cohort. Individuals 
                                                
1 James Boocock (Research Assistant) performed the sequence alignment and variant calling in preparation 
for use by other Merriman Laboratory members. 
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with missing or partial data were excluded. Analyses were performed in R 3.1.1 (www.r-
project.org/). 
 
Power to detect a POR < 0.05 was calculated for both sample sets using the methodology 
set out by Johnson et al. (2001). Both sample sets were only adequately powered (> 80%) 
to detect a strong association (OR = 2.0) in SNPs with a minor allele frequency > 0.2 
(Figure 2.7). No formal multiple-testing correction was applied to p-values due to the low 
power of this study. 
 
Figure 2.7: Association detection power in the European (A) and Polynesian (B) 
ReSequencing cohorts across a range of odds ratio effect sizes and minor allele 
frequencies. 
   
The dashed red line indicates adequate detection power (≥ 80%). 
 
2.3.2.6. Burden Analysis 
Burden testing of rare variants and non-synonymous variants for each gene separately was 
conducted in each sample set. This type of analysis compensates for the inherent lack of 
power single variant association analyses have to detect rare variant effects, by assessing 
the effect of all rare variants (or non-synonymous variants) together (Lee et al., 2014). Rare 
variants were defined as those with a minor allele frequency < 0.05 in the two sample sets 
combined; this resulted in a list of 39 variants within SLC22A11 and 16 within SLC22A12 
for use in the rare variant burden analysis (SLC22A11: 11:64323160, rs751083234, 
11:64323312, rs79629887, rs141159367, rs150750095, rs200593751, rs35008345, 
rs2277313, 11:64323853, rs72559737, rs367925828, rs150160581, rs138399841, 
rs142027244, rs141760078, rs75933978, 11:64337291, rs762218420, rs12294207, 
A B 
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rs76328331, 11:64338681, 11:64338783, rs144263160, 11:64339274, 11:64339354, 
11:64339440, 11:64339451, rs550564385, rs73490294, rs17159320, 11:64339669, 
11:64339735, rs369494145, 11:64339971, rs570376746, rs150452751, rs17159321, 
rs78988810; SLC22A12: rs71581770, 11:64358569, rs527437207, rs577512029, 
rs72922827, 11:64359086, rs144313367, rs761942522, rs749900943, 11:64367316, 
rs142344676, rs147647315, rs201423508, rs747742344, 11:64368382, 11:64369015). The 
allele collapsing method described by Li and Leal, (2008) was used to calculate a rare 
variant indicator variable where individuals are classified as either having or not having a 
rare allele at any site (!" = 1 rare allele present0 rare allele absent  ). The frequency of individuals with any 
rare variant was then calculated and the difference in this frequency between 
hyperuricaemic cases and normouricaemic controls assessed using the Pearson χ2 test (Li 
and Leal, 2008). 
 
An adaptive burden test (or weighted sum test) which allowed for the possibility of 
opposing effects between variants was also performed using the methodology of Ionita-
Laza et al. (2011). In short, variants are classified into those that are more frequent in cases 
(&′ = caseMAF > controlMAF) and those that are more frequent in controls (& = caseMAF < 
controlMAF). Two weighted summary statistics are then calculated (S+ and S−) representing 
a possible burden of risk variants and a possible burden of protective variants, respectively. 
A one-sided p-value is calculated for each statistic based on a standard permutation 
whereby case/control status is randomly shuffled and the S statistic recalculated. A two-
sided p-value, assessing the combined risk and protective effect of the variants was also 
calculated (Sc = S+ + S−) and the same permutation analysis performed. C++ source code 
for this analysis was downloaded from the study author’s website 
(www.columbia.edu/~ii2135) and run for both the Polynesian and European sample sets 
separately with 1,000; 10,000; and 50,000 permutation rounds (Ionita-Laza et al., 2011). 
Both these burden testing analyses were repeated for the sub-set of non-synonymous 
variants. 
 
2.3.2.7. Non-Synonymous Variant Characterisation 
Non-synonymous variants within the cohort were identified using the GEMINI and Ve!P 
annotations added to the VCF file during the variant calling phase of analysis. To assess 
the impact of these variants on protein function SIFT 5.1.1 (http://sift.bii.a-star.edu.sg), 
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PolyPhen-2 2.2.2 (http://genetics.bwh.harvard.edu/pph2), and PROVEAN 1.1 
(http://provean.jcvi.org) prediction scores were obtained and the corresponding binary 
classifications (deleterious or neutral effect) were applied based on the default cut-off 
threshold for each tool (SIFT: score ≤ 0.05 is deleterious; PROVEAN: score ≤ -2.5 is 
deleterious; PolyPhen-2: score ≥ 0.43 is deleterious). In addition, to assess whether these 
variants were possibly modifying serum urate levels within the individuals of this cohort a 
predicted serum urate for each individual (based on common SNPs as described below) 
was compared to the measured serum urate level. Those with a difference in measured and 
predicted serum urate greater than 3 standard deviations from the mean difference were 
considered to have a measured serum urate significantly different to their predicted serum 
urate. 
 
2.3.2.7.1. Predicted Serum Urate Levels 
A prediction model was built using the New Zealand Gout Case-Control Cohort with all 
individuals in the ReSequencing Cohort, and those who did not have a serum urate 
measurement, removed (n = 2,361; 1,560 Polynesian and 1,071 European). For the 
Polynesian sample set, a linear regression model associating serum urate levels with sex, 
age at collection, body mass index, Eastern/Western Polynesian ethnicity, self-reported 
grandparental ancestry, use of urate-lowering medications, and seven common SNPs 
representative of the genes that have been most reliably associated with serum urate levels 
(ABCG2: rs2231142, GCKR: rs1260326/rs780094,1 PDZK1: rs1967017, SLC2A9: 
rs11942223, SLC17A gene cluster: rs1183201, SLC22A11: rs2078267, and SLC22A12: 
rs3825018) was conducted in this model-training cohort. The effect of each of these 
variables on serum urate levels was then used to predict the serum urate level of each 
Polynesian individual in the ReSequencing Cohort. This prediction method was also 
applied to the model-training cohort to assess how well the prediction method performed. 
The mean difference in predicted and measured serum urate levels and the standard 
deviation of this difference was calculated in the model-training cohort and these values 
were used as the thresholds for significance in the variant effect assessment. This same 
analysis method was applied to the European sample set, however due to the lack of 
phenotype information provided for the Nurse’s Health Study (NHS) and Health 
Professionals Follow-Up Study (HPFS) samples, the linear regression used for serum urate 
                                                
1 rs780094 was used as a proxy SNP for rs1260326 in the model-training group (r2 = 0.98). 
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prediction only included sex and the seven serum urate related SNPs. These prediction 
analyses were performed in R 3.1.1, individuals with missing or partial data were excluded. 
 
The seven serum urate related SNPs were obtained from the aligned sequence data for the 
ReSequencing cohort. For the model-training cohort these SNPs were genotyped using 
TaqMan® assays (Applied Biosystems, Foster City) in a Lightcycler® 480 Real-Time PCR 
System (Roche, Indianapolis) (assay ID: rs1183201: C_1911034_10; rs11942223: 
C_1216479_10; rs1967017: C_1862243_10; rs2231142: C_15854163_70; rs2078267: 
C_16110318_10 (this SNP was also genotyped using the MassArray system as described 
in Section 2.2, for 1,780 individuals); rs3825018: C_27162391_10; rs780094: 
C_2862873_10). Genotyping concordance in those individuals of the ReSequencing cohort 
that were both TaqMan® genotyped and sequenced ranged from 98.0% to 100.0%.  
 
2.3.3. Results 
A total of 25,379 single nucleotide variants from across the full 2.6 Mb of targeted sequence 
passed the quality control criteria. Almost 80% (19,967 of 25,379) of these variants had a 
minor allele frequency ≤ 0.05, and approximately 42% (10,645 of 25,379) did not have a 
reference SNP cluster ID (rs#) on the National Centre for Biotechnology Information 
(NCBI) dbSNP database (http://www.ncbi.nlm.nih.gov/snp). Within the SLC22A11 and 
SLC22A12 sequence region, 182 variants were identified (SLC22A11: 120; SLC22A12: 62), 
66 of these fell within the transcribed gene regions (SLC22A11: 40; SLC22A12: 26). Ten 
non-synonymous variants (9 missense, 1 nonsense) were identified in SLC22A11 and eight 
non-synonymous variants (7 missense, 1 nonsense) were found in SLC22A12. No variants 
were found in exons three, seven, and eight of SLC22A11, and exons three, four, and five 
of SLC22A12; summarised in Table 2.16. 
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Table 2.16: Summary of variable nucleotide sites identified within the coding regions 
of SLC22A11 (OAT4) and SLC22A12 (URAT1). 
Exon SLC22A11 (OAT4)  SLC22A12 (URAT1) 
Length n % Ts Tv Ts/Tv Syn Non  Length n % Ts Tv Ts/Tv Syn Non 
5' UTR 374 5 1.34 2 3 0.67 - -  747 9 1.20 8 1 8.00 - - 
Exon 1 393 6 1.53 6 0 - 2 4  402 4 1.00 3 1 3.00 3 1 
Exon 2 104 1 0.96 0 1 - 1 0  104 2 1.92 2 0 - 1 1 
Exon 3 155 0 - - - - - -  155 0 - - - - - - 
Exon 4 169 3 1.78 2 1 2.00 1 2  169 0 - - - - - - 
Exon 5 121 1 0.83 1 0 - 0 1  124 0 - - - - - - 
Exon 6 116 2 1.72 1 1 1.00 0 2  116 1 0.86 1 0 - 0 1 
Exon 7 215 0 - - - - - -  215 3 1.40 2 1 2.00 3 0 
Exon 8 109 0 - - - - - -  109 4 3.67 4 0 - 1 3 
Exon 9 207 1 0.48 1 0 - 0 1  204 1 0.49 1 0 - 0 1 
Exon 10 64 1 1.56 1 0 - 1 0  64 1 1.56 1 0 - 0 1 
3' UTR 1,833 20 1.09 13 7 1.86 - -  797 1 0.13 1 0 - - - 
Total 3,860 40 1.04 27 13 2.08 5 10  3,206 26 0.81 23 3 7.67 8 8 
Exon lengths/positions are according to the longest gene transcript recorded in the Genome Reference 
Consortium human genome build 37 (GRCh37) on Ensembl (http://grch37.ensembl.org/). UTR – 
untranslated region. n – number of single nucleotide variants within the specified exon. % – percentage of 
the exon containing single nucleotide variants. Ts – number of transitions. Tv – number of transversions. 
Ts/Tv – ratio of transitions to transversions. Syn – number of synonymous variants. Non – number of non-
synonymous variants.  
 
2.3.3.1. Single Variant Association Analysis 
Population-specific variants were found in both genes, with 72.7% of variants being present 
in only one population (European: 29; Polynesian: 19; Both populations: 18). Of these 
population-specific variants three had a minor allele frequency > 0.05, these three were all 
Polynesian specific variants (SLC22A11: rs561874071; and SLC22A12: rs369153816, and 
rs543512307). Two of these Polynesian specific variants were novel, and in complete 
linkage disequilibrium (r2 = 1.00). Neither caused a non-synonymous change within their 
respective gene, but regression analysis suggested a possible protective effect against 
hyperuricaemia (OR = 0.52, POR = 0.06; Table 2.17) 1. A protective effect was also seen in 
five SNPs in the European sample set, these variants were all within SLC22A12 and in 
complete linkage disequilibrium (r2 = 1.00) with each other (rs9734313, rs559946, 
rs3825108, rs3825016, and rs11231825: OR = 0.67, POR = 0.04). The same effect was not 
seen in the Polynesian group (OR = 0.88, POR = 0.46). None of these five variants are non-
synonymous, and this association has been documented previously – including in Section 
                                                
1 At identification these SNPs were novel. In the most recent 1000 Genomes release one person had the 
rs561874071 variant and three people had the rs543512307 variant. Consequently, these variants have been 
given reference SNP cluster ID numbers (1000 Genomes Project Consortium, 2015). 
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2.2 of this thesis. One other variant in SLC22A12 showed a significant effect, rs72922827. 
This variant is not in linkage disequilibrium with the other five SLC22A12 SNPs (r2 = 0.08), 
but also only showed an effect in the European sample set (European: OR = 3.25, POR = 
0.03; Polynesian: OR = 0.33, POR = 0.37). No significant effects (POR < 0.05) were observed 
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2.3.3.2. Burden Analysis 
Analysis of the rare variant burden within SLC22A11 and SLC22A12 revealed no 
significant effects. The number of individuals with a rare variant allele was approximately 
equal between normouricaemic and hyperuricaemic individuals in both the Polynesian and 
European sample sets. The number of individuals with a rare variant allele was also 
approximately equal between these two populations for SLC22A11, but was much greater 
in Europeans than Polynesians at SLC22A12 (Table 2.18). 
 
Table 2.18: Rare variant burden analysis of SLC22A11 (OAT4) and SLC22A12 
(URAT1). 
Permutations 
Polynesian  European 
Frequency  PBurden  Frequency  PBurden 
Normo Hyper  All Risk Protect  Normo Hyper  All Risk Protect 
SLC22A11 (OAT4) 
- 16 (0.08) 16 (0.07)  0.997 - -  12 (0.07) 25 (0.13)  0.089 - - 
1,000    0.955 0.601 0.668     0.294 0.198 0.674 
10,000    0.956 0.606 0.677     0.319 0.206 0.708 
50,000    0.955 0.616 0.674     0.317 0.206 0.703 
SLC22A12 (URAT1) 
- 6 (0.03) 8 (0.04)  0.880 - -  16 (0.09) 22 (0.11)  0.640 - - 
1,000    0.063 0.226 0.369     0.111 0.542 0.179 
10,000    0.083 0.212 0.361     0.099 0.556 0.175 
50,000    0.080 0.216 0.359     0.097 0.555 0.174 
Normo – normouricaemic controls (serum urate levels < 370 µmolL-1). Hyper – hyperuricaemic cases (serum 
urate levels > 410 µmolL-1). Frequency – number and frequency of individuals where a rare variant allele is 
present (!" = 1). PBurden – burden analysis p-value for all (combined), risk only, and protective only variants. 
The initial combined PBurden is relevant to the Pearson χ2 test from the collapsing method (Li and Leal, 2008), 
the remaining PBurden values are relevant to the adaptive burden test permutations (Ionita-Laza et al., 2011). 
 
In contrast, burden testing of only non-synonymous variants indicated a significant burden 
of risk variants in SLC22A11 and protective variants in SLC22A12 in the European sample 
set. The same effect was not seen in the Polynesian sample set (Table 2.19). For SLC22A12, 
both the allele collapsing and adaptive burden methods detected a significant burden of 
non-synonymous variants. At SLC22A11 only the adaptive burden method produced a 
significant result, with the allele collapsing method producing only a nominally significant 
p-value (PBurden < 0.1). Across all adaptive burden tests the number of permutations used 
to calculate the p-value did not substantially change the results (Table 2.18 and Table 2.19). 
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Table 2.19: Non-synonymous variant burden analysis of SLC22A11 (OAT4) and 
SLC22A12 (URAT1). 
Permutations 
Polynesian  European 
Frequency  PBurden  Frequency  PBurden 
Normo Hyper  All Risk Protect  Normo Hyper  All Risk Protect 
SLC22A11 (OAT4) 
- 3 (0.01) 1 (0.00)  0.571 - -  2 (0.01) 10 (0.05)  0.065 - - 
1,000    0.290 0.936 0.290     0.240 0.008 0.988 
10,000    0.293 0.943 0.293     0.260 0.016 0.984 
50,000    0.288 0.945 0.288     0.258 0.015 0.984 
SLC22A12 (URAT1) 
- 1 (0.00) 1 (0.00)  0.999 - -  6 (0.03) 0 (0.00)  0.027 - - 
1,000    0.710 0.756 0.710     0.013 0.999 0.013 
10,000    0.729 0.762 0.729     0.011 0.999 0.011 
50,000    0.733 0.765 0.733     0.010 0.999 0.010 
Normo – normouricaemic controls (serum urate levels < 370 µmolL-1). Hyper – hyperuricaemic cases (serum 
urate levels > 410 µmolL-1). Frequency – number and frequency of individuals where a non-synonymous 
variant allele is present (!" = 1). PBurden – burden analysis p-value for all (combined), risk only, and protective 
only variants. The initial combined PBurden is relevant to the Pearson χ2 test from the collapsing method (Li 
and Leal, 2008), the remaining PBurden values are relevant to the adaptive burden test permutations (Ionita-
Laza et al., 2011). 
 
2.3.3.3. Non-Synonymous Variant Characterisation 
The binary classification of non-synonymous variants into those with a deleterious or a 
neutral effect on protein function was consistent across all three prediction programmes in 
68.8% of cases (Figure 2.8). In all cases, a prediction score and corresponding functional 
classification could not be obtained for the two nonsense mutations. 
 
Figure 2.8: Consistency between three methods predicting the functional 
consequences of sixteen non-synonymous variants in SLC22A11 (OAT4) and 
SLC22A12 (URAT1).  
 
Predictions are relevant to the default binary classification system (deleterious or neutral) of each method. 
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Six variants (SLC22A11: 1; SLC22A12: 5) were consistently classified as having a 
deleterious effect on protein function by all three prediction methods. Another five (all 
within SLC22A11) were consistently predicted to have a neutral effect on protein function. 
Of the remaining five variants three (SLC22A11: 2; SLC22A12: 1) were predicted to have 
a deleterious effect on protein function by two of the three programmes, whilst the other 
two (SLC22A11: 1; SLC22A12: 1) were predicted to have a neutral effect by two of the 
three programmes (Table 2.20).  
 
Table 2.20: Predicted consequences of SLC22A11 (OAT4) and SLC22A12 (URAT1) 
non-synonymous variants on protein function.  
Exon Position rs# Protein 
SIFT  PolyPhen-2  PROVEAN 
Score Prediction  Score Prediction  Score Prediction 
SLC22A11 (OAT4) 
Exon 1 11:64323476 rs141159367 A2V 0.00 Deleterious  1.00 Deleterious  -3.56 Deleterious 
Exon 1 11:64323607 rs200593751 G46S 0.36 Neutral  0.00 Neutral  -1.45 Neutral 
Exon 1 11:64323613 rs35008345 R48X - -  - -  - - 
Exon 1 11:64323853 - I128V 0.02 Deleterious  0.04 Neutral  -0.62 Neutral 
Exon 4 11:64329804 rs150160581 A240P 0.12 Neutral  0.01 Neutral  -1.93 Neutral 
Exon 4 11:64329814 rs138399841 A243V 0.64 Neutral  0.14 Neutral   1.51 Neutral 
Exon 5 11:64331830 rs142027244 Q291R 0.26 Neutral  0.00 Neutral  -0.81 Neutral 
Exon 6 11:64332766 rs141760078 V339M 0.14 Neutral  0.13 Neutral  -0.18 Neutral 
Exon 6 11:64332779 rs75933978 R343L 0.10 Neutral  1.00 Deleterious  -5.41 Deleterious 
Exon 9 11:64337291 - G517E 0.05 Deleterious  0.92 Deleterious  -1.94 Neutral 
SLC22A12 (URAT1) 
Exon 1 11:64359086 - Q20E 0.03 Deleterious  1.00 Deleterious  -2.62 Deleterious 
Exon 2 11:64360275 rs761942522 A143T 0.56 Neutral  0.86 Deleterious  -1.71 Neutral 
Exon 6 11:64366370 rs749900943 R315W 0.11 Neutral  0.51 Deleterious  -5.44 Deleterious 
Exon 8 11:64367854 rs147647315 R400H 0.03 Deleterious  0.87 Deleterious  -3.91 Deleterious 
Exon 8 11:64367902 rs201423508 T416I 0.01 Deleterious  1.00 Deleterious  -4.54 Deleterious 
Exon 8 11:64367925 rs747742344 E424K 0.00 Deleterious  1.00 Deleterious  -3.51 Deleterious 
Exon 9 11:64368382 - P490S 0.00 Deleterious  1.00 Deleterious  -7.01 Deleterious 
Exon 10 11:64369015 - Q518X - -  - -  - - 
Exons and variant position are according to the Genome Reference Consortium human genome build 37 
(GRCh37) on Ensembl (http://grch37.ensembl.org/). UTR – untranslated region. rs# – reference SNP cluster 
ID. Protein – amino acid substitution. Amino acids are specified using the IUPAC one letter amino acid codes. 
Predictions are based on the default threshold for each method; SIFT: score ≤ 0.05 is deleterious (for 
continuity SIFT prediction terminology was converted from damaging/tolerated to deleterious/neutral); 
PolyPhen-2: score ≥ 0.43 is deleterious; PROVEAN: score ≤ -2.5 is deleterious. 
 
2.3.3.3.1. Predicted Serum Urate Levels 
The regression models used to predict serum urate levels based on an individual’s genotype 
at seven common serum urate-influencing variants and covariate phenotypes explained a 
similar level of variation in serum urate levels between the European (Adjusted R2 = 0.11) 
and Polynesian (Adjusted R2 = 0.13) model-training sample sets, despite the inclusion of a 
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greater number of serum urate-influencing phenotypes in the Polynesian model (sex, age 
at collection, body mass index, Eastern/Western Polynesian ethnicity, self-reported 
grandparental ancestry, and use of urate-lowering medications) as compared to the 
European model (only including sex). The difference between measured and predicted 
serum urate levels in both sample sets had an approximate normal distribution around zero 
(European: (mean ± standard deviation) 0.00 ± 105.50; Polynesian: 0.00 ± 91.29), with a 
larger standard deviation in the European sample set (Figure 2.9). 
 
Figure 2.9: Difference between measured and predicted serum urate (µmolL-1) in the 
European (A) and Polynesian (B) model-training sample sets. 
    
Individuals with a difference between their measured and predicted serum urate levels > 3 standard deviations 
from the mean were classified as having a significantly different predicted serum urate level. In the European 
sample set this threshold value was ± 304.5 µmolL-1. In the Polynesian sample set this threshold was ± 273.9 
µmolL-1. A difference > 2 standard deviations from the mean was considered nominally significant 
(European: 203.0 µmolL-1; Polynesian 182.6 µmolL-1). 
 
Predicted serum urate levels in the ReSequencing Cohort also had an approximate normal 
distribution within each hyperuricaemia/normouricaemia sub-set. Within the European 
sub-set, five individuals had a predicted serum urate significantly different to their 
measured serum urate. One of these individuals was a hypouricaemic male with a measured 
serum urate of 80 µmolL-1 and a predicted serum urate of 398 µmolL-1, the other four were 
hyperuricaemic individuals with an average measured serum urate of 723 µmolL-1 and 
average predicted serum urate of 362 µmolL-1 (Figure 2.10: A). In the Polynesian sub-set 
ten individuals had a predicted serum urate significantly different from their measured 
B A 
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serum urate. All these individuals were hyperuricaemic, with a predicted serum urate in the 
normouricaemic range (average measured serum urate: 705 µmolL-1; average predicted 
serum urate: 387 µmolL-1; Figure 2.10: B). 
 
Figure 2.10: Difference between measured and predicted serum urate (µmolL-1) in the 
European (A) and Polynesian (B) ReSequencing Cohort sample sets. 
   
Individuals with a difference between their measured and predicted serum urate levels > 3 standard deviations 
from the mean (based on the model-training cohort) were classified as having a significantly different 
predicted serum urate level. In the European sample set this threshold value was ± 304.5 µmolL-1. In the 
Polynesian sample set this threshold was ± 273.9 µmolL-1. A difference > 2 standard deviations from the 
mean (based on the model-training cohort) was considered nominally significant (European: 203.0 µmolL-1; 
Polynesian 182.6 µmolL-1). 
 
None of the individuals identified as having significantly different measured and predicted 
serum urate levels had a non-synonymous variant in their SLC22A11 (OAT4) or SLC22A12 
(URAT1) gene. Two individuals carrying the SLC22A11 (OAT4) nonsense mutation 
(rs35008345: R48X) had a difference in their measured and predicted serum urate levels 
that was considered nominally significant (greater than 2 standard deviations from the 
mean), whilst the other two carriers of this mutation had very little difference between their 
predicted and measured serum urate levels (Table 2.21). The individual carrying the 
SLC22A11 (OAT4) non-synonymous variant A240P (rs150160581) also had a nominally 
significant difference in their measured and predicted serum urate level, although the SIFT, 
PolyPhen-2, and PROVEAN scores for this variant suggest it has no influence on protein 
function (Table 2.18 and Table 2.21). 
B A 
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Table 2.21: Summary of patient details for individuals carrying a non-synonymous 
variant within SLC22A11 (OAT4) and SLC22A12 (URAT1). 
Exon Position rs# Protein 
Patient Details 
Sex Ethnicity 
Serum Urate (mmolL-1) 
Measured Predicted Difference 
SLC22A11 (OAT4) 
Exon 1 11:64323476 rs141159367 A2V Female European 476 327 149 
Exon 1 11:64323607 rs200593751 G46S MaleA European 590 390 200 
Exon 1 11:64323613 rs35008345 R48X Female NZ Māori/Samoan 320 411 -91 
Exon 1 11:64323613 rs35008345 R48X Male European 650 387 263 
Exon 1 11:64323613 rs35008345 R48X Male European 480 391 89 
Exon 1 11:64323613 rs35008345 R48X Male European 583 360 223 
Exon 1 11:64323853 - I128V Male CI Māori/Tahitian 550 421 129 
Exon 4 11:64329804 rs150160581 A240P Male European 678 386 292 
Exon 4 11:64329814 rs138399841 A243V Male European 488 370 118 
Exon 5 11:64331830 rs142027244 Q291R Female NZ Māori/European 260 333 -73 
Exon 5 11:64331830 rs142027244 Q291R MaleA European 590 390 200 
Exon 6 11:64332766 rs141760078 V339M Male NZ Māori/European 320 389 -69 
Exon 6 11:64332779 rs75933978 R343L Male European 490 384 106 
Exon 6 11:64332779 rs75933978 R343L Male European 482 406 76 
Exon 6 11:64332779 rs75933978 R343L Male European 577 391 186 
Exon 6 11:64332779 rs75933978 R343L Female European 220 332 -112 
Exon 9 11:64337291 - G517E Male European 244 391 -147 
SLC22A12 (URAT1) 
Exon 1 11:64359086 - Q20E Female European 202 300 -98 
Exon 2 11:64360275 rs761942522 A143T Male CI Māori/European 430 425 5 
Exon 6 11:64366370 rs749900943 R315W Female European 226 325 -99 
Exon 8 11:64367854 rs147647315 R400H Male European 232 394 -162 
Exon 8 11:64367902 rs201423508 T416I Female European 268 317 -49 
Exon 8 11:64367925 rs747742344 E424K Female European 113 320 -207 
Exon 9 11:64368382 - P490S Male European 244 390 -146 
Exon 10 11:64369015 - Q518X Male Tongan 300 441 -141 
Individuals with a difference between their measured and predicted serum urate levels > 3 standard deviations 
from the mean (based on the model-training cohort) were classified as having a significantly different 
predicted serum urate level. In the European sample set this threshold value was ± 304.5 µmolL-1. In the 
Polynesian sample set this threshold was ± 273.9 µmolL-1. A difference > 2 standard deviations from the 
mean (based on the model-training cohort) was considered nominally significant (European: 203.0 µmolL-1; 
Polynesian 182.6 µmolL-1). Exons and variant position are according to the Genome Reference Consortium 
human genome build 37 (GRCh37) on Ensembl (http://grch37.ensembl.org/). rs# – reference SNP cluster ID. 
Protein – amino acid substitution. Amino acids are specified using the IUPAC one letter amino acid codes. 
AThis individual had both the G46S and the Q291R non-synonymous variants. 
 
Interestingly, individuals with a non-synonymous variant in SLC22A11 (OAT4) were more 
likely to have a predicted serum urate below their measured serum urate, whilst individuals 
with a non-synonymous variant in SLC22A12 (URAT1) were more likely to have a 
predicted serum urate above their measured serum urate (difference < 0: SLC22A11: 4/16 
= 0.25, SLC22A12: 7/8 = 0.88; χ2 = 8.39, Pχ2 = 3.8×10-3). 
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2.3.4. Discussion 
Characterisation of the SLC22A11 (OAT4) and SLC22A12 (URAT1) sequences revealed a 
significant burden of non-synonymous variants within both these genes, with this burden 
creating a risk of hyperuricaemia in SLC22A11 and a protection from hyperuricaemia in 
SLC22A12. A number of ancestry-specific variants were also identified, including two 
novel Polynesian specific variants with a potential hyperuricaemia protective effect. The 
evidence presented here supports that presented in Section 2.2, with both SLC22A11 and 
SLC22A12 playing a role in hyperuricaemia risk in Polynesian and European individuals, 
and by proxy gout. 
 
The identification of three Polynesian specific variants (SLC22A11: rs561874071; and 
SLC22A12: rs369153816, and rs543312307), with an allele frequency > 0.05 and the 
potential protective effect seen in two of these SNPs (rs561874071 and rs543312307: OR 
= 0.52, POR = 0.06, r2 = 1.0) is of particular interest to the study of gout within New Zealand. 
Each of these variants has been identified within very few individuals in the 1000 Genomes 
populations. rs561874071 and rs369153816 were each found in an individual from the 
“CHB” population (Han Chinese in Beijing, China; NA18533 and NA18646, 
respectively), whilst rs543512307 was found in three individuals from the “CDX” (Chinese 
Dai in Xishuangbana, China; HG00766), “CHB” (Han Chinese in Beijing, China; 
NA18629), and the “KHV” (Kinh in Ho Chi Minh City, Vietnam; HG02521) populations. 
This very rare population prevalence in people of East Asian ancestry (allele frequency = 
0.001, 0.001, and 0.003, respectively) but higher prevalence in the Polynesian population 
(allele frequency = 0.06, 0.08, and 0.06, respectively) is possibly a reflection of the shared 
ancestry between these populations and the genetic bottle necks that occurred during the 
settlement of Polynesia (Flint et al., 1989; Friedlaender et al., 2008; Kayser et al., 2008; 
Wollstein et al., 2010). Interestingly, the rs369153816 variant has a higher allele frequency 
in the West Polynesian individuals than East Polynesian individuals (allele frequency = 
0.12 and 0.04, respectively), whilst rs561874071 and rs543512307 (r2 = 1.0) were seen 
almost solely in East Polynesian individuals (1 heterozygote West Polynesian, 3 
heterozygote Mixed East/West Polynesians, 43 heterozygote East Polynesians, and 1 
homozygote East Polynesian). Logistic regression analysis in the East Polynesian 
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individuals (only)1, in response to this observation, produced a protective effect that was 
slightly stronger than that seen in the full Polynesian group, but was still only nominally 
significant (OR = 0.50 [0.23; 1.01], POR = 0.06). Follow-up genotyping of these variants in 
the larger New Zealand Gout Case-Control Cohort Polynesian individuals is necessary to 
confirm the linkage disequilibrium and association seen here. If the effect replicates, this 
will be the first Polynesian population-specific variant that influences hyperuricaemia/gout 
risk identified. 
 
The significant burden of non-synonymous SNPs identified in both SLC22A11 and 
SLC22A12 is also the first evidence that rare non-synonymous variants play a role in 
determining risk of hyperuricaemia in European individuals. As with other analyses of the 
SLC22A12 (URAT1) sequence, no non-synonymous SNPs were identified in the European 
hyperuricaemic individuals, reflected in a significant protective burden (PBurden = 0.01) 
(Cho et al., 2015; Iwai et al., 2004; Li et al., 2010). Additionally, five of the eight missense 
variants found within SLC22A12 had a consistent prediction of a deleterious effect on 
protein function by the SIFT, PolyPhen-2, and PROVEAN algorithms. A deleterious effect 
on protein function in the context of SLC22A12 should indicate a reduction in protein 
function, leading to a reduction in uric acid uptake, and a consequent reduction in overall 
serum urate levels. This is then consistent with the protective effect identified in the burden 
analysis. The transport activity of the R400H2 (rs147647315) variant has been functionally 
characterised, with a significant reduction in uric acid uptake ability (~50% capacity) being 
identified for the 400H URAT1 protein compared to wild-type URAT1 400R 
(approximately 18 pmol/mg protein/min compared to 36 pmol/mg protein/min, 
respectively) (Tasic et al., 2011). This is the only SLC22A12 non-synonymous variant 
identified in this study that has been functionally characterised (to my knowledge). 
 
A much larger number of variants were identified in SLC22A11 than in SLC22A12 (40 
compared to 26), and of these variants, a much higher percentage were rare variants (allele 
frequency < 0.05: 97.5% (39/40) compared to 61.5% (16/26), χ2 = 14.67, Pχ2 = 1.3×10-4). 
Previously, selection analysis of the protein coding sequence of SLC22A11 (OAT4) 
                                                
1 Adjusted for sex. Power to detect a strong effect (OR = 2.0) was 45.7% based on 106 hyperuricaemic cases, 
117 normouricaemic controls, and a control allele frequency of 0.07. 
2 Labeled R434H in Tasic et al. (2011). 
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produced possible evidence for purifying selection1 of OAT4, as defined by negative values 
in three selection statistics (Tajima’s D = -2.06, PD < 0.05; Fu and Li’s D = -2.83, PD <0.05; 
and Fu and Li’s F = -3.05, PF < 0.05) and characterised by a large number of low frequency 
variants spread throughout the gene (Barreiro and Quintana-Murci, 2010; Nielsen, 2005; 
Xu et al., 2005). These selection statistics could also be indicative of population expansion 
and this was implied by a fourth negative selection statistic (Fu’s Fs = -15.93, PFs < 1.0×10-
3) (Xu et al., 2005). In either case, the identification of a large number of low frequency 
variants is consistent with the results seen within this work. The prediction that very few 
of the non-synonymous variants have a deleterious effect on protein function is also 
consistent with the idea that OAT4 is possibly under purifying selection as those variants 
with a negative effect on protein function may be selected against, resulting in an extremely 
low frequency of these variants in the population (Barreiro and Quintana-Murci, 2010; 
Nielsen, 2005; Xu et al., 2005). 
 
The identification of a significant burden of risk variants within SLC22A11 in European 
individuals is inconsistent with the prediction that most of these variants have a neutral 
effect on protein function. In addition, functional analysis of the nonsense mutation 
identified here (rs35008345: R48X) has shown reduced uptake of uric acid by the truncated 
protein to approximately 50% that of the wild-type protein (Shima et al., 2010). As OAT4 
is involved in the absorption of uric acid within the renal proximal tubule, a lower protein 
functionality should reduce overall serum urate as seen in URAT1. Interestingly, in the 
same functional study of R48X the ability of the truncated protein to transport oestrone 
sulphate was reduced to a greater degree than uric acid transport (approximately 10%) 
(Shima et al., 2010). Perhaps in vivo this reduced capacity to transport oestrone sulphate 
creates a lower level of competition between substrates, resulting in a higher uric acid 
transport rate than usual despite the truncated protein being less able to transport uric acid 
in general. This lack of substrate competition, and resultant increase in uric acid uptake, 
could then translate to a burden of risk variants within the SLC22A11 gene. Functional 
assays that include uric acid/oestrone sulphate uptake competition need to be conducted in 
a model system to test this hypothesis. 
 
 
                                                
1 Purifying selection (or negative selection) is the selection against deleterious alleles. 
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2.3.4.1. Study Limitations 
This study is substantially limited by the very low detection power in each sample set, 
particularly in relation to rare variants. Low powered studies, such as this one, are biased 
toward producing false positive results with inflated effect sizes and it has been estimated 
that replication rates for a study such as this are 25% or less (Button et al., 2013). This 
trend in low powered studies is termed “winners curse,” whereby an under-powered study 
identifies an inflated effect that is then un-reproducible in subsequent follow-up studies 
(Button et al., 2013). Careful design of any follow-up analysis of this work will be required, 
in particular the use of a large sample size and a priori power calculations will be essential 
to reliably replicate or refute the results presented here (Button et al., 2013; Do et al., 2012). 
 
Several elements of this study design are able to reduce the impact of the low detection 
power. The use of extreme phenotypes (hyperuricaemia vs. normouricaemia) instead of 
serum urate as a continuous variable is somewhat combative of this problem (Button et al., 
2013; Do et al., 2012). In addition, the use of burden testing increases the power to detect 
a rare variant effect (Do et al., 2012). The inclusion of two different burden testing 
methodologies, an allele collapsing test and an adaptive test, also increases the power to 
detect an effect, as does the use of only non-synonymous SNPs in these analyses (Do et al., 
2012). In addition, the identification of a set of five common SNPs in the European sample 
set that reproduce a known association in SLC22A12 is an encouraging result that indicates 
the genotype calls from the sequence data are of good quality and the samples used were 
well chosen (Do et al., 2012). This result is also not biased toward reproduction, with only 
10.9% overlap in samples used between Section 2.2 and this section (40 individuals from 
the 2012 New Zealand Gout Case-Control Cohort), the majority of the European sample 
set being from the two American studies (78.0%, Health Professionals Follow-Up Study = 
167 individuals and Nurses’ Health Study = 120 individuals). 
 
The choice of burden tests used in this study is also a possible limitation. Many different 
burden test designs have been proposed in recent years, falling within five broad design 
categories each with their own advantages and disadvantages (Lee et al., 2014). Some tests 
are more able to detect effects when all the rare variants included are causal, others are able 
to compensate for a mixture of causal and neutral variants in the analysis group, whilst still 
others are able to compensate for opposite directions of effect (Lee et al., 2014). Each of 
these analyses also have their drawbacks; losing power when their assumptions are not well 
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met or being computationally intensive are the two most common disadvantages of burden 
testing (Lee et al., 2014). The use of two burden tests from different design categories 
(allele collapsing and adaptive) allows for some compensation for these differing analysis 
capabilities. Yet there are still other tests (within the same categories or in different 
categories) that could have been conducted and these analyses may have produced results 
that led to a different set of conclusions. Choice of analysis is always a major consideration 
in rare variant studies (Do et al., 2012). Those chosen in this work were selected based on 
simplicity of application and their complementary effect detection capabilities. The 
analysis of this same cohort with more sophisticated burden test methodologies may be of 
interest in future studies. 
 
Finally, the prediction of serum urate levels based on common SNPs and comparison to 
measured serum urate levels had a limited application within this study. This analysis did 
not produce any convincing results, although the tendency for individuals with non-
synonymous SLC22A11 variants to have a lower predicted serum urate level than 
measured, and for individuals with non-synonymous variants in SLC22A12 to have a higher 
predicted serum urate level than measured, does support the significant risk and protective 
burden effects detected. In the Polynesian cohort, the inclusion of a variable indicating 
whether an individual is taking urate-lowering drugs in the model, whilst necessary, may 
lead to underestimations of some individual’s serum urate levels as this variable does not 
take into account each individual’s adherence to these drugs. All the individuals with a 
significantly different measured and predicted serum urate in the Polynesian cohort were 
hyperuricaemic individuals taking urate-lowering drugs. In all cases their predicted serum 
urate was within the normouricaemic range, perhaps their mismatched serum urate 
measurement and prediction are an indicator of non-adherence to urate-lowering drugs. In 
addition, natural fluctuations in serum urate levels between measurements at different time 
points could have a significant influence on the ability to identify individuals with very 
different serum urate levels than genetically expected, although the inclusion of serum 
urate-influencing phenotypic data may compensate for this. As none of the individuals with 
a significantly different predicted and measured serum urate level had a non-synonymous 
variant in either gene, very little can be inferred from this analysis. It is likely the people 
who had very different measured and predicted serum urate levels have functional variants 
at other urate related loci. Characterisation of the non-synonymous variants in these 
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In conclusion, this section presents a detailed characterisation of the exonic sequences of 
SLC22A11 (OAT4) and SLC22A12 (URAT1). A significant burden of rare non-
synonymous risk variants was identified in SLC22A11 in European individuals; a novel 
finding. Similarly, a significant burden of protective non-synonymous variants was 
detected in SLC22A12 in the European sample set. This protective burden is consistent with 
prior studies of the SLC22A12 exonic sequence in hypouricaemic, hyperuricaemic, and 
gouty individuals. In addition, the first report of a Polynesian population-specific common 
variant with a potential hyperuricaemic protective effect is recorded here. Functional 
predictions of non-synonymous SNP effects agree (some what) with the effects detected, 
although proper functional characterisation of the novel variants detected in this study 
needs to be conducted. Replication of the results presented here is required, to confirm that 



















BLANK PAGE FOR PRINTING 
Gout in New Zealand 
Page | 117 
As part of any in-depth study of disease, the lived experiences of the disease sufferers must 
not be ignored. This thesis section is concerned with discovering the focus of patient 
experiences in New Zealand using two contrasting research styles. The first, a small scale 
ethnographic study of six individuals aimed at interpreting what these six people 
understand to be the cause of their gout. The second, a large-scale descriptive and statistical 
analysis of people’s responses to an open ended question concerned with gout triggers, 
aimed at building a more detailed picture of the wide variety of foods considered to trigger 
acute gout attacks. 
 
Illness is lived, social, rational, irrational, emotional, and personal; and whilst some 
understandings can be stripped back to the cold hard facts of a clinical disease aetiology 
this does not fully represent the individualised, complex, and “messy” nature of disease 
experiences (Madden, 2010; Thorne, 1999). Furthermore, in the case of chronic illnesses, 
such as gout, the perceptions and understandings a person holds are constantly shifting, 
informed by social context and life events (Paterson, 2001). Qualitative research recognises 
the personal aspect of disease understandings and strives to find meanings representative 
of this complex array of realities (Oakley, 2000). In contrast, quantitative research attempts 
to find commonalities that can be used to diagnose individuals, educate on symptoms and 
disease progression, create treatment strategies or cures, and ideally minimise the impact 
of living with a life-long condition (Oakley, 2000; Thorne, 1999). By intermingling both 
quantitative and qualitative research approaches, a greater understanding of the common 
generalisable aspects of disease can be developed, whilst recognising the vast expanse of 
individualised experiences. Qualitative research allows the recognition of multiple 
meanings operating together and has the potential to uncover new disease aspects that can 
then be assessed for “truth” in quantitative studies (Oakley, 2000).  
 
By talking to people whom this research is trying to help and uncovering their personal 
meanings and understandings of gout, new avenues of investigation can be opened. With 
the ultimate goal of disease research being to improve quality of life, either through better 
disease management or developing a cure, an assessment of what aspects of a disease 
individuals believe most in need of improvement must be conducted. It is therefore 
important to include this mingled qualitative and quantitative research section, that 
considering patient views and priorities, in this targeted analysis of gout within New 
Zealand.  
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Section 3.1. Understanding the Lived Experience of 
Gout Through Ethnographic Interviews  
3.1.1. Background 
Lived experience of disease informs the way in which an individual understands their 
condition (Petrie and Weinman, 2006). In recent years, patient understandings of disease 
have become of more interest to researchers, with a small number of qualitative studies 
being published that look at how patients understand the different aspects of gout. Three 
ethnographic studies of gout patients in New Zealand have been conducted in the past four 
years, each using semi-structured, one-on-one interviews to gather in-depth information on 
several different aspects of understanding gout (Lindsay et al., 2011; Martini et al., 2012; 
Te Karu et al., 2013). Lindsay et al. (2011) aimed to discover how 11 men living in South 
Auckland experienced gout and what impact it had upon their life, whilst Martini et al. 
(2012) focused on exploring the disease perceptions held by 60 people with gout from 
within the Auckland/Waikato region. Te Karu et al. (2013) extended these studies, 
interviewing 12 Māori individuals from both Auckland city and an unnamed rural New 
Zealand town, to assess their perceptions of the causes and impact of gout along with the 
understandings and attitudes held by these individuals (Lindsay et al., 2011; Martini et al., 
2012; Te Karu et al., 2013). 
 
Each of these studies mentioned the extreme pain of acute gout attacks and how this 
influenced many aspects of the participant’s experiences and understandings of gout. Pain 
was borne stoically, but left people dependant and isolated, unable to work or attend social 
activities (Lindsay et al., 2011; Martini et al., 2012). The experience of this pain was not 
restricted solely to the gout sufferers, with close family members bearing the brunt of 
sufferers’ frustration and dependency (Lindsay et al., 2011; Te Karu et al., 2013). This 
influence was further extended through the use of friends/whānau as a source of support 
and information (Martini et al., 2012). However, for some people, family and friends 
trivialised gout attacks and there was a general feeling of blame amongst families and 
communities which led to sufferers denying their condition, often for many years, not 
seeking treatment or medical advice (Lindsay et al., 2011; Te Karu et al., 2013). 
 
Interview and focus-group based qualitative studies of gout sufferers living in the United 
States of America and the United Kingdom have produced results comparable to these New 
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Zealand studies (Harrold et al., 2010b; Singh, 2014a; Spencer et al., 2012). A reluctance to 
seek medical advice, common to that seen in New Zealand patients, was discussed by gout 
sufferers from the United Kingdom interviewed by Spencer et al. (2012). This reluctance 
was instigated by embarrassment and the negative stereotypes held by themselves, family, 
and friends, that labelled gout as a self-inflicted and comical condition (Spencer et al., 
2012). Similarly, both Harrold et al. (2010) and Singh (2014) described an overall impact 
of gout analogous to that seen in New Zealand patients with severe pain, family 
dependence, work limitations, food restrictions, significant lifestyle adaptions, and social 
life changes being listed as examples of the far reaching social impact of gout (Harrold et 
al., 2010b; Singh, 2014a). 
 
These studies also discussed a general lack of knowledge about the biological causes and 
potential consequences of gout. All participants involved in the study by Te Karu et al. 
(2013) believed food to be the overall cause of gout, and a similar trend was contained in 
the representative interview quotes provided by Lindsay et al. (2011), along with the fears 
of reprimand for lifestyle and dietary practices held by patients from the United Kingdom 
(Lindsay et al., 2011; Spencer et al., 2012). Knowledge gaps were also found surrounding 
medication use and availability. Participants from all three countries, but especially those 
living in rural New Zealand, were unaware that preventative medications (such as 
Allopurinol) exist (Harrold et al., 2010b; Spencer et al., 2012; Te Karu et al., 2013). 
Furthermore, many people who were aware of preventative medications did not fully 
understand they need to be taken daily, were concerned about side-effects, and/or were 
sceptical of their effectiveness in preventing attacks (Martini et al., 2012; Spencer et al., 
2012). These differing levels of knowledge about gout medications were identified as 
potential barriers to medication adherence and successful management of gout in the United 
States of America by participants of a focus-group based qualitative study (Singh, 2014b). 
Participants with a high level of medication adherence had incorporated taking tablets into 
their daily routine, a key difference to participants with low adherence rates. But there was 
also a strong sense of the purpose and effectiveness of preventative medications understood 
by these people, which differed significantly from the scepticism expressed by patients with 
a low adherence to preventative medication (Singh, 2014b). 
 
Knowledge gaps were encouraged by the complex relationship patients held with the health 
professional treating their condition. Extreme differences in opinion between the gout 
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sufferers and health providers interviewed by Harrold et al. (2010b) and Spencer et al. 
(2012) were found. Providers in both countries viewed gout as less severe than patients did, 
and in the United States of America providers viewed gout as an easily treatable disease, 
although this was not the case in the United Kingdom. Providers in both countries believed 
gout patients had a good knowledge of the causes of gout and did not provide a high level 
of patient education resources, whilst patients complained about the lack of explanations 
about their condition (Harrold et al., 2010b; Spencer et al., 2012). New Zealand gout 
sufferers also felt the consequences of similar differences in opinion between patients and 
providers. Martini et al. (2012) found that general practitioners were the first source of gout 
sufferers’ information; however, the information obtained was often not completely 
understood and did not answer all the questions that individuals had. Te Karu et al. (2013) 
found a similar trend, noting that their study participants were reluctant to ask for 
clarification when information was not understood, and participants felt their doctors did 
not fully understand the experience of gout – a fundamental misunderstanding perpetuating 
sub-optimal disease management (Te Karu et al., 2013). 
 
All of these studies used their findings to propose changes to the current management of 
gout in the healthcare system. Better patient and community education resources, the 
encouragement of gout awareness, reciprocal patient-doctor conversations, and intensified 
efforts by providers to learn about and follow best practice recommendations were 
suggested. Following on from this current published work, this small ethnographic study 
aimed to find out how gout sufferers who have had access to community-based gout 
education resources understand gout, specifically focused on testing the hypothesis that 
their beliefs about the causes of gout will centre on the visible aspects of gout and overlook 
the less visible genetic or biological aspects. 
 
3.1.2. Methods 
3.1.2.1. Study Participants 
During the recruitment of individuals into the New Zealand Gout Case-Control Cohort 
(detailed in Appendix A.1; page 255), a research nurse regularly visited several Auckland 
community/iwi groups and work places. During visits people were able to have their serum 
urate and blood glucose levels measured (termed “gout testing”) and the results were 
discussed. Verbal and written education resources focused on gout, but including other 
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related conditions (such as diabetes and obesity), was provided in a culturally appropriate 
manner. Questions were encouraged, and for those with gout tracking of serum urate levels 
over time was offered. Community members who agreed to be enrolled in the New Zealand 
Gout Case-Control Cohort were also provided with a more comprehensive blood lipid, 
renal function, and urine analysis with an appropriate explanation of results. An Outing 
Gout hui (meeting) aimed at educating both healthcare providers and community members 
about the most recent research developments in gout was also held yearly. 
 
Six individuals (5 male, 1 female) from these Auckland communities who were over 18 
years of age (63 ± 8 years, mean ± standard deviation), spoke English, had been diagnosed 
with gout for a year or more (14.5 ± 11.6 years), and that the research nurse thought would 
agree to be interviewed, were asked to participate in a semi-structured interview focused 
on triggers, causes, remedies for, and research of gout (Table 3.1). These individuals were 
recruited from several of the different community groups that had received a high level of 
information tailored toward educating gout sufferers and their families. 
 
Table 3.1: Brief demographic details of the six interviewees. 
Interview ID Gender Age Ethnicity 
Gout History 
Duration Attack Freq. 
GW1117 Female 59 New Zealand Māori 1 10 
GM0417 Male 66 New Zealand Māori 22 8 
GM1018 Male 66 New Zealand Māori 16 3 
GM1119 Male 67 Cook Island Māori 17 24 
GM0320 Male 48 Cook Island Māori 1 0 
GM1121 Male 69 New Zealand Māori 30 2 
Duration – years since first attack. Attack freq. – approximate number of gout flares per year. 
 
3.1.2.2. Semi-Structured Interviews 
All interviews were conducted within a single week and were held in the community 
group/work place of each individual. Brief field notes were made throughout the process 
and a form collecting a minimal amount of demographic data filled in. The interviews 
themselves were approximately one hour in duration (50 ± 14 minutes) and consisted of 
semi-formal conversations between the interviewee and myself. Open-ended questions 
were used to direct the conversation topic towards the pre-determined interview topics 
(Appendix C.1; page 265), whilst allowing the interviewee to answer questions in their own 
time and with tangential details. The range of topics for discussion developed throughout 
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the interview process, supplementing the initial list with further topics that arose in earlier 
interviews – a grounded theory approach to ethnographic research (Strauss and Corbin, 
1998). Several days after the interview, participants were contacted for a brief follow-up 
call allowing them to share their thoughts on the interview process and add any further 
details they wished. Participants also received a small koha (thank you gift) for 
participating. 
 
3.1.2.3. Interview Coding and Analysis 
All interviews were audio recorded and transcribed in full. After transcription, interviews 
were read thoroughly and conversational themes noted. Each interview was then re-read 
and the content was systematically coded into five major themes made up of twelve sub-
themes (Figure 3.1).  
 
Figure 3.1: Themes and sub-themes systematically coded throughout six semi-
structured interviews with gout sufferers. 
 
The font size of each word is weighted according to how often each code was applied. Sub-themes are 
clustered around their major theme, although all themes are linked. 
 
After all interviews had been coded, they were organised into one possible story that 
faithfully represents what each individual said, assessing the similarities and differences 
between individual interviewees and the ways the themes interrelated to inform their 
understandings of gout (Madden, 2010; Oakley, 2000). Ethical approval for this project 
was granted by the University of Otago Human Ethics Committee (12/119) and written 
informed consent was received from each participant before the interview began. 
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3.1.3. Results and Analysis 
3.1.3.1. Pain 
Sudden, severe, unexplainable pain was the first experience all participants had of gout. As 
each of them recalled their first attack, a similar timeline of an unknown pain in their joints, 
prompting a visit to the doctor, and the subsequent diagnosis of gout became evident.  
 
I had a dull pain … and it got progressively worse and eventually it got so bad that I 
nearly fainted … I lay on the couch … and kept as still as possible to not aggravate 
it. The next day I went to Middlemore Hospital … they said it was gout. [GM1018] 
 
The severity of pain was further described with recounts of attacks so bad participants had 
to “lean against [someone] to hop along the passage way” [GM1018] or use “two sticks 
to get to the doctor” [GW1117]. Descriptions of the severity of a gout attack were vivid 
and distressing. They were characterised by comments about the way an attack “creeps up 
on you” [GM1121] and how they can “deter [you] from thinking about day to day living” 
[GW1117] As such, patients were keen to avoid this extreme pain in any way possible. 
Understandably, pain became the focus of treatment strategies. In some cases, this lead to 
the conclusion that “I better take my medication because I want to sleep at night” 
[GM1018], encouraging compliance with Allopurinol treatment to prevent attacks from 
ever occurring. For others avoiding the pain of a gout attack became such a priority that 
treatment for the pain became their sole focus at the expense of preventative measures. 
 
I went in to see [my doctor], she looked at me and she says “you’ve got gout” … and 
I go “well how did I get gout?” … She put it down to the fact that one, I’d been eating 
a lot of shellfish and two, that I’d had marmite … apparently there’s something that 
causes um, uric acid … I had no idea what she was talking about all I wanted was 
[for] her to take the pain away. [GW1117] 
 
Pain became a motivator, it shocked participants into “thinking how [they could] rearrange 
[their] eating so [they didn’t] keep coming back to ... this pain” [GW1117]. Some 
participants mentioned how they wished they could avoid attacks completely, and so were 
compliant with all their doctor’s suggestions, with a good level of success.  
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3.1.3.2. Triggers 
3.1.3.2.1. Identification 
All the participants spoke about the times they had experienced an acute gout attack brought 
on by an environmental trigger. Everyone listed a large number of trigger foods they had 
identified, many of which were not from the short list of recognised food triggers found in 
patient education pamphlets or provided by doctors (Johnston et al., 2015). 
 
There’s corned beef, pork, some seafood, tomatoes. I like my oranges, I like my 
lemons, onions. Those ones mainly ... my toe hurts at the sight of a beverage, you 
know, anything acidic, and mangoes ... there are others apart from mango, you know, 
like other fruits and veges. [GM1119] 
 
Whilst participants were able to provide these detailed lists there was a general consensus 
that “it’s hard to pin-point” [GM1119] which foods trigger attacks, but it’s important “to 
separate the foods that don’t give you gout and the foods that can give you gout” 
[GM1121]. Trigger foods were initially identified from discussions with doctors, the 
research nurse visiting the community, and patient education resources, but there was also 
a secondary step of realisation that “it’s not necessarily all because of the things that we’d 
been told” [GW1117] leading to a more active identification through reflection and 
experimentation. Trigger identification was also characterised by a feeling of confusion 
and frustration when individuals actively avoided trigger foods they had been told about or 
identified but were still experiencing acute attacks. 
 
You always go back to “What have I eaten? What have I done?” Then you sit back 
and think, well I never went into those areas that I know I’m not to go into, so is there 
something else for crying out loud? [GM0417] 
 
3.1.3.2.2. Avoidance 
Discussions of which foods triggered attacks included comments about the need to avoid 
these foods. Individual trigger avoidance strategies ranged from a moderate reduction in 
trigger food consumption, to complete removal of identified triggers from the diet. But this 
trigger avoidance “is hard … nobody is gunna stand up there and tell me it isn’t hard” 
[GM1119]. A number of factors created the difficulties faced when trying to avoid these 
foods. One participant expressed the sentiment that he “might as well become a rabbit, 
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hang around and chew on grass” [GM0417] as it seemed that everything he ate was a 
trigger. Participants also mentioned personal trigger foods being particular favourites, but 
they knew they had to “be more disciplined” [GM1018] to ensure attacks didn’t happen. 
Several people also mentioned the problems with the foods being “mixed up, you know, 
like a salad” [GM1119] or containing hidden “chemicals in the foods” [GM0320], 
particularly in reference to sugar, resulting in a situation where “you try [to] avoid them, 
but you just keep coming back to it” [GM1119]. 
 
Trigger avoidance did not only include avoiding certain foods. Several participants briefly 
mentioned non-food triggers, although these did not seem to be a major focus and some 
“didn’t take notice of whether non-food [items] would set off [the gout]” [GM1018]. As a 
consequence these were not avoided in the same active way, although some people had 
made lifestyle changes which led to the avoidance of non-food triggers. 
 
When the weather gets cold you start to [feel] a pinching … tightness in the feet … I 
like to go around in my “island safety footwear” [jandals] and sometimes … I gotta 
try and get out of them, put socks or shoes or boots on to keep warm. [GM1119] 
 
Gout triggers were generally considered to be a very important aspect of gout and for some 
the initial need to avoid these triggers developed into a complete lifestyle change to 
improve overall health. The avoidance of triggers was considered essential to good disease 




3.1.3.3.1. Of Pain/To Manage 
Treatment of gout has two separate goals, to relieve the severe pain of an acute attack, and 
to reduce uric acid levels to prevent recurrent attacks (detailed in Section 1.1.2.6). Both 
these purposes were discussed to varying degrees by interviewees. The immediate focus of 
individuals, discussed in each person’s story of their first attack, was to treat the pain. For 
two, at least initially, they understood that the “only cure was Voltaren” [GM0417] and 
they used this to “[get] us to work really” [GM1121], and carry on with their everyday 
activities. Pain relief was the focus and the faster acting doses were favoured, but over time 
they had learnt that “Voltaren is one of the worst things you could be taking in respect to 
Chapter 3 | Experiences of Gout 
Page | 126 
managing [gout]” [GM0417]. Interestingly, when some participants were discussing pain 
relief medications they mentioned their Allopurinol use, a drug intended to lower urate for 
the prevention of acute gout attacks, not pain relief. 
 
The doctor prescribed me Allopurinol … but that didn’t help much ... I went back and 
complained … that what he gave me wasn’t strong enough so they changed it … 
sometimes the gout is … unbearable so I would have to take an extra … one or two 
or three to really, you know, get rid of the pain. [GM1119] 
 
This confusion about each drug’s purpose could encourage incorrect medication use and 
treatment expectations for these people. Others were very clear on the different purposes 
and ways to take the medication they are prescribed, although several people also 
mentioned they “take a tablet [Allopurinol] before indulging” [GM1018] in their trigger 
foods. 
 
Discussions of gout treatment naturally progressed onto the idea that “with any sickness 
management is the cure” [GM0417] and descriptions of how each person achieved this 
management differently. All interviewees avoided their acute attack trigger foods, but in 
addition to this three relied heavily upon their medication, and were very pleased with how 
well “it’s working … I don’t feel pain anymore” [GM0320]. Two relied upon their drugs, 
but had also made major lifestyle changes to improve their overall health. 
 
I have been concentrating on eating only two types of meat, either fish or chicken and 
… changing the type of vegetables that I eat [GW1117]. 
 
One man had not had such a favourable experience taking Allopurinol to manage gout and 
was resistant to taking the drug every day for the rest of his life. He therefore preferred to 
manage his gout by not eating his trigger foods and exercising, despite pressure from his 
family doctor and rheumatologist to take Allopurinol. 
 
Allopurinol, if you take it while you got the gout it seems to be getting worse and 
more sore ... I’m a wimp when it comes to pain [GM0417]. 
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However, for many participants their management of gout was not solely concerned with 
lowering their uric acid levels to prevent attacks (best practice), rather management 
consisted of both the prevention of attacks and the treatment of pain. For some participants 
the pain was a motivating force encouraging attack prevention, for others this was not as 
big a focus as treating the severe pain of attacks. As gout treatment has two separate goals 
(reducing serum urate levels and relieving pain) and these goals received different levels 
of focus by each participant it was evident that discordant ideas and purposes were present 
and these led to misunderstandings with their doctor, blame, and compliance barriers.  
 
3.1.3.3.2. Compliance 
Throughout the interviews several participants mentioned the problems that can be inherent 
in taking medications or maintaining lifestyle changes over a long period of time. Two 
participants specifically mentioned forgetting to take their medication on occasion – for 
participant GM0417 forgetting his medication led to his complete cessation of Allopurinol 
therapy. He recounted how he “forgot to take the Allopurinol” when he “went North … for 
two weeks” and within these two weeks he “got the gout” after going “for six months 
without a bout” [GM0417]. This story highlights how quickly forgetting medication can 
set a person back when it comes to managing their condition, and how disheartening this 
can be.  
 
Additionally, three participants told stories about how they’d “get [Voltaren] from the 
doctor and share it with [their] whānau” [GM1121] in response to the recognition that 
“99% of the whānau had ... the same symptoms of gout” [GM1121]. The main flaw in 
sharing pills was pointed out by one participant who recounted the story of his cousin, 
which contained some parallels to the stories of forgetting to take medication. 
 
He was a silly fool ... the Allopurinol was given for him and he was giving it to his 
mates ... I said “what happens if you run out? What are you going to do?” ... “I told 
him don’t ever give your pills to anybody ... you’ll need them one day”. That day 
came and he didn’t have [them]. [GM1119] 
 
However, sharing also had a beneficial effect for some as those who had run out of 
medication could find a supplementary supply until they were able to fill their own 
prescription. One person was reluctant to borrow treatment from a friend when a gout attack 
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hit because “it belongs to you not to me” [GW1117]; however, due to the absolute agony 
she was experiencing and because she did not have any pain medication of her own she 
decided “I’ll have it, ‘cause there’s no way I’m gunna get to the doctor before Monday” 
[GW1117]. 
 
In contrast to these stories of unintentional treatment non-compliance a single participant 
revealed that when she initially received the diagnosis of gout she spent the first months 
avoiding following her doctor’s instructions about preventative medication. This began 
because “[the doctor] sent me to get blood tests done. I’m not the best person with needles 
and so I didn’t get them” [GW1117]. This avoidance of blood tests due to the participant’s 
dislike of needles continued for four months across multiple doctors visits and each time 
the doctor would be “really moaning at me about not having blood tests.” Eventually her 
doctor succeeded in convincing her to get a blood test by getting “the nurse to actually 
make an appointment … and they would ring the nurse when I got to the lab … and then 
they told my husband that he needed to make sure that I went ... so I got kind of cornered.” 
However, this was only the first step toward implementing a successful gout prevention 
program for this patient. Her doctor summarised the blood test results “which wasn’t really 
good” and prescribed Allopurinol. The patient “realised that I really seriously had to do 
something,” but through lack of motivation this resolution to improve her health “didn’t 
really sink in” and she did not take the Allopurinol treatment for any length of time. 
Interestingly, the patient recounted how the next time she needed to go to the doctor 
because of a gout attack she “thought I would go to a different doctor” to avoid being told 
off for not taking the drugs and also admitted to refraining from mentioning that she was 
no longer taking Allopurinol on a regular basis. It was not until she was forced to go back 
to her own doctor who said “you should be running out of Allopurinol by now” that she 
was once again cornered, and admitted that she had not been taking it regularly. The doctor 
sat down and carefully explained to her “that the reason why you take [Allopurinol] every 
single day is because it builds up in your system so that it’s a preventative” and this pointed 
explanation coupled with “much persuasion” from the New Zealand Gout Case-Control 
study research nurse that regularly visited this patient’s community group led to her starting 
to take Allopurinol every day, nine months after her first attack. At the time of our interview 
she had begun to see results and was still taking Allopurinol regularly. 
 
Gout in New Zealand 
Page | 129 
Interestingly, throughout this time of medication non-compliance she was very strictly 
following the dietary and lifestyle advice her doctor had given her. She was also taking 
pain medications for gout as prescribed and had further daily medications for her other 
health issues that she was compliant with. These facts create a contradictory story of 
mingled compliance and non-compliance, and potentially indicate a difference in 
importance placed on the different styles of treatment. 
 
The eventual success of the doctor highlights the importance of persistence in encouraging 
patients to adhere to treatment and in explaining why this compliance is important. The 
additional persuasion from the research nurse begins to indicate how important having 
someone to back up the doctor’s advice and encourage the patient is, especially as this 
encouragement happened outside of a doctor’s clinic. 
 
3.1.3.4. Overall Health 
For some people, gout is not the only medical condition they have to consider in their 
everyday life. For four participants, other health issues were mentioned as an important 
factor influencing the level of focus gout received and in the treatment strategies they could 
or couldn’t follow. 
 
One participant had osteoarthritis, and discussed how she got “used to a certain amount of 
pain, you just deem it to be normal” [GW1117], and although she was in constant pain she 
“wouldn’t allow it to get to me” unlike gout attacks which left her unable to function. 
Another participant had diabetes and thought this affected how his gout acted. 
 
I’m not quite sure if it’s coupled with diabetes … it brings it on a little quicker. 
[GM0417] 
 
He was also concerned that if he didn’t manage both conditions “the next train down the 
track is ... dialysis.” A third participant had recently had a stroke and made some major 
lifestyle changes that not only helped his stroke recovery, but also lowered his risk of 
constant gout attacks. 
 
When I had the stroke that was the biggest shock … it was on my left side which 
affects your co-ordination … I had to work on it … I worked so hard that I started 
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doing marathons and it kept my weight intact. Keeping the weight down is a great 
help for those who had a stroke and of course the gout. [GM1121] 
 
Other health issues also came with their own treatment plans and medications. One 
participant was taking Furosemide to lower his blood pressure, but knew from a relative’s 
experience that this can trigger gout flares and was concerned this might happen to him. 
He did however, consider it important to continue taking this medication as it “may be 
better … than taking it from [me] and getting rid of the aggravation of the gout,” but that 
it “ought to be explained why one needs that medication … even though [it] flares the 
gout” [GM1018]. It was also pointed out by another participant that “older people seem to 
attract more disease than anybody else” and this could lead to the need to take “a good 
half a dozen pills” [GM1121]. This increase in daily medication needs could become 
unwieldy and make it harder to remember if a pill had already been taken, or which pills 
needed to be taken, if an organised system was not in place. 
 
Interestingly, the recommended lifestyle changes for each of the conditions participants 
mentioned are similar to those that are recommended to treat gout; a nutritious diet, regular 
exercise, and maintaining a healthy weight. Recognition of this overlap in treatment 
strategies was not emphasised by patients, although one man did consider obesity to be “a 
ground sheet for all other diseases to come on top of” [GM1121] and another man 
mentioned that he had observed in friends/whānau that “all those foods they been eating 
… before they got, you know, diabetes … the same foods are causing gout” [GM1119]. 
Therefore, a more holistic approach to managing overall health along with personalised 
patient education may be beneficial to managing chronic health conditions. 
 
3.1.3.5. Building Knowledge 
3.1.3.5.1. Talking with Doctor/Research Nurse 
All six participants made comments throughout their interviews about the need to 
understand and build-up their knowledge of gout so they can better manage their disease 
and help prevent its development in friends/whānau. The process of building this 
knowledge was complex. Very few participants recounted actively requesting information 
from their doctor, instead participants sought information online, from the visiting research 
nurse, from gout educators in the community, or from older family members or friends. 
 
Gout in New Zealand 
Page | 131 
I have been getting my information … from those [people] who have been going 
around informing people on gout and testing them for gout and uric acid … rather 
than looking at the pamphlets and books. [GM1018] 
 
Recollections of conversations with doctors varied. Some were recalled as perfunctory, 
hurried visits that focused primarily on the pain participants were in during the visit and 
the need to get pain relief treatment. Others included recommendations their doctor made 
for the inclusion of dietary and lifestyle changes and explanations concerned with the cause 
of gout. Most of the participants recalled their doctor telling them to “watch your diet” 
[GM1119] and many had been told to specifically avoid seafood. For years two participants 
had only ever been prescribed Voltaren by their doctor, receiving no information about the 
causes of gout, potential consequences of untreated gout or the option of going onto urate-
lowering therapies. 
 
I didn’t have a clue, the doctor said to me you’ve got gout and I took his word. What 
the hell gout was I didn’t know … never questioned what gout was. [GM1121] 
 
In contrast, when participants recalled their conversations with the research nurse that 
regularly visited their community group/work place as part of our New Zealand Gout Case-
Control Cohort participant recruitment, they did so with a happy countenance, with 
interviewees mentioning “she’s got a touch to her personality when she goes to meet people 
that draws them in … they can mix with her” [GM1121]. It was also mentioned that the 
information she provided was clear and simple to follow, although there were still some 
comments about how too much information at once could be overwhelming. 
 
I didn’t really take in what she was saying ‘cause … it was bad enough realising it 
was sugar … rather than seafood [triggering gout attacks] … anything else she might 
of said … didn’t stick in my brain [GW1117]. 
 
A strong point of the research nurse’s regular visits to each person’s community 
group/work place was the instant testing of serum urate levels provided to anyone who 
wanted it. Simple finger prick tests (Roche Reflotron® Plus), which produced almost 
instant results, enabled participants to keep track of how well their gout management 
strategies were working. This encouraged participants to keep going when their results 
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were favourable, or to change strategies when it wasn’t working. For some this was the first 
time a test for serum urate levels had been performed, and made quite a difference to their 
understanding of gout. 
 
After having the blood test ... three months ago, ... I never had it done until the 
researcher came, ... I got tested and I was quickly told ... I was a walking cannon 
ball ... that made me take notice. [GM0417] 
 
3.1.3.5.2. Underlying Causes 
The research nurse had regular contact with participants and encouraged the building of 
knowledge through conversations, even encouraging some participants to further research 
gout online. However, despite this group of people having very good access to educational 
resources designed to emphasise all the different components of gout risk and causes, when 
specifically asked “what do you think causes gout?” participant’s answers varied, but 
focused on the dietary and lifestyle aspects of gout before the biological explanations. 
 
Probably the food, or my weight, or no exercise, yeah, I think the food ... or not 
enough liquid ... that’s a hard question. [GM0320] 
 
This was the case for all interviewees except one who described the underlying biological 
cause of gout exactly as it is presented in patient education resources. 
 
My understanding is that if there’s too much uric acid in the body then it tends to 
cause gout. Unfortunately, it causes crystals and if there is crystals then a person is 
going to suffer gout. [GM1018] 
 
The other participants recalled their doctor or the research nurse mentioning “that gout 
blood thing” [GM0417] (uric acid) to them at some point, but often struggled to recall its 
name and did not know how it was relevant to gout. One participant knew there are “these 
little things that [grow] crystals” [GM1121] in your joints which cause the pain of gout, 
but did not know what these were made of. No participants knew how food relates to uric 
acid despite food being their major focus. 
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Furthermore, although five of the six interviewees had also been collected into our New 
Zealand Gout Case-Control Cohort for genetic research on a prior occasion and were 
provided with information about the genetics of gout by the research nurse, none of these 
participants could recall any information about the genetics of gout in detail. One 
participant had a vague idea that gout “goes from generation to generation” [GW1117] 
and mentioned this when questioned about the genetics of gout. Another man mentioned 
family members having gout, but was uncertain if this meant gout has a genetic component. 
 
Being aware one’s father suffered from the gout … my mother did not … but I know 
other relations have … as far as whether its genetic or not I can’t say because I’m 
not sure. [GM1018] 
 
Some of the participants thought they had probably been told about gout genetics “but I 
can’t remember” [GM0320], whilst others, despite agreeing to be in a study about gout 
genetics were unaware that the research is going on, although all participants were keen to 
hear about research findings once this was brought up in the conversations. 
 
Interviewer: Have you heard about the genetic research that is being done looking 
at what’s different in people with gout to people without? 
 
GM1119: Is this a thing going on? That’s good to know … that is awesome because 
you people are trying to find a cure.  
 
The only participant who had a good grasp of the genetic element of gout was the one 
participant who is not enrolled in our genetic study (dislikes needles). He knew that the 
“[uric] acid rate, because of our genetics, in Māori, … in Pacific Island they’re quite high” 
and understood that “every person has got uric acid, it’s just unfortunate that I happen to 
be Polynesian and my uric acid is a little bit, whole lot higher than yours will ever get” 
[GM0417]. However, whilst he demonstrated a clear understanding of the different genetic 
risks between ethnicities, he interspersed into these comments a summary of the different 
types of foods that contribute to this difference. Even with a good understanding of the 
genetic causes of gout the relationship between gout and food was still considered most 
important, and when directly asked “do you think food causes gout?” this man replied with 
“the type of food, yes … I ain’t kidding you of course it does!” [GM0417]. 
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3.1.3.5.3. For Friends/Whānau 
Despite not specifically knowing about the genetic element of gout all participants 
expressed concern for their children/grandchildren and for some this extended to their 
community/iwi as a whole. All participants were keen to build their knowledge of gout to 
help prevent such health problems affecting future generations. 
 
Initially I think being informed enough to manage it is good, but it’ll be far better if 
we’re more informed because if we’re not well informed how can we educate our 
families? [GM1018] 
 
Complementary to this need to pass on knowledge to the younger generation participants 
sought information from older family members. Friends with gout were also a source of 
information as participants saw “they know about it and they talk about it” [GM0320]. In 
some cases, this could encourage bad habits, although this was often recognised and 
participants tried to encourage their friends to take better care of themselves. 
 
They were talking to me about their gout, they say they feel pain, they still eating ... 
I was telling them ... you’ve been told by the doctor not to eat that ... you supposed to 
look after what the doctor tells you. [GM0320] 
 
The building up of participant knowledge, especially through the research nurse’s visits, 
encouraged discussion of gout within the wider community, fostering support and social 
inclusion. One participant mentioned noticing others in his community were reluctant to 
discuss gout, feeling the shame often associated with gout attacks, but this participant 
thought it important to encourage discussion of gout and it’s causes rather than hiding the 
condition. 
 
People say “what’s the matter with you?” “Well, I got gout.” I’m not ashamed to 
say I got gout … [but others] keep it to themselves … now I think it would be good to 
go back and really talk to them, get them to understand what gout is all about. 
[GM1119] 
Although this person was not ashamed of his condition he did admit “I wish I didn’t have 
[gout]” [GM1119], a sentiment shared by all participants. 
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3.1.4. Discussion 
Five major themes became evident within these six interviews. Pain, acute gout attack 
triggers, treatment strategies, overall health, and the build-up of knowledge were all central 
to the participant’s understandings and experiences of gout. These five major themes were 
made up of twelve interweaving and overlapping sub-themes and explained much of (but 
not all of) what was said in the six interviews. Participant experiences contained many 
commonalities, but the way that each participant understood their disease was distinctly 
their own, reflective of the unique social context and life events of each individual. 
 
It has been proposed that studies searching for meaning within understandings of chronic 
disease (such as gout) could consider the use of a “shifting perspectives model” to frame 
these meanings in to a representation of disease understandings and management strategies 
(Paterson, 2001; Petrie and Weinman, 2006). This model is made up of two spheres of 
focus, illness in the foreground and wellness in the foreground, and over time an 
individual’s dominant sphere of focus shifts according to disease symptoms, personal 
situation, and context (Paterson, 2001). The accounts of gout experiences presented here 
fit well within these shifting perspectives (Figure 3.2). 
 
Figure 3.2: The shifting perspective model and patient understandings of gout. 
 
Adapted from Figure 1 of Paterson (2001) – elements of patient understandings found within this study have 
been placed within the perspective they encourage. 
 
Participants’ accounts primarily reflected a wellness in the foreground perspective. The 
need to manage and control acute attacks and prevent further symptoms through medication 










interrupted daily life, 
high serum urate 
results, additional 
health problems.  
Illness in the Foreground Wellness in the Foreground 
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recognition that despite having a chronic illness, everyday health was not compromised. 
Accounts of the extreme pain of acute attacks showed an unavoidable shift toward an illness 
in the foreground perspective. The evident disruption of daily activities caused by an acute 
attack and the enforced need to focus on this pain and its treatment reflected an illness in 
the foreground perspective equivalent to that described in Paterson’s summary of the 
shifting perspectives model (Paterson, 2001). This shift in perspective was further 
maintained when other health conditions added their own symptoms and complications to 
daily life and when attacks became more frequent despite the avoidance of trigger foods. 
 
Interestingly, although the themes identified in this analysis are reflective of those found 
within the wider literature of qualitative studies, from both New Zealand and overseas, a 
review of the findings in these other studies would suggest a greater tendency for gout 
sufferers to have an illness in the foreground perspective than seen in this analysis (Lindsay 
et al., 2011; Singh, 2014a; Spencer et al., 2012; Te Karu et al., 2013). In these other 
qualitative studies, patients mentioned a greater level of social isolation, embarrassment 
about their condition, frequent excruciating attacks, undesirable lifestyle changes, and less 
awareness of preventative treatments or the underlying causes of gout (Lindsay et al., 2011; 
Martini et al., 2012; Singh, 2014b; Singh, 2014a; Spencer et al., 2012; Te Karu et al., 2013). 
It could be suggested that the greater focus on wellness found within the individuals of this 
study may be due to their increased access to clear, concise information provided to both 
themselves and their community as a whole (Paterson, 2001). Through regular 
encouragement to build knowledge about the causes, consequences, and ways to manage 
gout as a chronic condition and minimise the impact it has on everyday life through the 
prevention of frequent attacks, a wellness in the foreground perspective was fostered 
amongst these six people. This may have been further aided by a reduction in common 
negative stereotypes, shame, and blame through the education of family and friends, 
preventing the social isolation felt by participants of other qualitative studies. 
 
To maintain a wellness in the foreground perspective of disease, an acceptance of the 
situation and a feeling of control within this new situation is required (Paterson, 2001). It 
is therefore not surprising that when participants were learning about the causes of gout in 
order to better manage their disease, they focused on the controllable elements, such as 
making lifestyle and dietary changes or adhering to medication prescriptions. Much less 
importance was placed on the unchangeable elements of gout aetiology, particularly 
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genetics. This then led to participants forgetting these elements, which could be interpreted 
as a knowledge gap in terms of the biological and scientific “truth” of gout (Oakley, 2000). 
However, perhaps instead of labelling this a knowledge gap, it should be interpreted instead 
as a form of unconscious self preservation and maintenance of the wellness in the 
foreground perspective of disease which allows for a much healthier overall lifestyle than 
the illness in the foreground perspective. 
 
It is common for qualitative studies of patient understandings of gout to find knowledge 
gaps and conclude that better patient education programs are required (Lindsay et al., 2011; 
Singh, 2014b; Spencer et al., 2012). Despite having access to the same community-based 
education program there is still a range of understandings were evident amongst the six 
people interviewed here. Unique understandings informed by experience and within the 
context of an individual’s life will always exist. In some cases, these unique understandings 
(along with individual priorities) will encourage good disease management strategies, 
whilst in others these unique understandings and priorities may hinder good disease 
management. The stories recounted by the six people interviewed here are examples of this 
variety of understandings that people with the same disease may hold. Perhaps optimal 
treatment of a chronic disease should recognise the unique understandings that individuals 
hold and find the best way to work with each individual, whilst interacting within the 
framework of generalisation that defines biological disease understandings and diagnostic 
criteria, to help patients achieve optimal management of their disease. 
 
3.1.4.1. Study Limitations 
This study is limited in several ways common to qualitative studies. Firstly, a very small 
number of people were interviewed, making any extrapolation of the results to reflect a 
wider community understanding unreliable and the inclusion of a different six people may 
have wielded different results. Secondly, during the interview process the questions asked 
and an unconscious encouragement of responses deemed “correct” or logical, may have 
biased patient responses towards those that supported the aims of this study. However, after 
a thorough consideration of all interview content and the identification of common themes, 
a comparatively small portion of the interviews was specifically about the causes of gout. 
Much more of the findings were not initially anticipated, suggesting this unconscious 
biasing of interviews was not as great as it may have appeared. Finally, the additional 
patient education that participants received from the research nurse, whilst clear, concise 
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and regularly enforced was also highly specific. As the majority of information was 
verbally provided by the research nurse, her own biases in focus and understanding will 
have filtered into her education style, a factor that may be less common in a more wide-
spread community-based education program provided by multiple people. In addition, 
patient education was only a secondary element to the research nurse’s presence within the 
community, with her primary aim being to recruit participants into the New Zealand Gout 
Case-Control Cohort for genetic analysis. Despite these limitations, the findings presented 
here hold similarities to those of other studies, both within New Zealand and other 
countries, and provide a holistic picture of the complex and social experiences of gout, 
which can be used to direct the focus of larger, more generalisable quantitative studies. 
 
3.1.4.2. Conclusion 
In conclusion, the six ethnographic conversations with gout patients presented here 
revealed unique and shared understandings of the causes of gout between participants. The 
elements of gout aetiology that were recognised as changeable, such as diet, were the 
primary focus in the understandings of gout causes expressed here. The unchangeable 
biological “truth” received much less focus. Increased community-based patient education 
targeted at both patients and their friends/whānau seemed to reduce the negative 
stereotypes of gout commonly found in other qualitative studies and encouraged increased 
learning about disease management. This study tentatively suggests a greater community 
awareness of gout causes is beneficial to patients and the encouragement of personal 
understandings that foster a wellness in the foreground perspective of disease is important. 
Further research into the effects of community targeted gout education programs is required 
before more solid conclusions can be made. In addition, more research into the changeable 
aspects of gout aetiology is needed so patient education resources and healthcare providers 
can support the focus on these elements.  
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Section 3.2. Descriptive Analysis of the Frequency and 
Variety of Food Items Listed as Acute Gout Attack 
Triggers by New Zealand Gout Patients. 
A portion of the work presented here (along with a portion presented in Section 4.2) has 
been published in BMC Musculoskeletal Disorders: 
Flynn, TJ, Cadzow, M, Dalbeth, N, Jones, PB, Stamp, LK, Harré Hindmarsh, J, . . . Merriman, TR. 2015. Positive 
association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of 
gout flares. BMC Musculoskeletal Disorders. 16(1): 196. 
 
3.2.1. Background 
The focus on dietary influences of gout seen in the ethnographic interviews (presented 
above) suggests further research in this area may be of benefit. It is commonly accepted 
that certain environmental factors, such as consuming certain foods, are able to induce the 
severe pain of an acute gout attack (Zhang et al., 2006). These factors are called acute gout 
attack triggers. Alcohol, red meat, and seafood are the traditional, accepted trigger foods. 
All three of these foods have been associated with incident gout and increased serum urate 
levels in large North American cohorts, whilst alcohol has also been associated with serum 
urate and prevalent gout in New Zealand Māori and Pacific Island individuals (Choi et al., 
2004b; Choi et al., 2004a; Choi and Curhan, 2004; Choi et al., 2005a; Rasheed et al., 2013). 
High-purine foods, particularly from animal sources (meat, organ meats, seafood), and 
alcohol have also been directly associated with recurrent gout attacks in an internet-based 
case-crossover study designed to assess foods influencing the onset of acute gout attacks 
(Zhang et al., 2012; Zhang et al., 2006). As such health professionals often advise gout 
sufferers to reduce their consumption of alcohol, red meat, and seafood in the hope that this 
will reduce the frequency of their gout flares (Harrold et al., 2013; Johnston et al., 2015; 
Zgaga et al., 2012). 
 
However, gout patients themselves often mention avoiding a large variety of foods that are 
not on this short list of medically accepted trigger foods (Section 3.1). In a study conducted 
by Shulten et al. (2009) information on the normal dietary habits of 29 Australian gout 
sufferers was collected, 62% of the participants reported avoiding other foods additional to 
the accepted list (such as citrus fruits, tomatoes, and vegetables), as a result of identifying 
them as gout attack triggers (Shulten et al., 2009). Shulten et al. viewed the avoidance of 
additional foods as concerning because it is “not supported by current evidence” and may 
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lead to “sub-optimal nutrient intake” (Shulten et al., 2009). Lindsay et al. (2011) proposed 
a “model of gout” which suggested that “traditional triggers” are characteristic of early 
gout and the identification of the wide variety of additional unsupported trigger foods is a 
consequence of progressive, untreated disease (Lindsay et al., 2011). Harrold et al.’s survey 
of 240 United States gout patients found that many individuals report foods that are not 
“documented to cause gout” as trigger foods, and similar to Shulten et al. (2009) claimed 
patients “incorrectly reported [these foods] as triggers,” citing this as a reason for better 
education resources in clinical practice (Harrold et al., 2012). 
 
Yet anecdotal evidence indicates avoidance of foods in addition to those recommended by 
health professionals regularly occurs and it is likely that the patients reporting these food 
avoidances have very good experience-based reasoning behind their decision (Zhang et al., 
2006). This experience-based reasoning was clearly seen in the interviews with six gout 
sufferers presented in Section 3.1 of this thesis. Additionally, Martini et al.’s semi-
structured interviews with 60 gout patients about their knowledge of gout attack triggers 
and gout risk factors determined that 85% of their study participants knew foods can trigger 
gout, and 51% of these avoided personal trigger foods. Martini et al. (2012) suggested in 
their discussion that a food diary might assist patients to discover their personal triggers, 
not favouring the medically accepted knowledge surrounding alcohol, red meat, and 
seafood; but rather allowing individuals to develop their own knowledge of triggers, and 
encouraging the personalisation of gout management (Martini et al., 2012).  
 
Despite the evidence that a large variety of foods are anecdotally listed as acute gout attack 
triggers no study (to my knowledge) has attempted to characterise the frequency and variety 
at which different foods are identified as gout triggers. Therefore, this work aimed to fill 
this research gap and test the hypothesis that a large variety of food items will be listed as 




3.2.2.1. Study Participants 
New Zealand men and women with clinically-ascertained gout (n = 2,106) recruited as part 
of the New Zealand Gout Case-Control Cohort (n = 1,789) and the Ngati Porou Hauora 
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iwi-based initiative (n = 317; described in Appendix A.1; page 255) were included in this 
study. The cohort was split into four ancestral groups, New Zealand and Ngati Porou Māori 
(n = 639), Pacific Island (Samoan, Cook Island Māori, Tongan, Niuean; n = 491), New 
Zealand European (n = 833), and other ethnicities (Indian, Chinese, Filipino, Fijian; n = 
143). Individuals with ancestry from multiple groups were preferentially categorised into 
New Zealand/Ngati Porou Māori, Pacific Island, and then other ethnicities in that order. 
The New Zealand European group consisted of individuals with only European ancestry. 
A brief summary of the demographic data for this cohort is presented in Table 3.2. 
 












Sex (% Female)  149 (17.89%)  125 (19.56%)  73 (14.87%)  14 (9.79%) 
Age (Years)  65 ± 13  57 ± 13  50 ± 13  54 ± 14 
BMI (kg/m2)  30.23 ± 6.77  35.66 ± 8.15  36.80 ± 7.92  28.54 ± 4.88 
Serum Urate (µmolL-1)  403.15 ± 114.49  423.07 ± 112.79  454.74 ± 108.94  414.38 ± 120.25 
Relative with Gout  367 (44.06%)  420 (65.73%)  302 (61.51%)  54 (37.76%) 
Grandparental Ancestry (%)  96.59 ± 12.07  74.63 ± 27.06  91.38 ± 17.49  89.29 ± 25.34 
Self-Reported Comorbidities 
Diabetes  124 (14.89%)  177 (27.70%)  119 (24.24%)  29 (20.28%) 
High Blood Pressure  448 (53.78%)  397 (62.13%)  247 (50.31%)  65 (45.45%) 
High Cholesterol  401 (48.14%)  298 (46.64%)  240 (48.88%)  66 (46.15%) 
Heart Problems  292 (35.05%)  232 (36.31%)  101 (20.57%)  30 (20.98%) 
Kidney Problems  180 (21.61%)  109 (17.06%)  77 (15.68%)  26 (18.18%) 
Gout Severity 
Age at Onset  49 ± 17  41 ± 16  38 ± 13  43 ± 13 
Years since Diagnosis  15.19 ± 13.07  16.49 ± 13.77  12.29 ± 11.14  10.98 ± 11.49 
Urate at Diagnosis (µmolL-1)  478.02 ± 115.41  520.00 ± 118.88  538.21 ± 104.33  495.54 ± 108.87 
On Urate-Lowering Medication  595 (71.43%)  493 (77.15%)  398 (81.06%)  106 (74.13%) 
Number of Attacks  7.39 ± 36.63  6.96 ± 30.58  9.38 ± 27.13  7.76 ± 31.86 
Tophi Present  266 (31.93%)  160 (25.04%)  189 (38.49%)  31 (21.68%) 
Total number of participants is shown in brackets. Data are shown as the mean ± standard deviation, or as 
number of participants (percentage). 
 
3.2.2.2. Data Collection and Analysis 
Participants were asked about gout attack trigger foods in several question formats. 2,106 
individuals were asked the question “do certain foods/drinks trigger your gout?” and given 
the opportunity to list gout trigger foods/drinks in an open-text format. They were then 
further prompted to specify whether alcohol or seafood triggered their gout “does 
[alcohol/seafood] trigger your gout? Yes/No.” Some individuals were only asked about the 
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trigger foods using the prompting style questions, and as such these individuals were not 
included in this analysis. 
 
The listed trigger foods given in the open-text question were edited for spelling errors and 
consistency of naming (eg. cornbeef vs. corned beef) before being summarised into two 
categories, traditional (alcohol, fish/seafood, and meat) and non-traditional, and the 
frequency at which people mentioned each category was assessed. Foods were further split 
into eleven food categories (alcohol, beverages, dairy products, desserts/sweets, 
fish/seafood, fruit, grains, legumes/nuts, meat, vegetables, and other food items). The range 
of different foods specified within each of these eleven food categories was examined and 
the frequency of each category calculated.  
 
Multivariate logistic regression adjusted for sex, age at collection, body mass index, 
number of gout flares in the past year, and family history of gout was conducted to assess 
whether the number of years since an individual’s first attack influenced the style of triggers 
listed (traditional or non-traditional). An additional logistic regression adjusting for gout 
severity indicators (sex, body mass index, number of years since first attack, number of 
gout flares in the past year, and family history of gout) was conducted to determine whether 
ancestry influenced the reporting of acute gout attack triggers, both overall and for each 
food category. In all regression analyses, individuals with missing or partial data were 
disregarded. All statistical analyses were performed in R 3.1.1 (www.r-project.org). POR < 
0.05 was considered statistically significant. 
 
3.2.3. Results 
3.2.3.1. Traditional and Non-Traditional 
Of the 2,106 New Zealand men and women with gout who were surveyed, 2,034 (96.6%) 
provided an answer to the trigger question. 1,474 (72.5%) self-reported ≥ one food or drink 
trigger of acute gout attacks. 1,305 people (64.2%) listed a traditional trigger (alcohol, 
fish/seafood, or meat), whilst 772 people (38.0%) listed a non-traditional trigger.  
 
Individuals who had been diagnosed with gout for a longer time were more likely to 
mention any trigger (2% more likely per year since diagnosis, POR = 1.0×10-5) than those 
who had not had gout for as long. This was irrespective of whether triggers were traditional 
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or non-traditional (OR = 1.02, POR = 1.8×10-4; OR = 1.02, POR = 6.3×10-8, respectively). 
When this analysis was split into the four ancestral groups New Zealand European and New 
Zealand/Ngati Porou Māori maintained a significant association, irrespective of the type of 
trigger listed. However, Pacific Island individuals who had been living with gout for a long 
time were no more likely to list any gout triggers than those who had only had gout a short 
time (Table 3.3). 
 
Table 3.3: Association between years since first gout attack and number of people 
listing traditional or non-traditional trigger foods. 
 




POR  % 
OR 
[95% CI] 




NZ European 58.8 
1.02 
[1.01; 1.03] 
2.00×10-03  49.7 
1.02 
[1.01; 1.03] 




NZ/NPH Māori 77.2 
1.03 
[1.01; 1.04] 
0.01  65.0 
1.02 
[1.00; 1.03] 




Pacific Island 88.7 1.03 
[0.99; 1.07] 
0.16  85.6 1.02 
[0.98; 1.05] 
0.35  45.7 1.01 
[0.99; 1.04] 
0.17 
Other Ethnicities 75.6 
1.03 
[0.96; 1.09] 0.44  71.1 
1.01 
[0.95; 1.06] 0.79  37.0 
1.05 
[0.96; 1.14] 0.29 
Traditional triggers were alcohol, fish/seafood, and meat. Non-traditional triggers were all other food items. 
NZ – New Zealand. NPH – Ngati Porou. % – percentage of people mentioning each trigger type. OR – 
adjusted odds ratio. 95% CI – 95% confidence interval. POR – p-value for odds ratio. 
 
3.2.3.2. Trigger Food Categories 
When trigger foods were further split into eleven food categories fish/seafood, alcohol, and 
meat (traditional triggers) were the most commonly mentioned trigger food groups. 935 
people (46.0%) specified fish/seafood (82 only mentioned seafood after the additional 
prompting questions), 713 people (35.1%) mentioned alcohol (213 only after additional 
prompting) and 539 people (26.5%) listed meat. The most commonly listed non-traditional 
trigger was vegetables (408 people, 20.1%), then beverages, and fruit (180 people (8.8%) 
and 178 people (8.8%), respectively) (Figure 3.3). 1,041 people (51.2%) listed > one trigger 
food, with the number of different foods listed by an individual ranging from one to nine. 
 
When the cohort was split into ancestral groups, it became evident that triggers were more 
commonly reported in people of New Zealand/Ngati Porou Māori and Pacific Island 
ancestry than in New Zealand European (79.7%, 88.7%, and 58.8%, respectively). 
Compared to New Zealand European, after adjusting for factors influencing the severity of 
gout, Pacific Island people were 4.97-fold (POR = 1.2×10-16) and New Zealand/Ngati Porou 
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Māori 2.22-fold (POR = 7.9×10-8) more likely to self-report any trigger of gout attacks. In 
general this trend was seen across all food categories (Table 3.4). Additionally, the most 
frequently mentioned trigger food categories differed slightly between ancestral groups. 
New Zealand European individuals were most likely to mention alcohol as a trigger food 
(32.2%), with fish/seafood (30.1%), vegetables (15.4%), and meat (14.2%) being listed 
second, third, and fourth most often, respectively (Table 3.4). In New Zealand/Ngati Porou 
Māori and Pacific Island individuals fish/seafood was the most commonly mentioned acute 
gout attack trigger (47.8% and 70.6%, respectively). New Zealand/Ngati Porou Māori 
individuals then listed alcohol (29.9%), vegetables (26.1%), and meat (20.0%) most 
commonly. In Pacific Island individuals this order was different again, with meat (53.0%), 
alcohol (45.7%), and vegetables (22.3%) being listed second, third, and fourth most 
commonly after fish/seafood (Table 3.4). 
 
Figure 3.3: Frequency at which 2,034 individuals reported foods within 11 categories 
as triggers of gout flares. 
 
There were 811 New Zealand European, 609 New Zealand/Ngati Porou Māori, 479 Pacific Island, and 135 
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3.2.3.3. Individual Food Items 
Answers to the question “do certain foods/drinks trigger your gout?” contained 196 
different food items, with 123 being listed by three or more people (Figure 3.4 and 
Appendix Table C.1; page 266). In some cases, individuals listed multiple foods within one 
of the eleven food categories created. In other cases, individuals mentioned foods across 
multiple categories preferring to use generic or grouping terms for foods of the same kind. 
An assessment of the frequency at which each of the 196 foods were listed revealed that 
several foods were obviously contributing to a much higher percentage of their food 
category than others in the same category. 
 
In the alcohol and fish/seafood categories some of the biggest contributing food items listed 
were the generic category names – the word alcohol was mentioned by 181 (36.2%) of the 
500 people who mentioned any alcohol as a trigger without additional prompting; the word 
seafood was listed by 335 (39.3%) of the 853 people who mentioned any fish/seafood as a 
trigger without additional prompting and the word fish was mentioned by 141 (16.5%) of 
these people. Beer was listed slightly more often than the generic term “alcohol” (216 
people (43.2%)) and red wine was the next most frequently mentioned alcohol at 18.0% 
(90 people). Mussels and shellfish contributed to the majority of the seafood category after 
the generic terms (264 people (30.9%) and 143 people (16.8%), respectively). The meat 
category was mainly contributed to by three foods – red meat, pork, and corned beef (177 
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Interestingly, the high frequency of vegetables being listed as a trigger food was clearly 
driven by people listing tomatoes, with 295 people (72.3%) of the 408 who mentioned any 
vegetable as a trigger mentioning tomatoes. The next most commonly mentioned 
vegetables were asparagus (41 people) and cabbage (30 people) at 10.0% and 7.4% of the 
category, respectively. Without the inclusion of tomatoes with the other vegetables, this 
category dropped from being the fourth most common category to being mentioned by only 
8.4% of people (170), seventh place. In the separate ancestral groups, tomatoes were the 
sixth, third, and fourth most commonly mentioned trigger food (for New Zealand 
European, New Zealand/Ngati Porou Māori, and Pacific Island individuals; respectively). 
Vegetables (excluding tomatoes) were the fourth most commonly mentioned trigger food 
in New Zealand European individuals and the eighth most commonly listed trigger food in 
the New Zealand/Ngati Porou Māori and Pacific Island groups. In response to this marked 
effect additional analyses were performed on tomatoes and other vegetables as separate 
categories (Table 3.5). 
 
Table 3.5: Percentage of New Zealand gout patients who listed tomatoes or other 
vegetables as acute gout attack triggers and an odds ratio comparing each ethnic 
groups percentage to the New Zealand European group. 
 Tomatoes  Other Vegetables 
 n (%) OR [95% CI] POR  n (%) OR [95% CI] POR 
NZ European 65 (8.0%) 1.00 -  72 (8.9%) 1.00 - 
NZ/NPH Māori 133 (21.8%) 
2.67 
[1.89; 3.78] 




Pacific Island 88 (18.4%) 
2.36 
[1.63; 3.44] 




Other Ethnicities 9 (6.7%) 
0.63 
[0.27; 1.50] 




All Ethnicities 295 (14.5%) - -  170 (8.4%) - - 
NZ – New Zealand. NPH – Ngati Porou. n – number of individuals who mentioned the food item/category. % 
– percentage of people who mentioned each food item/category, this percentage is calculated with the total 
number of individuals who answered the trigger questions as the denominator. OR – odds ratio compared to 
New Zealand European. 95% CI – 95% confidence interval. POR – odds ratio p-value. 
 
Similar to other food categories tomatoes were more likely to be reported as a trigger food 
by New Zealand/Ngati Porou Māori (21.8%) and Pacific Island people (18.4%) than New 
Zealand European (8.0%). This difference in report frequencies was 2.67-fold (POR = 
2.6×10-8) and 2.36-fold (POR = 6.9×10-6) greater, respectively, than in New Zealand 
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European after accounting for gout severity. No ancestral group listed other vegetables as 
gout triggers at a significantly different frequency to the other groups. 
 
3.2.4. Discussion 
Almost 200 different foods were listed as gout triggers by a large group of New Zealand 
gout patients. The most frequently mentioned foods fell into the traditional gout trigger 
food groups (fish/seafood, alcohol, and meat), however a large proportion of people also 
mentioned non-traditional trigger foods. The standout trigger food amongst all the non-
traditional triggers was tomatoes, with only the word seafood being listed more often. A 
greater number of years since their first gout attack, or being of Māori or Pacific Island 
ancestry, both influenced a person’s likelihood of mentioning any trigger irrespective of 
gout severity indicators and family history of gout.  
 
The tendency for traditional triggers to be mentioned more frequently than non-traditional 
triggers could be partially attributed to their acceptance in clinical practice. Health 
professionals and patient education documents consistently mention seafood, beer, and red 
meat in their dietary advice and whilst some temper this with disclaimers about 
personalised triggers, many contain statements that could imply these three foods are 
certain triggers for all individuals and advise complete avoidance (Zgaga et al., 2012). 
During the initial data handling for this section it became apparent that some people were 
merely reciting back what they had been told, with “alcohol, seafood, and red meat” 
commonly being listed together with no further clarification or other foods added to the 
list. One participant listed “high-purine foods” as their trigger, most likely an exact quote 
from patient education resources. Therefore, common patient education resources and 
clinical practice may artificially inflate the frequency of traditional trigger reporting. 
 
Inflated mention of traditional triggers was also reflected through the number of people 
who did not initially list seafood or alcohol as trigger foods, but an extra 4.0% and 10.5% 
of people (respectively) were willing to say seafood and/or alcohol trigger their gout attacks 
after additional prompting. Without the inclusion of the additional prompting information, 
the fish/seafood category was still the most frequently mentioned, however alcohol dropped 
down to third place after meat.  
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In direct contrast to these three traditional triggers, tomatoes were mentioned by 14.5% of 
people without any clinical or literature support. A cursory search of online patient 
education resources for gout (www.google.com; search terms “gout patient information”) 
revealed three resources that mentioned tomatoes, two listing them as “safe to eat” 
(www.webmd.com and http://umm.edu/health), whilst the other acknowledged that some 
people list tomatoes as triggers and advised the avoidance of them if they appeared to be a 
personal trigger (www.ukgoutsociety.org). Six other websites, five online pamphlets, and 
two print pamphlets commonly available to New Zealand gout patients did not mention 
tomatoes in relation to gout. 
 
Interestingly, several studies that have assessed the different understandings of gout have 
looked into how often gout patients mention non-traditional gout triggers. Several of these 
studies have provided examples of the unsupported foods gout patients avoid and tomatoes 
feature on several of these lists. Shulten et al. (2009) listed examples of food avoidances 
not supported by current evidence, these were “tomatoes, tomato products, citrus fruits, 
lentils, wholemeal bread, and vegetables” (Shulten et al., 2009). Lindsay et al. (2011) and 
Singh (2014a) both provided example patient quotes that mention tomatoes – “[I] can’t 
have peanuts, pecans, and tomatoes” (Singh, 2014a), “the triggers will be food so I am 
trying to work out the actual food. People say tomato does it” (Lindsay et al., 2011). 
Similarly my own patient quotes from the work described in Section 3.1 mention tomatoes 
in their listed trigger foods “I’ve noticed it’s not just seafood, tomatoes, anything with a bit 
of acid in” [GM0417]; “corned beef, pork, some seafood, tomatoes” [GM1119]. 
 
As both Singh (2014a) and Shulten et al. (2009) studied gout patients outside of New 
Zealand (United States and Australia, respectively), and the patient education pamphlet that 
mentioned tomatoes as a trigger was produced in the United Kingdom, it could be suggested 
that this high frequency of tomatoes being identified as a gout trigger is not a country-
specific or ethnicity-specific event, despite both New Zealand/Ngati Porou Māori and 
Pacific Island people being more likely than New Zealand European individuals to mention 
tomatoes as a trigger food. The evident difference in frequency that each food was listed as 
a trigger in New Zealand European, New Zealand/Ngati Porou Māori, and Pacific Island 
individuals does suggest there is some ethnicity-specific effects occurring, but overall 
tomatoes seem to be of relevance in many different populations. Potentially the high 
frequency of tomatoes being mentioned as a gout trigger by Māori and Pacific Island 
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individuals is encouraged by a greater community familiarity with gout due to the higher 
disease prevalence in Māori and Pacific Island populations (Winnard et al., 2012).  
 
The other non-traditional trigger foods that were mentioned at a frequency greater than 
2.0% (the highest frequency at which a single food was mentioned was seafood at 16.5%) 
were soft drink (4.7%), oranges (2.7%), and asparagus (2.0%). Non-diet soft drinks have 
been associated with raised serum urate levels and an increased risk of gout (Batt et al., 
2013; Choi and Curhan, 2008; Choi et al., 2008), and as such recent patient education 
resources (in New Zealand especially) have begun to incorporate this new information 
(Johnston et al., 2015). Fruit however, has been inconsistently associated with serum urate 
and gout, with some studies presenting no significant findings (Ryu et al., 2014; Schmidt 
et al., 2013), whilst others observed a decrease in urate and/or gout risk with increased fruit 
consumption (Lyu et al., 2003; Williams, 2008; Zykova et al., 2015). A single study has 
reported an increased risk of incident gout with increased fruit consumption (Choi and 
Curhan, 2008). Vegetables have consistently not shown an association with serum urate, 
gout, and onset of acute gout attacks; but some patient resources advise avoidance of 
purine-rich vegetables, such as asparagus, cabbage, spinach, and beans (Choi et al., 2004a; 
Schmidt et al., 2013; Zgaga et al., 2012; Zhang et al., 2012). Similarly, resources found 
during the brief Google search mentioned above had images of oranges, asparagus, and/or 
other fruits and vegetables although these weren’t mentioned in text (Sautner et al., 2015). 
This presents a confusing picture of the role of fruits and vegetables in gout; however, it 
might suggest these foods also have an increased likelihood of being mentioned over other 
foods that are not pictured or mentioned in any resource. 
 
The mechanisms by which these non-traditional trigger foods may trigger acute gout 
attacks are unknown. At present it is thought that the NLRP3 inflammasome is central to 
the onset of acute gout attacks (Busso and So, 2010; Kingsbury et al., 2011). Activation of 
the NLRP3 inflammasome requires the binding of two stimulatory elements to the TLR4 
or TLR2 proteins, signalling the initiation of the immune-cascade, and resulting in the 
production of active IL-1ß (Joosten et al., 2010; Kingsbury et al., 2011). In gout, 
monosodium urate crystals are one of these stimulatory elements. Interestingly, the three 
traditional trigger foods all raise serum urate levels to differing degrees; however, 
monosodium urate crystals form slowly, and a sudden rise in serum urate levels has not 
been shown to trigger gout attacks. Functional studies have shown free fatty acids can act 
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as the second stimulatory element in activation of the NLRP3 inflammasome. The 
consumption of alcohol, red meat, or seafood can encourage the release of fatty acids from 
adipose tissue and increase the concentration of circulating fatty acids (Lopes et al., 1991; 
Sozio and Crabb, 2008). It has therefore been suggested that alcohol, red meat, and seafood 
are able to trigger gout attacks through this change in free fatty acid concentration as 
opposed to their role in raising serum urate levels (Joosten et al., 2010). Several of the non-
traditional trigger foods listed by gout patients in this section are also likely to modify 
serum fatty acid concentrations, such as sugary drinks/foods, and fast food or fatty food. It 
is not obvious whether the other commonly listed non-traditional gout attack trigger foods 
modify fatty acids. 
 
In addition, a sudden decrease in serum urate levels, which encourages the shedding of 
monosodium urate crystals and recognition of these crystals by the NLRP3 inflammasome, 
has been identified as a potent gout attack trigger (Doherty, 2009; Rees et al., 2014; Zhang 
et al., 2006). However, foods that are known to lower serum urate levels (dairy products, 
coffee, perhaps fruit (Choi and Curhan, 2007a; Dalbeth and Palmano, 2011; Zykova et al., 
2015)) were not commonly mentioned as triggers of gout flares in this study (Figure 3.4). 
Perhaps small fluctuations in serum urate levels may be able to encourage crystal shedding; 
however, it is unknown if any of the more frequently mentioned non-traditional triggers are 
able to modify serum urate levels (besides soft drinks and perhaps fruit). Furthermore, as 
all three traditional triggers raise serum urate levels instead of lowering them, this suggests 
either these foods are able to instigate an inflammatory response through some other 
mechanism, or the acute raising of serum urate levels is able to instigate an acute attack. 
 
3.2.4.1. Study Limitations 
This study has its limitations. Firstly, the way in which the trigger food lists were collected, 
specifically the additional prompting questions for seafood and alcohol, creates a potential 
inflation in trigger frequency that may not have been completely removed by assessing 
those that listed these foods separately to those who only answered the additional 
prompting questions. Second, whilst all statistical analyses were adjusted for gout severity 
markers, in particular a family history of gout, the bias introduced by living in a community 
with a shared experience and knowledge of gout (evidenced in Section 3.1) may not be 
entirely removed, and perhaps a better adjusting variable could be created based on 
community involvement, familiarity with gout before diagnosis, and the different sources 
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used to identify triggers (eg. told by a doctor, family member or friend; read in a pamphlet 
or online; identified from own experience). And lastly, several foods may have an 
underestimated trigger identification frequency for several reasons. Overlapping names for 
food items were listed – for example red wine, white wine, and wine were all mentioned 
and it cannot be determined whether wine includes both red wine and white wine, or is in 
fact only made up of red wine but the wine type was merely not listed. Additionally, 
participants were not asked about their normal dietary habits and as such people who never 
eat a certain food, and consequently do not know if it triggers their gout or not, could not 
be excluded from the frequency calculations. 
 
The list of trigger foods each participant provided could only reflect what foods they eat 
frequently enough to recognise as acute gout attack triggers. What food a person eats is 
informed partially by cultural tendencies and partially by socio-economic status. And as 
New Zealand is a multi-cultural society with several distinctive “foodways” (cultural food 
preferences) this will be reflected in the food trigger lists provided (Morris, 2006). The 
three traditional triggers reflect the historical European-centric knowledge of gout, which 
may overestimate their influence in other cultures. Similarly, the common non-traditional 
triggers presented here and the ethnic differences in trigger identification frequencies will 
reflect the many different “foodways” present amongst this large group of New Zealand 
individuals and may not hold true for other societies. The much higher frequency of 
fish/seafood being mentioned by Pacific Island individuals compared to Māori or New 
Zealand European indicates even within the traditional trigger foods substantial differences 
in trigger food frequency can be seen. Future study designs should take these limitations 
into consideration to hopefully combat some of the biases in this study. 
 
3.2.4.2. Conclusion 
In conclusion, a wide variety of foods are identified by gout patients as personal gout attack 
triggers and whilst the most common of these are the accepted, traditional trigger foods 
many non-traditional triggers are also mentioned. Despite the present lack of supporting 
evidence for these other foods playing a role in the onset of acute gout attacks they should 
not be discounted as trigger foods. Additional research is required to further assess the 
frequency at which different foods are considered to be gout triggers and the mechanisms 
through which non-traditional trigger foods may be acting. As evidenced in the previous 
section, experiencing recurrent attacks despite strict avoidance of those foods listed as gout 
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triggers by health professionals can be frustrating. This frustration could be combatted if 
advice given to gout patients mentioned the wide variety of anecdotal gout attack trigger 
foods and encouraged the identification of personal trigger foods through the 
implementation of a food diary (as suggested by Martini et al., 2012), along with the usual 
cautions about traditional triggers. This systematic analysis of the variety and frequency of 
gout attack trigger foods is the first of its kind (to my knowledge) and provides a starting 
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Section 4.1. The Role of Diet in Gout: Current Evidence 
As evidenced in the previous section perceptions of gout place substantial emphasis on the 
role of diet in the aetiology and progression of gout. With over 70% of New Zealand gout 
patients identifying a large number of different foods as acute gout attack triggers, an 
investigation of the biological role of diet in gout aetiology is essential. Diet has been 
recognised as a substantial contributor to gout for over 2,000 years, particularly in relation 
to the role of overindulgence in acute gout attack onset (Bhattacharjee, 2009; Nuki and 
Simkin, 2006; Porter and Rousseau, 1998).  
 
Figure 4.1: Simplified schematic of the currently proposed mechanisms by which food 
items modify serum urate levels. 
 
The green circle encompasses the direct purine synthesis pathway. The orange rectangle represents renal 
excretion and to a lesser extent extra-renal excretion of uric acid. Τ – indicates an inhibitory action. Evidence 
for each mechanism is further detailed within the text. Red meat/seafood mechanism based on (Johnson et 
al., 2009). Soft drink mechanism based on (Bode et al., 1971; Johnson et al., 2008). Alcohol mechanism 
based on (Lieber, 1965; Nishioka et al., 2002; Yamamoto et al., 2005). Dairy mechanism based on (Dalbeth 
and Palmano, 2011; Garrel et al., 1991). Tea mechanism based on (Aucamp et al., 1997; Towiwat and Li, 
2015). 
 
Current evidence indicates diet is involved in multiple aspects of gout aetiology, with many 
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been proposed to explain the associations seen between serum urate levels and alcohol, 
meat, seafood, sugar-sweetened beverages (soft drinks and juice), and dairy products 
(Figure 4.1) (Towiwat and Li, 2015; Zykova et al., 2015). It is unknown whether these 
same mechanisms explain the associations between these foods and gout. 
 
4.1.1. Alcohol 
Alcohol has been associated with increased serum urate levels and risk of gout in studies 
of individuals from many countries and ethnicities (Table 4.1). Increased consumption of 
beer has consistently shown an association with increased urate levels (1 µmolL-1 to 4 
µmolL-1 increase in urate per serve per week) and risk of incident gout in American men or 
prevalent gout in New Zealand men and women (incident gout RR = 1.06, prevalent gout 
OR = 1.03 for each serve per week) (Choi et al., 2004b; Choi and Curhan, 2004; Gaffo et 
al., 2010; Nishioka et al., 2002; Rasheed et al., 2013; Schmidt et al., 2013; Zykova et al., 
2015). Beer has a high purine content (average purine content = 535 mg/100 g (Kaneko et 
al., 2009)), which could explain its urate-increasing properties. However, a randomised 
control trial conducted by Nishioka et al. (2002), with 20 healthy Japanese men, found no 
significant difference between the effect of normal beer and low-purine beer on serum urate 
levels (Nishioka et al., 2002). Conversely Zykova et al. (2015) observed a reduced effect 
on urate levels between low-alcohol beer (~15 µmolL-1 increase in urate) and normal beer 
(~33 µmolL-1 increase in urate) when consumption twice a week was compared to no 
consumption in a large Australian cohort (Nishioka et al., 2002; Zykova et al., 2015). These 
associations suggest that the alcohol in beer has a more significant urate-influencing effect 
than the purines, which is further supported by the association seen between spirits/liquor 
and serum urate levels. 
 
Many studies have shown spirits/liquor increase urate levels with an approximately 
equivalent effect size to beer (1 µmolL-1 to 3 µmolL-1 increase in urate per serve per week; 
Table 4.1) (Choi and Curhan, 2004; Gaffo et al., 2010; Nakamura et al., 2012; Nishioka et 
al., 2002; Zykova et al., 2015). Liquor has also been associated with an increased risk of 
incident gout in American men (RR = 1.02 per serve per week) and prevalent gout in New 
Zealand European men and women (OR = 1.05 per serve per week) (Choi et al., 2004b; 
Rasheed et al., 2013). All forms of alcohol have also associated with an increased risk of 
acute gout flares in a study designed by Zhang et al. (2006) to formally assess which foods 
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trigger gout attacks within 24 to 48 hours of consumption (Neogi et al., 2014; Zhang et al., 
2006). Liquor consumption conferred the greatest risk of acute gout attacks (OR = 4.44 for 
up to two servings compared to none). Wine produced the next greatest increase in risk 
(OR = 3.96), and then beer (OR = 3.63) for equivalent consumption levels (Neogi et al., 
2014). 
 
Interestingly, despite all alcoholic beverages triggering acute gout attacks they do not all 
seem to have the same effect on urate levels and gout (Table 4.1). Several studies have 
identified a decrease in serum urate levels of 8 µmolL-1 to 14 µmolL-1 in American and 
Australian women consuming ≥ three glasses of wine per week compared to none (Choi 
and Curhan, 2004; Gaffo et al., 2010; Zykova et al., 2015). But these same studies also 
presented no association between wine and serum urate levels in other cohorts. Wine 
consumption did not change the risk of incident gout in American men participating in the 
Health Professionals Follow-Up Study (n = 47,150; RR = 1.01, per serve per week), but in 
American men in the National Runners’ Health Study (n = 28,990), wine significantly 
increased risk of incident gout (RR = 1.03 per serve per week). In contrast, a decreased risk 
of prevalent gout has been reported in New Zealand European men and women drinking 
any amount of wine compared to those drinking none (OR = 0.66) (Choi et al., 2004b; 
Rasheed et al., 2013; Williams, 2008). 
 
This difference in effect with differing alcohol preparations is also seen when whiskey is 
associated with serum urate levels. Nishioka et al.’s randomised control trial, conducted on 
20 healthy Japanese men, found that consumption of specific types of spirits had different 
effects (Nishioka et al., 2002). Consuming whiskey had a urate-lowering effect equivalent 
to the consumption of water, via increased urinary urate excretion (27% more excretion 
within two hours of consumption), whilst a Japanese liquor (shochu) did not seem to have 
any effect on urate levels in this study (Nishioka et al., 2002). Another larger Japanese 
study found that sake significantly associated with an increased risk of developing 
hyperuricaemia (HR = 1.63 for individuals drinking ≥ three serves per day compared to 
those drinking none), which parallels the findings in beer and general spirits/liquor 
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Table 4.1: Effect of alcohol (serves/week) on serum urate levels or gout. 
Study  Serum Urate  Gout 
Reference Population Size  β Pβ  OR POR 
Total Alcohol 
(Teng et al., 2013) Chinese 483  0.08 0.02    
(Rasheed et al., 2013) New Zealand European 837  0.70 1.98×10-09  1.01 0.26 
(Rasheed et al., 2013) Polynesian 1,799  0.80 0.01  1.02 4.00×10-03 
(Choi and Curhan, 2004) American (General Population) 14,809  2.29 <1.00×10-03    
(Williams, 2008) American (General Population) 5,291  0.76 <1.00×10-04  1.03 < 1.00×10-04 
Beer 
(Teng et al., 2013) Chinese 483  0.12 4.00×10-03    
(Choi and Curhan, 2004) American (General Population) 14,809  3.91 <1.00×10-03    
(Williams, 2008) American (General Population) 5,291  0.85 <1.00×10-04  1.03 < 1.00×10-04 
(Rasheed et al., 2013) New Zealand European 837     1.03 0.03 
(Rasheed et al., 2013) Polynesian 1,799     1.03 2.00×10-03 
(Choi et al., 2004b) American Men (General Population) 51,529     1.06 < 0.05 
Spirits/Liquor 
(Teng et al., 2013) Chinese 483  0.08 0.26    
(Choi and Curhan, 2004) American (General Population) 14,809  2.46 <1.00×10-03    
(Williams, 2008) American (General Population) 5,291  0.76 3.00×10-03  1.02 0.18 
(Rasheed et al., 2013) New Zealand European 837     1.05 0.05 
(Rasheed et al., 2013) Polynesian 1,799     1.01 0.54 
(Choi et al., 2004b) American Men (General Population) 51,529     1.02 < 0.05 
Wine 
(Choi and Curhan, 2004) American (General Population) 14,809  -0.34 0.60    
(Williams, 2008) American (General Population) 5,291  0.59 0.01  1.03 2.00×10-03 
(Rasheed et al., 2013) New Zealand European 837     0.99 0.33 
(Rasheed et al., 2013) Polynesian 1,799     1.00 0.84 
(Choi et al., 2004b) American Men (General Population) 51,529     1.01 > 0.05 
Only studies that used alcohol consumption as a continuous variable were included in this summary table. β 
– serum urate beta value in µmolL-1. If serum urate was measured in mg/dL or mmolL-1 the study β was 
converted to µmolL-1 (mg/dL * 59.485; mmolL-1 * 1000). OR – study odds ratio. If alcohol was measured in 
serves per day the study β and/or odds ratio was converted to reflect the effect of serves per week (β/7; 
eln(OR)/7). 
 
Several mechanisms for the influence of alcohol on serum urate levels and gout risk have 
been proposed. In the liver, ethanol is converted to Acetyl CoA which requires ATP, this 
results in acute ATP depletion and the consequent conversion of AMP to IMP – a precursor 
to uric acid in the purine synthesis pathway (Figure 1.2 and Figure 4.1) (Yamamoto et al., 
2005). In addition, the conversion of ethanol to Acetyl CoA is coupled with the reduction 
of pyruvic acid to lactic acid, through the intermediary reduction of NAD+ to NADH and 
the oxidation of NADH to NAD+, and increased serum lactate levels have been associated 
with decreased urinary uric acid excretion (Lieber et al., 1962). It has been suggested this 
association is due to the coupled transfer of uric acid and lactic acid at SLC22A12 
(URAT1). When serum lactate levels are high, lactic acid is secreted into the lumen at a 
greater rate. As this is coupled with uric acid absorption a greater rate of uric acid uptake 
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occurs resulting in higher serum urate levels (Figure 4.1) (Lieber et al., 1962; Yamamoto 
et al., 2005; Yü et al., 1957).  
 
In contrast, the urate-lowering effect of whiskey has been attributed to inhibition of 
xanthine oxidase activity during uric acid synthesis and/or the inhibition of uric acid 
absorption by URAT1 (SLC22A12) during renal excretion (Figure 4.1) (Lu et al., 2014; 
Nishioka et al., 2002). Experiments examining the influence of whiskey on uric acid 
production in vitro found xanthine oxidase activity was reduced by 5% to 35% (dependent 
on whiskey age) compared to enzyme activity in the presence of an equivalent amount of 
ethanol (Nishioka et al., 2002). A follow-on study assessing the effect of whiskey on 
URAT1 (SLC22A12) and GLUT9 (SLC2A9) transport activity in vitro found significant 
inhibition of URAT1-mediated uric acid uptake and a lesser level of GLUT9 uric acid 
transport inhibition (Figure 4.1) (Lu et al., 2014; Nishioka et al., 2002). The different 
effects seen between alcohol types is likely due to the different congeners (chemical 
constituents) created during the fermentation and distilling processes. This is reflected in 
the changing influence of whiskey on xanthine oxidase activity as it ages (Nishioka et al., 
2002). Perhaps congeners in wine are also able to inhibit the production/excretion of urate, 
explaining the variable association effect directions reported within the literature and the 
difference in the percentage of people who specifically listed red wine or white wine as a 
gout trigger food in Section 3.2 of this thesis (4.4% and 0.4% of the people who mentioned 
and trigger food, respectively). 
 
4.1.2. High-Purine Foods 
Whilst research into the influence of alcohol on urate levels and gout was being conducted, 
foods with a high purine content were also being studied (Table 4.2). Foods with a very 
large purine content (> 300 mg per 100 g) include several seafoods (anchovies, shrimp, 
sardines), shiitake mushrooms, and chicken liver, whilst those with a large purine content 
(200 to 300 mg per 100 g) include organ meats (beef or pork liver), fresh fish, and some 
vegetables (spinach and parsley) (Johnson et al., 2013; Kaneko et al., 2014). Foods high in 
purines are able to directly increase urate levels by providing an increase in the levels of 
substrate available for conversion to uric acid in the purine synthesis pathway (Figure 1.2 
and Figure 4.1) (Johnson et al., 2009; Yamamoto et al., 2005). However, all high-purine 
foods do not have equal effects on serum urate levels and gout (Table 4.2). Total meat 
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consumption has been significantly associated with serum urate levels both in American 
and Australian cohorts, increasing urate by 0.5 µmolL-1 to 1 µmolL-1 per serve per week 
(Choi et al., 2005a; Zykova et al., 2015). A British study also found that individuals who 
had a meat eating diet had urate levels higher than those with a pescetarian or vegetarian 
(although not vegan) diet in both men and women (average difference in urate levels = 6 to 
9 µmolL-1 higher in men and 10 to 7 µmolL-1 higher in women compared to fish eaters and 
vegetarians, respectively) (Schmidt et al., 2013). Meat consumption has also been 
associated with prevalent and incident gout in American cohorts (prevalent gout RR = 1.03 
and incident gout RR = 1.05 for each serve per week), but other studies have found no 
association between urate levels and meat consumption in Korean, Taiwanese, and 
Norwegian individuals (Chang, 2011; Choi et al., 2004a; Ryu et al., 2014; Williams, 2008; 
Zykova et al., 2015). This lack of association may be due to lower frequencies of meat 
consumption in these individuals (highest consumption in the Norwegian group was ~2 
serves per week, and in the Korean group average consumption was ~1/2 a serve per day) 
(Ryu et al., 2014; Zykova et al., 2015). Seafood has also been associated with serum urate 
and gout with a much larger effect than meat (7 µmolL-1 increase per serve per week; Table 
4.2) (Choi et al., 2004a). Interestingly, this effect is limited to shellfish, with fish 
consistently showing no association with urate levels (Chang, 2011; Ryu et al., 2014; 
Schmidt et al., 2013; Zykova et al., 2015). Similarly, seafood increases the risk of incident 
gout (RR = 1.01 per serve per week), but fish does not (Choi et al., 2004a; Williams, 2008). 
 
Consumption of high-purine foods has also associated with an increased risk of acute 
attacks in the internet-based case-crossover study (OR = 4.61 when comparing the highest 
consumption quintile (3.5 g) to the lowest (0.9 g)) (Zhang et al., 2012). When this analysis 
was split into purines from animal sources (meat, organ meats, gravy, and seafood) or plant 
sources (beans, peas, lentils, oatmeal, spinach, asparagus, and mushrooms) the animal 
source purines continued to show an increased risk of attacks (OR = 2.41), but the plant 
source purines did not (OR = 1.39, POR > 0.05) (Zhang et al., 2012). Zhang et al. (2012) 
attributed this difference in association to the much lower purine content of vegetables than 
meats (average purine content = 121 mg/100 g for meat and 43 mg/100 g for vegetables) 
(Kaneko et al., 2014). A single study has found an association between vegetable 
consumption and serum urate levels, with Korean hyperuricaemic individuals consuming 
approximately three grams fewer vegetables per day than Korean normouricaemic 
individuals (Ryu et al., 2014). Another study found a similar trend in Taiwanese gout 
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patients and controls, with individuals with gout consuming vegetables ~2.5 times less 
often per month than controls (Lyu et al., 2003). Other studies that have assessed the 
association between vegetables and serum urate levels and/or gout have shown no 
significant association (Chang, 2011; Schmidt et al., 2013; Zykova et al., 2015). Studies 
assessing only purine-rich vegetables have also found no association with either serum 
urate levels or incident gout risk (Table 4.2) (Choi et al., 2004a; Zgaga et al., 2012). 
 
Table 4.2: Effect of high-purine foods (serves/week) on serum urate levels and gout. 
Study  Serum Urate  Gout 
Reference Population Size  β Pβ  OR POR 
Meat 
(Zgaga et al., 2012) British (General Population) 2,037  0.43 0.04    
(Choi et al., 2005a) American (General Population) 14,809  0.51 0.02    
(Williams, 2008) American (General Population) 5,291  0.93 0.02  1.05 2.00×10-03 
(Choi et al., 2004a) American Men (General Population) 47,150     1.03 < 0.05 
Purine-Rich Vegetables 
(Choi et al., 2004a) American Men (General Population) 47,150     1.00 > 0.05 
(Zgaga et al., 2012) British (General Population) 2,037  -0.20 0.38    
Seafood 
(Zgaga et al., 2012) British (General Population) 2,037  0.09 0.69    
(Choi et al., 2005a) American (General Population) 14,809  7.14 0.06    
(Choi et al., 2004a) American Men (General Population) 47,150     1.01 < 0.05 
Only studies that used high-purine food consumption as a continuous variable were included in this summary 
table. β – serum urate beta value in µmolL-1. If serum urate was measured in mg/dL or mmolL-1 the study β 
was converted to µmolL-1 (mg/dL * 59.485; mmolL-1 * 1000). OR – study odds ratio. If high-purine foods 
were measured in serves per day the study β and/or odds ratio was converted to reflect the effect of serves 
per week (β/7; eln(OR)/7). For the associations by (Zgaga et al., 2012) serum urate was z-transformed (dashed 
underline). 
 
4.1.3. Dairy Products 
Interestingly, the recent study by Schmidt et al. (2013) (mentioned above), that compared 
the serum urate levels of British individuals with different dietary habits (meat eaters, fish 
eaters, vegetarians, and vegans; ~420 people per group) produced the surprising result that 
vegans had the highest, on average, urate levels (340 µmolL-1 in men, 241 µmolL-1 in 
women) (Schmidt et al., 2013). From the associations between meat, seafood, and 
vegetables discussed above it, would logically be expected that an individual who eats no 
meat or seafood would have a lower urate level than an individual who regularly eats meat 
and/or seafood; however, this does not appear to be the case for vegans. Vegetarians had 
the lowest urate levels (303 µmolL-1 in men, 230 µmolL-1 in women), which is reflective of 
the lower purine content of vegetables and avoidance of meat and seafood. Schmidt et al. 
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(2013) suggested the high urate levels in vegans, as opposed to vegetarians, could be related 
to the lack of dairy products in the vegan diet. Dairy products have consistently associated 
with lower urate levels since Loenen et al. (1990) first observed a significant reduction in 
dairy intake (~30 g less per day) between elderly Dutch women with low urate levels (< 
192 µmolL-1) and those with high urate levels (> 255 µmolL-1) (Loenen et al., 1990). This 
finding has been reliably replicated in multiple large cohorts across many different 
countries since this time (Table 4.3) (Choi et al., 2005a; Ghadirian et al., 1995; Ryu et al., 
2014; Zgaga et al., 2012; Zykova et al., 2015).  
 
Table 4.3: Effect of dairy products (serves/week) on serum urate levels and gout. 
Study  Serum Urate  Gout 
Reference Population Size  β Pβ  OR POR 
Dairy Products 
(Zgaga et al., 2012) British (General Population) 2,037  -0.56 0.01    
(Choi et al., 2005a) American (General Population) 14,809  -0.42 0.01    
(Choi et al., 2004a) American Men (General Population) 47,150     0.97 < 0.05 
Full-Fat Dairy Products 
(Zgaga et al., 2012) British (General Population) 2,037  -0.19 0.51    
(Choi et al., 2004a) American Men (General Population) 47,150     1.00 > 0.05 
Skim/Low-Fat Dairy Products 
(Zgaga et al., 2012) British (General Population) 2,037  -1.50 0.02    
(Choi et al., 2004a) American Men (General Population) 47,150     0.97 < 0.05 
Only studies that used dairy product consumption as a continuous variable were included in this summary 
table. β – serum urate beta value in µmolL-1. If serum urate was measured in mg/dL or mmolL-1 the study β 
was converted to µmolL-1 (mg/dL * 59.485; mmolL-1 * 1000). OR – study odds ratio. If dairy products were 
measured in serves per day the study β and/or odds ratio was converted to reflect the effect of serves per week 
(β/7; eln(OR)/7). For the association by (Zgaga et al., 2012) serum urate was z-transformed (dashed underline). 
 
Garrel et al. (1991) witnessed a reduction in urate levels in ten healthy American volunteers 
after consumption of two milk proteins – casein and lactalbumin (3 hours after consumption 
urate had decreased by 29 µmolL-1 and 34 µmolL-1 on average, respectively). Dalbeth et 
al. (2010) saw an equivalent effect when 16 healthy New Zealand men consumed skim 
milk (~10% reduction in urate levels three hours after consumption) (Dalbeth et al., 2010; 
Loenen et al., 1990). Furthermore, Ghadirian et al. (1995) found that the urate levels of 77 
French Canadian nuns rose significantly (average increase of 8 µmolL-1) when they 
followed a dairy-free diet for four weeks, similar to the observation made by Schmidt et al. 
(2013) of vegans having higher average urate levels than people with other dietary patterns 
(Ghadirian et al., 1995; Schmidt et al., 2013). 
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The ability of dairy products to lower urate levels has been ascribed to a protein overload 
(of casein, lactalbumin, and orotic acid), which creates a uricosuric effect (Figure 4.1). As 
dairy products do not have high purine levels (average purine content = 6 mg/100 g 
(Kaneko et al., 2014)) this uricosuric effect is not masked as it may be when other high 
protein, high-purine foods (such as meat) are consumed (Dalbeth et al., 2010; Garrel et al., 
1991). The uricosuric effect of dairy products does; however, seem to be masked by the fat 
content of milk, with skim or low-fat dairy products significantly decreasing urate, whilst 
full-fat dairy products seem to have no effect (Zgaga et al., 2012). This difference in effect 
was also seen in the only study assessing dairy products and the risk of incident gout (Table 
4.3). Dairy products overall showed a reduction in gout risk (RR = 0.97 per serve per week), 
but when this was split into low-fat and full-fat dairy products, the association only 
remained in the low-fat group (RR = 0.97 and RR = 1.00 per serve per week for low-fat 
and full-fat dairy products, respectively) (Choi et al., 2004a). 
 
4.1.4. Sugar-Sweetened Beverages 
There is strong evidence that sugar-sweetened beverages raise serum urate levels (Table 
4.4), with studies of people from America, Korea, Mexico, New Zealand, and Scotland all 
reporting increased serum urate levels ranging from 14 µmolL-1 to 26 µmolL-1 in 
individuals consuming ≥ two soft drinks per day compared to those drinking none (Bae et 
al., 2014; Choi et al., 2008; Dalbeth et al., 2013b; Gao et al., 2007; Meneses-Leon et al., 
2014; Zgaga et al., 2012). Fruit juice consumption has also shown a significant association 
with urate levels (1 µmolL-1 to 9 µmolL-1 increase per serve per week) in North American 
and British People, but not in Chinese, Korean, or Taiwanese people (Bae et al., 2014; 
Chang, 2011; Choi et al., 2008; Teng et al., 2013; Zgaga et al., 2012). Chinese and 
Taiwanese studies have also found no association between serum urate and soft drinks, 
inconsistent with all other studies (Table 4.3). Sugars used as ingredients in processed and 
prepared foods (excluding natural sugars) have also associated with an increase in serum 
urate of 12 µmolL-1 between the highest and lowest consumption quartiles (Bae et al., 2014; 
Choi et al., 2008; Gao et al., 2007). Supporting these associations, a fructose feeding study 
conducted on 76 healthy New Zealand volunteers observed a significant rise in urate levels 
(~70 µmolL-1) after consumption of sugar water (64 g fructose and 16 g glucose in 300 mL 
water), which peaked one hour after the drink was consumed (Dalbeth et al., 2013b). 
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Sugar-sweetened beverages have also been associated with gout in American, Taiwanese, 
and New Zealand individuals (Table 4.4). Choi and Curhan (2008) reported a significant 
increase in risk of incident gout in American men consuming one sugar-sweetened soft 
drink per day compared to those consuming them less than once per month (RR = 1.45). 
Cola contributed a smaller risk than other soft drink flavours (RR = 1.50 and RR = 2.76, 
respectively), but was equivalent to fruit juice of any kind (fruit juice RR = 1.74, apple 
juice RR = 1.53, and orange juice RR = 1.64) (Choi and Curhan, 2008). The Taiwanese 
prevalent gout cohort did not consume soft drinks at a significantly different rate to 
controls, but fruit juice consumption did show a strong risk association (OR = 2.55) (Chang, 
2011). Consumption of any type of sugar-sweetened beverage conveyed a significant risk 
of prevalent gout in individuals from New Zealand (Pacific Island OR = 1.02, and New 
Zealand European OR = 1.03; Table 4.4) (Batt et al., 2013). 
 
Table 4.4: Effect of sugar-sweetened beverages (serves/week) on serum urate levels 
and gout. 
Study  Serum Urate  Gout 
Reference Population Size  β Pβ  OR POR 
Fruit Juice 
(Teng et al., 2013) Chinese 483  -0.01 0.75    
(Zgaga et al., 2012) British (General Population) 2,037  0.50 0.02    
Soft Drink 
(Zgaga et al., 2012) British (General Population) 2,037  0.47 0.02    
(Teng et al., 2013) Chinese 483  -0.04 0.40    
(Batt et al., 2013) European 563     1.03 0.02 
(Batt et al., 2013) New Zealand Māori 463     1.02 0.11 
(Batt et al., 2013) Pacific Island 489     1.02 0.03 
(Batt et al., 2013) European 6,574  0.49 6.90×10-06    
Diet Soft Drink 
(Zgaga et al., 2012) British (General Population) 2,037  -0.26 0.25    
(Batt et al., 2013) European 6,574  0.03 0.48    
Only studies that used sugar-sweetened beverage consumption as a continuous variable were included in this 
summary table. β – serum urate beta value in µmolL-1. If serum urate was measured in mg/dL or mmolL-1 the 
study β was converted to µmolL-1 (mg/dL * 59.485; mmolL-1 * 1000). OR – study odds ratio. If sugar-
sweetened beverages were measured in serves per day the study β and/or odds ratio was converted to reflect 
the effect of serves per week (β/7; eln(OR)/7). For the associations by (Zgaga et al., 2012) serum urate was z-
transformed (dashed underline). 
 
Like alcohol, when fructose is broken down ATP becomes depleted and AMP conversion 
to IMP results in the greater production of uric acid (Figure 4.1) (Bode et al., 1971). 
However, this is not the only mechanism by which soft drinks are able to modify urate 
Gout in New Zealand 
Page | 167 
levels. Significant interactions between variants in two uric acid transporter genes (SLC2A9 
(GLUT9) and ABCG2) have been reported in a New Zealand fructose feeding study 
(mentioned above) (Dalbeth et al., 2013b; Dalbeth et al., 2014). Whilst consumption of 
300 mL sugar water resulted in an average increase in serum urate in all participants in this 
study those with at least one ABCG2 141K (rs2231142) allele, experienced a smaller 
increase in serum urate than those without this allele (~50 µmolL-1 increase compared to 
~70 µmolL-1 after 60 minutes, respectively) (Dalbeth et al., 2014).  For individuals with at 
least one protective C allele of the rs11942223 SNP within SLC2A9, the serum urate 
increase in response to sugar water consumption after 60 minutes was much greater than in 
those without this allele (~60 µmolL-1 increase compared to ~40 µmolL-1, respectively). In 
both cases, the effect of the allele was counteracted by the consumption of sugar (Dalbeth 
et al., 2013b). Sugar-sweetened beverages have also shown a significant interaction with 
SLC2A9 in a population-based study, with the same effect direction as observed in the 
fructose feeding study. The same interaction effect was not seen when artificially 
sweetened beverages were considered (Batt et al., 2013). This evidence indicates sugar-
sweetened beverages raise serum urate levels by interfering with both extra-renal and renal 




Even the added sugar in a daily cup of coffee has been associated with a higher risk of 
hyperuricaemia (Bae et al., 2015), although this may be counteracted by the potential urate-
lowering ability of coffee (Table 4.5). Both regular and decaffeinated coffee have been 
associated with lower urate levels in a large American cohort (urate decreased by 14 µmolL-
1 for regular coffee and 25 µmolL-1 for decaffeinated coffee in individuals drinking ≥ four 
cups per day compared to those drinking none) (Choi and Curhan, 2007a). A reduction in 
risk of incident gout in American men and women has also been shown for both regular 
and decaffeinated coffee (RR = 0.41 and RR = 0.43 for men and women drinking ≥ four 
cups of regular coffee per day and RR = 0.71 and RR = 0.77 for men drinking ≥ four cups 
of decaffeinated coffee per day) (Choi and Curhan, 2010; Choi et al., 2007). This has also 
been seen in Japanese men (decrease of 42 µmolL-1 in men drinking ≥ four cups of coffee 
per day compared to none), but not in British, Korean, Chinese, and Taiwanese individuals 
(Bae et al., 2015; Chang, 2011; Pham et al., 2010; Schmidt et al., 2013; Teng et al., 2013).  
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Studies looking at coffee and serum urate often also look at tea consumption (Table 4.5). 
Two association studies have shown an increase in serum urate levels by ~0.5 µmolL-1 per 
cup of tea per week (Bae et al., 2015; Teng et al., 2013) and two intervention studies 
observed a reduction in serum urate levels when individuals consumed either green tea 
extract tablets twice daily for two weeks (3.5% reduction in urate) or three cups of black 
tea every day for 12 weeks (8.5% reduction in urate) (Bahorun et al., 2010; Jatuworapruk 
et al., 2014). Of note, in population studies assessing the influence of both tea and coffee 
on serum urate levels, either one or the other showed an association, never both – which 
could be reflective of the frequency at which each beverage is consumed in different 
countries. In these studies, 83.4% and 12.6% of Japanese and Chinese individuals drank 
green tea daily, 6.9% and 11.4% of Japanese and Chinese people drank black tea daily. 
4.9% of American individuals drank any type of tea daily. 57.1%, 69.2%, and 18.1% of the 
Japanese, Chinese, and American individuals drank coffee daily (Choi and Curhan, 2007a; 
Pham et al., 2010; Teng et al., 2013). 
 
Table 4.5: Effect of coffee/tea (serves/week) on serum urate levels. 
Study  Serum Urate 
Reference Population Size  β Pβ 
Coffee 
(Teng et al., 2013) Chinese 483  0.01 0.62 
(Bae et al., 2015) Korean (Men) 3,564  0.14 0.48 
(Bae et al., 2015) Korean (Women) 5,836  0.23 0.06 
Tea 
(Teng et al., 2013) Chinese 483  0.07 0.44 
(Teng et al., 2013) Chinese 483  0.23 0.01 
(Bae et al., 2015) Korean (Men) 3,564  0.61 0.02 
(Bae et al., 2015) Korea (Women) 5,836  0.31 0.04 
Only studies that used coffee/tea consumption as a continuous variable were included in this summary table. 
β – serum urate beta value in µmolL-1. If serum urate was measured in mg/dL or mmolL-1 the study β was 
converted to µmolL-1 (mg/dL * 59.485; mmolL-1 * 1000). OR – study odds ratio. If coffee/tea were measured 
in serves per day the study β and/or odds ratio was converted to reflect the effect of serves per week (β/7; 
eln(OR)/7). For the associations with tea by (Teng et al., 2013) tea was split into black tea (dashed underline) 
and green tea (wave underline).  
 
A study conducted in 2014 observed an ~20% inhibition in xanthine oxidase activity when 
exposed to 0.6 mgmL-1 of a boiling water extract from roasted coffee beans. This study also 
identified a xanthine oxidase inhibitory effect of chlorogenic acids, purified from the coffee 
extract (Honda et al., 2014). As chlorogenic acid is not removed during the decaffeination 
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process (maximum 20% loss dependent on bean and decaffeination process; Farah et al., 
2006), and both decaffeinated and regular coffee associate with serum urate levels and/or 
gout, along with the lack of direct association between serum urate levels and/or gout with 
caffeine, it seems coffee may be influencing serum urate and gout risk through xanthine 
oxidase inhibition by chlorogenic acids (Honda et al., 2014; Torralba et al., 2012). 
Similarly, tea is known to contain catechins (phenolic acids), which are also able to inhibit 
xanthine oxidase activity and prevent uric acid production (Figure 4.1). Although, with the 
inconsistent association results between studies, particularly two that report increased urate 
levels with increased tea consumption, there may be other mechanisms involved (Aucamp 
et al., 1997; Towiwat and Li, 2015). 
 
There are many different foods and mechanisms that modify urate levels and gout risk, as 
evidenced by this review of currently understood dietary influences; however, many more 
foods have been identified as acute gout attack triggers (~200 listed by New Zealand gout 
patients). Therefore, it is important to continue assessing the dietary influences of gout and 
serum urate levels in different cohorts using the anecdotal experiences of gout sufferers as 
a guide to focus biological research aims. 
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Section 4.2. The Role of Tomato Consumption on 
Serum Urate Levels: A Large Association Study. 
A portion of the work presented here (along with a portion presented in Section 3.2) has 
been published in BMC Musculoskeletal Disorders: 
Flynn, TJ, Cadzow, M, Dalbeth, N, Jones, PB, Stamp, LK, Harré Hindmarsh, J, . . . Merriman, TR. 2015. Positive 
association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of 
gout flares. BMC Musculoskeletal Disorders. 16(1): 196. 
4.2.1. Background 
As presented in the previous section, tomatoes are the fourth most common trigger food 
mentioned by New Zealand gout patients (Section 3.2), and individuals in other countries 
also mention tomatoes as a trigger food (frequency unknown) (Shulten et al., 2009; Singh, 
2014a). At present there is little support within the literature and medical practice for this 
identification of tomatoes as an acute gout attack trigger. The three most commonly 
mentioned dietary triggers of gout (fish/seafood, alcohol, and meat) have been reliably 
correlated with raised serum urate levels, as has the 5th most common trigger food (sugar-
sweetened beverages) (Choi and Curhan, 2004; Choi et al., 2005a; Choi et al., 2008). 
Therefore, I hypothesised that tomatoes (the fourth most common self-reported trigger of 
gout flares in New Zealand) also increase serum urate levels. This section aimed to test this 
hypothesis by associating weekly consumption of tomatoes with serum urate levels in a 
large cohort of American European individuals. 
 
4.2.2. Methods 
4.2.2.1. Study Participants 
Information on tomato consumption was not available in the New Zealand cohort. 
Therefore, five North American cohorts (ARIC, CARDIA, CHS, FHS, and NHANES III; 
described in Appendix A.2; page 256) that had both serum urate measurements and data on 
usual dietary habits were used to test the hypothesis that tomato consumption associates 
with serum urate levels. A group of American European individuals from the five cohorts 
who had no obvious reason for artificially raised serum urate levels were used in analyses 
(Appendix Figure A.1; page 262). Specifically, people without serum urate measurements 
or genome-wide genotyping were excluded, as well as individuals with kidney disease, 
established or potential gout, taking urate-lowering drugs, on diuretic medication, or of 
non-European descent. Quality controls for the food frequency data were also applied to 
ensure the best quality information was used (Appendix Figure A.2; page 262). Participants 
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who answered less than 10% of the food frequency survey were excluded, as were 
individuals whose estimated average daily calorie intake was less than 600 kcal/day and 
greater than 4,200 kcal/day (inclusive). Participants whose questionnaire answers were 
deemed unreliable by the study interviewer were also excluded. After all exclusion criteria 
18,348 individuals were available for analysis. The five sample sets were further divided 
into male only (n = 8,523) and female only (n = 9,825) sub-sets. A demographic summary 
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4.2.2.2. Data Collation 
Food frequency questionnaires administered during the baseline examination for each 
cohort asked about tomato/tomato juice consumption (tomato sauce information was 
excluded from this analysis where possible). The questionnaires also asked about 
consumption of alcohol (beer, liquor, and wine), coffee (not decaffeinated), dairy products 
(butter, cheese, cream, ice cream, milk (flavoured, skim, and whole), and yoghurt), 
fish/seafood (canned tuna fish, fish, and shellfish), fruit (citrus fruit and non-citrus fruit), 
red meat (bacon, beef, pork, lamb, processed meat, hamburgers, hotdogs, and organ meats) 
and sugar-sweetened beverages (cola, fruit juices/drinks, and regular soft drinks) 
(Appendix Table D.1; 268). For each questionnaire participants were asked to record the 
frequency of consumption of these food items using slightly different answer formats. 
ARIC, CHS, and FHS participants chose from a list of categories (nine categories in ARIC 
and FHS, six categories in CHS), whilst NHANES III answers were collected as continuous 
variables. All answers were converted to average serves per week for analysis (Appendix 
Table D.2; page 272). The CARDIA data set was already converted from categorical 
answers to serves per week by the study investigators (Schakel et al., 1997). A summary 
of the average consumption of each food item within each sample set is presented in 
Appendix Table D.3 (page 273). 
 
4.2.2.3. Association Analysis 
Multivariate linear regression adjusted for known serum urate-influencing factors (sex, age, 
body mass index, and menopausal status), average daily calorie intake (kcal/day), and 
whole-genome principal component analysis vectors 1 to 4 was conducted on each sample 
set separately. The NHANES III analysis could not be adjusted for whole-genome principal 
component analysis vectors as this data set has not been whole-genome genotyped. Whole-
genome principal component analysis vectors were calculated using SmartPCA in the 
EIGENSOFT 2.0 software package with an output of ten eigenvectors, no outlier removal, 
and no population size limit (Patterson et al., 2006). The SmartPCA analysis was performed 
on all genotyped individuals within each cohort (including those of non-European 
ancestry). The first four vectors were chosen for inclusion as covariates in the linear 
regression to account for population stratification and cryptic relatedness (especially within 
the FHS family groups) which may cause confounding. Beta values from the linear 
regression analyses were combined using an inverse-variance weighted fixed-effect meta-
analysis using the meta v4.3-2 package within R v3.1.1. 
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During meta-analysis a Q-statistic was calculated to determine the heterogeneity between 
cohorts, the fixed-effect model was replaced with a random-effect model if a significant 
heterogeneity p-value was found (PQ < 0.05). The same analysis was repeated including 
each of the known dietary influences of urate (fish/seafood, red meat, alcohol, dairy, coffee, 
tea, and fruit) as additional adjusters both separately and together. All analyses were also 
repeated in the male only and female only sub-sets adjusted for age, body mass index, 
calorie intake, and whole-genome principal component analysis vectors 1 to 4 (in ARIC, 
CARDIA, CHS, and FHS). The female only analysis was additionally adjusted for 
menopausal status. A Pβ < 0.05 was considered statistically significant for all analyses. 
 
4.2.2.4. Genotyping and Imputation 
A gene-environment interaction analysis between tomato consumption and common serum 
urate-influencing SNPs was conducted in the ARIC, CARDIA, CHS, and FHS sample sets. 
Seven SNPs representative of the genes that have been most reliably associated with serum 
urate levels were included in these interaction analyses (ABCG2: rs2231142, GCKR: 
rs780094, PDZK1: rs1967017, SLC2A9: rs11942223, SLC17A gene cluster: rs1183201, 
SLC22A11: rs2078267, and SLC22A12: rs3825018). These SNPs were obtained from the 
whole-genome genotyping data. Where the specified SNP was not directly genotyped, the 
information for this variant was imputed using IMPUTE 2.3.0 (Howie et al., 2009). 
Imputed genotypes were calculated using the posterior probability of haplotypes, an 
effective population size of 20,000, a burn in period of 10, 30 Markov chain Monte Carlo 
iterations, 80 haplotypes for phasing, and 500 reference haplotypes for imputing. The 1000 
Genomes phase 1 integrated variant set (phased with SHAPEIT2 
https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html) was used as a 
reference panel for imputation with all populations included in this reference set and NCBI 
dbSNP build 135 (GRCh37) was used as the genetic map. Imputation regions were 
approximately ± 200 kb either side of the gene of interest. Imputation quality was high for 
all SNPs analysed (info score > 0.90; Table 4.7). 
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ARIC  CARDIA  CHS  FHS 
Chr Start End Info PHWE  Info PHWE  Info PHWE  Info PHWE 
PDZK1 1 145,500,000 146,000,000 rs1967017 0.98 0.33  0.98 0.66  0.99 0.98  0.99 0.26 
GCKR 2 27,500,000 28,000,000 rs780094 - 0.73  - 0.99  - 0.39  - 0.22 
SLC2A9 4 9,500,000 10,300,000 rs11942223 0.98 0.39  0.99 0.84  0.98 0.51  0.99 0.61 
ABCG2 4 88,800,000 89,400,000 rs2231142 0.96 0.21  0.95 0.15  - 0.01  - 0.99 
SLC17A1 6 25,500,000 26,100,000 rs1183201 0.98 0.14  0.98 0.07  0.98 0.85  0.98 0.48 
SLC22A11 11 64,100,000 64,600,000 rs2078267 - 0.02  0.94 0.90  - 0.08  0.95 0.92 
SLC22A12 11 64,100,000 64,600,000 rs3825018 0.99 0.60  0.99 0.13  0.98 0.62  0.98 0.36 
Impute regions are approximately ± 200 kb around the gene position according to the Genome Reference 
Consortium human genome build 37 (GRCh37). Chr – chromosome. Info – the IMPUTE info score indicating 
imputation quality; 0 indicates low quality, 1 indicates high quality. SNPs with no info score were genotyped 
on the study specific whole-genome genotyping chip. PHWE – Hardy Weinberg equilibrium asymptomatic p-
value for the sample sub-set used in analyses. rs2231142 in CHS and rs2078267 in ARIC showed some 
evidence for a departure from Hardy Weinberg equilibrium, both were genotyped SNPs. Genotyping success 
rates for non-imputed SNPs in the sample set used in analyses were: ARIC: rs780094 – 99.9%, rs2078267 – 
97.6%; CARDIA: rs780094 – 100.0%; CHS: rs780094 – 99.8%, rs2231142 – 100.0%; rs2078267 – 98.9%; 
FHS: rs780094 – 99.4%, rs2231142 – 99.4%. 
 
4.2.2.5. Gene-Environment Interaction Analysis 
Linear regression analyses for each sample set were conducted including an interaction 
term between tomato consumption and each SNP separately. These analyses were adjusted 
for sex, age, body mass index, menopausal status, calorie intake, and whole-genome 
principal component analysis vectors 1 to 4. The main-effect of both tomato consumption 
and the SNP were also included in the linear model. Inverse-variance weighted fixed-effect 
meta-analysis was used to combine the interaction term beta values between studies. This 
fixed-effect model was replaced with a random-effect model if the Q-statistic and 
corresponding p-value indicated there was significant heterogeneity between study results. 
This analysis was repeated in the male only and female only sub-sets. A Pβ < 0.05 was 
considered nominally significant. A Pβ < 7.1×10-3 was considered statistically significant 
after Bonferroni correction for multiple-testing was applied using a correction factor of 
seven (seven SNPs). Individuals with missing or partial data were excluded from analyses. 
All statistical analysis was performed in R 3.1.1 (www.r-project.org). 
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4.2.3. Results 
4.2.3.1. Association Analysis 
A positive direction of association was observed in all five sample sets and this effect was 
significant when the cohorts were combined (β = 0.45 µmolL-1 increase in serum urate per 
serve per week of tomatoes, Pβ = 0.03; Figure 4.2). The male only combined sub-set 
produced a significant association (β = 0.69 µmolL-1, Pβ = 0.04), while the female only sub-
set showed a consistent, but non-significant association (Figure 4.3). Of note, within the 
separate sample sets only the ARIC cohort had a significant result although all other sample 
sets had a consistent association direction in the full cohort. 
 
Figure 4.2: Association between serum urate levels (µmolL-1) and tomato 
consumption (serves/week). 
 
β – multivariate adjusted linear regression beta value (µmolL-1). 95% CI – 95% confidence interval. Pβ – 
association p-value. Combine – inverse-variance weighted meta-analysis result. Q – heterogeneity Q-statistic. 
df – degrees of freedom. PQ – heterogeneity p-value. 
 
The association between tomato consumption and serum urate levels was maintained after 
adjustment for most other accepted dietary influences of urate in a univariate model (coffee, 
tea, dairy products, fruit, red meat, and sugar-sweetened beverages: Pβ ≤ 0.04), but not 
when adjusted for consumption of alcohol (Pβ = 0.10), or fish/seafood (Pβ = 0.07), or in a 
multivariate model (Pβ = 0.14) (Table 4.8). This was also the case for the male only sub-
set (coffee, tea, dairy products, fruit, red meat, and sugar-sweetened beverages: Pβ ≤ 0.05; 
alcohol: Pβ = 0.11; fish/seafood: Pβ = 0.06; all urate-influencing foods: β = 0.47 µmolL-1, 
Pβ = 0.14) and the female only sub-set produced consistent non-significant results (Table 
4.8). 
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Figure 4.3: Association between serum urate levels (µmolL-1) and tomato 
consumption (serves/week) in the male only (A) and female only (B) sub-sets. 
 
 
β – multivariate adjusted linear regression beta value (µmolL-1). 95% CI – 95% confidence interval. Pβ – 
association p-value. Combine – inverse-variance weighted fixed-effect meta-analysis results. Q – 
heterogeneity Q-statistic. df – degrees of freedom. PQ – heterogeneity p-value. 
 
Table 4.8: Association between serum urate levels (µmolL-1) and tomato consumption 
(serves/week) adjusted for serum urate-influencing foods. 
Adjustor 
All  Male Only  Female Only 























0.04  0.68 
[0.03; 1.33] 
0.04  0.27 
[-0.25; 0.79] 
0.32 
Dairy Products 0.44 
[0.02; 0.85] 
0.04  0.65 
[0.00; 1.30] 





[-0.03; 0.80] 0.07  
0.62 
[-0.03; 1.28] 0.06  
0.24 































All Urate-Influencing Foods 0.31 
[-0.10; 0.73] 
0.14  0.49 
[-0.17; 1.15] 
0.14  0.27 
[-0.27; 0.80] 
0.33 
Adjustor – known serum urate-influencing food included as a covariate within the regression model. β – 
multivariate adjusted linear regression beta value (µmolL-1). 95% CI – 95% confidence interval. Pβ – 
association p-value. All heterogeneity p-values were > 0.05. 
B 
A 
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4.2.3.2. Gene-Environment Interaction Analysis 
Six of the seven SNPs chosen to represent the seven genes that have been most reliably 
associated with serum urate levels in previous studies significantly associated with serum 
urate levels within this study (PDZK1 (rs1967017) was not significant; Table 4.9). Only 
SLC2A9 (rs11942223) and ABCG2 (rs2231142) showed a statistically significant 
association in every sample set separately. In the male only and female only sub-sets, 
several sex-specific effects were observed, with GCKR (rs780094) being significant in 
males but not females, and SLC22A11 (rs2078267) being significant in females but not 
males (Table 4.9). In the male only sub-set ABCG2 (rs2231142) was the only SNP that had 
a significant effect in all sample sets separately. In the female only sub-set SLC2A9 
(rs11942223) was significant across all sample sets separately. 
 
Table 4.9: Association between seven SNPs representative of serum urate-influencing 
genes and serum urate levels (µmolL-1) . 
Gene SNP 
Allele  All  Male Only  Female Only 
A1 Freq  β [95% CI] Pβ  β [95% CI] Pβ  β [95% CI] Pβ 
PDZK1 rs1967017 T 0.48 
 2.06 
[-0.59; 4.71] 0.13  
3.71 
[-0.33; 7.75] 0.07  
0.72 
[-2.72; 4.16] 0.68 






























SLC17A1 rs1183201 A 0.47  -6.35 
[-9.17; -3.53] 
1.00×10-05  -6.52 
[-10.72; -2.31] 
2.38×10-03  -6.45 
[-10.17; -2.73] 
6.83×10-04 





[-0.60; 8.09] 0.09  
4.86 
[1.06; 8.65] 0.01 










A1 – effect allele. Freq – effect allele frequency. β – inverse-variance weighted meta-analysis beta value. 
95% CI – 95% confidence interval. Pβ – meta-analysis p-value. All heterogeneity p-values were non-
significant (PQ > 0.05) except at rs11942223 in the female only sub-set (PQ = 0.02). 
 
Interaction analysis between these seven SNPs and tomato consumption did not produce 
any significant results in either the combined or separate sample sets before sex-specific 
sub-setting (Table 4.10). In the male only sub-set, a significant interaction between 
SLC22A12 (rs3825018) and tomato consumption was identified. This interaction term 
indicated that in the presence of the rs3825018 urate-raising allele (G), increased tomato 
consumption raises serum urate levels to a lesser extent than in the presence of the 
rs3825018 A allele (tomato association: β = 0.69 µmolL-1, Pβ = 0.04; rs3825018 
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association: β = 4.73 µmolL-1, Pβ = 0.01; interaction term association: β = -1.48 µmolL-1, 
Pβ = 0.02; Figure 4.3 (A), Table 4.9, and Table 4.10). After Bonferroni correction for 
multiple-testing, this interaction term association was no longer significant (PBonferroni = 
0.14). 
 
Table 4.10: Gene-environment interaction analysis between tomatoes (serves/week) 
and seven serum urate-influencing SNPs in relation to serum urate levels (µmolL-1). 
Gene SNP A1 
All  Male Only  Female Only 
β [95% CI] Pβ  β [95% CI] Pβ  β [95% CI] Pβ 






































































A1 – effect allele. β – inverse-variance weighted meta-analysis beta value for the allelic interaction term 
(tomatoes (serves/week) * SNP effect allele count (coded 0, 1, or 2)). 95% CI – 95% confidence interval. Pβ 
– meta-analysis p-value. All heterogeneity p-values were non-significant (PQ > 0.05) except at rs1183201 in 
the male only sub-set (PQ = 0.01). 
 
Repetition of the interaction analysis using SLC22A12 (rs3825018) genotypes (as opposed 
to alleles) in the male only sub-set showed a nominally significant difference between the 
effect of tomato consumption on serum urate levels in people with the AG genotype 
compared to people with the AA genotype (β = -1.61, Pβ = 0.05), and a larger but non-
significant difference in effect was seen in people with the GG genotype compared to 
individuals with the AA genotype (β = -2.90, Pβ = 0.07; Figure 4.4). In both cases a negative 
interaction term was seen, indicating tomatoes increase serum urate levels to a lesser extent 
in people with the AG or GG genotypes than in people with the AA genotype. 
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Figure 4.4: Gene-environment interaction between SLC22A12 (rs3825018) genotype 
and tomato consumption (serves/week) in relation to serum urate levels (µmolL-1) in 
males. 
 
The blue line shows the effect of rs3825018 genotype on serum urate levels. The green line shows the effect 
of tomato consumption and rs3825018 genotype interaction. The effect of the AA genotype was used as a 
reference.  – Pβ < 0.1. * – Pβ < 0.05. ** – Pβ < 0.01. 
 
4.2.4. Discussion 
This section provides evidence that suggests tomato consumption raises serum urate levels. 
Regression analysis revealed a significant increase in serum urate levels associated with 
increased tomato consumption in American European men, but not women. This 
association was maintained after adjustment for consumption of most other urate-
influencing foods, but not alcohol or fish/seafood. Whilst this effect is confounded by 
consumption of alcohol or fish/seafood, the evidence presented in this section suggests that 
the avoidance of tomatoes by gout patients (Section 3.2) may have a biological basis, 
although this analysis is unable to claim that tomato consumption is definitely a trigger of 
gout attacks. 
 
The results presented here support the hypothesis that tomatoes increase serum urate levels, 
similar to the traditionally accepted gout trigger foods. The extent to which a one serve per 
week increase in tomato consumption associated with increased serum urate levels in this 
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large American European cohort (0.5 µmolL-1 increase per serve per week) is comparable 
to the increases seen in association studies of other gout trigger foods in American 
individuals (Table 4.1 to Table 4.5). Sugar-sweetened beverages and total meat raise urate 
by 0.5 µmolL-1 per serve per week, very similar effect sizes to that seen in tomatoes (Batt 
et al., 2013; Choi et al., 2005a). Total alcohol increases urate by ~0.8 µmolL-1 and seafood 
by 7.1 µmolL-1 per serve per week, two and fourteen times as much as tomatoes, sugar-
sweetened beverages, and total meat. This may explain the high frequency of identification 
of alcohol and seafood as gout trigger foods (35.1% and 46.0%, respectively: Section 3.2) 
and consistent acceptance as such by medical professionals (Choi and Curhan, 2004; Choi 
et al., 2005a). 
 
As foods are rarely consumed in isolation, it is possible that the effect tomatoes are having 
could be influenced by the foods tomatoes are consumed with (Anderson, 2014). 
Adjustment of the association seen here by consumption of other food items that influence 
serum urate levels indicated that tomatoes have an effect independent of these other foods, 
except in the adjustments for alcohol and seafood consumption. This may indicate that the 
effect of tomatoes is over shadowed by that of alcohol and seafood as they have a much 
larger effect on serum urate levels than tomatoes. In addition, different ethnic and cultural 
groups commonly combine different food items within meals and food items modify urate 
levels to differing degrees in different ethnic groups (Table 4.1 to Table 4.5) (Chang, 2011; 
Fieldhouse, 2013; Ryu et al., 2014; Schmidt et al., 2013; Zykova et al., 2015). As tomatoes 
were mentioned as a trigger food more often by New Zealand Māori and Pacific Island 
individuals than New Zealand European (21.8%, 18.4%, and 8.0%, respectively), it is 
possible a repetition of this association study in these ethnic groups would reveal a stronger 
effect of tomatoes on urate levels in these people. 
 
As this is an observational study, the causal relationship between serum urate levels and 
tomato consumption along with the acute effect of tomatoes on serum urate (which is 
important in the onset of acute gout attacks) can not be fully elucidated. Interventional 
studies assessing the influence of tomatoes and tomato products on other biomarkers have 
been conducted (Section 4.3) and several of these studies have reported serum urate 
measurements from before and after the intervention period (Abete et al., 2013; Biddle et 
al., 2015; Bub et al., 2000; Engelhard et al., 2006; García-Alonso et al., 2012; Hininger et 
al., 2001; Jacob et al., 2008; Lee et al., 2009a; Sanchez-Moreno et al., 2004; Sanchez-
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Moreno et al., 2006; Sanchez-Moreno et al., 2005; Todd et al., 2010; Todd et al., 2012; 
Tsitsimpikou et al., 2013; Vinha et al., 2014). These studies have produced conflicting 
results. Lee et al. (2009) saw a marked increase in plasma urate levels in ten young Chinese 
men within six hours of consuming a single dose of 150 g tomato sauce mixed with 5 mL 
olive oil and 150 g boiled rice (38 µmolL-1 ± 37.1 standard deviation, P = 0.01). The same 
effect was not seen when a placebo of 5 mL olive oil and 150 g boiled rice was consumed 
(Lee et al., 2009a). This acute effect of tomato consumption on serum urate levels may be 
part of the mechanism involved in triggering gout attacks, although in general, a sudden 
decrease in serum urate levels is considered a better trigger of gout attacks than a sudden 
increase (Doherty, 2009; Rees et al., 2014; Zhang et al., 2006). Additionally, other 
intervention studies have identified a serum urate-decreasing effect of tomato consumption, 
which directly contradicts the results of both Lee et al. (2009) and this thesis section 
(Sanchez-Moreno et al., 2004; Sanchez-Moreno et al., 2006; Vinha et al., 2014). 
 
The association seen here between tomatoes and increased serum urate along with the 
interaction between SLC22A12 (URAT1) could be explained by an effect of tomatoes on 
uric acid excretion. The interaction between SLC22A12 and tomatoes, along with the 
increase in serum urate levels in general may be mediated by the high phenolic acid content 
of tomatoes (Mattila and Kumpulainen, 2002). Evidence has suggested that some phenolic 
acids are transported by the intestinal monocarboxylate transporter (MCT) (Konishi and 
Shimizu, 2003). This protein is in the same family of transporters as SLC16A9 (MCT9). As 
URAT1 transport is dependent on the co-transport of monocarboxylates by MCT9 (or other 
transporters) it is possible this is responsible for the interaction between SLC22A12 and 
tomato consumption. 
 
This mechanism is not the only feasible explanation for the urate-raising effect of tomatoes. 
The inhibitory effects of nine phenolic acid compounds on three renally expressed organic 
anion transporters (OAT1, OAT3, and OAT4) have been tested (Wang and Sweet, 2012). 
All compounds modified the capability of OAT1 and OAT3 (basolateral renal uric acid 
transporters) to transport endogenous substrates in vitro, whilst two compounds (syringic 
acid and sinapinic acid) weakly affected OAT4 (Wang and Sweet, 2012). Inhibition of the 
transport activity of any of these uric acid transporters could create substantial differences 
in serum urate levels. URAT1 was not included in this study. It is possible repetition of this 
analysis with URAT1 would also provide evidence for direct transport of phenolic acids by 
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this transporter, although URAT1 has a much more limited array of transport substrates 
than its partner transporter, OAT4 (Ekaratanawong et al., 2004; Enomoto et al., 2002). 
Tomatoes contain some of the known OAT1/OAT3 interacting compounds (p-coumaric 
acid, ferullic acid, p-hydroxybenzoic acid and vanillic acid) along with other phenolic acids 
that were not tested in this analysis (Mattila and Kumpulainen, 2002). It has been shown 
that total phenolic content is not reduced during processing to make various tomato 
products (tomato puree and tomato paste) which further supports the possibility that 
tomatoes in general (the data used in this analysis does not specify how tomatoes were 
processed) are able to influence serum urate levels (Agarwal et al., 2001; Lavelli et al., 
2000; Sahlin et al., 2004). 
 
Alternatively, tomatoes may be influencing urate levels through modified hepatic 
production. Tomatoes have a very low purine content (cherry tomato 3.1 mg per 100 g) 
(Johnson et al., 2013; Kaneko et al., 2014). Instead tomatoes contain high levels of 
glutamate. Glutamate is a non-essential amino acid that is responsible for the savoury 
(Umami) flavour of food. Most high-purine foods also have a high glutamate content 
(Johnson et al., 2013). Glutamate’s primary role within the body is to dispose of excess 
nitrogen, this is achieved through the conversion of glutamate to glutamine within the 
liver/intestines. Glutamine is then able to stimulate or amplify the synthesis of uric acid by 
acting as a nitrogen donor in the purine synthesis pathway (Feigelson and Feigelson, 1966; 
Johnson et al., 2009; Johnson et al., 2013; Raivio and Seegmiller, 1973). Raised glutamate 
levels have been identified in the fasting plasma of gout patients (23 ± 22.6 µmolL-1, P < 
0.01; 18 patients compared to 14 controls) and after consumption of 0.5 g/kg body weight 
of casein a further increase was seen with a peak rise 30 to 60 minutes after consumption 
(30 min: 43 ± 42.4 µmolL-1, P < 1.0×10-3; 60 min: 46 ± 48.5 µmolL-1, P < 1.0×10-3) 
(Pagliara and Goodman, 1969). Furthermore experiments in rat models have shown 
injection of L-glutamic acid and L-glutamine (raising overall glutamate) stimulates the 
hepatic synthesis of purines with a maximal action within 30 minutes (Feigelson and 
Feigelson, 1966). It has also been shown that glutamate efflux in the placenta is mediated 
by OAT4 transport, encouraging uptake of co-transported organic anions (Lofthouse et al., 
2015). A similar effect may occur within the kidneys, increasing uric acid uptake and 
raising overall serum urate levels. 
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4.2.4.1. Study Limitations 
This research is limited by the dissimilar questionnaires used to collect the consumption 
data, particularly the difference in possible answer categories and the different inclusions 
of tomato products within each question (Appendix Table D.1; page 268). Additionally, 
the accuracy of answers provided by individuals filling out the food frequency 
questionnaires is affected by many factors including questionnaire style, presence or 
absence of portion sizes, the number of different answer categories, and whether the 
questionnaire was interviewer-administered or self-administered (Cade et al., 2002). The 
questionnaires used in the five studies here vary across all these factors. Assessments of 
the reproducibility of the specific questionnaires used here have been conducted in the 
ARIC, CARDIA, and CHS cohorts, with mean correlation coefficients of 0.55, 0.44, and 
0.46 (respectively) when comparing the derived nutritional information from multiple food 
frequency questionnaires answered by the same people at two different time points 
(Kumanyika et al., 1996; Slattery et al., 1994; Stevens et al., 1996). Such comparisons are 
often conducted to assess the reproducibility and reliability of food frequency 
questionnaires. The correlation values for these three studies are slightly lower than the 
usual coefficients calculated in similar assessments (commonly 0.50 to 0.70) (Cade et al., 
2002). To combat this limitation, three quality control conditions (> 10% of questionnaire 
answered, average calorie intake per day ≥ 600 and ≤ 4200 kcal/day, and study investigators 
deemed answers reliable: Appendix Figure A.2; page 262) were applied to all cohorts along 
with the inclusion of estimated calorie intake per day as an adjustor in all analyses, 
minimising the impact of recall errors. However, for a food such as tomatoes, which are 
often consumed as a small portion of many meals rather than as the feature ingredient (eg. 
in sandwiches, salads, or pizza), recall error may be greater thus encouraging the 
underestimation of true tomato consumption levels. 
 
4.2.4.2. Conclusion 
In conclusion, this is the first time a targeted assessment of the influence of tomatoes on 
serum urate levels has been conducted, to my knowledge. The results here suggest tomatoes 
are able to raise serum urate levels by an amount equivalent to other accepted triggers of 
acute gout attacks. This suggests the avoidance of tomatoes by people with gout may have 
a biological basis although these results must not be over interpreted and any claims about 
the role of tomatoes on risk of gout onset or attacks must be made with caution. Further 
research needs to be conducted to clarify the true relationship between tomato consumption 
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and serum urate levels and/or gout, particularly in a Polynesian cohort. Additional studies 
into the relationship between gout (and onset of gout attacks) and tomatoes also need to be 
performed to further investigate the trigger relationship, potentially with a case-crossover 
study design as used to demonstrate that both alcohol and a purine-rich diet trigger acute 
gout attacks (Dalbeth et al., 2011; Neogi et al., 2014; Zhang et al., 2006). Studies to clarify 
the mechanism by which tomatoes are acting to increase serum urate levels should also be 
undertaken, with analyses testing the hypothesised effects on urinary uric acid excretion 
and glutamate metabolism or transport required. 
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Section 4.3. The Role of Tomato Consumption on 
Serum Urate Levels: A Systematic Meta-Analysis of 
Intervention Studies. 
4.3.1. Background 
Tomatoes are the fourth most commonly mentioned trigger of acute gout attacks in New 
Zealand (Section 3.2). Tomato consumption also associates with increased serum urate 
levels (Section 4.2). However, some studies using tomatoes or tomato products in dietary 
intervention trials have produced results inconsistent with this finding (Sanchez-Moreno et 
al., 2004; Sanchez-Moreno et al., 2006; Vinha et al., 2014). Specifically, during the review 
process of the article detailing the results of Section 3.2 and Section 4.2 (now published 
(Flynn et al., 2015)), a reviewer made a point of mentioning the contradictory results of 
one particular study. 
 
A recently published study (Vinha et al., 2014) has prospectively investigated the 
effect of tomato on serum urate, and found … [a] decrease in urate levels … I think 
the authors should be very cautious in the interpretation of their data. [Reviewer 3] 
 
This particular study found decreased serum urate levels in 35 Portuguese women 
consuming an average sized tomato for lunch every day for 28 days (in addition to their 
regular meal) (Vinha et al., 2014). It became evident when including this information in 
the article discussion, that this study was not the only intervention study that had used 
tomatoes or tomato products in an intervention and measured serum urate levels before and 
after the intervention period. It was also obvious that these studies were inconsistent in their 
results, with most showing no significant effect, whilst others reported an increase or 
decrease in serum urate levels after intervention (Abete et al., 2013; Engelhard et al., 2006; 
Jacob et al., 2008; Lee et al., 2009a; Todd et al., 2010; Todd et al., 2012; Vinha et al., 
2014). With such variable results between studies, it became difficult to make any clear 
statements about the acute effect of tomatoes or tomato products on serum urate levels. A 
meta-analysis of these studies needed to be conducted; however, each of the crossover trials 
only reported summary level data for serum urate before and after intervention, with no 
record of a mean difference ± standard deviation. In such a study design the comparison of 
the reported data would substantially overestimate the standard error of the difference in 
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effect and combining these studies would not accurately reflect the real effect within the 
data (Elbourne et al., 2002). It was not until an article detailing a series of mathematical 
equations that are able to calculate the standard error of a paired mean difference from 
summary data of a crossover trial came to my attention that a meta-analysis of these 
intervention studies became feasible (Elbourne et al., 2002). This section aimed to combine 
the results of intervention studies that have used tomatoes or tomato products during the 
intervention period and measured serum urate levels before and after intervention, in a 
systematic meta-analysis, to assess whether these studies support the hypothesis from the 
previous section – that tomatoes increase serum urate levels in a similar manner to other 
common acute gout attack trigger foods. 
 
4.3.2. Methods 
4.3.2.1. Literature Search and Inclusion Criteria 
A literature search of two article databases (Web of Science Core Collection: 
webofscience.com and Google Scholar: scholar.google.com) using the search terms 
“tomato intervention uric acid,” or “tomato intervention,” or “tomato uric acid,” or 
“tomato urate” was conducted to identify any further intervention studies of interest. The 
resultant list of publications was assessed for inclusion in a meta-analysis. Additionally, 
the reference list of each identified study was searched for any further studies fitting the 
initial inclusion criteria. Human clinical trials with randomised or crossover intervention 
methodologies, using tomatoes or tomato products as part of the intervention trial, and 
reporting urate levels measured before (or during a placebo intervention) and after the 
intervention period were initially included. The corresponding author of studies that 
reported measuring urate levels, but did not publish these measurements for both time 
points was contacted, and the missing data politely requested. Once a list of studies 
fulfilling the initial inclusion criteria was compiled, the publications were further 
scrutinised for comparability and two additional exclusion criteria developed. Studies with 
an intervention period < two weeks and/or that used an intervention product that was not 
primarily composed of tomato were excluded. 
 
4.3.2.2. Data Extraction 
Information from each study that fulfilled the initial inclusion criteria was extracted and 
summarised. The study location (country), number of individuals taking part in the entire 
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study, number of individuals who completed the study, average age of participants, specific 
type of tomato product used during intervention (including brand name), the intervention 
length, and the mean serum urate ± standard deviation before (or during placebo) and after 
intervention were recorded. Serum urate measurements were converted to µmolL-1 where 
necessary (µmolL-1 = mg/dL * 59.485 or mmolL-1 * 1,000).  
 
4.3.2.3. Calculating Mean Difference 
For those studies where raw serum urate measurements were provided (in the publication 
or by the study authors on request), a paired mean difference ± standard deviation was 
calculated. The summary before/after serum urate information was used to estimate the 
paired mean difference ± standard deviation using the methodologies outlined by Elbourne 
et al. (2002). In short, the within-person correlation (ρ) between urate levels measured 
before and after intervention was calculated (ρCalc) for those studies where raw 
measurements were available, this was then used to create a standardised conservative 
within-person correlation estimate (ρEst) for use in calculating the standard deviation of 
paired samples in the remaining studies with only summary values available (Equation 4.1). 
 
Equation 4.1: Method for the estimation of mean difference ± paired standard 
deviation in studies providing summary data before and after intervention only. 




2 −  [SDd]2
2 * SDa * SDb
 
 Step 2: Estimation of mean difference ± paired standard deviation (summary data). 
[SDd]2 = [SDa]2 + [SDb]2 – 2 * ρEst * SDa * SDb 
MD = Meana – Meanb 
Step 1 was performed on all studies providing raw data. Step 2 was performed for all studies providing only 
summary data. ρ – within-person correlation. The lowest ρ value calculated in Step 1 was identified and 
rounded down to the nearest 0.1. This value was the conservative ρ value estimated for Step 2. SDa – standard 
deviation after intervention. SDb – standard deviation before intervention. SDd – standard deviation for the 
difference before and after intervention. MD – mean difference. Meana – mean after intervention. Meanb – 
mean before intervention.  
 
4.3.2.4. Meta-Analysis 
Interventions using similar tomato products were grouped together into sub-sets (tomato 
juice, tomato soup, and tomato extract) and the paired mean differences combined using an 
inverse-variance random-effect meta-analysis model. The entire group of studies was also 
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combined in the same way. Student’s t-statistic was used to calculate a p-value 
corresponding to the estimated paired data and this p-value was compared to that reported 
within the study to assess estimate accuracy. All statistical analysis was performed using R 
3.1.1 (www.r-project.org). PMD < 0.05 was considered statistically significant. 
 
4.3.3. Results 
4.3.3.1. Search Results and Study Summary 
The literature search terms returned over 400 results, 99 of which were human clinical trials 
involving tomatoes or tomato products in the intervention period. ten of these studies 
contained data useful to this analysis within the publication and an additional four were 
useful after the corresponding author provided the necessary data1. This resulted in 14 
comparable studies for meta-analysis. All 14 of these studies used a crossover trial study 
design. The search results and study inclusion/exclusion criteria are summarised in Figure 
4.5. 
 
Within the 14 studies available for meta-analysis, half used tomato juice as the intervention 
food (one used vegetable juice with ~84% tomato content; Low Sodium V8®, Campbell’s, 
Australia), three used a tomato based soup (gazpacho ~60% tomato content (Sanchez-
Moreno et al., 2004)), two used a tomato extract, and one each used tomato sauce, and 
whole tomatoes. Eleven studies were conducted on healthy individuals, two used 
hypertensive individuals, and one studied individuals with confirmed heart failure (Table 
4.11). 
  
                                                
1 Professor Robert Walker and Professor Achim Bub are thanked for their kind provision of raw serum urate 
measurements. Dr. Christina Tsitsimpikou is thanked for her provision of summary level serum urate data. 
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Figure 4.5: Schematic detailing the inclusion/exclusion assessment of literature search 
results. 
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4.3.3.2. Study Result Summary and Meta-Analysis 
Three of the fourteen studies reported a significant decrease in serum urate levels after the 
intervention period was completed (mean difference (MD) = -57.8 µmolL-1, PMD < 0.03; 
MD = -59.0 µmolL-1, PMD < 0.05; and MD = -9.3 µmolL-1, PMD < 0.05; for males in 
Sanchez-Moreno et al. (2004), and Sanchez-Moreno et al. (2006), and for females in Vinha 
et al. (2014), respectively). Another study, whilst reporting non-significant changes in 
serum urate levels found a significant increase in urinary uric acid excretion after 
consumption of 250 mL tomato juice twice a day for 14 days (MD = 0.13 mg/mg creatinine, 
PMD < 0.05) (Jacob et al., 2008). All other studies had non-significant results. 
 
Table 4.12: Serum urate levels before and after consumption of tomatoes/tomato 
products in fourteen human clinical intervention trials. 





(Bub et al., 2000) 23 M 330.4 ± 68.6 341.8 ± 59.0 0.83  11.4 ± 38.0 NS 
(Jacob et al., 2008) 12 M/F 221.4 ± 49.8 221.0 ± 45.9  0.80 -0.4 ± 30.5 NS 
(Todd et al., 2010) 33 M/F 326.1 ± 73.9 329.1 ± 77.5 0.88  3.0 ± 37.8 NS 
(Todd et al., 2012) 22 F 284.1 ± 72.3 292.3 ± 67.0 0.86  8.2 ± 37.5 NS 
(García-Alonso et al., 2012) 7 M/F 217.1 ± 66.1 216.5 ± 67.7  0.80 -0.6 ± 42.3 NS 
(Tsitsimpikou et al., 2013) 9 M/F 309.3 ± 35.7 291.5 ± 112.4  0.80 -17.8 ± 86.6 - 
(Biddle et al., 2015) 18 M/F 428.3 ± 89.2 428.3 ± 77.3  0.80 0.0 ± 53.9 NS 
Tomato Extract 
(Engelhard et al., 2006) 31 M/F 344.4 ± 76.2 349.1 ± 86.1  0.80 4.8 ± 52.2 NS 
(Hininger et al., 2001) 52 M 340.0 ± 50.5 352.0 ± 64.9  0.80 12.0 ± 39.0 NS 
Tomato Soup 
(Sanchez-Moreno et al., 2004) 6 M 420.2 ± 51.4 362.4 ± 22.5  0.80 -57.8 ± 36.0 <0.03 
(Sanchez-Moreno et al., 2004) 6 F 276.5 ± 27.2 253.2 ± 26.2  0.80 -23.3 ± 16.9 NS 
(Sanchez-Moreno et al., 2005) 6 M/F 315.9 ± 74.0 271.4 ± 73.5  0.80 -44.5 ± 46.6 NS 
(Sanchez-Moreno et al., 2006) 6 M 399.0 ± 28.7 340.0 ± 47.8  0.80 -59.0 ± 30.2 <0.05 
(Sanchez-Moreno et al., 2006) 6 F 287.0 ± 33.1 265.0 ± 39.4  0.80 -22.0 ± 23.7 NS 
Tomato Sauce 
(Abete et al., 2013) 27 M/F 267.7 ± 53.5 261.7 ± 71.4  0.80 -5.9 ± 43.0 NS 
Whole Tomato 
(Vinha et al., 2014) 35 F 207.4 ± 56.0 198.1 ± 46.1 0.99  -9.3 ± 12.9 <0.05 
Urate is reported as mean ± standard deviation in µmolL-1. n – number of individuals who completed the 
tomato intervention. M – male. F – female. ρCalc – calculated within-person correlation between start and end 
urate measures. ρEst – within-person correlation conservatively estimated based on the four ρCalc values. Mean 
difference – difference between start and end urate ± paired standard deviation. PMD – p-value for mean 
difference as quoted within the study text ((Tsitsimpikou et al., 2013) did not quote a p-value for their data). 
NS – non-significant. 
 
For the four studies where full serum urate measurements were available (three provided 
through correspondence with the study authors, one published in text), the within-person 
correlation of urate levels before and after intervention was calculated. This correlation 
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ranged from 83% to 99% (ρCalc = 0.83, 0.88, 0.86, and 0.99 for Bub et al. (2000), Todd et 
al. (2010), Todd et al. (2012), and Vinha et al. (2014), respectively). Based on these 
correlations, a conservative within-person correlation estimate of 80% was chosen to 
calculate the paired standard deviation for all other studies (Table 4.12).  
 
Serum urate levels decreased in response to consumption of tomatoes/tomato products 
when all studies were combined (MD = -9.3 µmolL-1, PMD = 0.03). This was driven by the 
large decrease in serum urate levels seen in the three tomato soup intervention studies 
conducted by Sanchez-Moreno et al. (2004, 2005, and 2006) (MD = -38.5 µmolL-1, PMD = 
6.4×10-6) and the strong effect of whole tomatoes found by Vinha et al. (2014). Conversely, 
tomato extract caused a significant increase in serum urate levels (MD = 10.2 µmolL-1, PMD 
= 0.03) and tomato juice was also trending toward a serum urate-increasing effect (MD = 
4.5 µmolL-1, PMD = 0.21). 
 
Figure 4.6: Meta-analysis of the mean difference in serum urate levels from fourteen 
published tomato intervention trials. 
 
All studies were combined using an inverse-variance weighted random-effects meta-analysis. n – number of 
individuals who completed the intervention. MD – mean difference (µmolL-1). 95% CI – 95% confidence 
intervals. PMD – p-value for the mean difference. Weight – inverse-variance random-effect meta-analysis 
weighting. Q – heterogeneity Q-statistic. df – degrees of freedom. PQ – heterogeneity p-value. * – male only 
group. ^ – female only group. # – both male and female group. 
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4.3.4. Discussion 
This meta-analysis of human clinical intervention trials involving tomatoes or tomato 
products showed a significant decrease in urate levels after regular daily tomato 
consumption for two or more weeks. An overall urate-decreasing effect was observed; 
however, a large amount of heterogeneity between studies was evident. Whole tomatoes 
and tomato soup both showed a significant serum urate-lowering effect and tomato sauce 
showed a similar decrease in serum urate, although this was non-significant (PMD = 1.5×10-
4, PMD = 6.4×10-6, and PMD = 0.48, respectively). Conversely, tomato extract showed a 
significant serum urate-increasing effect and tomato juice had a similar, but non-significant 
urate-raising effect (PMD = 0.03 and PMD = 0.21, respectively). The effects of tomato extract 
and juice are consistent with that of the association seen in Section 4.2, adding support to 
the hypothesis proposed in that section – that tomatoes increase serum urate levels in a 
similar way to other gout attack trigger foods. However, the contradictory effects of tomato 
soup and whole tomatoes weakens this support. 
 
The significant heterogeneity between these clinical intervention studies (PQ = 6.2×10-6) 
could have several explanations. Firstly, the average age of the people involved in these 
studies ranged from 20 to 65 and the number of females/males in each sample set varied, 
with some studies including both male and female subjects, whilst others were limited to a 
single sex. As serum urate levels naturally differ between males and females and they also 
differ with age, these differences in study population could change the detectable effect of 
tomatoes on serum urate levels (Franco et al., 2006; Harkness and Nicol, 1969; Snaith, 
2003). Secondly, the studies were conducted in several different countries, which may have 
an influence on the specific variety of tomato used to create the intervention tomato 
product. Interestingly, all studies conducted in Spain or Portugal showed a serum urate-
decreasing effect. It is possible the variety(s) of tomato used in these Spanish/Portuguese 
studies have a differing effect to varieties in other countries, and as these studies contribute 
to almost half of the meta-analysis weightings (48.5%) this variety specific effect may be 
overemphasised. The serum urate decreasing effect seen in all Spanish/Portuguese studies 
may also be caused by an ancestry-specific gene-environment interaction effect. With 
evidence from the previous section suggesting SLC22A12 (URAT1) and tomato 
consumption interact to modify serum urate levels, and the differing frequency at which 
tomatoes were identified as a gout attack trigger between ancestry groups in Section 3.2, it 
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is possible the strong effect observed in these Spanish/Portuguese individuals is caused by 
an ancestry-specific genetic effect (at SLC22A12 or other genes). Thirdly, the effect of 
tomatoes measured by these studies may reflect a difference between an acute and chronic 
response. Each of the studies had to have a minimum intervention period of two weeks, 
making these studies less focused on the acute effect of tomatoes; however, the association 
study in the previous section focused on average tomato consumption within a year – a 
measure of the chronic effect of tomatoes. These intervention studies sit somewhere in the 
middle of an acute and chronic effect and it is unclear how much time had elapsed between 
the final tomato consumption of each study and the final serum urate level measurement 
was taken. If the acute effect of tomato consumption is to create a sudden reduction in 
serum urate levels, this could explain why a large number of people identify tomatoes as a 
trigger of acute gout attacks. A sudden reduction in serum urate levels can lead to shedding 
of monosodium urate crystals within the joints and onset of an acute gout attack (Doherty, 
2009; Rees et al., 2014). In contrast, if serum urate levels are raised in response to regular 
consumption of tomatoes, this could lead to an increase in risk of hyperuricaemia and gout. 
This chronic effect parallels that of other acute gout attack trigger foods. 
 
And lastly, the different tomato products used between studies may be influencing the 
response detected, despite experimental evidence suggesting the various nutrients within 
tomatoes are not significantly changed by processing (Mattila and Kumpulainen, 2002). Of 
particular interest is the distinct difference in effect between tomato soup and tomato juice. 
Both tomato juice and gazpacho (tomato-based soup) are consumed in a liquid form, with 
the tomatoes treated in a similar manner during production, and both commonly being 
consumed cold – mitigating any temperature related differences in nutrient absorption. The 
interventions in both categories also involved consumption of approximately equivalent 
quantities of liquid for a similar length of time (Table 4.11). The specific products used in 
this group of studies also had a similar carbohydrate (primarily sugar), salt, and vitamin C 
content, although there is some variation (Table 4.13). These nutrients have all been shown 
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(Bub et al., 2000) 2.5 8.0 - 
(Jacob et al., 2008) 3.0 - 9.1 
(Todd et al., 2010) 4.9 0.0^ 30.0 
(Todd et al., 2012) 4.9 0.0^ 30.0 
(García-Alonso et al., 2012) 3.5 500.0 - 
(Tsitsimpikou et al., 2013) 4.2 - 18.3 
(Biddle et al., 2015) 3.6 98.0 16.0 
Tomato Soups (Gazpacho) 
(Sanchez-Moreno et al., 2004) 2.0 0.8 14.4 
(Sanchez-Moreno et al., 2005) 2.3 0.8 15.2 
(Sanchez-Moreno et al., 2006) 2.0 - 15.5 
Tomato Sauce 
(Abete et al., 2013) 9.1 625.0 - 
Values per 100 mL are shown. ^ – juice with no salt content was specifically made for the study.   
 
The single distinct difference between tomato juice and gazpacho is the presence of other 
vegetables within the gazpacho soup. Whilst gazpacho is made up of 60% tomatoes, it is 
also made of cucumber (18%), green pepper (12%), onion (4%), and small amounts of 
garlic, salt, olive oil, vinegar, sugar, and lemon (< 2%) (Don Simon, Spain; (Sanchez-
Moreno et al., 2004; Sanchez-Moreno et al., 2005). In contrast, the tomato juices used in 
these intervention studies were all > 80% tomato (McCoy, New Zealand and Campbell’s 
Soups, Australia), including the vegetable juice (Low Sodium V8®) used in the study by 
Biddle et al. (2015) (84% tomato), although for this particular intervention the presence of 
other vegetables may have been confounding the results in a similar way to gazpacho (7% 
carrot; 4% celery; < 1% each of beetroot, parsley, lettuce, watercress, and spinach; 
Campbell’s Soups, Australia). With only a single study using whole tomatoes as the 
intervention product, and this study being conducted in very young women (Age: 20 ± 1) 
it is difficult to determine whether the strong urate-lowering effect seen in this study (MD 
= -9.3 µmolL-1, PMD = 1.5×10-4) reflects what would happen within a group of gouty 
individuals (traditionally older males) consuming whole tomatoes (Vinha et al., 2014; 
Winnard et al., 2012). 
 
Tomato soup may decrease serum urate levels through an increase in renal uric acid 
clearance. Increased liquid intake leads to an increase in urination and a consequent 
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decrease in serum urate due to increased urinary uric acid excretion (Berl, 2008; Nishioka 
et al., 2002). However, tomato soup decreases urate in these three studies to a level far 
greater than water alone (11.9 ± 11.3 µmolL-1 one hour after consumption) and whole 
tomatoes also have a urate-lowering effect (Nishioka et al., 2002; Vinha et al., 2014). 
Additionally, tomato juice does not seem to have the same effect as tomato soup, despite 
the equivalent liquid volume (Table 4.11), indicating that the effect seen in tomato soup is 
most likely additional to the water content. The study by Jacob et al. (2008) was the only 
intervention study that measured renal urate clearance (urate:creatinine ratio), finding an 
increase of 0.13 mg/mg Cr (PMD < 0.05) in 12 individuals (Age: 23 ± 2 years) after 
consumption of 500 mL tomato juice per day for two weeks. In this same group, a minor 
reduction in serum urate levels was observed (-0.14 ± 30.5 µmolL-1, PMD > 0.05), possibly 
as a result of the increased renal uric acid clearance (Jacob et al., 2008). If this is the case, 
it could be assumed that the three groups consuming gazpacho have a much higher 
urate:creatinine ratio than the individuals in the Jacob et al. study. None of the studies 
conducted with tomato soup consumption measured urinary uric acid clearance making this 
claim difficult to confirm (Sanchez-Moreno et al., 2004; Sanchez-Moreno et al., 2006; 
Sanchez-Moreno et al., 2005). 
 
The mechanisms by which tomatoes possibly influence serum urate proposed in Section 
4.2 do not explain the serum urate-decreasing effect observed in this analysis. Perhaps 
tomatoes influence serum urate levels in multiple ways dependent on other factors (such as 
processing style) and resulting in differing responses to tomato intake. This idea could 
explain the difference in observational and interventional study results, along with the 
differences seen between specific tomato products. An alternate mechanism to those 
proposed in Section 4.2, that may lead to an increase in serum urate, is the possible 
inhibition of xanthine oxidase activity by the phenolic acids in tomatoes. Tomatoes act as 
antioxidants in vivo and are able to reduce the level of reactive oxygen species produced 
by the conversion of xanthine to hypoxanthine by xanthine oxidase under “stress” 
conditions (Lavelli et al., 2000). The phenolic acids found in tomatoes play a role in 
modifying this reaction and it has been suggested that they may directly inhibit xanthine 
oxidase activity; however, others have argued this is not the case and tomato components 
are merely able to scavenge the reactive oxygen species produced during the reaction 
instead (Lavelli et al., 2000; Meyer et al., 1995). If tomatoes are able to inhibit xanthine 
Chapter 4 | Dietary Influences 
Page | 198 
oxidase activity this could explain the urate-lowering effect seen in these intervention 
studies. 
 
4.3.4.1. Study Limitations 
Intervention studies are commonly small, with limited power to detect non-extreme effect 
sizes. Post hoc calculation of the power for each of the intervention trials included in this 
meta-analysis indicated only three of the 14 studies were adequately powered (≥ 80%) to 
detect an effect size equal to or greater than the observed effect (Minitab 17.2.1: 
www.minitab.com). These studies were Sanchez-Moreno et al. (2004) male only sub-set, 
Sanchez-Moreno et al. (2006) male only sub-set, and Vinha et al. (2014). Of note, the 
effects seen in the two interventional trials by Sanchez-Moreno et al. were extremely large, 
with no other study producing an effect estimate close to that seen in these trials (except 
for the third study by Sanchez-Moreno et al. (2005)). These studies do not provide details 
of an a prioi power calculation during study design to determine an adequate sample size 
to detect an effect and (at least in the first study) an expected effect as large as that observed 
would have been unrealistic. Sanchez-Moreno et al. also appear to have used the same 
cohort of 12 individuals in all three studies (6 men, 6 women, age: 22 ± 0.5 years old, body 
mass index: 22.5 ± 0.9 kg/m2), making it unsurprising the results of these three studies are 
consistently extreme (Sanchez-Moreno et al., 2004; Sanchez-Moreno et al., 2006; Sanchez-
Moreno et al., 2005).  This evidence calls into question the validity of the results produced 
in these three studies. The result found by Vinha et al. (2014) is more reliable than that of 
the Sanchez-Moreno et al. studies. Vinha et al. (2014) showed a significant, but not 
unreasonably large, urate-decreasing effect in response to the consumption of whole 
tomatoes (Vinha et al., 2014). The study was adequately powered to detect an association 
this large, although again there was no mention of a priori calculation of the necessary 
study sample size to obtain a detection power ≥ 80% for their expected result. The study 
authors also published the complete raw data they collected within the study, allowing for 
easy confirmation of the effects seen (Vinha et al., 2014). 
 
In addition to limited detection power, these intervention trials are limited by the potential 
for participants to unintentionally deviate from the study protocols. In particular, for those 
studies where participants were instructed to maintain their usual dietary habits (10 of 14 
studies), the additional consumption of tomato products may have led to a greater feeling 
of satiety and a subsequent reduction in postprandial snacking. A decrease in postprandial 
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snacking due to a greater feeling of satiety could lead to a decrease in consumption of urate-
raising foods and an overall reduction in serum urate levels despite tomato consumption 
possibly raising serum urate. This increased satiety and decrease in postprandial snacking 
was considered one of the main drivers of the reduction in serum urate, weight, serum 
glucose, triglycerides, and cholesterol seen in the women studied by Vinha et al. (2014). 
Alternatively, for those studies where participants were given a strict diet to follow 
throughout the intervention phase (low carotenoid, low salt, or low lycopene (Bub et al., 
2000; Jacob et al., 2008; Todd et al., 2010; Todd et al., 2012)) adherence to this diet may 
have been less stringent than desirable, adding extra variability into the biochemical 
measures within an already small group of individuals. 
 
Whilst these limitations are significant issues to be considered during the interpretation of 
this meta-analysis, the major limitation of this study was the need to estimate paired 
standard deviations for ten of the 14 studies included due to insufficient reporting of data 
within publications. From the four studies that provided raw urate measurements, it was 
apparent that within-person correlations for these small groups of individuals can vary 
substantially (ρCalc = 0.83 to ρCalc = 0.99). Although a conservative estimate of ρEst was 
made, this may be an overestimate in some groups, creating a smaller standard error than 
the raw data would produce, and resulting in the incorrect weighting of the study within the 
inverse-variance weighted meta-analysis model. Other studies may have had an 
underestimation of the true standard error, having the opposite effect. To demonstrate this 
problem, an example recalculation of the paired standard deviation for the Vinha et al. 
(2014) study group, which had the strongest within-person correlation (ρCalc = 0.99) is 
presented in Equation 4.2. Using the conservative correlation value of 0.8 (which was 
applied to all groups with only summary data available), the paired standard deviation for 
the Vinha et al. (2014) data is 33.6, ~2.5 times greater than the actual paired standard 
deviation of 12.9. This then results in a wider confidence interval and a non-significant p-
value (MD = -9.3 [-20.8; 2.0], PMD = 0.11), unlike the very significant result obtained from 
the raw data. Therefore, the conservative estimate applied to all studies may be 
underestimating the true effect of tomatoes, although every study had an estimated p-value 
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Equation 4.2: Recalculation of the paired standard deviation for Vinha et al. (2014) 
intervention result using the conservative estimated within-person correlation value. 
 Step 1: Recalculation of the paired standard deviation using ρEst = 0.8 
  SDd	= [SDa]2 + [SDb]2 – 2 * ρEst * SDa * SDb 
 SDd	= [46.1]2 + [56.0]2 – 2 * 0.8 * 46.1 * 56.0 = 33.6 
 Step 2: Recalculation of confidence intervals 






  CI     =  MD ± "#* SEd =  -9.3 ± 2.03 * 5.68 = -20.83 and 2.23 
 Step 3: Recalculation of the p-value 




 = -1.6 
  P(") = 0.11 
SDa – standard deviation after intervention. SDb – standard deviation before intervention. MD – mean 
difference. SDd – paired standard deviation of the mean difference. n – number of participants. ρ – within-
person correlation. 95% CI – 95% confidence interval. "# – students t distribution critical value ("# = 2.03 (ν 
– degrees freedom (n – 1) = 34). " – paired t-statistic. P(") – two-tailed p-value for the paired t-statistic. 
Original Data – SDa = 46.1; SDb = 56.0; MD = -9.3; SDd = 12.9; n = 35. 
 
4.3.4.2. Conclusion 
In conclusion, this section found a significant reduction in serum urate levels after 
combining the results of 14 crossover intervention trials that used tomatoes or tomato 
products during the intervention period. This result is inconsistent with Section 4.2. Within 
this group of 14 studies there was significant heterogeneity of the effects seen. The 
difference in effect between this study and the observational study of the previous section 
may reflect a difference in acute/chronic exposure to tomatoes. An acute reduction in serum 
urate after tomato consumption is consistent with the currently understood mechanisms for 
triggering of acute gout attacks and with the high frequency at which tomato consumption 
was listed as an acute gout attack trigger in Section 3.2. Larger interventional studies 
designed specifically to test for an effect of tomatoes on serum urate levels need to be 
conducted. An interventional study that uses tomato juice, tomato soup, and whole 
tomatoes as intervention products and that repeats the analysis in the same group of 
individuals at several time points could elucidate whether these three products do modify 
serum urate levels in consistently different ways. 
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Section 4.4. Diet-Wide Association Study (DWAS) of 
Serum Urate Levels in 18,348 American European 
Individuals. 
4.4.1. Background 
Many studies have assessed the relationship between serum urate levels and certain food 
items, initially with a focus on alcohol and foods with a high-purine content, but more 
recently studies have begun to widen their analysis scope (as detailed in Section 4.1). 
Several studies have taken a diet-wide approach to this analysis, but for most studies, 
similar food items are grouped together into categories. This leaves the possibility that 
foods within these categories have differing effects that are not identified. The first of these 
broader studies was conducted by Loenen et al. (1990), who assessed the contribution of 
ten food categories (containing most food items) in elderly men and women from The 
Netherlands. Since this study Chang (2011) has assessed the influence of 22 food 
items/categories on urate levels in Taiwanese men; Schmidt et al. (2013) have assessed the 
contribution of 14 food items/categories to serum urate levels in British men and women; 
Ryu et al. (2014) have compared the consumption of food items in 17 food categories by 
Korean hyperuricaemic and normouricaemic individuals; and recently Zykova et al. (2015) 
analysed 13 different food items/categories in relation to serum urate levels in two large 
cohorts from Australia and Norway (Chang, 2011; Loenen et al., 1990; Ryu et al., 2014; 
Schmidt et al., 2013; Zykova et al., 2015). 
 
The results of these studies are comprised of mostly previously known associations, 
although some novel associations have also been found. Chang (2011) identified significant 
associations between shellfish, eggs, soy products, fried food, and juice; Schmidt et al. 
(2013) saw significant associations for dairy products and beer; Ryu et al. (2014) observed 
significant differences in consumption of vegetables, seaweed, dairy products, and alcohol 
between hyperuricaemic and normouricaemic individuals; Loenen et al. (1990) found a 
single association in men between serum urate levels and alcohol, whilst serum urate levels 
in women associated with meat, fish, bread, milk products, and margarine; and finally 
Zykova et al. (2015) identified significant associations between serum urate levels and 
beer, spirits, wine, alcohol, eggs, coarse bread, cereals, meat, milk, cheese, yoghurt, and 
Chapter 4 | Dietary Influences 
Page | 202 
fruit (Chang, 2011; Loenen et al., 1990; Ryu et al., 2014; Schmidt et al., 2013; Zykova et 
al., 2015). 
 
Despite these studies assessing a broader range of food items, there are still many foods 
(especially specific fruits and vegetables) that have not been assessed for an association 
with serum urate levels, including many foods that are identified by gout patients as acute 
gout attack triggers (Section 3.2). Therefore, the application of a large diet-wide association 
study that considers many food items separately could elucidate several previously 
unknown associations, and potentially clarify some previously inconsistent effects. The 
specific aim of this section was to apply the methodologies of a “hypothesis-free” genome-
wide association study to food frequency questionnaire data to assess the contributions of 




4.4.2.1. Study Participants 
Participants of the ARIC, CARDIA, CHS, FHS, and NHANES III North American cohorts 
described in Appendix A.2 (page 256) were used in this diet-wide association study. The 
same group of 18,348 American European individuals used in Section 4.2 were used in this 
analysis. The five cohorts were also further divided into the same male only (8,523) and 
female only (9,825) sub-sets. 
 
4.4.2.2. Data Collation 
Each study administered a slightly different food frequency questionnaire, with a differing 
number of questions and a slightly different list of food items. Answers to the food 
frequency questionnaires administered during the baseline examination for each cohort 
were converted to serves/week (as described in Appendix Table D.2; page 272). 
Questionnaires were assessed for between study comparability1. This resulted in the 
formation of 65 comparable food items for analysis (Appendix Table D.1; page 268). To 
                                                
1 This between study comparability was initially conducted without the inclusion of the NHANES III 
questionnaire in preparation for a conference (European Crystal Network Workshop, Paris: March 5th and 6th 
2015). Several changes were made after the inclusion of the NHANES III questionnaire for this section. Some 
decisions may have been made differently if NHANES III had been included initially. 
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be included in the analysis a food item had to be comparable between the food frequency 
questionnaires of three out of the five cohorts. 
 
4.4.2.3. Diet-Wide Association Analysis 
For each food item, a multivariate linear regression adjusted for sex, age, body mass index, 
menopausal status, and average daily calorie intake (kcal/day) was conducted in the five 
cohorts separately. Analyses in ARIC, CARDIA, CHS, and FHS were additionally adjusted 
for whole-genome principal component analysis vectors 1 to 4 (calculated as in Section 
4.2.2.3) to account for population stratification and cryptic relatedness. NHANES III could 
not be adjusted for principle component analysis vectors as this cohort has not been whole-
genome genotyped. Regression beta values were combined using an inverse-variance 
weighted meta-analysis. This analysis was repeated for the cohorts split into male only and 
female only sub-sets. For all combining analyses, a Q-statistic was calculated to determine 
the heterogeneity between cohorts, a fixed-effect model was used if there was no significant 
heterogeneity and was replaced with a random-effect model if a significant heterogeneity 
p-value was found (PQ < 0.05). 
 
4.4.2.4. Confounding Due to Dietary Habits 
To assess the level of confounding created by food items that are consumed as a 
complement to (eg. bacon and eggs) or substitute for (eg. butter vs. margarine) other food 
items in normal dietary patterns, three different analyses were conducted. 
 
4.4.2.4.1. Correlation Matrix 
A matrix describing the consumption of each food correlated with each other food was 
produced. Unadjusted correlation values and their corresponding p-values were calculated 
and plotted for all cohorts combined. The correlogram produced was used as an indication 
of normal dietary habits within the cohort.  
 
4.4.2.4.2. Other Serum Urate-Influencing Foods 
The regression analysis for each significantly associated food item was repeated in the full, 
male only, and female only sub-sets; with the inclusion of each other significantly 
associated food item separately in a series of discrete analyses. These linear regressions 
were additionally adjusted for sex, age, body mass index, menopause status, average calorie 
intake, and whole-genome principal component vectors 1 to 4 (except in NHANES III) and 
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inverse-variance weighted fixed or random-effect meta-analysis of the sample set specific 
results was conducted. Additional analyses adjusting each significantly associated food 
item by all other food items together were also conducted in the same manner. 
 
4.4.2.4.3. Healthy Eating Score  
A healthy eating score was calculated based on the Harvard Healthy Eating Pyramid (2008) 
and Healthy Eating Plate (2011) guidelines and an adaptation of the methodologies used 
by Nettleton et al. (2013) (Department of Nutrition Harvard, 2015; Nettleton et al., 2013). 
This healthy eating score was not tailored to reflect a urate-lowering diet, but rather a 
general “healthy” diet. Briefly, food items (in serves/week) were combined into four 
categories representing the different levels of the Harvard Healthy Eating Pyramid/Plate 
(Level 1: red meat, butter, refined grains, potatoes, sugar-sweetened beverages, and 
desserts/sweets; Level 2: dairy products (excluding butter) and alcohol; Level 3: 
nuts/seeds/beans, fish, poultry, and eggs; Level 4: vegetables, fruits, and whole grains; 
Figure 4.7). Quartiles of these four levels were determined and labelled numerically (0, 1, 
2, 3) before being multiplied by a number representing the “healthiness” of the pyramid 
level. Level 1 was multiplied by negative two to indicate consumption of food items in this 
group is least favourable, level 2 was multiplied by negative one, level 3 was multiplied by 
one, and level 4 was multiplied by two indicating the consumption of food items in this 
group is most favourable. These values were summed together to create a healthy eating 
score with a minimum value of -9 and a maximum value of 9. A higher number indicated 
a healthier diet. 
 
The calculated healthy eating score was tested for an association with serum urate levels 
using a multivariate linear regression adjusted for sex, age, body mass index, menopausal 
status, average calorie intake, and whole-genome principal component analysis vectors 1 
to 4 (except in NHANES III) and combined using an inverse-variance weighted fixed or 
random-effect meta-analysis model as described for the individual food items. This was 
repeated in the male only and female only sub-sets. The healthy eating score was also 
included as an adjustor in multivariate linear regression (along with all other standard 
covariates mentioned above) to assess whether the food items significantly associated with 
serum urate were markers of a healthy diet in general. All statistical analysis was performed 
using R v3.1.1 (www.R-project.org). For all regression analyses individuals with partial or 
missing data were excluded.  
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Figure 4.7: Harvard Healthy Eating Pyramid showing food categories and their 
healthy eating score multiplication value. 
 
Copyright© 2011, Harvard University. Adapted from the Harvard Healthy Eating Pyramid/Plate dietary 
recommendation (Department of Nutrition Harvard, 2015). Salt, healthy oils, and multivitamin consumption 
were removed from the pyramid as they were not asked about in all cohorts’ food frequency questionnaires. 
Alcohol was added to the same level as dairy products based on the more detailed consumption 
recommendations provided as a supplement to the pyramid.   
 
4.4.2.5. Statistical Significance and Study Power 
Pβ < 0.05 was considered nominally significant, whilst the diet-wide significance threshold 
was set at Pβ < 7.69×10-4 after Bonferroni correction for multiple-testing (0.05 divided by 
65 food items = 7.69×10-4). PCor < 2.4×10-5 was considered statistically significant for the 
diet-wide correlation analysis (0.05 divided by (652)/2 = 2.4×10-5). 
 
Level 1 
(multiply x -2) 
Level 2 
(multiply x -1) 
Level 3 
(multiply x 1) 
Level 4 
(multiply x 2) 
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Power to detect an association at the diet-wide significance level (Pβ = 7.69×10-4) was 
calculated for each sample set and the full cohort combined using the methodology set out 
by Cohen (1988). All sample sets were adequately powered (≥ 80%) to detect an effect size 
(Cohen’s ƒ2) of 0.02 (Figure 4.8). This corresponded to a linear regression partial R2 value 
of approximately 1% in all sample sets separately. The combined sample set had power to 
detect an association with a partial R2 approximately equivalent to 0.1% (Cohen’s ƒ2 = 
0.002). 
 
Figure 4.8: Detection power in five American European sample sets combined and 
separately across a range of effect sizes. 
 
Cohen’s ƒ2 = 
RB2
1−	RAB2
 where RB2  is the partial R2 corresponding to the specific food item of interest and RAB2  is 
the R2 for the entire regression analysis (Selya et al., 2012).  
 
4.4.3. Results 
4.4.3.1. Diet-Wide Associations 
Ten food items produced a significant association (Pβ < 7.69×10-4) with serum urate levels 
in the full cohort (Figure 4.9). Six of these food items have been studied previously in 
relation to serum urate levels (beer, liquor, tea, cheese, skim milk, shellfish, and non-citrus 
fruits), whilst the other four associations were with novel food items or replicated 
previously overlooked associations (brown bread, peanuts, margarine, and eggs). Ten other 
foods showed a nominal association including five known serum urate-influencing food 
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items (wine, soft drinks, whole milk, organ meats, and tomatoes1) and five novel food items 
(cold cereal, poultry, muffins/corn bread, cake/pie, and potatoes). Full details are presented 
in Table 4.14 and Appendix Table D.4 (page 276). 
 
Interestingly, the five novel or previously overlooked food items all associated with 
decreased serum urate, whilst five of the other six food items with previously identified 
serum urate effects, associated with raised serum urate levels. Individually these food items 
explained 0.07% to 0.95% of the variation in serum urate levels within the cohort. Together 
these significantly associated food items explained 3.07% of serum urate variation (Table 
4.14). In the male only sub-set, seven foods (beer, liquor, wine, soft drinks, skim milk, 
peanuts, and eggs) produced statistically significant associations with serum urate levels 
(Table 4.14 and Appendix Table D.5; page 280) . The female only sub-set produced three 
statistically significant results (beer, liquor, and brown bread; Table 4.14 and Appendix 
Table D.6; page 284). All associations in the sex-specific sub-sets were in a consistent 
direction with each other. In the male only sub-set specific food items explained 0.07% to 
1.23% of the variation in serum urate levels, with beer having the greatest influence on 
serum urate. All serum urate-influencing foods together explained 3.92% of the variation 
in serum urate levels within the male only sample set. In the female only sub-set 0.01% to 
0.47% of variation in serum urate was explained by specific food items and 2.10% was 
explained by all the significantly associated food items added together (Table 4.14). 
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Table 4.14: Diet-wide association “top-hits”: thirteen food items showing a significant 
association with serum urate levels in the full or sex-specific cohorts. 
Food Item 
Full Cohort  Male Only  Female Only 




1.05×10-10 0.94%  
1.33 
[1.07; 1.58] 







1.97×10-05 0.39%  
1.16 
[0.76; 1.56] 







0.02 0.17%  
1.38 
[0.70; 2.05] 







1.71×10-05 0.10%  
0.33 
[0.10; 0.56] 




Soft Drink 0.72 
[0.29; 1.16] 
9.97×10-04 0.27%  0.76 
[0.48; 1.04] 






-05 0.07%  
-0.62 







1.65×10-05 0.38%  
-0.83 
[-1.09; -0.58] 







3.06×10-07 0.15%  
6.07 
[3.16; 8.98] 








1.80×10-04 0.06%  
-0.38 
[-0.62; -0.13] 




Brown Bread -0.54 
[-0.73; -0.35] 
1.43×10-08 0.17%  -0.90 
[-1.56; -0.23] 






-06 0.16%  
-1.13 
[-1.68; -0.57] 6.76×10
-05 0.24%  
-0.59 




-04 0.08%  
-0.38 







1.72×10-07 0.14%  
-1.56 
[-2.15; -0.98] 




β – inverse-variance weighted meta-analysis beta value (µmolL-1). 95% CI – 95% confidence interval. Pβ – 
meta-analysis p-value. R2 – partial R2 value converted to a percentage (R2 * 100) calculated from multivariate 
linear regression of all samples together (adjusted by study). An inverse-variance random-effects meta-
analysis model was used to combine beer, liquor, wine, soft drinks, and skim milk in the full cohort (PQ = 
0.02, PQ = 0.02, PQ = 0.01, PQ = 0.02, and PQ = 0.03). In the male only cohort brown bread and margarine 
had significant heterogeneity p-values (PQ = 0.02 and PQ = 0.02). In the female only cohort wine, soft drinks, 
skim milk, and eggs had significant heterogeneity p-values (PQ = 0.01, PQ = 0.01, PQ = 0.04, and PQ = 0.03). 
All other heterogeneity p-values were > 0.05 and an inverse-variance fixed-effects meta-analysis model was 
used. * – indicates the number of cohorts missing data for this food item. 
 
4.4.3.2. Dietary Correlations 
Significant correlations (PCor < 2.4×10-5) were seen between every food item and at least 
one other food item. The strongest correlation was seen between non-citrus fruit and melons 
(cor = 0.69, Pcor < 1.0×10-300), with apples/pears, bananas, and peaches also strongly 
correlating with non-citrus fruit (cor = 0.64, cor = 0.58, and cor = 0.58; respectively. Pcor < 
1.0×10-300 for all). This correlation was inflated, as apples/pears, bananas, and peaches 
(along with other fruits) were combined together to create the non-citrus fruit variable in 
some cohorts (Appendix Table D.1; page 268). The next five strongest correlations were 
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between broccoli and cabbage (cor = 0.46, Pcor < 1.0×10-300), coffee and cream (cor = 0.45, 
Pcor < 1.0×10-300), bacon and eggs (cor = 0.39, Pcor < 1.0×10-300), peaches and melons (cor 
= 0.39, Pcor < 1.0×10-300), and lettuce and mayonnaise/dressing (cor = 0.37, Pcor < 1.0×10-
300). The strongest negative correlation was between lettuce and whole milk (cor = -0.15, 
Pcor =1.6×10-33) (Figure 4.10). 
 
Figure 4.10: Correlogram of consumption of 65 food items (serves/week) by 18,348 
American European individuals. 
 
Blue indicates a positive correlation; orange indicates a negative correlation. X – non-significant correlation 
p-value (Pcor > 2.4×10-5). * – indicates the number of cohorts missing data for this food item. 
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Interestingly, consumption of most food items was significantly correlated with the 
majority of food items within the same category; eg. all alcohols correlated, almost all 
vegetables correlated (51 of 55 significant pairwise correlations). The beverages category 
was the only category that did not produce a predominance of significant correlations 
within the same category (8 of 21 significant pairwise correlations). Many categories also 
correlated with other categories, such as fruits and vegetables (62 of 66 significant pairwise 
correlations), or meats and dairy products (37 of 49 significant pairwise correlations), 
whilst other categories did not commonly correlate, (alcohol and desserts/sweets (2 of 12 
significant pairwise correlations), dairy products and vegetables (38 of 88 significant 
pairwise correlations; Figure 4.10). 
 
4.4.3.3. Other Serum Urate-Influencing Foods  
The thirteen food items that were significantly associated with urate levels in either the 
male only, female only, or complete cohort (Table 4.14) were each reanalysed for an 
association with serum urate levels with each other significantly associated food item 
included as an adjusting variable (individual and combined). For most foods, a significant 
association was maintained after this adjustment. Soft drinks showed a nominal association 
(0.05 > Pβ > 7.69×10-4) after individual adjustment by eight of the twelve other urate 
associated foods (beer, liquor, cheese, skim milk, non-citrus fruit, brown bread, peanuts, 
and eggs), whilst it gained significance after adjustment for consumption of wine (Pβ = 
3.2×10-4), tea (Pβ = 6.8×10-4), shellfish (Pβ = 7.1×10-4), margarine (Pβ = 6.1×10-4), and all 
other urate-influencing foods combined (Pβ = 4.8×10-5) in the full cohort (Figure 4.11). 
Similarly, adjustment of the non-citrus fruit and margarine associations by each other 
significantly associated food item resulted in nominally significant associations in four 
cases (non-citrus fruit adjusted by beer, liquor, soft drinks, and brown bread; margarine 
adjusted by beer, soft drink, shellfish, and brown bread). Both these foods had a non-
significant association after adjustment for the consumption of all urate-influencing foods 
combined. Interestingly, brown bread and peanuts showed a significant association when 
adjusted for all other foods individually, but were only nominally associated when adjusted 
for all urate-influencing foods combined (Pβ = 2.1×10-3 and Pβ = 4.0×10-3, respectively). 
Wine was nominally significant across all adjustments, except when adjusted by liquor and 
all other foods, which reduced the association between wine and serum urate levels to a 
non-significant level in the full cohort (Pβ = 0.05 and Pβ = 0.09, respectively; Figure 4.11). 
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Figure 4.11: Plot of the thirteen “top-hits” adjusted by each other “top-hit” food item 
in 18,348 American European individuals. 
 
Green indicates a urate-raising effect, purple indicates a urate-lowering effect. Test variable – the food item 
whose beta value is being reported. Adjusting variable – the food item being included as a covariate. The 
column labelled no adjustor is a replicate of the results in Table 4.14 for ease of comparison. x – nominally 
significant p-value (0.05 > Pβ > 7.69×10-4). Χ – non-significant association p-value (Pβ > 0.05). * – indicates 
the number of cohorts missing data for this food item. An inverse-variance random-effects meta-analysis 
model was used to combine most beer, liquor, wine, soft drink and skim milk analyses due to a heterogeneity 
p-value < 0.05. All other heterogeneity p-values were > 0.05. 
 
In the male only sub-set, beer, liquor, soft drinks, skim milk, peanuts, and eggs maintained 
a significant association with serum urate levels when adjusted by consumption of each of 
the other urate associated food items (Figure 4.12: A). Wine and shellfish were both 
reduced to nominal significance after adjustment by one other food item (wine adjusted by 
liquor; shellfish adjusted by peanuts), but maintained significance when adjusted by each 
of the other eleven food items separately and by all urate-influencing foods together. In the 
female only sub-set, beer and liquor maintained significant associations after adjustment 
for the other twelve food items. Brown bread was reduced to nominal significance by 
adjustment for consumption of soft drinks (Pβ = 8.8×10-4), but maintained significance 
when individually adjusted for all other serum urate associated foods and for all foods 
combined (Figure 4.12: B). Unsurprisingly food items that were nominally significant 
when the analysis was not adjusted for other food items did not regularly show diet-wide 
significant associations after adjustment (Figure 4.12). 
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Figure 4.12: Plot of thirteen “top-hits” individually adjusted by each other “top-hit” 
food item in 18,348 American European individuals within the male only (A) and 
female only (B) groups. 
    
Green indicates a urate-raising effect, purple indicates a urate-lowering effect. Test variable – the food item 
whose beta value is being reported. Adjusting variable – the food item being included as a covariate. The 
column labelled no adjustor is a replicate of the results in Table 4.14 for ease of comparison. x – nominally 
significant p-value (0.05 > Pβ > 7.69×10-4). X – non-significant association p-value (Pβ > 0.05). * – indicates 
the number of cohorts missing data for this food item. An inverse-variance random-effects meta-analysis 
model was used to combine brown bread and margarine in the male only sub-set and most of the wine, soft 
drink, skim milk, and eggs analyses in the female only sub-set due to heterogeneity p-values < 0.05. All other 
heterogeneity p-values were > 0.05 
 
4.4.3.4. Healthy Eating Score 
The healthy eating scores calculated from full dietary information for each cohort were 
normally distributed around zero with no significant difference between the cohorts (mean 
± standard deviation ARIC: 0.00 ± 3.60, CARDIA: 0.00 ± 3.77, CHS: -0.02 ± 3.56, FHS: 
-0.01 ± 3.76, NHANES: 0.01 ± 3.60; Pt = 0.76 to 0.99 for pairwise cohort t-test 
comparisons). These scores significantly associated with lowered serum urate levels in the 
full cohort combined (β = -0.64 µmolL-1, Pβ = 7.5×10-6). This significant association was 
also seen in the male only sub-set (β = -0.82 µmolL-1, Pβ = 1.7×10-4), but not the female 
only sub-set, although the association direction was consistent (β = -0.48 µmolL-1, Pβ = 
0.22; Table 4.15). 
  
A B 
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Table 4.15: Association between serum urate levels (µmolL-1) and healthy eating score 
in five sample sets separately and combined. 
Cohort 
Full Cohort  Male Only  Female Only 




3.47×10-03 0.13%  
-0.40 
[-1.06; 0.25] 







0.23 0.11%  
-1.43 
[-3.00; 0.13] 







1.64×10-04 0.74%  
-1.51 
[-2.99; -0.02] 







0.13 0.08%  
-1.62 
[-2.63; -0.62] 




NHANES III -0.34 
[-0.91; 0.22] 
0.04 0.03%  -0.57 
[-1.43; 0.29] 






-06 0.14%  
-0.83 
[-1.26; -0.40] 1.31×10
-04 0.14%  
-0.37 
[-1.05; 0.32] 0.30 0.10% 
β – beta value (µmolL-1). 95% CI – 95% confidence intervals. Pβ – association p-value. R2 – partial R2 value 
converted to a percentage (R2 * 100) calculated from multivariate linear regression of all samples together 
(adjusted by study). Combine – inverse-variance weighted meta-analysis combine. A random-effect meta-
analysis model was used to combine the female only group (PQ = 0.01). All other heterogeneity p-values were 
> 0.05. 
 
After adjustment for the healthy eating score, eleven of the thirteen “top-hits” were 
significantly associated with serum urate levels (Pβ < 7.69×10-4) in the analysis of all 
individuals (Table 4.16). Non-citrus fruit was non-significant after adjustment for the 
healthy eating score (Pβ = 0.10) and wine was nominally significant, as in the unadjusted 
analysis. The percentage variance explained by each food item after adjustment for the 
healthy eating score was approximately equivalent to that seen before adjustment. The 
largest decrease in variation explained was seen with soft drinks and brown bread (reduced 
by 0.08%) and the largest increase in variation explained was seen with poultry (0.09% 
increase). Overall the 13 “top-hits” explained less variation in serum urate levels after 
adjustment for the healthy eating score (2.81% vs. 3.07%; Table 4.16). In the male only 
sub-set, all eight of the previously associated foods maintained their significance after 
adjustment for the healthy eating score (Table 4.16). After adjustment beer explained less 
variation in serum urate than previously (1.15% vs. 1.23%) and the variance explained by 
all these foods together was also less (3.55% vs. 3.92%). In the female only sub-set, only 
beer remained significant after adjustment for the healthy eating score, whilst liquor and 
brown bread did not maintain diet-wide significance after adjustment for the healthy eating 
score (Pβ = 0.01 and Pβ = 3.8×10-3). As with the male only sub-set these foods explained 
less variation in serum urate after adjustment for the healthy eating score (1.96% vs. 2.10%; 
Table 4.16). 
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Table 4.16: Thirteen “top-hits” adjusted by the calculated healthy eating score in the 
full, male only, and female only cohorts. 
Food Items 
Full Cohort  Male Only  Female Only 




1.86×10-10 0.90%  
1.30 
[1.04; 1.56] 







6.17×10-05 0.35%  
1.10 
[0.70; 1.50] 







0.03 0.18%  
1.45 
[0.77; 2.13] 







1.39×10-05 0.10%  
0.34 
[0.11; 0.57] 




Soft Drink 0.60 
[0.39; 0.81] 
1.91×10-08 0.19%  0.67 
[0.37; 0.96] 






-05 0.07%  
-0.67 
[-1.10; -0.23] 2.62×10







7.62×10-06 0.41%  
-0.87 
[-1.12; -0.61] 







1.22×10-08 0.19%  
6.70 
[3.77; 9.62] 








0.10 0.01%  
-0.22 
[-0.50; 0.07] 




Brown Bread -0.47 
[-0.67; -0.27] 
6.22×10-06 0.09%  -0.49 
[-0.78; -0.20] 






-04 0.11%  
-1.01 
[-1.57; -0.44] 5.00×10
-04 0.17%  
-0.37 




-04 0.08%  
-0.38 
[-1.03; 0.26] 0.24 0.07%  
-0.57 




4.08×10-07 0.13%  
-1.49 
[-2.07; -0.90] 




β – inverse-variance weighted meta-analysis beta value (µmolL-1). 95% CI – 95% confidence interval. Pβ – 
meta-analysis p-value. * – indicates the number of cohorts missing data for this food item. An inverse-
variance random-effects meta-analysis model was used to combine beer, liquor, wine, and skim milk in the 
full cohort; margarine in the male only cohort; and liquor, wine, soft drink, margarine, and eggs in the female 
only cohort due to heterogeneity p-values < 0.05 (PQ = 0.02, PQ = 0.02, PQ = 0.01, PQ = 0.04; PQ = 0.03; PQ 
= 0.01, PQ = 0.01, PQ = 0.02, PQ = 0.04, and PQ = 0.02; respectively). All other heterogeneity p-values were 
> 0.05. and an inverse-variance fixed-effects meta-analysis model was used. 
 
4.4.4. Discussion 
Thirteen different food items significantly associated with serum urate levels in this diet-
wide association analysis. These foods included seven well established urate-modifying 
foods; beer, liquor, wine, soft drinks, cheese, skim milk, and shellfish. The six other foods 
included two less well established urate-modifying foods (tea and non-citrus fruit) and four 
food items with novel or previously overlooked associations – brown bread, peanuts, 
margarine, and eggs. Some foods had a sex-specific effect on urate levels and most 
associations were maintained after adjustment for potential confounding created by 
consumption of other food items. In addition to the individual food item associations, a 
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healthy eating score calculated to estimate the overall quality of each individual’s diet 
significantly associated with serum urate levels, with individuals estimated to eat an overall 
healthier diet having lower urate levels than those with a less healthy diet. 
 
The seven associations observed in this diet-wide study that were with known, confirmed 
serum urate-influencing food items (beer, liquor, wine, soft drinks, cheese, skim milk and 
shellfish) were consistent in effect size and direction with previously reported associations 
(Table 4.1 to Table 4.5), and the associations were maintained after adjustment for possible 
confounding by other food items. This identification of significant associations between 
serum urate levels and known urate-modifying foods acts as a positive control for this 
analysis. Of note, no form of meat showed a diet-wide significant association in this study. 
Within the different types of meat analysed, poultry showed a nominally significant 
association with raised serum urate levels, whilst organ meats had a nominally significant 
association with lowered serum urate levels. Additionally, coffee showed no association 
with serum urate in this study. However, tea showed a significant association. This is 
consistent with other studies that have looked at coffee/tea consumption in relation to serum 
urate and/or gout, which have only ever produced a significant association in one of these 
drinks, never both (Table 4.5). These were the only established serum urate-modifying food 
items that did not replicate here. 
 
Of real interest in this study are the associations between novel, or uncommonly assessed 
food items and serum urate levels. Due to the diet-wide approach to this analysis (as 
opposed to a hypothesis-driven approach), a number of unexpected associations were 
identified. Most prominent amongst these findings is the association between peanuts 
(and/or peanut butter) and decreased serum urate levels, an effect that (to my knowledge) 
has never been reported. In the past 20 years, a growing pool of evidence has indicated 
frequent consumption (at least once a week) of peanuts and/or tree nuts significantly 
reduces an individual’s risk of cardiovascular disease and type 2 diabetes (Albert et al., 
2002; Fraser et al., 1992; Hu et al., 1998; Jiang et al., 2002; Kris-Etherton et al., 2008; 
Kris-Etherton et al., 2001). Many studies have assessed the effect of tree nuts (particularly 
walnuts) as opposed to peanuts on cardiovascular disease outcomes and risk factors; 
however, peanuts appear to have an effect equivalent to or potentially stronger than that of 
tree nuts in several studies (Hu et al., 1998; Jiang et al., 2002; O'Byrne et al., 1997). Hu et 
al. (1998) identified a reduced risk of cardiovascular disease in women consuming any type 
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of nut ≥ 2 times per week (RR = 0.77) compared to those who almost never consumed nuts. 
When nuts were separated into peanuts and tree nuts, a stronger protective effect was seen 
for women consuming peanuts than those consuming tree nuts (RR = 0.66 and RR = 0.79, 
respectively). Peanut butter had a similar, but weaker effect in this cohort (RR = 0.92 for 
women consuming peanut butter ≥ five times per week compared to those consuming none) 
(Hu et al., 1998). A reduction in risk of sudden death from cardiovascular disease has also 
been seen in men consuming ≥ 2 serves of any kind of nut compared to those eating none 
(RR = 0.53); however, this study did not assess the influence of peanuts separately to other 
nuts (Albert et al., 2002). Intervention studies assessing the influence of nuts on serum lipid 
profiles as a marker of cardiovascular disease risk have also identified a protective effect 
of tree nuts and peanuts. Frequent consumption of almonds, macadamia nuts, peanuts and 
walnuts has been shown to reduce total cholesterol levels, low-density lipoproteins, and 
triglycerides in intervention trials. This average reduction was in general larger than that 
seen when the same individuals consumed a diet specifically designed to lower cholesterol 
levels and heart disease risk (Abbey et al., 1994; Chisholm et al., 1998; Colquhoun et al., 
1996; Curb et al., 2000; Edwards et al., 1999; Kris-Etherton et al., 1999; Kris-Etherton et 
al., 2001; Morgan and Clayshulte, 2000; O'Byrne et al., 1997; Sabate et al., 1993; Spiller 
et al., 1998; Zambon et al., 2000). Furthermore, nut consumption has associated with a 
37% decrease in risk of developing type 2 diabetes in women who ate ≥ five serves of nuts 
per week (RR = 0.73) when compared to women who never ate nuts. Peanut butter 
consumption had an equivalent effect (RR = 0.79) (Jiang et al., 2002). 
 
Cardiovascular disease and type 2 diabetes are common comorbidities of hyperuricaemia 
and gout. Gout patients in New Zealand and America have significantly higher rates of type 
2 diabetes and cardiovascular disease than individuals without gout (type 2 diabetes with 
gout: 17% and 26%; type 2 diabetes without gout: 5% and 2%; cardiovascular disease with 
gout: 9% and 14%; cardiovascular disease without gout: 3% and 2%, in New Zealand and 
American individuals, respectively) (Winnard et al., 2013; Zhu et al., 2012). Additionally, 
as serum urate levels increase an individuals’ serum lipid profile change to reflect a 
cardiovascular risk profile (increased low-density lipoprotein and triglycerides, decreased 
high-density lipoprotein) and their risk of developing type 2 diabetes increases (Kodama et 
al., 2009; Moriarity et al., 2000). Recent evidence from a Mendelian randomisation study 
has shown that genetically determined serum urate levels (as opposed to measured) do not 
influence triglyceride levels, but rather genetically determined triglyceride levels associate 
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with increased serum urate levels. This indicates increased triglycerides cause serum urate 
levels to rise (Rasheed et al., 2014a). As peanuts are able to lower triglyceride levels and 
triglycerides directly influence serum urate levels the association between peanuts and 
decreased serum urate seen here may reflect the triglyceride-lowering effect of peanuts. 
Other nuts weakly associated with decreased serum urate, which supports this hypothesis 
(β = -0.56, Pβ = 0.05; Appendix Table D.4; page 276). 
 
The mechanism through which peanuts influence cardiovascular disease and type 2 
diabetes risk is unknown, although several proposals have been made. Nuts have a high fat 
content (44 g to 76 g per 100 g of nuts) with the majority of this fat content being 
monounsaturated or polyunsaturated fats (32 g to 61 g per 100 g of nuts) (US Department 
of Agriculture, 2015). These are commonly considered to be “good” fats and have been 
associated with decreased insulin resistance, lower low-density lipoprotein, and reduced 
risk of type 2 diabetes and cardiovascular disease (Jiang et al., 2002; Kris-Etherton et al., 
2001). In addition, replacement of saturated fats with monounsaturated fats and 
polyunsaturated fats in the diets of 13 men with gout resulted in a reduction of average 
serum urate from 0.57 ± 0.1 mmolL-1 to 0.47 ± 0.1 mmolL-1 and a decrease in frequency of 
gout attacks (2.1 ± 0.8 attacks per month to 0.6 ± 0.7) after 16 weeks (Dessein et al., 2000). 
This mechanistic reduction in urate levels via the replacement of “bad” fats (saturated and 
trans fats) with “good” fats (monounsaturated and polyunsaturated) may also explain the 
association found in this study and in the study by Loenen et al. (1990) between serum 
urate and margarine (used as a spread), as margarine contains approximately one third 
“bad” fats and two thirds “good” fats and very little else. However, neither 
monounsaturated fats nor polyunsaturated fats associated with hyperuricaemia in a cohort 
of > 9,000 Korean individuals (Lyu et al., 2003) and it has been demonstrated that the 
cholesterol lowering properties of nuts are greater than would be expected if the mechanism 
of reduction was through “good” fats alone (Kris-Etherton et al., 2001). 
 
Additional mechanisms may contribute to the urate-lowering effect of peanut consumption. 
Peanuts have a high dietary fibre content (dietary fibre: 8 g per 100 g) in addition to their 
high fat content. This high fibre content is equivalent to that measured in whole grain bread 
varieties (4 g to 7 g per 100 g) and may be contributing to the urate-lowering effect of 
peanuts (US Department of Agriculture, 2015). Increased intake of dietary fibre has been 
shown to encourage greater excretion of uric acid within the faeces and reduced overall 
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serum urate levels in rats treated with allantoin to artificially inflate their uric acid to 
“human-like” levels (Koguchi et al., 2002). The associations between serum urate levels 
and brown bread/non-citrus fruit found in this study may also be reflective of an increased 
faecal uric acid excretion as both these food items have a high dietary fibre content.  
 
Fruit have a dietary fibre content ranging from 0 g per 100 g (watermelon) to 7 g per 100 g 
(prunes) with an average of approximately half the fibre content of whole grain breads, and 
a third of that in peanuts (2 g per 100 g average) (US Department of Agriculture, 2015). 
Both fruit and bread have previously shown an association with decreased serum urate, as 
has dietary fibre (Loenen et al., 1990; Zykova et al., 2015). These foods have also been 
associated with reduced risk of cardiovascular disease (Hu, 2003). However, consumption 
of oranges and apples once per day (compared to less than once per month) has been 
associated with an increased risk of incident gout (RR = 1.64), inconsistent with the urate-
lowering effect seen here and in other studies (Choi et al., 2004a). The loss of significance 
when the association of brown bread/non-citrus fruit with serum urate was adjusted for the 
healthy eating score may indicate that greater consumption of fruit and brown bread is 
reflective of a healthier diet in general (also inferred from the correlation matrix; Figure 
4.10) and as such the decrease in serum urate observed here may be an artefact of this 
healthier diet (although this does not explain the increased risk of gout observed by Choi 
et al. (2004)). 
 
Usual dietary patterns differ greatly between individuals and this has the potential to 
confound analyses assessing the influence of individual food items on disease risk. The 
significant association between the healthy eating score and serum urate levels seen in this 
study, indicates this is likely the case. Several studies have conducted similar analyses that 
use food frequency data to estimate the effect of individual dietary habits on serum urate 
levels with varying results. Heidemann et al. (2011) created two indicators of dietary habits 
in a group of German individuals. This study showed that individuals whose diet was 
characterised by high intake of refined grains, processed meats, eggs, and sugar-sweetened 
beverages (processed food dietary pattern) had significantly higher urate levels than those 
people who did not commonly eat these foods (317 ± 109 µmolL-1  compared to 295 ± 109 
µmolL-1, Ptrend = 1.0×10-3). However, when this analysis was reversed, using a diet score 
that represented a health conscious dietary pattern (characterised by a high intake of fruit, 
vegetables, and whole grains), no association with serum urate was seen (Ptrend = 0.65) 
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(Heidemann et al., 2011). Similarly, Tsai et al. (2012) assessed the association between 
estimates of three dietary patterns and serum urate levels in Taiwanese individuals, finding 
no significant association between estimates of a urate-raising dietary pattern (consuming 
high levels of seafood, meat, sugar-sweetened beverages, and organ meats), a fish and fried 
food dietary pattern, or a vegetable and fruit dietary pattern. Tsai et al. (2012) argued other 
clinical situations are more important than diet in determining serum urate levels (Tsai et 
al., 2012). The low percentage variance explained by the healthy diet score created for this 
study (0.14%) along with the low variance in serum urate levels explained by all the urate-
modifying foods added together (3.07%) also indicates diet plays a relatively minimal role 
in determining overall serum urate levels. The percentage variance explained by genetic 
variants (5% to 7%) is much higher than that explained by diet, and the SLC2A9 (GLUT9) 
gene alone explains an approximately equivalent amount of serum urate variance (3.5%) 
as the combined individual food effects seen here (Kolz et al., 2009; Kottgen et al., 2013). 
 
As the role of diet in gout has been recognised for almost 2,500 years and there is a 
substantial amount of research and clinical focus on this aspect of hyperuricaemia and gout 
risk, the evidence provided here for a minimal effect for overall dietary habits on serum 
urate levels is controversial. In addition, the healthy eating score calculated here was built 
from easily accessible dietary recommendations that were developed using the “best 
available scientific evidence about the links between diet and health” [Harvard School of 
Public Health]. Reports of a reduction in risk of cardiovascular disease, cancer, and all-
cause mortality in American men and women who follow these dietary recommendations 
have also been published (Akbaraly et al., 2011; Belin et al., 2011; McCullough et al., 
2002). As many risk factors for hyperuricaemia and gout are also risk factors for 
cardiovascular disease it is interesting that an estimate of overall diet based on dietary 
recommendations that have been shown to reduce cardiovascular disease seems to play a 
minimal role in determining serum urate levels. The significant association between the 
healthy eating score calculated here and reduced serum urate levels does; however, align 
with these previous reports of reduced cardiovascular risk in response to adherence to the 
Harvard Healthy Eating Pyramid/Plate dietary recommendations. 
 
Of note, studies assessing the influence of whole diet in disease risk use a variety of 
methods to calculate estimates of dietary patterns. Each of the papers assessing the 
influence of the Harvard Healthy Eating Pyramid/Plate dietary recommendations in chronic 
Gout in New Zealand 
Page | 221 
disease risk used an Alternate Healthy Eating Index (AHEI) as their measure of dietary 
patterns. The calculation of this healthy eating index uses a similar methodology to that 
used to calculate the healthy eating score used in this thesis, but it allows for a greater scope 
of adherence to recommendations, using a graded scoring system that classifies people into 
categories based on how closely their normal dietary intake of each food group aligns with 
the Harvard Healthy Eating Pyramid/Plate recommendations (Akbaraly et al., 2011; Belin 
et al., 2011; McCullough et al., 2002). In contrast the studies that assessed the influence of 
dietary patterns on serum urate levels used a different methodology to estimate diet habits. 
These studies used principal component analysis to identify and weight the variables from 
food frequency questionnaires that explained the most common dietary habits within the 
group studied and associated these vectors with serum urate (Heidemann et al., 2011; Tsai 
et al., 2012). The creation of a diet score based on dietary recommendations (as performed 
in this study) has been attributed a greater generalisability across populations and more 
meaning in a health recommendation setting (Maynard et al., 2005). However, the 
calculation of a diet score which accurately reflects the complexities of dietary habits is 
difficult and small changes in the method used to calculate any diet score can lead to 
substantial changes in association results and applicability (Maynard et al., 2005). 
Recalculation of the healthy eating score used in this study following the exact 
methodologies of Akbaraly et al. (2011), Belin et al. (2011), and McCullough et al. (2002), 
along with those of Heidemann et al. (2011) and Tsai et al. (2012), and an assessment of 
the agreement between these different methodologies may provide more substantial 
evidence to either refute or support the claim that diet plays a relatively minimal role in 
determining serum urate levels compared to genetics. 
 
4.4.4.1. Study Limitations 
Limitations in this study mean caution must be taken when interpreting the results. As with 
the targeted analysis of tomato consumption, the difference in food frequency questionnaire 
used between studies causes methodological problems for this study. The major factor in 
this limitation is the difference in the number of foods listed in each questionnaire and the 
inconsistent grouping of certain foods together. To compensate for the limitation caused by 
differing questionnaires, caution was taken when deciding which variables to analyse. Non-
comparable groupings of food items were excluded from analysis and at least three of the 
five cohorts had to have a comparably listed food item before that food item was included 
in the analysis. These cautious rules may have mitigated some of the variable effects 
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potentially created by the differing questionnaires, along with those described in the 
previous section’s discussion (Section 4.2.4), reducing the false positive rate. Differences 
in the questionnaires may have also led to the study participants giving more or less 
accurate information between studies. This may contribute to the significant heterogeneity 
seen during the meta-analysis of several food items (Appendix Table D.4; page 276 to 
Appendix Table D.6; page 284). There is also the possibility that as each cohort was 
collected at a different time (1985 to 2002), food compositions have changed, resulting in 
non-comparable food items being combined in this analysis and producing significant 
heterogeneity p-values. This situation may be particularly important when processed foods 
are being assessed (cereals, bread, mayonnaise/dressing) where the production method has 
changed over time and certain ingredients (particularly sugar) have become more abundant 
(Johnson, 2012b). This is also an important consideration in the extrapolation of the effects 
observed here to the present day situation. Additionally, as with any large-scale set of 
analyses, the likelihood of finding a falsely significant result increases with every extra test 
added. With the application of a Bonferroni correction to account for this multiple-testing 
effect, this likelihood is reduced back to that of a single test. It does however, allow for the 
possibility that some of the food items which were nominally significant may be having a 
real effect that is overlooked in this study (false negative).  
 
4.4.4.2. Conclusion 
In conclusion, this section details the results of a diet-wide association analysis that assesses 
the influence of many different food items on serum urate levels. Thirteen different food 
items showed a diet-wide significant effect. Seven previously associated food items (beer, 
liquor, wine, soft drinks, cheese, skim milk, and shellfish) and six novel or unconfirmed 
food items (tea, non-citrus fruit, brown bread, peanuts, margarine, and eggs) significantly 
associated with serum urate at the diet-wide level. This work also provides evidence for a 
urate-lowering effect of a healthy diet score based on the current Harvard Healthy Eating 
Pyramid/Plate dietary recommendations. This information can be used to inform clinical 
recommendations, encouraging a healthier diet for individuals with gout to help lower 
serum urate levels and prevent attacks. However, overall diet explained very little variation 
in serum urate levels, possibly indicating less focus on diet in the treatment of gout and a 
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Section 5.1. Overall Conclusions 
The overall objective of this thesis was to contribute toward the development of a greater 
understanding of the genetic and dietary influences of gout risk in New Zealand. Through 
the implementation of cross-disciplinary research methods, several important and novel 
findings have been made. The first research chapter of this thesis (Chapter 2) provided 
evidence for associations between two uric acid transporter genes (SLC22A11 (OAT4) and 
SLC22A12 (URAT1)) and gout/hyperuricaemia risk in New Zealand European and 
Polynesian individuals. Ancestry-specific effects were identified when both common and 
rare non-synonymous variants were analysed within these two genes (Chapter 2). The 
qualitative research detailed in Chapter 3 showed that individuals with gout have a greater 
focus on the changeable elements (diet and lifestyle) of gout aetiology over the 
unchangeable biological “truth” (genetics) of this disease. This emphasis on dietary and 
lifestyle interventions to manage gout was present, despite regular access to an informal 
community-based gout education program (Section 3.1). The heavy emphasis on acute gout 
attack trigger foods recognised within both the New Zealand and overseas gout community 
is a manifestation of this focus on the changeable elements of gout. Over 70% of New 
Zealand gout patients identified at least one acute gout attack trigger food (Section 3.2), 
and in Chapter 4 evidence for associations between the most commonly mentioned of these 
dietary triggers and increased serum urate levels is presented. The identification of 
tomatoes as a common gout trigger food in New Zealand and subsequent evidence for an 
influence of tomatoes on serum urate levels (although there were inconsistent directions of 
effect between analysis styles) is a novel and controversial finding (Section 3.2, Section 
4.2, and Section 4.3). The four novel associations between specific food items and 
decreased serum urate levels (peanuts, brown bread, margarine, and eggs) identified in a 
diet-wide association study are also important findings. In addition, the identification of a 
significant, but minimal, serum urate lowering effect attributable to a healthy diet score is 
a useful and important finding (Section 4.4). 
 
The prevalence of gout differs between New Zealand European and Polynesian individuals 
(approximately 3% and 7%, respectively) (Winnard et al., 2012). The ancestry-specific 
genetic effects identified in Chapter 2 may be involved in creating or exacerbating this 
difference. Previous analyses from the Merriman Laboratory looking at other genes in 
relation to gout in New Zealand European and Polynesian individuals have also identified 
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differing ancestral effects of variants within these genes, with opposite effect directions or 
differing levels of attributable risk (Table 5.1) (Hollis-Moffatt et al., 2011; Hollis-Moffatt 
et al., 2012; Hollis-Moffatt et al., 2009b; McKinney et al., 2015; Phipps-Green et al., 2010; 
Rasheed et al., 2014b; Tanner et al., 2015). The significant associations identified in 
Chapter 2 (single variant, haplotypic, and non-synonymous variant burden) add to the 
current understanding of gout genetics in New Zealand. At present evidence suggests the 
SLC2A9 (GLUT9) rs11942223 variant has an approximately equivalent effect in New 
Zealand European and Polynesian, whilst a non-synonymous SNP rs3733591 (R294H) has 
a lower frequency of the protective C allele in the Polynesian population compared to 
European (0.3 vs. 0.8) (Hollis-Moffatt et al., 2011; Hollis-Moffatt et al., 2009b; Phipps-
Green et al., 2016). At ABCG2, the rs2231142 141K allele, that reduces the activity of 
ABCG2 to half the normal protein function, is slightly more prevalent in the Polynesian 
population (0.2 vs. 0.1) and contributes a larger risk of gout in Polynesian individuals (OR 
= 2.45) than New Zealand European individuals (OR = 2.01) (Phipps-Green et al., 2010; 
Phipps-Green et al., 2016). In the SLC17A gene cluster, the effects in the New Zealand 
European and Polynesian sample sets appear to be very similar (Table 5.1) and the trans-
ancestral effect identified between the SLC22A12 (URAT1) promoter region variant 
(rs3825018) or the rs3825018 | rs475688 | rs7932775 | rs476037 | rs478607 haplotype 
(A|C|G|T|A) and gout within this work is a similar finding (Section 2.2). In contrast, the 
evidence at SLC22A11 (OAT4) and the region ~26 kb upstream of this gene suggests 
SLC22A11 has ancestry-specific effects and expression of this gene may also be controlled 
in an ancestry-specific manner. Although the strong protective effect of rs17299124 in 
Polynesian individuals and the significant burden of rare non-synonymous risk variants in 
European individuals suggest this gene is influencing gout risk in a manner opposite to 
other genes (Section 2.2 and Section 2.3). The additional identification of a potential 
Polynesian-specific protective variant (rs561874071) in SLC22A11 also reflects this 
ancestry-specific gout preventative effect, although this SNP is also in complete linkage 
disequilibrium with a SNP in SLC22A12 (rs543512307) and the causal variant between 
these two is currently unclear (Section 2.3). Another Polynesian- or East Asian-specific 
variant (rs4148500) has also been identified through ReSequencing of ABCC4 (MRP4) 
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Several association studies by Merriman Laboratory members have also been conducted in 
genes outside of those coding for uric acid transporters. The GCKR (GKRP) gene (from 
the glycolysis pathway) has been strongly associated with gout risk in both New Zealand 
European and Polynesian individuals. Two other genes in the glycolysis pathway (PKLR 
and PRKAG2) have both shown ancestry-specific effects in these groups, with strong risk 
associations identified in New Zealand European individuals, but no apparent effect in 
Polynesian individuals (Phipps-Green et al., 2016). Inflammasome genes have also been 
assessed for associations with gout in these populations. In general, these genes have 
similar effects between European and Polynesian individuals, with nominally significant 
risk effects identified between gout and IL-1B ((IL)-1β) and CARD8, which both 
significantly associated with gout when European and Polynesian individuals were 
analysed together (OR = 1.10, POR = 0.02; and OR = 1.12, POR = 0.01 for IL-1B and CARD8 
in the combined European and Polynesian sample set, respectively) (McKinney et al., 
2015). In contrast, TLR4, another inflammasome gene, has an ancestry-specific effect. This 
gene appears to only associate with gout in New Zealand European individuals, although 
weakly (Rasheed et al., 2014b). Together these genetic associations provide reasons for the 
significant difference in prevalence of gout between Polynesian and European individuals 
in New Zealand. The ancestry-specific effects seen between European and Polynesian 
individuals are also sometimes evident between Eastern Polynesian (New Zealand Māori, 
Cook Island Māori, and Tahitian) and Western Polynesian (Samoan, Tongan, Niuean, and 
Tokelauan) individuals in these studies (Hollis-Moffatt et al., 2009b; Phipps-Green et al., 
2010). Some of the variants identified in this work may also be having ancestry-specific 
effects within the Polynesian sub-populations. 
 
Despite the significant contribution of genetic factors in gout risk, people with gout have a 
much greater focus on the role of diet in gout (Section 3.1). Through discussions with gout 
patients it became evident that a focus on disease management that encouraged a wellness 
in the foreground outlook also encouraged people to focus on the changeable aspects of 
gout aetiology. Whilst a feeling of control in disease management is important (Paterson, 
2001; Petrie and Weinman, 2006), this focus on dietary elements of gout (particularly acute 
gout attack triggers) could be encouraging others in the community to believe the common 
stereotypes associated with gout and blame the sufferers for their condition, despite the 
uncontrollable genetic element of gout disease risk. 
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Interestingly, the frequency at which specific trigger foods were mentioned by people with 
gout also showed evidence for ancestry-specific effects. People of Pacific Island or New 
Zealand Māori ancestry were more likely than European individuals to list any gout trigger 
food, with Pacific Island individuals also being more likely than New Zealand Māori 
individuals to mention a trigger food. These three ancestry groups also had different 
patterns of commonly mentioned gout trigger foods, with New Zealand European people 
listing alcohol, fish/seafood, meat, and vegetables (excluding tomatoes; 41.3% asparagus, 
30.6% broccoli/cabbage/cauliflower, and 21.3% peas) as the first, second, third, and fourth 
most common trigger foods, respectively. Pacific Island individuals listed fish/seafood, 
meat, alcohol, then tomatoes; and New Zealand Māori individuals listed fish/seafood, 
alcohol, tomatoes, then meat as the first, second, third, and fourth most common triggers, 
respectively. These differing patterns of acute gout attack trigger food frequencies, along 
with the higher frequency of mentioning any trigger food seen in New Zealand Māori and 
Pacific Island people, may reflect different mechanisms of action within these people. The 
finding that tomatoes interact with SLC22A12 genotype (although weakly; Section 4.2) and 
the previously observed interactions between sugar-sweetened beverages and both ABCG2 
and SLC2A9, and between alcohol and SLC2A9 suggest these ancestry-specific food effects 
could be created by ancestry-specific genetic effects (Batt et al., 2013; Dalbeth et al., 
2013b; Dalbeth et al., 2014; Voruganti et al., 2009). Such differences have been 
demonstrated previously, with the interaction between ABCG2 and sugar-sweetened 
beverages being stronger in Polynesian people compared to New Zealand European, whilst 
the interaction between SLC2A9 and sugar-sweetened beverages was only evident in New 
Zealand European individuals (Dalbeth et al., 2013b; Dalbeth et al., 2014). Without dietary 
information available in the New Zealand Gout Case-Control Cohort, current evidence is 
unable to assess whether the influence of all foods, or overall diet, on serum urate levels or 
gout differs between these two populations; however, the work presented in Chapter 3 is 
the first step toward conducting such research. 
 
The dietary analyses in American European individuals presented here (instead of New 
Zealand populations) demonstrate several novel effects. The associations found between 
tomatoes, peanuts, brown bread, margarine, and eggs, all represent novel or unconfirmed 
associations with serum urate levels (Chapter 4). Specifically, the tomato association 
analysis and intervention trial results were able to support patient understandings of gout 
triggers, despite the two analysis sections having contradictory results (Section 4.2 and 
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Section 4.3). The heterogeneity between the observational and intervention trial sections of 
this thesis, along with the substantial heterogeneity within the various intervention results 
may also be reflective of ancestry-specific responses to dietary intakes – although there are 
many other possible explanations. This work on tomatoes is important, demonstrating a 
need to support gout patients in the task of identifying their personal gout attack trigger 
foods, whilst encouraging the management of gout through urate-lowering medications. 
These results have already gained world-wide media attention due to their controversial 
nature and direct translatability into the lives of gout patients. A similarly controversial 
result identified within Chapter 4 is the evidence suggesting overall diet plays a relatively 
minimal role in determining serum urate levels (compared to genes; Section 4.4). An 
estimate of overall diet explained 0.14% of the variation in serum urate levels and the 
strongest effect by a single food item explained only 0.95% of this variation (beer, up to 
1.23% in the male only sub-set). When considering the effect of all serum urate-influencing 
foods added together, the variation in serum urate explained was still only 3.07% and this 
effect was reduced to 2.81% when dietary habits were included as an adjustor in these 
association models. The finding by Tsai et al. (2012) that diet played no significant role in 
determining serum urate levels in a cohort of 266 Chinese individuals also supports the 
claim that diet appears to have a minimal role in determining risk of hyperuricaemia/gout 
(Tsai et al., 2012). This evidence suggests diet should possibly be focused on less in clinical 
practice and a greater focus on treating the biological causes of gout may need to be 
encouraged, with an emphasis on the disease control that adherence to urate-lowering 
medications can provide. This change in focus within the clinical setting may help to 
disperse some of the negative stereotypes associated with gout and encourage patients to 
adhere to urate-lowering medications rather than focusing on dietary changes. In saying 
this, diet must still be discussed within the clinical setting due to the contribution of dietary 
triggers in acute gout attack onset. Perhaps an emphasis on the possibility that patients will 
be able to eat whatever food they like, including gout attack trigger foods, if they adhere to 
their treatment regime would motivate people to focus on modifying the biological causes 
of gout rather than the dietary and lifestyle “causes.” 
 
The work within this thesis contributes substantially to the research of gout in New Zealand, 
joining the research of world-leaders in the field to develop a greater understanding of the 
genetic and dietary contributors to gout risk in New Zealand. This work requires further 
validation and development of the results presented here before any recommendations can 
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be disseminated to health professionals and the wider community. However, it provides 
some of the stepping stones in the path toward better healthcare outcomes for gout patients 
in New Zealand by contributing to the conversations necessary for change. 
 
5.1.1. Study Limitations 
There are several limitations to the work presented within this thesis. Firstly, the genetic 
analyses presented here focus on a very narrow portion of the genetic risk of gout. The 
decision to focus solely on two uric acid transporter genes in this thesis does not allow for 
an assessment of the contributions of other genes to serum urate levels and gout risk. Whilst 
many of the other uric acid transporters have been assessed for an association between 
common variants and gout in the New Zealand European and Polynesian populations by 
other members of the Merriman Laboratory, the role of rare non-synonymous variants 
within these genes has not been assessed (Table 5.1) (Hollis-Moffatt et al., 2012; Hollis-
Moffatt et al., 2009b; McKinney et al., 2015; Phipps-Green et al., 2010; Phipps-Green et 
al., 2016; Rasheed et al., 2014b). The sequence information for each of these genes is 
available within the ReSequencing cohort; however, analyses comparable to that presented 
within Section 2.3 have so far not been conducted (except in ABCC4 (Tanner et al., 2015)). 
In addition, there is a substantial amount of research that looks at the role of uric acid 
transporters in gout, but very little that assesses the role of genes in onset of inflammation. 
These analyses are required to improve the understanding of gout genetics within New 
Zealand populations but they were deemed outside the scope of this thesis research. 
Recognition that there are many other genetic factors involved in the risk of gout is essential 
within the interpretation of the results presented here, and studies that replicate the methods 
of Section 2.3 in relation to other genes are necessary to further improve the understanding 
of gout genetics within New Zealand. 
 
Second, the assessment of the variety and frequency of food items listed as trigger foods is 
limited in the way that the trigger lists were collected. Whilst participants were given the 
opportunity to list any and all trigger foods that they noticed act as personal gout attack 
triggers, no corresponding assessment of the foods these people regularly ate was 
conducted. This lack of knowledge about the normal dietary habits of people within the 
New Zealand Gout Case-Control Cohort meant individuals who did not regularly eat a food 
item (out of preference, availability issues, or allergies/dietary restrictions) could not be 
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excluded from the calculation of the frequency at which each food was listed as a gout 
trigger. For instance, people were not given the opportunity to specify they were vegetarian, 
logically a vegetarian would not know if red meat triggered their gout attacks as they do 
not eat red meat. The inclusion of these people in the frequency calculation would therefore 
underestimate the true proportion of people who have gout attacks triggered by red meat 
consumption. Despite this problem the results presented within Section 3.2 provide an 
important, and previously unstudied, insight into the dietary triggers of acute gout attacks. 
The inclusion of questions assessing both the foods that trigger people’s gout attacks and 
their usual dietary habits in any future research would help refine the results presented here 
and perhaps further identify novel trigger foods that significantly contribute to acute gout 
attack onset. 
 
And finally, the lack of full dietary information (food frequency questionnaire data) in the 
New Zealand Gout Case-Control Cohort limited the analyses that could be conducted on 
these individuals in relation to the influences of diet on gout. As it was within the New 
Zealand population, particularly the Māori and Pacific Island populations, that tomatoes 
were identified as an important acute gout attack trigger food, an assessment of the 
association between serum urate levels and tomato consumption in these people would have 
been an ideal analysis to conduct. However, with no useful data from a New Zealand study 
being available, five large American European cohorts had to be used instead. This allowed 
the analysis to be conducted; however, the conclusions drawn within this work may not 
apply to the New Zealand population. Differences in usual dietary habits between 
American and New Zealand individuals, along with the varieties of tomato most commonly 
available in these countries, may have a large influence on the outcomes of a similar study 
conducted within a New Zealand cohort. Furthermore, the five American European cohorts 
did not have reliable gout classification criteria within their study questionnaires (self-
report of physician diagnosis, or no question asked), making a diet-wide association study 
in relation to gout risk infeasible. Therefore, these data availability issues limit the extent 
to which the results of this section can be applied to the New Zealand population; however, 
they provide a starting point for the design of future studies assessing the role of diet on 
serum urate levels and gout within New Zealand. 
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5.1.2. Future Research 
Analyses that address the limitations detailed above and that further replicate and elaborate 
on the results presented within this thesis need to be conducted. Several suggestions of 
future research projects are detailed below. 
 
Genetic and functional analyses that expand on the results described in Chapter 2 are 
needed to confirm the effects reported here. Replication of the single variant association 
analysis of SLC22A11 (OAT4) and SLC22A12 (URAT1) SNPs has already been 
conducted; however this was not in an entirely dependent New Zealand cohort (the 2012 
New Zealand Gout Case-Control Cohort significantly overlaps with the current New 
Zealand Gout Case-Control Cohort) and was not conducted on all the SNPs analysed in 
Section 2.2. An analysis that independently replicates the findings presented within this 
section and further expands on the possible causal elements driving these associations, 
through fine-mapping of the differentially associated haplotypes, would further improve 
the understandings of the role these two genes play within gout aetiology. A study that 
identifies individuals carrying the protective or risk haplotypes identified within Section 
2.2, and then analyses the full SLC22A11 (OAT4) and SLC22A12 (URAT1) gene sequences 
for possible causal variants, could find an explanation for the associations and ancestry-
specific effects identified here. Furthermore, as the linkage disequilibrium block 1 
association appears to be of relevance to the control of gene expression, research designed 
to assess whether variants within this upstream region are truly able to modify the 
expression of these two genes needs to be conducted. 
 
Follow-up of the results presented within the ReSequencing analysis in Section 2.3 of this 
thesis also needs to be conducted to confirm the results are reflective of true effects. 
Genotyping of the Polynesian specific variants (rs561874071 and rs543512307) that almost 
produced a significant association with hyperuricaemia status in a larger cohort is 
necessary. An analysis of the relevance of these variants in relation to gout is also required. 
In addition, functional assays that assess the ability of the non-synonymous variants 
identified in this study to determine whether the predicted functional consequences of these 
variants align with their actual function are necessary. Replication of the burden analyses 
in a larger cohort is also needed to confirm these effects. 
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Replication of the anthropological section of this thesis may reveal further avenues of 
research necessary to the understanding of gout. A study that increases the number of 
people interviewed and also extends the criteria for interviewees to people within the wider 
New Zealand community, including people of non-Māori ancestry, may identify further 
aspects of gout that are important to individuals living with this condition that were not 
identified in the small study presented within Section 3.1. In addition, an assessment of the 
influence that community-based education programs (that are specifically designed for this 
purpose) have on the quality of life for gout patients through the reduction in negative 
stereotypes of gout within a community, could help encourage the development of more 
community awareness campaigns or inform the content of the current New Zealand 
campaigns (Section 1.1.3.3.1). Perhaps a study that interviews individuals before and after 
such a program was put in place would be able to identify positive and negative impacts 
that these gout education programs may have. 
 
Further assessments of the role of diet in serum urate levels and gout need to be conducted 
within a New Zealand cohort. A study that combines a food frequency questionnaire with 
questions about gout triggers could be of great benefit within this endeavour. The use of a 
food frequency questionnaire, paired with questions that assess the specific dietary triggers 
of each patient, would allow an assessment of the frequency at which each food is identified 
as a gout trigger without the underestimation issues caused by the lack of usual dietary 
habit information that was a limitation within Section 3.2. This information could also be 
used to assess the contribution of diet to gout risk in a diet-wide association study similar 
to that presented in Section 4.4 if a control cohort were also asked to fill in the food 
frequency questionnaire. This study could possibly be conducted through a postal survey 
sent to all participants within the New Zealand Gout Case-Control Cohort. This postal 
survey could include a question reassessing gout status in each individual, to ensure case 
and control groups are accurately defined, but would not require any biochemical measures 
or blood collection as would be the case for an analysis of serum urate levels and diet in 
this same cohort. A study design such as this should be relatively cheap to implement, only 
requiring funding for postage. It could also produce extremely informative results, and 
potentially novel findings as was seen in the diet-wide association study conducted here. A 
replication of the serum urate related diet-wide association study within a New Zealand 
cohort would be more logistically difficult due to the need to collect biochemical measures 
at the same time as the food frequency questionnaire is administered. Despite these 
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logistical difficulties a study such as this needs to be conducted to confirm the hypothesis 
that tomatoes are able to modify serum urate levels in Polynesian individuals and that this 
modification is larger than that observed in the American European cohort as proposed in 
Section 4.2. 
 
5.1.3. Concluding Remarks 
This thesis set out to assess the genetic influences of gout in New Zealand and discover the 
different understandings of gout held by New Zealand gout patients. In response to the 
anthropological findings of Section 3.1, a further goal to assess the dietary influences of 
serum urate levels and gout was set. The cross-disciplinary approach to this thesis allowed 
a broader picture of the understandings surrounding gout to be developed, mingling the 
personal experiences of patients with biological “truths” into a single cohesive piece of 
work. Throughout this thesis research I have learnt new skills, developed my research 
capabilities, and become more aware of the vast expanse of known and unknown elements 
within gout aetiology and biology as a whole. The work within this thesis represents both 
a personal learning experience and a significant contribution to the understandings of gout. 
I hope the findings presented here are able to help the people who this research is intended 
to benefit (gout patients) and that it encourages discussions of the issues contributing to the 
high prevalence of gout within New Zealand. This work adds to the pool of knowledge 
surrounding the experience of gout in New Zealand through research of the genetic and 
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Appendix 
Appendix A. Participant Collection Protocols 
This appendix section details the collection methods and information available for each of 
the different study cohorts used in the analyses presented within this thesis. 
 
Appendix A.1. New Zealand Gout Case-Control Cohort 
The New Zealand Gout Case-Control Cohort (used in Sections 2.2, 2.3, and 3.2) was 
developed to assess the genetic and environmental risk factors for gout within the New 
Zealand population, with the recruitment for this cohort going through several different 
stages. Initial recruitment of gout subjects began in 2001 under the supervision of Dr. Lachy 
McLean (University of Auckland, Auckland). In 2006 the project supervision was 
transferred to Professor Tony Merriman (University of Otago, Dunedin).  Initially 
participants were recruited from two cities in the North Island of New Zealand (Auckland 
and Rotorua). After 2006 individuals with gout were recruited at healthcare facilities within 
four New Zealand cities (Auckland, Wellington, Christchurch, and Dunedin). In 2009 
recruitment of the control cohort began. Recruitment sites were extended to include 
community groups, workplaces, and outreach events. In 2010 recruitment also began in 
Gisborne and the surrounding region, working with Ngati Porou Hauora Charitable Trust 
(NPH; www.nph.org.nz) to create an additional gout cohort which is separate to, but able 
to be analysed alongside the original New Zealand cohort. After participants provided 
written informed consent they were asked to fill out a general questionnaire about their 
socio-demographic status, selected medical history, family history of gout, grandparental 
ancestry, and some brief questions on exercise and dietary habits. Individuals who self-
reported having gout were further assessed by the research nurse or rheumatologist 
collecting their information for fulfilment of the American College of Rheumatology 
(ACR) gout classification criteria (discussed in more detail in Section 2.2; (Wallace et al., 
1977)). Participants with gout were also asked to complete a detailed questionnaire about 
the severity of their disease, including questions on the frequency of acute attacks, presence 
of tophi, dietary triggers of acute attacks, and gout medications. After completing the 
relevant questionnaire(s) participants were then asked to provide blood, serum, and urine 
samples to be sent to the Merriman Laboratory (University of Otago, Dunedin) for 
processing. Upon receipt of the samples, technical staff at the Merriman Laboratory sent a 
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portion of the serum and urine for biochemical analysis at the Southern Community 
Laboratories (SCL; www.sclabs.co.nz) and stored the other portion at -80°C for later use. 
Serum urate levels were measured using a Roche Cobas 8000 Modular analyser and 
reagents (median coefficient of variation for this machine is 2.1% and the within-sample 
measurement correlation is 99.6%) (Jiang et al., 2014; von Eckardstein et al., 2013). DNA 
was extracted from the remaining blood sample using a chloroform/ethanol extraction 
protocol. 
 
The Auckland Ethics Committee initially approved recruitment of gout patients (97/258), 
and then in 2006 the New Zealand Multi-Region Ethics Committee granted subsequent 
ethical approval (MEC/05/10/130). Recruitment of the Ngati Porou Hauora cohort was 
initially approved by the Northern Y Region ethics committee (NTY/07/07/074) then by 
the University of Otago Human Ethics Committee (13/117). The New Zealand Health 
Research Council (www.hrc.govt.nz), University of Otago (www.otago.ac.nz), Lottery 
Health Research (www.communitymatters.govt.nz), and Arthritis New Zealand 
(www.arthritis.org.nz) funded the formation and continued recruitment into this cohort. 
 
Appendix A.2. North American Cohorts 
To allow analyses in several sections of this thesis a selection of large cohort studies from 
the United States of America were used. The data for four of these studies (Atherosclerosis 
Risk in Communities, Coronary Artery Risk Development in (Young) Adults, 
Cardiovascular Heart Study, and Framingham Heart Study) is made available to researchers 
through the database of Genotypes and Phenotypes (dbGaP) (www.ncbi.nlm.nih.gov/gap), 
which was developed to archive and distribute the results and raw collection data of studies 
investigating the interaction between genotypes and phenotypes. Access to this data was 
permitted under the dbGaP controlled access agreement (project ID #834). Anonymised 
data from the Third National Health and Nutrition Examination Study can be downloaded 
directly from the study website (ftp://ftp.cdc.gov/nchs/nhanes/nh3data.htm) without any 
special access requirements. Access to data from the Health Professionals Follow-Up Study 
and the Nurses’ Health Study is restricted, and requires collaborations with the research 
groups involved in data collection. 
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Appendix A.2.1. Atherosclerosis Risk in Communities Study 
The Atherosclerosis Risk in Communities (ARIC) study is a population-based cohort study 
designed to examine new and established risk factors for atherosclerosis and coronary heart 
disease (dbGaP accession number phs000280; www2.cscc.unc.edu/aric/) (ARIC 
Investigators, 1989). 15,485 adults aged 45 to 64 from one of four United States 
communities (Forsyth County, North Carolina; Jackson, Mississippi; Northwest 
Minneapolis, Minnesota; and Washington County, Maryland) agreed to participate in the 
study. Between 1987 and 1989 each individual participated in an initial baseline 
examination, which included medical, social, dietary, and demographic data. Every three 
years after this baseline exam participants were re-examined (Exam 2 – 1990 to 1992; 
Exam 3 – 1993 to 1995; Exam 4 – 1996 to 1998; and Exam 5 – 2011 to 2013). Yearly 
telephone interviews were also performed to briefly assess health status and maintain 
contact with participants. At each examination blood was drawn and sent to the ARIC lipid, 
haemostasis, and chemistry laboratories for biochemical analysis; serum urate levels were 
measured at exam 1, exam 2, and exam 5 using a standard uricase oxidation assay (precision 
value of 8.6%) (ARIC Investigators, 1989; Henry et al., 1957). At exam 1, exam 2, and 
exam 3 an interviewer-administered modified Willett food frequency questionnaire was 
performed. This validated questionnaire consisted of 66 questions asking “How often, on 
average, in the past year did you eat [this food]?” Several additional questions about fried 
food and breakfast cereal eating habits were also asked (Stevens et al., 1996; Willett et al., 
1985). The ARIC cohort has also had whole-genome genotyping performed as part of the 
Gene-Environment Association Studies (GENEVA) initiative (dbGaP accession number 
phs000090; www.genome.gov/27541319). This genotyping was performed at the Broad 
Institute of MIT and Harvard (Boston, Massachusetts) using the Affymetrix 6.0 Chip 
(www.affymetrix.com). The ARIC study was supported by the National Heart, Lung, and 
Blood Institute (NHLBI; www.nhlbi.nih.gov), the National Institutes of Health (NIH; 
www.nih.gov), the National Human Genome Research Institute (NHGRI; 
www.genome.gov), and the Collaborative Studies Co-ordinating Centre, University of 
North Carolina at Chapel Hill (www.unc.edu). 
 
Appendix A.2.2. Coronary Artery Risk Development in (Young) Adults 
Study 
The Coronary Artery Risk Development in (Young) Adults (CARDIA) study was designed 
to examine the risk factors and development of cardiovascular disease (dbGaP accession 
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number phs000285; www.cardia.dopm.uab.edu) (Friedman et al., 1988). 3,622 adults 
under 30 years old from four United States field centres (Birmingham, Alabama; Chicago, 
Illinois; Minneapolis, Minnesota; and Oakland, California) were recruited into the study. 
In 1985 participants attended an initial year 0 examination. Follow-up examinations were 
held in 1987 (year 2), 1990 (year 5), 1992 (year 7), 1995 (year 10), 2000 (year 15), 2005 
(year 20), and 2010 (year 25). Each examination assessed the participant’s medical history, 
physical fitness, anthropometry, and blood chemistry. Serum urate levels were measured 
as part of the year 0, year 10, and year 15 examinations using a standard uricase assay 
(precision value of 8.6%) (Dyer et al., 1999; Henry et al., 1957). A specifically designed 
and validated interviewer-administered diet history was performed at the year 0, year 7, 
and year 20 examinations (McDonald et al., 1991). Frequency of consumption of 100 food 
items was assessed using several questions, “Do you eat [this food]?” if yes, “How much 
do you usually have?” and “How often do you usually have it?” Answers were then 
converted to servings per week for 168 food groups using the Nutrition Co-ordinating 
Centre (NCC) dietary analysis system (www.ncc.umn.edu). In addition, the CARDIA 
cohort has had whole-genome genotyping performed as part of the GENEVA initiative 
(dbGaP accession number phs000309). This genotyping was performed on the same 
platform as ARIC (Affymetrix 6.0) at the Broad Institute of MIT and Harvard (Boston, 
Massachusetts). The CARDIA study is supported by the National Heart, Lung, and Blood 
Institute (www.nhlbi.nih.gov), the National Institutes of Health (www.nih.gov), and the 
University of Alabama at Birmingham (www.uab.edu). 
 
Appendix A.2.3. Cardiovascular Health Study 
The Cardiovascular Health Study (CHS) is a prospective population-based cohort study 
aiming to evaluate risk factors for cardiovascular disease development and progression 
(dbGaP accession number phs000287; www.chs-nhlbi.org) (Fried et al., 1991). 5,582 
adults over 65 years of age were recruited at four United States field centres (Forsyth 
County, North Carolina; Sacramento County, California; Washington County, Maryland; 
and Pittsburgh, Philadelphia). Initial enrolment interviews occurred between 1989 and 
1990 and follow-up interviews were conducted annually, with additional phone interviews 
every six months. Examination questionnaires included data on medical history, stressful 
life events, anthropometric measures, dietary habits, and socio-demographic status. Dietary 
habits were assessed only at the initial baseline examination using a self-administered 
picture sort version of the National Cancer Institute food frequency questionnaire 
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(Kumanyika et al., 1996). This validated questionnaire asked participants “How often have 
you eaten [this food] in the past 12 months?” Portion sizes for each of the 99 food items 
were not considered. Additional questions about take-away/fast-food items, the use of fat 
in cooking, and alcohol consumption were included. A blood sample was also collected 
and sent for biochemical analysis at the University of Vermont Central Blood Analysis 
Laboratory (Berlington, Vermont). Serum urate levels were measured using a Kodak 
Ektachem 700 analyser and reagents which had a coefficient of variation of 2.4% (Cushman 
et al., 1995). As part of the SNP Typing for Association with Multiple Phenotypes from 
Existing Epidemiologic Data (STAMPEED) program (dbGaP accession number 
phs000226; dsgweb.wustl.edu/stampeed) the CHS cohort has been genotyped using the 
Illumina HumanCNV370 duo Beadchip (www.illumina.com). CHS is supported by the 
NHLBI, with additional support from the National Institute on Aging (NIA; 
www.nia.nih.gov), and the Collaborative Health Studies Co-ordinating Centre, University 
of Washington (www.washington.edu).  
 
Appendix A.2.4. Framingham Heart Study: Generation 3 
The Framingham Heart Study (FHS) was established in 1948 as a community-based 
longitudinal study aimed at identifying common factors that contribute to cardiovascular 
disease (dbGaP accession number phs000007; www.framinghamheartstudy.org). The 
original cohort consisted of 5,209 individuals aged 30 to 62 who lived in the town of 
Framingham, Massachusetts. Since the initial formation of this study several further 
cohorts have been recruited. The generation three cohort was established in 2002 and 
consists of 4,148 grandchildren of the original cohort participants (Splansky et al., 2007). 
These people were contacted via letter to assess interest in participating in the study, and if 
they agreed a baseline examination was conducted. Information on their medical history, 
socio-demographic status, family pedigree, and dietary habits was collected between 2002 
and 2005. A second follow-up examination was conducted between 2008 and 2011. A 
validated, self-administered Willett food frequency questionnaire was used to assess 
dietary habits (Rimm et al., 1992; Salvini et al., 1989). Participants were asked about 126 
food items with a question format identical to that used in the ARIC study. Additional 
questions about habits surrounding breakfast cereal and vitamin/mineral supplements were 
also asked. During exam 1 a blood sample was collected and analysed at the Heart Study 
laboratory in Framingham. Serum urate levels were measured with a phosphotungstic acid 
reagent autoanalyser (precision value of 2.8%) (Crowley, 1964; Henry et al., 1957). 
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Genotyping of FHS individuals was conducted as part of the SNP Health Association 
Resource (SHARe) project (dbGaP accession number phs000342; www.nhlbi.nih.gov) 
using the Affymetrix 500K mapping array and the Affymetrix 50K supplemental array 
(www.affymetrix.com). FHS is supported by the National Heart, Lung, and Blood Institute 
(www.nhlbi.nih.gov) and Boston University (www.bu.edu). 
 
Appendix A.2.5. Health Professionals Follow-Up Study 
The Health Professionals Follow-Up Study (HPFS) is a longitudinal study established in 
1986 (www.hsph.harvard.edu/hpfs) to research the links between diet and men’s health and 
to complement the all female Nurses’ Health Study (Appendix A.2.7, below). 51,529 men 
from across the United States of America, aged 40 to 75, and working as dentists, 
optometrists, osteopaths, pharmacists, podiatrists, or veterinarians have been recruited into 
the study. Every two years the participants are mailed questionnaires asking about their 
exercise habits, medical history, and medications. Every four years detailed food frequency 
questionnaires are mailed to the participants (Choi et al., 2007). The Health Professionals 
Follow-Up Study researchers also maintain a blood bank of whole blood samples from 
these men. The Health Professionals Follow-Up Study is supported by the National Cancer 
Institute (http://www.cancer.gov) and the Harvard School of Public Health (Boston, 
Massachusetts). 
 
Appendix A.2.6. Third National Health and Nutrition Examination Survey 
The Third National Health and Nutrition Examination Survey (NHANES III) is a national 
population-based study, focused on identifying prevalence of multiple diseases and their 
risk factors in the United States population (www.cdc.gov/nchs/nhanes) (National Center 
for Health Statistics, 1994). It includes 33,994 people over two months of age from 
households in 89 counties throughout all 50 states of the United States of America. These 
people were considered representative of the general United States population and were 
recruited into the study in two phases (phase 1 – 1988 to 1991 collection of individuals 
from 44 of the 89 counties; phase 2 – 1992 to 1994 collection of individuals in the 
remaining 45 counties). Each participant completed an extensive survey of his or her socio-
demographic status, medical history, and dietary habits during a home interview, before 
being asked to participate in a physical examination and provide blood and urine samples 
at a mobile examination centre. Serum urate levels were assessed at the White Sands 
Research Centre (Alamogordo, New Mexico) with a uricase oxidation analysis performed 
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on a Hitachi Model 737 Multichannel Analyser (this machine has a median coefficient of 
variation of 0.7%) (Jiang et al., 2014; National Center for Health Statistics, 1994). During 
the initial home interview dietary habits were assessed using two separate questionnaire 
styles, a 24-hour dietary recall questionnaire and a non-quantitative food frequency 
questionnaire equivalent to that used in the ARIC, CARDIA, CHS, and FHS studies. The 
food frequency questionnaire assessed consumption of 60 food items by asking the question 
“How often, in your usual diet over the past month, have you eaten [this food item]?” 
Additional questions about frequency of milk and alcohol consumption were asked. The 
NHANES III cohort had blood samples stored for DNA extraction, but no whole-genome 
genotyping of the dataset has been conducted at present. NHANES III is supported by the 
National Centre for Health Statistics (NCHS, www.cdc.gov/nchs) and the Centres for 
Disease Control and Prevention (CDC, www.cdc.gov). 
 
Appendix A.2.7. Nurse’s Health Study 
The Nurses’ Health Study (NHS) is a longitudinal study established in 1976 
(www.channing.harvard.edu/nhs) with the initial aim of investigating the long-term health 
impact of oral contraceptives. Female registered nurses aged 30 to 55 from 11 states in the 
United States of America (California, Connecticut, Florida, Maryland, Massachusetts, 
Michigan, New Jersey, New York, Ohio, Pennsylvania, and Texas) were mailed 
questionnaires about their medical history and lifestyle (Choi and Curhan, 2010). 
Approximately 70% of these women returned a completed questionnaire and were recruited 
into the Nurses’ Health Study. As with the Health Professionals Follow-Up Study, 
participants of the Nurses’ Health Study have been sent questionnaires every two years 
since the initial recruitment year. These questionnaires ask about medical history, hormone 
use, menopausal status, quality of life, and other health related topics. Food frequency 
questionnaires are sent to participants every four years to assess usual dietary habits (Choi 
and Curhan, 2010). Between 1982 and 1984 a sub-set of the participants were asked to 
submit toenail samples to the study researchers to enable biological analyses, and between 
1989 and 1990 another sub-set of women were asked to provide blood samples for 
biomarker analyses. DNA for a third sub-set of women was extracted from cheek cell 
samples between 2001 and 2004. The Nurses’ Health Study is funded by the National 
Institutes of Health (www.nih.gov) and supported by the Brigham and Women's Hospital, 
Harvard Medical School, and Harvard School of Public Health (Boston, Massachusetts). 
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Appendix Figure A.1: Schematic of exclusion criteria for the cohorts used in Section 
4.2 and Section 4.3. 
 
Exclusion criteria are shown on the left. The number of individuals excluded at each stage is shown under 
the study headings. The cohort sizes before and after exclusion are shown in bold font. CHS did not ask about 
gout status. Study specific criteria were exclusion of family members in the ARIC and NHANES III cohorts 
and exclusion of CHS individuals who were also part of the ARIC, Systolic Hypertension in the Elderly 
(SHEP), or NHANES III studies. 
 
Appendix Figure A.2: Schematic of food frequency questionnaire quality controls for 
the cohorts used in Section 4.2 and Section 4.3. 
 
Exclusion criteria are shown on the left. The number of individuals excluded at each stage is shown under 
the study headings. The cohort sizes before and after exclusion are shown in bold font. CHS interviewers did 
not assess the reliability of participant’s answers. 
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Appendix B. Genetic Associations 
This appendix section provides additional information for the analyses performed in 
Chapter 2; Sections 2.2 and 2.3. 
 
Appendix Table B.1: Sixty seven ancestry-informative markers genotyped to 
calculate estimates of individual Eastern Polynesian ancestry. 
TaqMan® Genotyped  Sequenom MassArray Genotyped 
SNP Position Gene Assay ID  SNP Position Gene 
rs12745968 1:93401837 FAM69A C_31051893_10  rs693916 1:37411844 GRIK3 
rs1539438 1:114430356 BCL2L15 C_1900118_10  rs615204 1:110759796 KCNC4 
rs12401573 1:156146218 SEMA4A C_11858023_10  rs3014875 1:153338751 - 
rs10733113 1:247622357 - C_30713847_10  rs4845622 1:154411419 IL6R 
rs7578597 2:43732823 THADA C_32653841_10  rs1205 1:159682233 CRP 
rs13419122 2:69596192 GFPT1 C_30740961_10  rs11119568 1:210852508 KCNH1 
rs3738919 2:187521260 ITGAV C_1278131_1  rs1143634 2:113590390 IL1B 
rs1816532 2:212268240 ERBB4 C_11933381_10  rs452204 2:113889061 IL1RN 
rs10511216 3:103379826 - C_29954694_20  rs9882205 3:186570398 ADIPOQ 
rs2059606 4:95255278 HPGDS C_11998155_10  rs10025373 4:74568318 - 
rs7725 5:179727957 GFPT2 C_1391323_1  rs6819597 4:76957171 ART3 
rs9358890 6:25779392 SLC17A4 C_25595118_10  rs6835636 4:154590349 - 
rs3799344 6:25786993 SLC17A1 C_194536_10  rs40401 5:131396478 IL3 
rs1183201 6:25823444 SLC17A1 C_1911034_10  rs9294168 6:80733884 TTK 
rs12664474 6:25876089 SLC17A3 C_11189653_10  rs9639436 7:22798216 - 
rs6945435 7:72269531 TYW1B C_31478651_10  rs12535365 7:87725522 ADAM22 
rs1929480 9:104189680 ALDOB C_2977275_10  rs8122 7:87906171 STEAP4 
rs573816 9:104204614 - C_587876_10  rs9690688 7:107720162 LAMB4 
rs7901695 10:114754088 TCF7L2 C_384583_10  rs7811892 7:127923778 - 
rs900865 11:15729843 - C_8914644_10  rs35958249 8:3693601 CSMD1 
rs831628 11:33744845 CD59 C_8746371_10  rs2683764 8:31715944 NRG1 
rs1130214 14:105259734 AKT1 C_26352825_10  rs4256629 8:121537036 MTBP 
rs12917707 16:20367690 UMOD C_31122302_10  rs2812378 9:34710260 CCL21 
rs2043211 19:48737706 CARD8 C_11708080_1  rs4571803 9:115976861 FKBP15 
rs2075876 21:45709153 AIRE C_15863141_10  rs11536879 9:120472211 TLR4 
rs755622 22:24236392 MIF C_2213785_10  rs1184835 9:135228721 SETX 
rs729749 22:37263846 NCF4 C_2481201_20  rs7118682 11:14274550 SPON1 
rs743777 22:37551607 IL2RB C_2403397_10  rs7108425 11:78382256 TENM4 
rs4129148 X:990180 - Custom Probe  rs507879 11:104877927 CASP5 
     rs795467 11:112031080 SDHD 
     rs7842 12:8211187 FOXJ2 
     rs12877336 13:110973086 COL4A2 
     rs4781011 16:10975311 CIITA 
     rs4780884 16:20353127 UMOD 
     rs4889640 16:31264267 - 
     rs11078855 17:2091308 SMG6 
     rs8075846 17:32632483 - 
     rs493430 17:72588326 C17orf77 
     rs344542 19:6687517 C3 
     rs4804221 19:7769188 FCER2 
     rs730275 20:58254093 PHACTR3 
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Appendix Table B.2: Brief summary of the 19 renal cell samples used to identify 
DNase hypersensitivity regions for sequencing. 
Sample  Analysis 
GEO accession Sex Age Tissue Type  Marker Type Protocol 
GSM621648 Male 67 (Years) Adult Kidney  Histone Methylation ChIP-Seq 
GSM701494 Male 15 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM701502 Male 15 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM701511 Male 16 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM701517 Male 15 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM701519 Male 15 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM701529 Male 13 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM701532 Female 17 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM772811 Male 67 (Years) Adult Kidney  Histone Acetylation Chip-Seq 
GSM773005 Male 50 (Years) Adult Kidney  Histone Methylation ChIP-Seq 
GSM773006 Male 50 (Years) Adult Kidney  Histone Acetylation ChIP-Seq 
GSM817176 Male 18 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM817190 Male 15 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM817202 Male 17 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM817203 Male 17 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM817210 Male 15 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM817211 Male 15 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
GSM878629 Male 14 (Weeks) Foetal Renal Cortex  DNase-Hypersensitivity DNase-Seq 
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Appendix C. Experiences of Gout 
This appendix section provides additional information for Chapter 3, Sections 3.1 and 3.2.  
 
Appendix C.1. Ethnographic Interview Topics 
The following section contains the guide of pre-determined interview topics used during 
the ethnographic interviews detailed in Section 3.1. 
 
1. Gout triggers – things that bring on gout attacks 
a. Food/drink triggers 
b. Non-food triggers (eg. flying, rainy/cold weather) 
c. Reasons for these things triggering gout 
d. How did you discover the trigger(s)? 
e. Do you think you have others you haven't discovered? 
f. Do you avoid your triggers? 
 “Why are all the triggers things I enjoy?” Do you identify?
 
2. Do you have any remedies to prevent gout attacks – home remedies not medicines? 
a. Have you heard of other people having remedies? 
b. How did you discover this remedy? 
i. Did a doctor recommend it? 
ii. Did you just try something new one day? 
c. Why do you think your remedy works? 
 
3. Causes of gout – things that make you have gout but not someone else 
a. Do food/drink cause it? 
b. Are your triggers causes? 
c. Why do you think these things cause gout? 
d. Do you think other diseases (eg. diabetes) are caused by the same things? 
e. Have you been told about any causes? 
i. Who by? Doctor? Family Member? Friend? Someone Else? 
f. Do you agree with what you’ve heard? 
g. Do you think anyone knows the real causes? 
h. Do you think we will ever know? 
i. Do you have gout all the time? 
 
4. Have you heard about genetic causes? 
a. Do you understand how genetics could play a role? 
b. Would you want to learn? 
c. Did you know genetic research is being done on gout? – family inheritance 
i. If yes have you seen any of the results? 
ii. Did you understand the results? 
iii. Where did you see it? 
d. Do you think genetic research is useful? 
e. Would you take part if you were asked? 
i. Have you been asked? 
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